SECURITIES AND EXCHANGE COMMISSION
AMENDMENT NO. 2
LHC Group, Inc.
Delaware | 8082 | 43-2074268 | ||
(State or other jurisdiction of
incorporation or organization) |
(Primary Standard Industrial
Classification Code Number) |
(I.R.S. Employer
Identification No.) |
LHC Group, Inc.
Keith G. Myers
With Copies to:
Steven L. Pottle, Esq.
Peter C. November, Esq. Alston & Bird LLP 1201 West Peachtree Street Atlanta, Georgia 30309-3424 (404) 881-7000 Telephone (404) 881-7777 Facsimile |
James R. Tanenbaum, Esq.
Nilene R. Evans, Esq. Morrison & Foerster LLP 1290 Avenue of the Americas New York, New York 10104-0050 (212) 468-8000 Telephone (212) 468-7900 Facsimile |
Approximate date of commencement of proposed sale to the public: As soon as practicable after this registration statement becomes effective.
If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. o
If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. o
If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. o
If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. o
If delivery of the prospectus is expected to be made pursuant to Rule 434, check the following box. o
The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to Section 8(a), may determine.
The information in this
prospectus is not complete and may be changed. We may not sell
these securities until the registration statement filed with the
Securities and Exchange Commission is effective. This prospectus
is not an offer to sell these securities, and we are not
soliciting an offer to buy these securities in any state where
the offer or sale is not permitted.
|
SUBJECT TO COMPLETION, DATED FEBRUARY 14, 2005
4,000,000 Shares
LHC Group, Inc. is offering 3,100,000 shares of its common stock. The selling stockholders identified in this prospectus are selling an additional 900,000 shares. We will not receive any of the proceeds from the sale of shares being sold by the selling stockholders.
This is our initial public offering and no public market currently exists for our shares. Our shares of common stock have been approved for quotation on the Nasdaq National Market under the symbol LHCG. We anticipate that the initial public offering price will be between $12.00 and $14.00 per share.
Investing in our common stock involves risks.
Per | ||||||||
Share | Total | |||||||
|
|
|||||||
Public offering price
|
$ | $ | ||||||
Underwriting discounts and commissions
|
$ | $ | ||||||
Proceeds, before expenses, to LHC Group
|
$ | $ | ||||||
Proceeds, before expenses, to the selling
stockholders
|
$ | $ |
Neither the Securities and Exchange Commission, any state securities commission, nor any other regulatory body has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The selling stockholders have granted the underwriters an option to purchase up to an additional 600,000 shares of common stock at the public offering price, less the underwriting discount, within 30 days from the date of this prospectus to cover over-allotments.
The underwriters expect to deliver the shares to purchasers on or before , 2005.
Jefferies & Company, Inc. | Legg Mason Wood Walker |
The date of this prospectus is , 2005.
TABLE OF CONTENTS
You should rely only on the information contained in this prospectus or to which we have referred you. We have not authorized anyone to provide you with information that is different. This prospectus may be used only where it is legal to sell these securities. The information in this prospectus may be accurate only on the date of this prospectus.
Until , 2005 (25 days after the commencement of this offering), all dealers that effect transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.
SUMMARY
The following is a summary of selected
information contained elsewhere in this prospectus. It does not
contain all of the information that may be important to you. You
should read this entire prospectus, including our consolidated
financial statements and the related notes, before making an
investment decision. You should also carefully consider the
information set forth under Risk Factors. Unless
otherwise indicated, LHC, we,
us, and the company refer to LHC Group,
Inc. and our consolidated subsidiaries.
Overview
We provide post-acute healthcare services
primarily to Medicare beneficiaries in rural markets in the
southern United States. We provide these post-acute healthcare
services through our home nursing agencies, hospices, long-term
acute care hospitals and outpatient rehabilitation clinics.
Since our founders began operations in 1994 with one home
nursing agency in Palmetto, Louisiana, we have grown to
86 locations in Louisiana, Alabama, Arkansas, Mississippi
and Texas as of December 31, 2004. We have grown our net
service revenue from $28.2 million in 2001 to
$72.4 million in 2003, representing a compound annual
growth rate of 60.2%. During this same period, our net income
grew from $787,000 in 2001 to $2.8 million in 2003. For the
nine months ended September 30, 2004, we reported
$88.0 million of net service revenue and $6.7 million
of net income. Medicare accounted for 85.7% of our net service
revenue for the nine months ended September 30, 2004. We
have been profitable every year since 1999.
Our objective is to become the leading provider
of post-acute healthcare services to Medicare patients in
selected rural markets, which we define as counties having
between 10,000 and 100,000 residents. We believe these markets,
which have a higher percentage of Medicare beneficiaries, are
underserved relative to urban or suburban markets. Upon entering
a new market, we implement our clinically-oriented business
model that emphasizes improved patient care, strong
relationships with local hospitals, physicians and other
healthcare providers and an expansion in the range of healthcare
services available to patients. Our model provides support and
clinical guidelines to our local caregivers while promoting
treatment flexibility that allows them to effectively address
individual patient needs. Our model also enhances our ability to
expand efficiently into these markets and deliver high quality
care consistently on a cost-effective basis across multiple
locations.
We provide home-based post-acute healthcare
services through our home nursing agencies and hospices. We own
and operate 63 home nursing locations, of which 56 are
certified to receive Medicare reimbursement. We also manage the
operations of four home nursing locations in which we currently
have no ownership interest. Our home nursing locations offer a
wide range of services, including skilled nursing, private duty
nursing, physical, occupational, and speech therapy and
medically-oriented social services. The nurses, home health
aides and therapists in our home nursing agencies work closely
with patients and their families to design and implement
individualized treatment responsive to a physician-prescribed
plan of care. We own and operate three Medicare-certified
hospices and manage the operations of two Medicare-certified
hospices in which we currently have no ownership interest. Our
hospices provide palliative care to patients with terminal
illnesses through interdisciplinary teams of physicians, nurses,
home health aides, counselors and volunteers. Of our
66 home-based services locations in which we have an
ownership interest, 40 are wholly-owned by us and 26 are
majority-owned by us through joint ventures or controlled
through other strategic relationships. For the year ended
December 31, 2003 and the nine months ended
September 30, 2004, our home-based services provided
$56.2 million and $60.4 million, respectively, of our
net service revenue.
We provide facility-based post-acute healthcare
services through our long-term acute care hospitals and
outpatient rehabilitation clinics. We own and operate four
long-term acute care hospitals with seven locations, with a
total of 132 licensed beds, and one inpatient rehabilitation
facility with 15 licensed beds. We plan to convert the inpatient
rehabilitation facility into a long-term acute care hospital.
Our long-term acute care hospitals, all of which are located
within host hospitals, provide services primarily to patients
who have transitioned out of a hospital intensive care unit and
suffer from complex medical
1
Industry and Market Opportunity
According to estimates of the Medicare Payment
Advisory Committee, or MedPAC, Medicare spending totaled
$12.8 billion in 2003 for the two primary post-acute
sectors in which we operate: home nursing and long-term acute
care. MedPAC estimates that Medicare spending on home nursing
services totaled $10.2 billion in 2003. The Centers for
Medicare and Medicaid Services, or CMS, estimates that there are
approximately 7,200 Medicare-certified home nursing
agencies in the United States, the majority of which are
operated by small local or regional providers. CMS also
estimates that approximately 32.0% of these home nursing
agencies are hospital-based or not-for-profit, freestanding
agencies, and MedPAC estimates that approximately 34.0% are
located in rural markets. CMS predicts that Medicare spending on
home nursing services will increase at an average annual growth
rate of 7.6% between 2005 and 2009. According to MedPAC
estimates, Medicare spending for services provided by long-term
acute care hospitals has grown from $0.4 billion in 1993 to
an estimated $2.6 billion in 2003.
We believe our post-acute healthcare services
provide valuable treatment alternatives to underserved, rural
patient populations. Rural areas typically do not offer the
range of post-acute healthcare services that are available in
urban or suburban markets; therefore, patients in rural markets
often face challenges in accessing healthcare in a convenient
and appropriate setting. Because most rural areas have the
population size to support only one or two general acute care
hospitals, the local hospital often plays a significant role in
rural market healthcare delivery systems. Rural patients who
require home nursing services frequently receive care from a
small home nursing agency or an agency that, while owned and
operated by the hospital, is not an area of focus for that
hospital. In addition, patients in these markets who require
services typically offered by long-term acute care hospitals
generally remain in the community hospital, as it is often the
only local facility equipped to deal with severe, complex
medical conditions.
Competitive Strengths
We believe the following competitive strengths
have enabled us to grow our business and increase our net income
while building strong market share:
2
Growth Strategy
Our objective is to become the leading provider
of post-acute healthcare services to Medicare beneficiaries in
rural markets in the southern United States. To achieve this
objective, we intend to:
3
Our Risks
Our business and our ability to implement our
operating and growth strategies are subject to numerous risks
which you should consider before investing in our common stock.
In particular, the risks we face include risks related to:
We might not be able to successfully manage our
risks and these risks could harm our business. The risks we face
are described in Risk Factors, which begins on
page 8 of this prospectus.
Address
Our principal executive offices are located at
420 West Pinhook Rd., Suite A, Lafayette, LA 70503,
and our telephone number is (337) 233-1307. Our Internet
address is www.lhcgroup.com. The information contained on our
website is not a part of this prospectus.
4
Table of Contents
We have a proven track record of success in
serving rural markets.
Of our
86 locations, 72.7% are located in counties with fewer than
100,000 residents. Our strategic plan for entering new
markets is specifically designed for rural markets and includes:
(1) building relationships with local hospitals, physicians
and other healthcare providers; (2) expanding the breadth
and quality of services provided; (3) recruiting qualified
nurses and other healthcare professionals; and
(4) transitioning acquired operations to our operating
model and technology platform.
We have a clinically-oriented and
patient-focused operating model.
We
have developed a decentralized, care management operating model
that enhances our ability to deliver high-quality care on a
consistent and cost-effective basis across multiple locations.
Our operating model provides clinical guidelines at the agency
and caregiver levels while promoting treatment flexibility to
address patient-specific needs. We believe this approach also
allows us to allocate more resources to patient care, which
enhances clinical outcomes and increases physician and patient
satisfaction.
Table of Contents
We incur low costs to enter new
markets.
We often enter a new market
by forming a strategic relationship with a local hospital for,
or by acquiring or assuming operations of, an existing
hospital-owned home nursing agency that may be underperforming
clinically or financially. Typically, we have acquired the
assets of these agencies with limited capital investment. Upon
acquiring these interests, we implement our standardized
operating model, which generally leads to increased patient
census, enhanced patient care and improved financial performance.
We focus on maintaining strong employee
relations.
Critical to our success is
our ability to attract and retain experienced and skilled
employees and our recognition of the importance of good
relations with our employees. The flexibility created by our
care management operating model, combined with our emphasis on
communication, education and competitive benefits, has allowed
us to attract and retain highly skilled and experienced
employees. As a result, we had an employee turnover rate for
full-time employees of approximately 14.6% for the year ended
December 31, 2004, which we believe is well below the
comparable national average.
We have an experienced management
team.
Our ability to grow
profitability, deliver high-quality service, and expand our
operations has been due, in large part, to the experience of our
senior management team. Our four executive officers have over
61 years of combined experience in the healthcare services
industry.
Drive internal growth in existing
markets.
We intend to drive internal
growth in our current markets by increasing the number of
healthcare providers in each market from whom we receive
referrals and by expanding the breadth of our services. We
intend to achieve this growth by: (1) continuing to educate
healthcare providers about the benefits of our services;
(2) reinforcing the position of our agencies and facilities
as community assets; (3) maintaining our emphasis on
high-quality medical care for our patients; and
(4) providing a superior work environment for our employees.
Achieve margin improvement through the active
management of costs.
The majority of
our net service revenue is generated under Medicare prospective
payment systems through which we are paid pre-determined rates
based upon the clinical condition and severity of the patients
in our care. Because our profitability in a fixed payment system
depends upon our ability to manage the costs of providing care,
we continue to pursue initiatives to improve our margins and net
income.
Expand into new rural
markets.
We will continue expanding
into new markets by developing new and acquiring existing
Medicare-certified home nursing agencies in attractive markets.
We currently plan to pursue expansion opportunities in
14 contiguous states, and we have identified approximately
500 underserved rural markets in those states where we
believe we can implement our operating model successfully.
Pursue strategic
acquisitions.
We will continue to
identify and evaluate opportunities for strategic acquisitions
in new and existing markets that will enhance our market
position, increase our referral base and expand the breadth of
services we offer. We may use a portion of the proceeds of this
offering to pursue acquisitions that would allow us to acquire
market share in our target states through the purchase of larger
home nursing operations.
Table of Contents
Dependence on Payments from
Medicare.
For the years ended
December 31, 2001, 2002 and 2003, and the nine months ended
September 30, 2004, we received 79.3%, 82.8%, 83.1% and
85.7%, respectively, of our net service revenue from Medicare.
Reductions in Medicare rates or changes in the way Medicare pays
for services could cause our net service revenue and net income
to decline, perhaps materially.
Extensive Governmental
Regulation.
We are subject to
extensive governmental regulation. If we fail to comply with
these regulations, we could suffer penalties, including the loss
of our licenses to operate and our ability to participate in
government-based reimbursement programs. Further, changes in
existing regulations or the implementation of new regulations
could increase our costs of doing business and cause our net
service revenue and net income to decline.
Dependence on Referral
Sources.
Our success depends
significantly on referrals from physicians, hospitals and other
healthcare providers. Our referral sources are not obligated to
refer business to us and may refer business to other healthcare
providers. Our failure to maintain relationships with our
existing referral sources or to develop relationships with new
referral sources could adversely impact our ability to expand
our operations and operate profitably.
Shortages in Qualified Healthcare
Professionals.
We rely on our ability
to attract and retain qualified nurses and other healthcare
professionals. The availability of qualified nurses has declined
nationwide and competition for healthcare professionals has
increased. If we are unable to attract and retain qualified
healthcare professionals, our ability to grow may be
constrained. Further, if the cost of attracting and retaining
these professionals increases, our net income could decline.
Satisfaction of Certificate of Need or Similar
Regulations.
Our ability to expand
will depend on our ability to obtain state licenses to operate.
Of the 14 states in which we currently operate or plan to
operate, 10 require healthcare providers to obtain prior
approval, known as a certificate of need or permit of approval,
or similar permission for the purchase, construction or
expansion of healthcare facilities. The failure to obtain any
requested certificate of need, permit of approval or other
license could impair our ability to operate or expand our
business.
Dependence on Additional
Capital.
We must have sufficient
capital in order to implement our growth strategy. If we do not
have sufficient capital resources, our growth could be limited
unless we obtain additional equity or debt financing.
Table of Contents
The Offering
The number of shares of common stock to be
outstanding after this offering is based on
12,085,150 shares outstanding as of December 31, 2004.
Except as otherwise noted, all information in
this prospectus:
5
Common stock offered by us
3,100,000 shares
Common stock offered by selling stockholders
900,000 shares
Common stock to be outstanding after this offering
16,191,867 shares
Use of proceeds
We plan to use the net proceeds of this offering
to repay indebtedness, fund joint venture conversion
obligations, finance potential acquisitions or joint venture
investments, and to fund other general corporate purposes.
We will not receive any proceeds from the sale of
shares of common stock by selling stockholders. See Use of
Proceeds.
Proposed Nasdaq National Market symbol
LHCG
assumes the underwriters do not exercise their
over-allotment option;
includes the issuance of 518,036 aggregate shares
of our outstanding common stock to be received upon the exercise
of rights held by two of our joint venture partners to convert
their joint venture equity interests into shares of our common
stock, which will occur upon the completion of this offering;
includes the issuance of 481,680 shares of
our common stock upon conversion of outstanding key employee
equity participation units, which will occur automatically upon
the completion of this offering;
includes 7,000 shares of vested restricted
common stock, but excludes an additional 14,000 shares of
unvested restricted common stock, all of which will be issued
upon completion of this offering pursuant to our 2005 Director
Compensation Plan; and
excludes, except for the 7,000 shares of vested
restricted common stock referred to above, 1,000,000 shares
available for future issuance under our equity incentive plans,
of which options to acquire 11,500 shares have been granted.
Table of Contents
Summary Consolidated Financial and Other
Data
The summary consolidated financial data presented
below is derived from our consolidated financial statements
included elsewhere in this prospectus. You should read this
summary consolidated financial data together with our
consolidated financial statements and related notes and
Managements Discussion and Analysis of Financial
Condition and Consolidated Results of Operations included
elsewhere in this prospectus. The summary financial information
set forth below as of and for the years ended December 31,
2001, 2002 and 2003 has been derived from our audited
consolidated financial statements. The summary financial
information as of and for the nine months ended
September 30, 2003 and 2004 has been derived from our
unaudited consolidated financial statements, which include all
adjustments consisting of normal recurring accruals that we
consider necessary for a fair presentation of the financial
position and the results of operations for these periods.
Historical results are not necessarily indicative of future
performance.
The as adjusted consolidated balance sheet data
as of September 30, 2004 presented below gives effect to
the following events as if each had occurred as of
September 30, 2004: (1) the completion of this
offering; (2) the application of approximately
$13.7 million of the net proceeds to us from this offering
to repay existing indebtedness; (3) the application of
approximately $3.0 million of the net proceeds from this
offering to satisfy our obligations to one of our joint venture
partners related to the conversion of its joint venture equity
interests; (4) the issuance of 518,036 aggregate
shares of our common stock to two of our joint venture partners
who are converting their joint venture equity interests into
shares of our common stock in connection with this offering;
(5) the issuance of 481,680 shares of our common stock
upon conversion of outstanding key employee equity participation
units, or KEEP Units, which will occur automatically upon the
completion of this offering; and (6) the grant of
7,000 shares of vested restricted common stock pursuant to
our 2005 Director Compensation Plan upon completion of this
offering. The as adjusted summary financial data is not
necessarily indicative of what our consolidated financial
position would have been had this offering been completed as of
the dates indicated, nor is such data necessarily indicative of
our consolidated financial position as of any future date.
6
7
Nine Months Ended
Year Ended December 31,
September 30,
2001
2002
2003
2003
2004
(unaudited)
(in thousands, except per share data)
$
28,208
$
48,950
$
72,365
$
49,315
$
87,958
13,466
23,438
37,146
24,789
45,415
14,742
25,512
35,219
24,526
42,543
11,011
16,430
24,761
17,205
26,433
31
111
124
864
156
1,257
3,620
8,958
9,563
7,165
14,853
411
1,135
1,226
806
1,048
(325
)
(124
)
(106
)
(52
)
109
3,534
7,947
8,443
6,411
13,696
1,151
2,139
2,320
1,694
4,173
1,355
2,699
2,837
2,113
3,066
1,028
3,109
3,286
2,604
6,457
(241
)
(267
)
(443
)
(200
)
(18
)
308
$
787
$
2,842
$
2,843
$
2,404
$
6,747
$
0.09
$
0.26
$
0.27
$
0.22
$
0.53
(0.02
)
(0.02
)
(0.03
)
(0.02
)
(0.00
)
0.03
$
0.07
$
0.24
$
0.24
$
0.20
$
0.56
$
0.08
$
0.26
$
0.26
$
0.22
$
0.53
(0.02
)
(0.02
)
(0.03
)
(0.02
)
(0.00
)
0.02
$
0.06
$
0.24
$
0.23
$
0.20
$
0.55
11,756,419
11,926,222
12,085,150
12,085,150
12,085,150
12,241,908
12,084,534
12,114,671
12,100,682
12,201,531
$
1,983
$
6,048
$
6,782
$
5,023
$
12,456
Table of Contents
As of December 31,
As of September 30, 2004
2001
2002
2003
Actual
As Adjusted
(unaudited)
(in thousands)
$
132
$
3,179
$
1,725
$
2,834
$
21,333
10,033
21,485
27,915
41,093
69,136
6,162
10,542
12,277
15,232
1,537
(403
)
3,593
6,909
13,879
56,662
(1)
Equity-based compensation expense is allocated as
follows:
Nine Months Ended
Year Ended December 31,
September 30,
2001
2002
2003
2003
2004
(unaudited)
(in thousands)
$
$
$
5
$
$
31
111
124
859
156
1,226
$
111
$
124
$
864
$
156
$
1,257
(2)
We will incur an equity-based compensation charge
in respect of the quarter ended December 31, 2004 of
$531,000. Assuming an initial public offering price of
$13.00 per share, upon the completion of this offering we
will also incur a final, non-recurring equity-based compensation
charge relating to the outstanding KEEP Units under our Key
Employee Equity Participation Plan, or KEEP Plan, in the amount
of approximately $3.4 million, recorded in the reporting
period the offering is completed. For a description of our KEEP
Plan, see Management Employee Benefit
Plans 2003 Key Employee Equity Participation
Plan.
(3)
All references to shares and per share amounts
have been retroactively restated to reflect our incorporation in
the State of Delaware and to give effect to a three-for-two
stock split with respect to our common stock as if such events
occurred as of the beginning of the earliest period presented.
See Note 1 to our consolidated financial statements.
(4)
EBITDA represents our portion of EBITDA,
excluding the minority interest and cooperative endeavor
allocations of third parties. EBITDA is not a substitute for
operating income, net income, or cash flow from operating
activities, as determined in accordance with Generally Accepted
Accounting Principles, or GAAP, as measures of liquidity. See
Non-GAAP Financial Measures. For each of the periods
indicated, the following table sets forth a reconciliation of
EBITDA to net cash provided by (used in) operating activities to
net income. The following reconciliation includes amounts
classified as discontinued operations in our consolidated
financial statements.
Nine Months
Ended
Year Ended December 31,
September 30,
2001
2002
2003
2003
2004
(in thousands)
$
1,983
$
6,048
$
6,782
$
5,023
$
12,456
98
230
441
283
688
351
411
1,153
1,246
823
1,058
1,012
1,956
2,007
1,565
4,361
(325
)
(133
)
(106
)
(52
)
(398
)
787
2,842
2,843
2,404
6,747
98
230
441
283
688
484
461
604
512
1,186
351
963
111
124
864
156
1,257
241
2,651
(168
)
157
310
(232
)
(89
)
(10
)
(2
)
(365
)
(4,574
)
(7,086
)
(4,476
)
728
(7,656
)
(299
)
(330
)
(221
)
(103
)
(283
)
707
3,686
534
(1,519
)
2,212
297
(168
)
4
769
(457
)
(3
)
258
(655
)
(83
)
(104
)
$
(1,686
)
$
174
$
830
$
3,145
$
5,644
Table of Contents
RISK FACTORS
You should carefully consider the risks described below, together with all the other information included in this prospectus, before making a decision to buy our common stock. If any of the following risks actually materialize, our business, financial condition or consolidated results of operations could be harmed. In that case, the trading price of our common stock could decline, and you could lose all or part of your investment.
Risks Related to Our Business and Industry
More than 80% of our net service revenue is derived from Medicare. If there are changes in Medicare rates or methods governing Medicare payments for our services, or if we are unable to control our costs, our net service revenue and net income could decline materially.
For the years ended December 31, 2001, 2002 and 2003, and the nine months ended September 30, 2004, we received 79.3%, 82.8%, 83.1% and 85.7%, respectively, of our net service revenue from Medicare. Reductions in Medicare rates or changes in the way Medicare pays for services could cause our net service revenue and net income to decline, perhaps materially. Reductions in Medicare reimbursement could be caused by many factors, including:
| administrative or legislative changes to the base rates under the applicable prospective payment systems; | |
| the reduction or elimination of annual rate increases; | |
| the imposition or increase by Medicare of mechanisms, such as co-payments, shifting more responsibility for a portion of payment to beneficiaries; | |
| adjustments to the relative components of the wage index used in determining reimbursement rates; | |
| changes to case mix or therapy thresholds; | |
| the reclassification of home health resource groups or long-term care diagnosis-related groups; or | |
| further limitations on referrals to long-term acute care hospitals from host hospitals. | |
We generally receive fixed payments from Medicare for our services based on the level of care provided to our patients. Consequently, our profitability largely depends upon our ability to manage the cost of providing these services. Medicare currently provides for an annual adjustment of the various payment rates, such as the base episode rate for our home nursing services, based upon the increase or decrease of the medical care expenditure category of the Consumer Price Index, which may be less than actual inflation. This adjustment could be eliminated or reduced in any given year. Our base episode rate for home nursing services is also subject to an annual market basket adjustment. MedPAC has recommended that a recent 2% increase in the market basket adjustment be eliminated. Further, Medicare routinely reclassifies home health resource groups and long-term care diagnosis-related groups. As a result of those reclassifications, we could receive lower reimbursement rates depending on the case mix of the patients we service. If our cost of providing services increases by more than the annual Medicare price adjustment, or if these reclassifications result in lower reimbursement rates, our net income could be adversely impacted.
8
We are subject to extensive government regulation. Any changes in the laws governing our business, or the interpretation and enforcement of those laws or regulations, could cause us to modify our operations and could negatively impact our operating results.
As a provider of healthcare services, we are subject to extensive regulation on the federal, state and local levels, including with regard to:
| agency, facility and professional licensure, certificates of need and permits of approval; | |
| conduct of operations, including financial relationships among healthcare providers, Medicare fraud and abuse, and physician self-referral; | |
| maintenance and protection of records, including the Health Insurance Portability and Accountability Act of 1996, or HIPAA; | |
| environmental protection, health and safety; | |
| certification of additional agencies or facilities by the Medicare program; and | |
| payment for services. |
The laws and regulations governing our operations, along with the terms of participation in various government programs, regulate how we do business, the services we offer, and our interactions with patients and other providers. These laws and regulations, and their interpretations, are subject to frequent change. Changes in existing laws or regulations, or their interpretations, or the enactment of new laws or regulations could increase our costs of doing business and cause our net income to decline. If we fail to comply with these applicable laws and regulations, we could suffer civil or criminal penalties, including the loss of our licenses to operate and our ability to participate in federal and state reimbursement programs.
We are subject to various routine and non-routine governmental reviews, audits, and investigations. In recent years federal and state civil and criminal enforcement agencies have heightened and coordinated their oversight efforts related to the healthcare industry, including with respect to referral practices, cost reporting, billing practices, joint ventures and other financial relationships among healthcare providers. A violation or change in the interpretation of the laws governing our operations, or changes in the interpretation of those laws, could result in the imposition of fines, civil or criminal penalties, the termination of our rights to participate in federal and state-sponsored programs, or the suspension or revocation of our licenses to operate. If we become subject to material fines or if other sanctions or other corrective actions are imposed upon us, we may suffer a substantial reduction in net income.
If any of our agencies or facilities fail to comply with the conditions of participation in the Medicare program, that agency or facility could be terminated from Medicare, which would adversely affect our net service revenue and net income.
Our agencies and facilities must comply with the extensive conditions of participation in the Medicare program. These conditions of participation vary depending on the type of agency or facility, but in general require our agencies and facilities to meet specified standards relating to personnel, patient rights, patient care, patient records, administrative reporting and legal compliance. If an agency or facility fails to meet any of the Medicare conditions of participation, that agency or facility may receive a notice of deficiency from the applicable state surveyor. If that agency or facility then fails to institute and comply with a plan of correction to correct the deficiency within the time period provided by the state surveyor, that agency or facility could be terminated from the Medicare program. We respond in the ordinary course to deficiency notices issued by state surveyors, and none of our facilities or agencies have ever been terminated from the Medicare program for failure to comply with the conditions of participation. Any termination of one or more of our agencies or facilities from the Medicare program for failure to satisfy the Medicare conditions of participation would affect adversely our net service revenue and net income.
In addition, if our long-term acute care hospitals fail to meet or maintain the standards for Medicare certification as long-term acute care hospitals, such as for average minimum length of patient stay, they will receive reimbursement under the prospective payment system applicable to general acute
9
CMS recently adopted new regulations that could materially and adversely impact the revenue and net income of our long-term acute care hospitals.
In August 2004, the Centers for Medicare and Medicaid Services, or CMS, adopted new regulations that implement significant changes affecting our long-term acute care hospitals. Among other things, these new regulations, effective October 2004, mandate that long-term acute care hospitals operating in the hospital within a hospital model receive lower rates of reimbursement for Medicare admissions from their host hospitals that are in excess of specified percentages. For new long-term acute care hospitals located within hospitals, the Medicare admissions limitation will be 25.0% for hospitals located in a Metropolitan Statistical Area, or MSA, and 50.0% for hospitals located in a non-MSA. This means a new long-term acute care hospital located within a hospital will receive lower rates of reimbursement from Medicare if more than 25.0%, or 50.0% if located in a non-MSA, of its admissions are derived from its host hospital. For existing long-term acute care hospitals within hospitals and those under development that meet specified criteria, the Medicare admissions limitations are being phased in over a four-year period that began October 1, 2004. The Medicare admissions limitations make distinctions between facilities located in MSAs and facilities located in non-MSAs as follows:
Allowable Admissions | ||||||||
from Host Hospital | ||||||||
Before Payment | ||||||||
Reduction | ||||||||
|
||||||||
Period | MSAs | Non-MSAs | ||||||
|
|
|
||||||
Until September 30, 2005
|
100.0% | 100.0% | ||||||
October 1, 2005
September 30, 2006
|
75.0% | 75.0% | ||||||
October 1, 2006
September 30, 2007
|
50.0% | 50.0% | ||||||
October 1, 2007 and thereafter
|
25.0% | 50.0% |
Of our seven long-term acute care hospital locations, five are physically located in a non-MSA. Of these five locations, two are satellite locations of a parent hospital that is located in a MSA. Based on our discussions with CMS, we believe these satellite locations will be viewed as being located in a non-MSA regardless of the location of their parent hospital and will be treated independently from their parent for purposes of calculating their compliance with the admissions limitations. For the nine months ended September 30, 2004, on an individual basis, four of our long-term acute care hospital locations admitted between 50.0% and 75.0% of their patients from their host hospitals and two of our long-term acute care hospital locations admitted more than 75.0% of their patients from their host hospitals. We have recently commenced operations at one of our long-term acute care hospital locations; therefore, we do not have sufficient data to determine the percentage of referrals that will come from its host hospital at this time.
Our ability to quantify the potential reduction in our reimbursement rates resulting from these new regulations is contingent upon a variety of factors, such as our ability to restructure the manner in which we receive referrals and, if necessary, our ability to relocate our existing long-term acute care hospitals to freestanding locations. We may not be able to successfully restructure or relocate these operations without incurring significant expense or in a manner that avoids reimbursement reductions. If these new regulations result in lower reimbursement rates, our net service revenue and net income could decline. As a result of these new rules, we do not intend to expand the number of hospital within a hospital long-term acute care hospitals that we operate.
10
We are reimbursed by Medicare for services we provide in our long-term acute care hospitals based on the long-term care diagnosis-related group assigned to each patient. CMS establishes these long-term care diagnosis-related groups by grouping diseases by diagnosis, which group reflects the amount of resources needed to treat the diseases. These new rules reclassified certain long-term care diagnosis-related groups, which could result in a decrease in reimbursement rates. Further, the new rules kept in place the financial penalties associated with the failure to limit the total number of Medicare patients discharged to the host hospital and subsequently readmitted to a long-term acute care hospital located within the host hospital to no greater than 5.0%. If we fail to comply with these readmission rates or if our reimbursement rates decline due to the reclassification of certain long-term care diagnosis-related groups, our net service revenue and net income could decline.
Legislative initiatives could negatively impact our operations and financial results.
In recent years, an increasing number of legislative initiatives have been introduced or proposed in Congress and in state legislatures that would result in major changes in the healthcare system, either at the national or state level. Many of these proposals have been introduced in an effort to reduce costs. For example, the Medicare Modernization Act of December 2003, or MMA, allocated significant additional funds to Medicare managed care providers in order to promote greater participation in those plans by Medicare beneficiaries. If these increased funding levels achieve their intended result, the rate of growth in the Medicare fee-for-service market could decline. For the years ended December 31, 2001, 2002 and 2003, and the nine months ended September 30, 2004, we received 79.3%, 82.8%, 83.1% and 85.7%, respectively, of our net service revenue from the Medicare fee-for-service market. Among other proposals that have been introduced are insurance market reforms to increase the availability of group health insurance to small businesses, requirements that all businesses offer health insurance coverage to their employees and the creation of a government health insurance or plans that would cover all citizens and increase payments by beneficiaries. We cannot predict whether any of the above proposals, or any other future proposals, will be adopted. If adopted, we could be forced to expend considerable resources to comply with and implement such reforms.
More than 80% of our net service revenue is currently generated in Louisiana, making us particularly sensitive to economic and other conditions in that state.
Our Louisiana agencies and facilities accounted for approximately 100.0%, 92.3%, 89.0% and 83.0% of our net service revenue during the years ended December 31, 2001, 2002 and 2003 and the nine months ended September 30, 2004, respectively. Any material change in the current economic or competitive conditions in Louisiana, which could result from events such as the implementation of certificate of need regulations or changes in state tax laws, could have a disproportionate effect on our overall business results.
If we are unable to maintain relationships with existing referral sources or establish new referral sources, our growth and net income could be adversely affected.
Our success depends significantly on referrals from physicians, hospitals, and other healthcare providers in the communities in which we deliver our services. Our referral sources are not obligated to refer business to us and may refer business to other healthcare providers. We believe many of our referral sources refer business to us as a result of the quality of patient service provided by our local employees in the communities in which our agencies and facilities are located. If we are unable to retain these employees, our referral sources may refer business to other healthcare providers. Our loss of, or failure to maintain, existing relationships or our failure to develop new relationships could affect adversely our ability to expand our operations and operate profitably.
Delays in reimbursement may cause liquidity problems.
Our business is characterized by delays in reimbursement from the time we request payment for our services to the time we receive reimbursement or payment. A portion of our estimated reimbursement (60.0% for an initial episode of care and 50.0% for subsequent episodes of care) for each Medicare episode is billed at the commencement of the episode and we typically receive payment within approximately
11
Future cost containment initiatives undertaken by private third party payors may limit our future net operating revenue and net income.
Initiatives undertaken by major insurers and managed care companies to contain healthcare costs may affect our net income. These payors attempt to control healthcare costs by contracting with hospitals and other healthcare providers to obtain services on a discounted basis. We believe that this trend may continue and may limit reimbursements for healthcare services. If insurers or managed care companies from whom we receive substantial payments were to reduce the amounts they pay for services, our profit margins may decline, or we may lose patients if we choose not to renew our contracts with these insurers at lower rates.
If the structures or operations of our joint ventures or strategic relationships are found to violate the law, our financial condition and consolidated results of operations could be materially adversely impacted.
We have entered into joint ventures with physicians and hospitals for the ownership and operation of our long-term acute care hospitals, home nursing agencies and hospices. Our relationships with physicians and hospitals are governed by the federal anti-kickback statute and similar state laws. These anti-kickback statutes prohibit the payment or receipt of anything of value in return for referrals of patients or services covered by governmental healthcare programs, such as Medicare. The Office of Inspector General of the Department of Health and Human Services has published numerous safe harbors that exempt qualifying arrangements from enforcement under the federal anti-kickback statute. We have sought to satisfy as many safe harbor requirements as possible in structuring these relationships. However, our joint ventures and other strategic relationships may not satisfy all elements of the safe harbor requirements. Our relationships with physicians are also governed by the federal Stark law and similar state laws, which restrict physicians from making referrals for particular healthcare services to entities with which the physicians or their families have a financial relationship. We also believe we have structured our physician relationships in a way that meets applicable exceptions under the federal Stark law and similar state physician referral laws. If any of our joint ventures or other strategic relationships were found to be in violation of federal or state anti-kickback or physician referral laws, we could be required to restructure them or refuse to accept referrals from the physicians or hospitals with which we have a relationship. We also could be required to repay to Medicare amounts we have received pursuant to any prohibited referrals, and we could suffer civil or criminal penalties, including the loss of our licenses to operate and our ability to participate in federal and state healthcare programs. If any of our joint ventures or other strategic relationships were subject to any of these penalties, our business could be damaged. In addition, our growth strategy is, in part, based on the continued development of new joint ventures and other strategic relationships with rural hospitals for the ownership and operation of home nursing agencies. If the structure of any of these relationships were found to violate federal or state anti-kickback statutes or physician referral laws, we may be unable to implement our growth strategy, which could have an adverse impact on our future net income and consolidated results of operations.
If we are required to either repurchase or sell a substantial portion of the equity interests in our joint ventures, our capital resources and financial condition could be materially adversely impacted.
Upon the occurrence of fundamental changes to the laws and regulations applicable to our joint ventures, or if a substantial number of our joint venture partners were to exercise the buy/sell provisions
12
Shortages in qualified nurses and other healthcare professionals could increase our operating costs significantly or constrain our ability to grow.
We rely on our ability to attract and retain qualified nurses and other healthcare professionals. The availability of qualified nurses nationwide has declined in recent years, and competition for these and other healthcare professionals has increased. Salary and benefit costs have risen accordingly. Our ability to attract and retain these nurses and other healthcare professionals depends on several factors, including our ability to provide desirable assignments and competitive benefits and salaries. We may not be able to attract and retain qualified nurses or other healthcare professionals in the future. In addition, the cost of attracting and retaining these professionals and providing them with attractive benefit packages may be higher than anticipated, which could cause our net income to decline. Moreover, if we are unable to attract and retain qualified professionals, the quality of services offered to our patients may decline or our ability to grow may be constrained.
The loss of certain senior management could have a material adverse effect on our operations and financial performance.
Our success depends upon the continued employment of certain members of our senior management, including our co-founder, President, Chief Executive Officer and Chairman, Keith G. Myers, our Senior Vice President, Chief Financial Officer, Treasurer and Director, R. Barr Brown, our Senior Vice President, Chief Operating Officer of Home-Based Services, Secretary and Director, John L. Indest, and our Senior Vice President and Chief Operating Officer of Facility-Based Services, Daryl J. Doise. We have entered into an employment agreement with each of these officers in an effort to further secure their employment. In addition, we have key employee life insurance policies, of which we are the beneficiary, in the amount of $2.0 million, $1.0 million and $500,000 on the lives of Messrs. Myers, Brown and Indest, respectively. The loss of service of any of these officers could have a material adverse effect on our operations and financial performance.
If we are subject to substantial malpractice or other similar claims, our net income could be materially adversely impacted.
The services we offer have an inherent risk of professional liability and related, substantial damage awards. We and the nurses and other healthcare professionals who provide services on our behalf may be the subject of medical malpractice claims. These nurses and other healthcare professionals could be considered our agents and, as a result, we could be held liable for their medical negligence. We cannot predict the effect that any claims of this nature, regardless of their ultimate outcome, could have on our business or reputation or on our ability to attract and retain patients and employees. We maintain malpractice liability insurance that provides primary coverage on a claims-made basis of $1.0 million per incident and $3.0 million in annual aggregate amounts. In addition, we maintain multiple layers of umbrella coverage in the aggregate amount of $5.0 million that provide excess coverage for professional malpractice and other liabilities. We are responsible for deductibles and amounts in excess of the limits of our coverage. Claims that could be made in the future in excess of the limits of such insurance, if successful, could materially adversely affect our ability to conduct business or manage our assets. In
13
The application of state certificate of need and permit of approval regulations and compliance with federal and state licensing requirements could substantially limit our ability to operate and grow our business.
Our ability to expand operations in a state will depend on our ability to obtain a state license to operate. States may have a limit on the number of licenses they issue. For example, as of December 31, 2004 we operated 45 home nursing agencies in Louisiana. Louisiana currently has a moratorium on the issuance of new home nursing agency licenses through July 1, 2008. We cannot predict whether this moratorium will be extended beyond this date or whether any other states in which we currently operate, or may wish to operate in the future, may adopt a similar moratorium.
In addition to the moratorium imposed by the State of Louisiana, nine of the states in which we currently operate, or plan to operate in the future, require healthcare providers to obtain prior approval, known as a certificate of need or a permit of approval, for the purchase, construction or expansion of healthcare facilities, to make certain capital expenditures or to make changes in services or bed capacity. Of the states in which we currently operate, or intend to operate in the future, Alabama, Arkansas, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee and West Virginia have certificate of need or permit of approval laws. In granting approval, these states consider the need in the service area for additional or expanded healthcare facilities or services. The failure to obtain any requested certificate of need, permit of approval or other license could impair our ability to operate or expand our business.
We face competition, including from competitors with greater resources, which may make it difficult for us to compete effectively as a provider of post-acute healthcare services.
We compete with local and regional home nursing and hospice companies, hospitals, and other businesses that provide post-acute healthcare services, some of which are large established companies that have significantly greater resources than we do. Our primary competition comes from local operators in each of our markets. We expect our competitors to develop new strategic relationships with providers, referral sources, and payors, which could result in increased competition. The introduction by our competitors of new and enhanced service offerings, in combination with industry consolidation and the development of strategic relationships, could cause a decline in net service revenue, loss of market acceptance of our services, or make our services less attractive. Future increases in competition from existing competitors or new entrants may limit our ability to maintain or increase our market share. We may not be able to compete successfully against current or future competitors, and competitive pressures may have a material adverse impact on our business, financial condition, or consolidated results of operations.
Our limited operating history as an owner and operator of long-term acute care hospitals could adversely affect our ability to operate them profitably.
We opened our first long-term acute care hospital in 2001 and today operate four long-term acute care hospitals with seven locations. Due to our limited history as an operator of long-term acute care hospitals, we may be unable to profitably manage our existing long-term acute care hospitals or compete with other, more experienced providers in the markets in which we serve. If we are unable to profitably operate our long-term acute care hospitals, our net service revenue and net income may decline.
If we are unable to protect the proprietary nature of our software systems and methodologies, our business and financial condition could be harmed.
We have developed a proprietary software system, which we refer to as our Service Value Point system, that allows us to collect assessment data, establish treatment plans, monitor patient treatment, and evaluate our clinical and financial performance. In addition, we rely on other proprietary methodologies or information to which others may obtain access or independently develop. To protect our proprietary
14
Failure of, or problems with, our critical software or information systems could harm our business and operating results.
In addition to our Service Value Point system, we also depend on other non-proprietary third-party accounting and billing software systems. We have recently converted to a third-party software information system for our long-term acute care hospitals. Additionally, we are in the process of consolidating our various home nursing agency databases into an enterprise-wide system, which we expect to fully implement by the second quarter of 2005. Problems with, or the failure of, these systems could negatively impact our clinical performance and our management and reporting capabilities. Any such problems or failure could materially and adversely affect our operations and reputation, result in significant costs to us, cause delays in our ability to bill Medicare or other payors for our services, or impair our ability to provide our services in the future. The costs incurred in correcting any errors or problems with regard to our proprietary and non-proprietary software may be substantial and could adversely affect our net income.
Our information systems are networked via public network infrastructure and standards based encryption tools that meet regulatory requirements for transmission of protected healthcare information over such networks. However, threats from computer viruses, instability of the public network on which our data transit relies, or other instances that might render those networks unstable or disabled would create operational difficulties for us, including the ability to effectively transmit claims and maintain efficient clinical oversight of our patients as well as the disruption of revenue reporting and billing and collections management, which could adversely affect our business or operations.
Future acquisitions may be unsuccessful and could expose us to unforeseen liabilities.
Our growth strategy involves the acquisition of home nursing agencies in rural markets. These acquisitions involve significant risks and uncertainties, including difficulties integrating acquired personnel and other corporate cultures into our business, the potential loss of key employees or patients of acquired agencies, and the assumption of liabilities and exposure to unforeseen liabilities of acquired agencies. We may not be able to fully integrate the operations of the acquired businesses with our current business structure in an efficient and cost-effective manner. The failure to effectively integrate any of these businesses could have a material adverse effect on our operations.
We generally structure our acquisitions as asset purchase transactions in which we expressly state that we are not assuming any pre-existing liabilities of the seller and obtain indemnification rights from the previous owners for acts or omissions arising prior to the date of such acquisitions. However, the allocation of liability arising from such acts or omissions between the parties could involve the expenditure of a significant amount of time, manpower and capital. Further, the former owners of the agencies and facilities we acquire may not have the financial resources necessary to satisfy our indemnification claims relating to pre-existing liabilities. If we were unsuccessful in a claim for indemnification from a seller, the liability imposed could materially adversely affect our operations.
Our acquisition and internal development activity may impose strains on our existing resources.
We have grown significantly over the past three years. As we continue to expand our markets, our growth could strain our resources, including management, information and accounting systems, regulatory compliance, logistics, and other internal controls. Our resources may not keep pace with our anticipated growth. If we do not manage our expected growth effectively, our future prospects could be affected adversely.
15
We may face increased competition for attractive acquisition and joint venture candidates.
We intend to continue growing through the acquisition of additional home nursing agencies and the formation of joint ventures and other strategic relationships with rural hospitals for the operation of home nursing agencies. We face competition for acquisition and joint venture candidates, which may limit the number of acquisition and joint venture opportunities available to us or lead to the payment of higher prices for our acquisitions and joint ventures. Recently, we have observed an increase in the acquisition prices for select home nursing agencies. We cannot assure you that we will be able to identify suitable acquisition or joint venture opportunities in the future or that any such opportunities, if identified, will be consummated on favorable terms, if at all. Without successful acquisitions or joint ventures, our future growth rate could decline. In addition, we cannot assure you that any future acquisitions or joint ventures, if consummated, will result in further growth.
We may be unable to secure the additional capital necessary to implement our growth strategy.
As of September 30, 2004, we had cash and cash equivalents of $2.8 million. Based on our current plan of operations, including acquisitions, we believe this amount, when combined with the proceeds of this offering and a revolving line of credit of approximately $25.0 million and a term loan of approximately $5.0 million, available under our new senior secured credit facility, will be sufficient to fund our growth strategy and to meet our currently anticipated operating expenses, capital expenditures and debt service obligations for at least the next 12 months. If our future net service revenue or cash flow from operations is less than we currently anticipate, we may not have sufficient funds to implement our growth strategy. Further, we cannot readily predict the timing, size, and success of our acquisition and internal development efforts and the associated capital commitments. If we do not have sufficient cash resources, our growth could be limited unless we are able to obtain additional equity or debt financing.
We are a holding company with no operations of our own.
We are a holding company with no operations of our own. Accordingly, our ability to service our debt and pay dividends, if any, is dependent upon the earnings from the business conducted by our subsidiaries. The distributions of those earnings or advances or other distributions of funds by these subsidiaries to us are contingent upon the subsidiaries earnings and are subject to various business considerations. In addition, distributions by subsidiaries could be subject to statutory restrictions, including state laws requiring that the subsidiary be solvent, or contractual restrictions. If our subsidiaries are unable to make sufficient distributions or advances to us, we may not have the cash resources necessary to service our debt or pay dividends.
Risks Related to this Offering
Our executive officers and directors and their affiliates hold a substantial portion of our stock and could exercise significant influence over matters requiring stockholder approval, regardless of the wishes of other stockholders.
Our executive officers and directors, and individuals or entities affiliated with them, will beneficially own an aggregate of approximately 44.5% of our outstanding common stock immediately following this offering or 42.2% if the underwriters exercise their over-allotment option in full. The interests of these stockholders may differ from your interests. If they were to act together, these stockholders would be able to significantly influence all matters that our stockholders vote upon, including the election of directors, business combinations, the amendment of our certificate of incorporation and other significant corporate actions.
16
Certain provisions of our charter, bylaws and Delaware law may delay or prevent a change in control of our company.
Delaware law and our corporate documents contain provisions that may enable our board of directors to resist a change in control of our company. These provisions include:
| a staggered board of directors; | |
| limitations on persons authorized to call a special meeting of stockholders; | |
| the authorization of undesignated preferred stock, the terms of which may be established and shares of which may be issued without stockholder approval; and | |
| advance notice procedures required for stockholders to nominate candidates for election as directors or to bring matters before an annual meeting of stockholders. |
These anti-takeover defenses could discourage, delay or prevent a transaction involving a change in control of our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire.
If a significant number of shares of our common stock are sold into the market following the offering, the market value of our common stock could significantly decline, even if our business is doing well.
Subject to certain exceptions and extensions described in Underwriting, we and all of our directors, executive officers and stockholders have agreed not to offer, sell or agree to sell, directly or indirectly, any shares of common stock for a period of 180 days from the date of this prospectus. If our existing stockholders sell, or the market perceives that they intend to sell, substantial amounts of our common stock in the public market after the 180 day contractual lock-up period and other legal restrictions on resale discussed in this prospectus lapse, the trading price of our common stock could decline below the initial public offering price.
Our stock price may be volatile and your investment in our common stock could suffer a decline in value.
The price at which our common stock will trade may be volatile. The stock market has from time to time experienced significant price and volume fluctuations that have affected the market prices of securities, particularly securities of healthcare companies. The market price of our common stock may be influenced by many factors, including:
| our operating and financial performance; | |
| variances in our quarterly financial results compared to research analyst expectations; | |
| the depth and liquidity of the market for our common stock; | |
| future sales of our common stock or the perception that sales could occur; | |
| investor perception of our business, acquisitions and our prospects; | |
| developments relating to litigation or governmental investigations; | |
| changes or proposed changes in healthcare laws or regulations or enforcement of these laws and regulations, or announcements relating to these matters; or | |
| general economic and stock market conditions. |
In addition, the stock market, and the Nasdaq National Market, or Nasdaq, in particular, has experienced price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of healthcare provider companies. These broad market and industry factors may materially reduce the market price of our common stock, regardless of our operating performance. In the past, securities class-action litigation has often been brought against companies following periods of volatility in the market price of their respective securities. We may become involved in this type of litigation in the
17
Purchasers in this offering will experience immediate and substantial dilution.
We expect the initial public offering price of our shares to be substantially higher than the net tangible book value per share of our outstanding common stock. Accordingly, investors purchasing shares of common stock in this offering will pay a per share price that substantially exceeds the per share value of our tangible assets minus our liabilities. Such investors will also contribute 99.8% of the total amount invested in us, but will own only 24.7% of the shares of common stock outstanding, assuming an initial public offering price of $13.00 per share. The issuance of shares of our common stock upon completion of this offering in connection with the conversion of our outstanding KEEP Units and the conversion of certain equity interests by our joint venture partners will result in further dilution to our investors.
Our senior management will have broad discretion to spend a large portion of the net proceeds of this offering and may do so in ways with which you do not agree.
We estimate the net proceeds to us from this offering to be approximately $35.2 million, after deducting underwriting discounts and commissions and estimated offering expenses. We have not determined specific uses for a large portion of these net proceeds. Our board of directors and senior management will have broad discretion over the use and investment of the net proceeds of this offering and they may apply these proceeds to uses that you may not consider desirable. The failure of management to apply these funds effectively could harm our business.
We currently do not intend to pay dividends on our common stock and, consequently, your only opportunity to achieve a return on your investment is if the price of our common stock appreciates.
We do not plan to declare dividends on shares of our common stock in the foreseeable future. Further, we expect our new senior secured credit facility to impose limits on our ability to pay dividends. Consequently, your only opportunity to achieve a return on your investment in our common stock will be if the market price of our common stock appreciates and you sell your shares at a profit. There is no guarantee that the price of our common stock that will prevail in the market after this offering will ever exceed the price that you pay.
We will incur increased costs as a result of being a public company.
As a public company, we will incur significant legal, accounting and other expenses that we did not incur as a private company. We will incur costs associated with our public company reporting requirements as well as costs associated with corporate governance requirements, including requirements under the Sarbanes-Oxley Act of 2002, or Sarbanes-Oxley, and the rules of the Securities and Exchange Commission and Nasdaq. We expect these requirements to increase our legal and financial compliance costs and to make some activities more time-consuming and costly. For example, we expect to incur significant costs in connection with the assessment of our internal controls. We also expect these new rules and regulations may make it more expensive for us to obtain director and officer liability insurance. We are currently evaluating and monitoring developments with respect to these new rules, and we cannot predict or estimate the amount of additional costs we may incur or the timing of such costs.
18
If we fail to complete the evaluation of our internal control over financial reporting in a timely manner, or if we identify deficiencies in our internal control over financial reporting, our business and our stock price could be adversely affected.
Beginning with our annual report for the year ended December 31, 2005, we will be required to report on the effectiveness of our internal control over financial reporting as required by Section 404 of Sarbanes-Oxley. Under Section 404, we will be required to assess the effectiveness of our internal control over financial reporting and report our conclusion in our annual report. Our auditor is also required to report its conclusion regarding the effectiveness of our internal control over financial reporting. The existence of one or more material weaknesses would require us and our auditor to conclude that internal control over financial reporting is not effective. We have prepared an internal plan of action for compliance, which includes a timeline and schedule of activities. Our efforts to comply with Section 404 and related regulations has required, and continues to require, the commitment of significant financial and managerial resources. If we fail to complete this evaluation in a timely manner, or if there are identified deficiencies in our internal control over financial reporting, we could be subject to regulatory scrutiny and a loss of public confidence in our financial reporting, which could have an adverse effect on our business and our stock price.
19
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus contains forward-looking statements. Forward-looking statements relate to expectations, beliefs, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts or that necessarily depend upon future events. In some cases, you can identify forward-looking statements by terms such as may, will, should, could, would, expect, plan, anticipate, believe, estimate, project, predict, potential, and similar expressions. Specifically, this prospectus contains, among others, forward-looking statements about:
| our expectations regarding financial condition or consolidated results of operations for periods after September 30, 2004; | |
| our future sources of and need for liquidity and capital resources; | |
| our expectations regarding the size and growth of the market for our services; | |
| our business strategies and our ability to grow our business; | |
| the implementation or interpretation of current or future regulations and legislation; | |
| the reimbursement levels of third-party payors; and | |
| our discussion of our critical accounting policies. |
These forward-looking statements reflect our current views about future events, are based on assumptions and are subject to known and unknown risks and uncertainties. Many important factors, some of which are discussed elsewhere in this prospectus, could cause actual results or achievements to differ materially from any future results or achievements expressed or implied by forward-looking statements. Many of the factors that will determine future events or achievements are beyond our ability to control or predict. Important factors that could cause actual results or achievements to differ materially from current expectations reflected in these forward-looking statements include, among others, the factors discussed under Risk Factors.
You should read this prospectus and the documents filed as exhibits to the registration statement of which this prospectus is a part, completely and with the understanding that our actual future results may be materially different from what we expect.
The forward-looking statements contained in this prospectus reflect our views and assumptions only as of the date of this prospectus. Except as required by law, we assume no responsibility for updating any forward-looking statements. These forward looking statements are excluded from the safe harbor protection provided by the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, or the Securities Act.
We qualify all of our forward-looking statements by these cautionary statements.
20
USE OF PROCEEDS
We estimate that the net proceeds to us from the sale of the 3,100,000 shares of common stock that we are offering will be approximately $35.2 million, based on an assumed initial public offering price of $13.00 per share and after deducting underwriting discounts and commissions and estimated offering expenses. We will not receive any proceeds from the sale of shares by the selling stockholders.
We intend to use approximately $13.7 million of the net proceeds from this offering to repay indebtedness under a new senior secured credit facility, which we expect to enter into prior to the completion of this offering. Under the terms of this new senior secured credit facility, we expect to have a revolving line of credit of approximately $25.0 million, as well as a term loan of approximately $5.0 million. The $13.7 million of indebtedness will be incurred prior to the completion of this offering when we borrow the following amounts under our new senior secured credit facility: (1) $12.0 million to repay in full our existing credit facility, bearing interest at prime plus 2.0% and due April 30, 2006, with Residential Funding Corporation; (2) $1.0 million to repay our outstanding obligations under our loan agreement, bearing interest at 12.0% and due July 1, 2006, with The Catalyst Fund, Ltd. and Southwest/Catalyst Capital, Ltd.; (3) $380,000 to repay our obligations under a subordinated promissory note bearing interest at 15.5% and due February 1, 2006, which is collateralized by shares of our common stock that were repurchased by us in consideration for the promissory note; and (4) approximately $300,000 to repay indebtedness assumed by us in connection with acquisitions completed by us in 2004. Following this offering and the application of the net proceeds, we do not expect to have any indebtedness outstanding under our new senior secured credit facility. During 2004 we borrowed funds under our credit facility with Residential Funding Corporation for acquisitions and general working capital purposes.
We also intend to use approximately $3.0 million of the net proceeds to satisfy our cash obligations to one of our joint venture partners with respect to its right to convert its equity interests in the joint venture into shares of our common stock and cash upon the consummation of this offering.
The remaining proceeds of approximately $18.5 million will be used for general corporate purposes, including working capital, payment of other indebtedness, sales and marketing and capital expenditures. Further, we may be required to use approximately $500,000 of the remaining proceeds to redeem joint venture interests held by minority owners in one of our joint ventures who, at their election, have a contractual right to require us to redeem their joint venture interests. We may also use a portion of the net proceeds from this offering to pursue strategic acquisitions of additional home nursing agencies or larger home nursing operations that would allow us to acquire market share in new and existing markets. We currently have no agreements or commitments for any such acquisitions or joint venture investments. The amounts that we actually expend for these specified purposes may vary significantly depending on a number of factors, including changes in our growth strategy, the amount of our future net service revenue and expenses, and our future cash flow. As a result, we will retain broad discretion in the allocation of the net proceeds of this offering and may spend such proceeds for any purpose, including purposes not presently contemplated.
Until we use the net proceeds of this offering for the above purposes, we intend to invest the funds in short-term, investment grade, interest-bearing securities. We cannot predict whether the proceeds invested will yield a favorable return.
DIVIDEND POLICY
For the years ended December 31, 2002, 2003 and 2004, we distributed $153,000, $184,000 and $440,000, respectively, to our stockholders in the form of cash dividends. Following this offering, we do not anticipate paying any cash dividends in the foreseeable future. We currently intend to retain future earnings, if any, to support the development and growth of our business. Payment of future dividends, if any, will be at the discretion of our board of directors and subject to any requirements under our then existing credit facility.
21
CAPITALIZATION
The following table sets forth our capitalization as of September 30, 2004, on an actual basis and on an as adjusted basis to reflect:
| our sale of 3,100,000 million shares of common stock in this offering at an assumed initial public offering price of $13.00 per share; | |
| our application of the estimated net proceeds therefrom in the manner described under Use of Proceeds; | |
| the issuance of 518,036 aggregate shares of our common stock to two of our joint venture partners, who are converting their joint venture equity interests into shares of our common stock in connection with this offering; | |
| the issuance of 481,680 shares of our common stock upon conversion of outstanding KEEP Units, which will occur automatically upon the completion of this offering; and | |
| the issuance of 7,000 shares of vested restricted common stock upon the completion of this offering. |
You should read this table together with the information under Use of Proceeds, Selected Consolidated Financial Data, Managements Discussion and Analysis of Financial Condition and Consolidated Results of Operations and Description of Our Capital Stock, and with our consolidated financial statements and related notes included elsewhere in this prospectus.
As of September 30, 2004 | ||||||||||
|
||||||||||
Actual | As Adjusted | |||||||||
|
|
|||||||||
(in thousands) | ||||||||||
Cash and cash equivalents
|
$ | 2,834 | $ | 21,333 | ||||||
|
|
|||||||||
Total debt, including current portion:
|
||||||||||
Lines of credit
|
$ | 139 | $ | | ||||||
Revolving debt arrangement
|
12,010 | | ||||||||
Capital lease obligations
|
1,537 | 1,537 | ||||||||
Long-term debt
|
552 | | ||||||||
Long-term debt held by related party
|
994 | | ||||||||
|
|
|||||||||
Total debt
|
$ | 15,232 | $ | 1,537 | ||||||
Stockholders equity:
|
||||||||||
Common stock: $0.01 par value; 40,000,000 shares
authorized; 15,000,000 shares issued; 12,085,150
outstanding; 16,191,867 outstanding as adjusted
|
121 | 162 | ||||||||
Treasury stock: 2,914,850 shares at cost
|
(2,242 | ) | (2,242 | ) | ||||||
Additional paid-in capital
|
4,421 | 51,161 | ||||||||
Retained earnings(1)
|
11,579 | 7,581 | ||||||||
|
|
|||||||||
Total stockholders equity
|
13,879 | 56,662 | ||||||||
|
|
|||||||||
Total capitalization
|
$ | 29,111 | $ | 58,199 | ||||||
|
|
The table above excludes 1,000,000 shares of our common stock available for future issuance under our equity incentive plans, of which options to acquire 11,500 shares have been granted, and 14,000 unvested shares of restricted common stock.
(1) | The reduction in retained earnings reflected in the September 30, 2004 As Adjusted column results from the equity-based compensation charges relating to the outstanding KEEP Units under our KEEP Plan and the vested restricted common stock that will be issued upon completion of this offering. We will incur a charge of $531,000 in the quarter ended December 31, 2004 relating to the KEEP Units. Upon the completion of this offering we will also incur a final, non-recurring equity-based compensation charge relating to the KEEP Units, in the amount of approximately $3.4 million. Additionally, upon the completion of this offering we will incur a charge of $91,000 relating to the vested restricted common stock. |
22
DILUTION
If you invest in our common stock, your interest will be diluted to the extent of the difference between the public offering price per share of our common stock and the adjusted net tangible book value per share of our common stock after this offering.
The net tangible book value of our common stock as of September 30, 2004 was $9.0 million, or $0.75 per share. Net tangible book value per share represents our total tangible assets less total liabilities, divided by the number of shares of common stock outstanding as of September 30, 2004.
Our as adjusted net tangible book value as of September 30, 2004 would have been $41.2 million, or $2.61 per share, after giving effect to the following: (1) the sale by us of 3,100,000 shares of our common stock in this offering, at an assumed initial public offering price of $13.00 per share; (2) the application of the estimated net proceeds therefrom in the manner described under Use of Proceeds; (3) the issuance of 518,036 aggregate shares of our common stock to two of our joint venture partners in connection with the conversion of their joint venture interests into shares of our common stock; (4) the issuance of 481,680 shares of our common stock upon conversion of outstanding KEEP Units, which will occur automatically upon the completion of this offering; and (5) the issuance of 7,000 shares of vested restricted common stock upon completion of this offering. This represents an immediate increase in net tangible book value of $1.86 per share to our existing stockholders and an immediate dilution of $10.39 per share to new investors purchasing shares of our common stock in this offering. The following table illustrates this per share dilution:
Assumed initial public offering price per share
|
$ | 13.00 | |||||||
Net tangible book value per share as of
September 30, 2004
|
0.75 | ||||||||
Increase in net tangible book value per share
attributable to this offering
|
1.86 | ||||||||
Adjusted net tangible book value per share after
this offering
|
2.61 | ||||||||
|
|||||||||
Dilution per share to new investors
|
$ | 10.39 |
The following table sets forth, on an as adjusted
basis, as of September 30, 2004, the differences between
the number of shares of common stock purchased from us, the
total consideration paid, and the average price per share paid
by existing stockholders and new investors purchasing shares of
our common stock in this offering, before deducting underwriting
discounts and commissions and estimated expenses at an assumed
initial public offering price of $13.00 per share.
Shares Purchased
Total Consideration
Average Price
Number
Percent
Amount
Percent
Per Share
13,091,865
80.9%
$
75,000
0.2
%
$
0.01
3,100,000
19.1%
40,300,000
99.8
%
13.00
16,191,865
100.0%
$
40,375,000
100.0
%
(1) | For purposes of this table, existing stockholders includes our shares of common stock outstanding as of September 30, 2004 plus 518,036 aggregate shares of common stock issuable to two of our joint venture partners upon completion of this offering, 481,680 shares issuable upon conversion of our outstanding KEEP Units and the 7,000 shares of vested restricted common stock issuable upon completion of this offering. |
Sales by the selling stockholders in this offering will reduce the number of shares held by our existing stockholders to 12,191,867, or 75.3% (or 11,591,865, or 71.6%, if the underwriters over-allotment option is exercised in full), of the total number of shares outstanding, and will increase the number of shares held by new investors to 4,000,000 shares, or 24.7% (or 4,600,000, or 28.4%, if the underwriters over-allotment option is exercised in full), of the total number of outstanding shares of common stock after the offering.
23
SELECTED CONSOLIDATED FINANCIAL AND OTHER DATA
The following table sets forth our selected consolidated financial data. We derived the selected consolidated financial data as of December 31, 2002 and 2003 and for the each of the three years in the period ended December 31, 2003 from our audited consolidated financial statements and related notes thereto included elsewhere in this prospectus. We derived the selected consolidated financial data as of December 31, 2001 from our audited consolidated financial statements and related notes which are not included in this prospectus. We derived the selected consolidated financial data as of and for the years ended December 31, 1999 and 2000 from our unaudited consolidated financial statements and related notes, which are not included in this prospectus. We derived our selected consolidated financial data as of and for the nine months ended September 30, 2003 and 2004 from our unaudited interim consolidated financial statements and related notes included elsewhere in this prospectus. We believe the unaudited consolidated financial data has been prepared on the same basis as our audited consolidated financial data and includes all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the results for the unaudited periods. The results for any interim period are not necessarily indicative of the results that may be expected for a full fiscal year. The selected consolidated financial data set forth below is not necessarily indicative of the results of future operations and should be read in conjunction with Managements Discussion and Analysis of Financial Condition and Consolidated Results of Operations, and the consolidated financial statements and related notes included elsewhere in this prospectus.
Nine Months Ended | |||||||||||||||||||||||||||||
Year Ended December 31, | September 30, | ||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||
1999 | 2000 | 2001 | 2002 | 2003 | 2003 | 2004 | |||||||||||||||||||||||
|
|
|
|
|
|
|
|||||||||||||||||||||||
(unaudited) | (unaudited) | ||||||||||||||||||||||||||||
(in thousands, except per share data) | |||||||||||||||||||||||||||||
Consolidated Statements of Income
Data:
|
|||||||||||||||||||||||||||||
Net service revenue
|
$ | 10,362 | $ | 16,262 | $ | 28,208 | $ | 48,950 | $ | 72,365 | $ | 49,315 | $ | 87,958 | |||||||||||||||
Cost of service revenue
|
7,532 | 11,549 | 13,466 | 23,438 | 37,146 | 24,789 | 45,415 | ||||||||||||||||||||||
|
|
|
|
|
|
|
|||||||||||||||||||||||
Gross margin
|
2,830 | 4,713 | 14,742 | 25,512 | 35,219 | 24,526 | 42,543 | ||||||||||||||||||||||
General and administrative expenses
|
2,642 | 3,975 | 11,011 | 16,430 | 24,761 | 17,205 | 26,433 | ||||||||||||||||||||||
Impairment loss
|
| | | | 31 | | | ||||||||||||||||||||||
Equity-based compensation expense(1)(2)
|
| | 111 | 124 | 864 | 156 | 1,257 | ||||||||||||||||||||||
|
|
|
|
|
|
|
|||||||||||||||||||||||
Operating income
|
188 | 738 | 3,620 | 8,958 | 9,563 | 7,165 | 14,853 | ||||||||||||||||||||||
Interest expense
|
121 | 144 | 411 | 1,135 | 1,226 | 806 | 1,048 | ||||||||||||||||||||||
Non-operating (income) loss, including gain on
sales of assets
|
| | (325 | ) | (124 | ) | (106 | ) | (52 | ) | 109 | ||||||||||||||||||
|
|
|
|
|
|
|
|||||||||||||||||||||||
Income from continuing operations before income
taxes and minority interest and cooperative endeavor allocations
|
46 | 323 | 3,534 | 7,947 | 8,443 | 6,411 | 13,696 | ||||||||||||||||||||||
Income tax expense
|
| 149 | 1,151 | 2,139 | 2,320 | 1,694 | 4,173 | ||||||||||||||||||||||
Minority interest and cooperative endeavor
allocations
|
21 | 271 | 1,355 | 2,699 | 2,837 | 2,113 | 3,066 | ||||||||||||||||||||||
|
|
|
|
|
|
|
|||||||||||||||||||||||
Income from continuing operations
|
46 | 174 | 1,028 | 3,109 | 3,286 | 2,604 | 6,457 | ||||||||||||||||||||||
Loss from discontinued operations, net
|
| | (241 | ) | (267 | ) | (443 | ) | (200 | ) | (18 | ) | |||||||||||||||||
Gain on sale of discontinued operations, net
|
| | | | | | 308 | ||||||||||||||||||||||
|
|
|
|
|
|
|
|||||||||||||||||||||||
Net income
|
$ | 46 | $ | 174 | $ | 787 | $ | 2,842 | $ | 2,843 | $ | 2,404 | $ | 6,747 | |||||||||||||||
|
|
|
|
|
|
|
24
Nine Months Ended | |||||||||||||||||||||||||||||
Year Ended December 31, | September 30, | ||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||
1999 | 2000 | 2001 | 2002 | 2003 | 2003 | 2004 | |||||||||||||||||||||||
|
|
|
|
|
|
|
|||||||||||||||||||||||
(unaudited) | (unaudited) | ||||||||||||||||||||||||||||
(in thousands, except per share data) | |||||||||||||||||||||||||||||
Earnings per share basic(3):
|
|||||||||||||||||||||||||||||
Income from continuing operations
|
$ | 0.00 | $ | 0.01 | $ | 0.09 | $ | 0.26 | $ | 0.27 | $ | 0.22 | $ | 0.53 | |||||||||||||||
Loss from discontinued operations, net
|
| | (0.02 | ) | (0.02 | ) | (0.03 | ) | (0.02 | ) | 0.00 | ||||||||||||||||||
Gain on sale of discontinued operations, net
|
| | | | | | 0.03 | ||||||||||||||||||||||
|
|
|
|
|
|
|
|||||||||||||||||||||||
Net income
|
$ | 0.00 | $ | 0.01 | $ | 0.07 | $ | 0.24 | $ | 0.24 | $ | 0.20 | $ | 0.56 | |||||||||||||||
|
|
|
|
|
|
|
|||||||||||||||||||||||
Earnings per share diluted(3):
|
|||||||||||||||||||||||||||||
Income from continuing operations
|
$ | 0.00 | $ | 0.01 | $ | 0.08 | $ | 0.26 | $ | 0.26 | $ | 0.22 | $ | 0.53 | |||||||||||||||
Loss from discontinued operations, net
|
| | (0.02 | ) | (0.02 | ) | (0.03 | ) | (0.02 | ) | | ||||||||||||||||||
Gain on sale of discontinued operations, net
|
| | | | | | 0.02 | ||||||||||||||||||||||
|
|
|
|
|
|
|
|||||||||||||||||||||||
Net income
|
$ | 0.00 | $ | 0.01 | $ | 0.06 | $ | 0.24 | $ | 0.23 | $ | 0.20 | $ | 0.55 | |||||||||||||||
|
|
|
|
|
|
|
|||||||||||||||||||||||
Weighted average shares outstanding(3)
|
|||||||||||||||||||||||||||||
Basic
|
15,000,000 | 15,000,000 | 11,756,419 | 11,926,222 | 12,085,150 | 12,085,150 | 12,085,150 | ||||||||||||||||||||||
Diluted
|
15,000,000 | 15,000,000 | 12,241,908 | 12,084,534 | 12,114,671 | 12,100,682 | 12,201,531 | ||||||||||||||||||||||
Cash dividends declared per common share
|
| | .009 | .013 | .016 | .011 | .031 | ||||||||||||||||||||||
Other Data:
|
|||||||||||||||||||||||||||||
EBITDA(4)
|
$ | 173 | $ | 483 | $ | 1,983 | $ | 6,048 | $ | 6,782 | $ | 5,023 | $ | 12,456 |
As of | ||||||||||||||||||||||||
As of December 31, | September 30, | |||||||||||||||||||||||
|
|
|||||||||||||||||||||||
1999 | 2000 | 2001 | 2002 | 2003 | 2004 | |||||||||||||||||||
|
|
|
|
|
|
|||||||||||||||||||
(unaudited) | ||||||||||||||||||||||||
(unaudited) | ||||||||||||||||||||||||
(in thousands) | ||||||||||||||||||||||||
Consolidated Balance Sheet Data:
|
||||||||||||||||||||||||
Cash and cash equivalents
|
$ | 295 | $ | 447 | $ | 132 | $ | 3,179 | $ | 1,725 | $ | 2,834 | ||||||||||||
Total assets
|
1,262 | 4,636 | 10,033 | 21,485 | 27,915 | 41,093 | ||||||||||||||||||
Total debt
|
1,384 | 1,302 | 6.162 | 10,542 | 12,277 | 15,232 | ||||||||||||||||||
Total stockholders equity (deficit)
|
(690 | ) | 769 | (403 | ) | 3,593 | 6,909 | 13,879 |
(1) | Equity-based compensation expense is allocated as follows: |
Nine Months | ||||||||||||||||||||||||||||
Ended | ||||||||||||||||||||||||||||
Year Ended December 31, | September 30, | |||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||
1999 | 2000 | 2001 | 2002 | 2003 | 2003 | 2004 | ||||||||||||||||||||||
|
|
|
|
|
|
|
||||||||||||||||||||||
(unaudited) | (unaudited) | |||||||||||||||||||||||||||
(in thousands) | ||||||||||||||||||||||||||||
Cost of service revenue
|
$ | | $ | | $ | | $ | | $ | 5 | $ | | $ | 31 | ||||||||||||||
General and administrative expenses
|
| | 111 | 124 | 859 | 156 | 1,226 | |||||||||||||||||||||
|
|
|
|
|
|
|
||||||||||||||||||||||
Total equity-based compensation expense
|
$ | | $ | | $ | 111 | $ | 124 | $ | 864 | $ | 156 | $ | 1,257 | ||||||||||||||
|
|
|
|
|
|
|
(2) | We will incur an equity-based compensation charge in respect of the quarter ended December 31, 2004 of $531,000. Assuming an initial public offering price of $13.00 per share, upon the completion of this offering we will also incur a final, non-recurring equity-based compensation charge relating to the outstanding KEEP Units under our KEEP Plan in the amount of $3.4 million, recorded in the reporting period the offering is completed. |
(3) | All references to shares and per share amounts have been retroactively restated to reflect our incorporation in the State of Delaware and to give effect to a three-for-two stock split with respect to our common stock as if such events occurred as of the beginning of the earliest period presented. See Note 1 to our consolidated financial statements. |
25
(4) | EBITDA represents our portion of EBITDA, excluding the minority interest and cooperative endeavor allocations of third parties. EBITDA is not a substitute for operating income, net income, or cash flow from operating activities, as determined in accordance with GAAP, as measures of liquidity. See Non-GAAP Financial Measures. For each of the periods indicated, the following table sets forth a reconciliation of EBITDA to net cash provided by (used in) operating activities to net income. The following reconciliation includes amounts classified as discontinued operations in our consolidated financial statements. |
Nine Months | ||||||||||||||||||||||||||||||
Ended | ||||||||||||||||||||||||||||||
Year Ended December 31, | September 30, | |||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||
1999 | 2000 | 2001 | 2002 | 2003 | 2003 | 2004 | ||||||||||||||||||||||||
|
|
|
|
|
|
|
||||||||||||||||||||||||
(unaudited) | (unaudited) | |||||||||||||||||||||||||||||
(in thousands) | ||||||||||||||||||||||||||||||
EBITDA
|
$ | 173 | $ | 483 | $ | 1,983 | $ | 6,048 | $ | 6,782 | $ | 5,023 | $ | 12,456 | ||||||||||||||||
Depreciation and amortization expense
|
6 | 16 | 98 | 230 | 441 | 283 | 688 | |||||||||||||||||||||||
Impairment loss
|
| | | | 351 | | | |||||||||||||||||||||||
Interest expense
|
121 | 144 | 411 | 1,153 | 1,246 | 823 | 1,058 | |||||||||||||||||||||||
Income tax expense
|
| 149 | 1,012 | 1,956 | 2,007 | 1,565 | 4,361 | |||||||||||||||||||||||
Non-operating income, including gain on sales of
assets
|
| | (325 | ) | (133 | ) | (106 | ) | (52 | ) | (398 | ) | ||||||||||||||||||
|
|
|
|
|
|
|
||||||||||||||||||||||||
Net income
|
46 | 174 | 787 | 2,842 | 2,843 | 2,404 | 6,747 | |||||||||||||||||||||||
|
|
|
|
|
|
|
||||||||||||||||||||||||
Depreciation
|
6 | 16 | 98 | 230 | 441 | 283 | 688 | |||||||||||||||||||||||
Provision for bad debts
|
66 | 134 | 484 | 461 | 604 | 512 | 1,186 | |||||||||||||||||||||||
Impairment loss
|
| | | | 351 | | | |||||||||||||||||||||||
Change in fair value of outstanding warrants
|
| | 963 | | | | | |||||||||||||||||||||||
Equity-based compensation expense
|
| | 111 | 124 | 864 | 156 | 1,257 | |||||||||||||||||||||||
Minority interest in earnings of subsidiaries
|
| | | | 241 | | 2,651 | |||||||||||||||||||||||
Deferred income taxes
|
| | (168 | ) | 157 | 310 | | (232 | ) | |||||||||||||||||||||
Gain on sales of assets
|
| | (89 | ) | | (10 | ) | (2 | ) | (365 | ) | |||||||||||||||||||
Changes in operating assets and liabilities, net
of acquisitions:
|
||||||||||||||||||||||||||||||
Receivables
|
(132 | ) | (2,992 | ) | (4,574 | ) | (7,086 | ) | (4,476 | ) | 728 | (7,656 | ) | |||||||||||||||||
Prepaid expenses, other assets
|
(211 | ) | (481 | ) | (299 | ) | (330 | ) | (221 | ) | (103 | ) | (283 | ) | ||||||||||||||||
Accounts payable and accrued expenses
|
204 | 1,552 | 707 | 3,686 | 534 | (1,159 | ) | 2,212 | ||||||||||||||||||||||
Net amounts due under cooperative endeavor
agreements
|
| 191 | 297 | (168 | ) | 4 | 769 | (457 | ) | |||||||||||||||||||||
Net amounts due governmental entities
|
| 90 | (3 | ) | 258 | (655 | ) | (83 | ) | (104 | ) | |||||||||||||||||||
|
|
|
|
|
|
|
||||||||||||||||||||||||
Net cash provided by (used in) operating
activities
|
$ | (21 | ) | $ | (1,316 | ) | $ | (1,686 | ) | $ | 174 | $ | 830 | $ | 3,145 | $ | 5,644 | |||||||||||||
|
|
|
|
|
|
|
26
NON-GAAP FINANCIAL MEASURES
EBITDA is a measure of our ability to meet our future debt service, capital expenditures and working capital requirements that is not required by, or presented in accordance with, GAAP. EBITDA should not be considered an alternative to operating income, net income, or any other performance measures derived in accordance with GAAP or as an alternative to cash flow from operating activities as a measure of our liquidity.
When we use the term EBITDA, we are referring to operating income plus depreciation and amortization expense and impairment loss. EBITDA represents our portion of EBITDA, excluding the minority interest and cooperative endeavor allocations of third parties, such as physicians, hospitals and other healthcare providers, that own interests in the home nursing agencies and long-term acute care hospitals that we consolidate for financial reporting purposes.
EBITDA has limitations as an analytical tool, and you should not consider this measure in isolation, or as a substitute for analysis of our results as reported under GAAP. This non-GAAP measure does not reflect:
| our cash expenditures, or future cash requirements for capital expenditures, or contractual commitments; | |
| changes in, or cash requirements for, our working capital needs; | |
| our interest expense or the cash requirements necessary to service interest and principal payments on our debts; | |
| any cash requirements for the replacement of assets being depreciated and amortized, which will often have to be replaced in the future, even though depreciation and amortization are non-cash charges; and | |
| the fact that other companies in our industry may calculate EBITDA differently than we do, limiting its usefulness as a comparative measure. | |
Because of these limitations, EBITDA should not be considered as a measure of discretionary cash available to us to invest in the growth of our business. We compensate for these limitations by relying primarily on our GAAP results and by supplementing our analysis of our GAAP results with EBITDA.
27
MANAGEMENTS DISCUSSION AND ANALYSIS OF
The following discussion should be read in conjunction with our consolidated financial statements and the related notes appearing elsewhere in this prospectus. This discussion contains forward-looking statements. Forward-looking statements reflect our current views about future events, are based on assumptions and are subject to known and unknown risks and uncertainties. Many important factors could cause actual results or achievements to differ materially from any future results or achievements expressed or implied by forward-looking statements. A number of these important factors are described under Risk Factors.
Overview
We provide post-acute healthcare services primarily to Medicare beneficiaries in rural markets in the southern United States. We provide these post-acute healthcare services through our home nursing agencies, hospices, long-term acute care hospitals and outpatient rehabilitation clinics. Since our founders began operations in 1994 with one home nursing agency in Palmetto, Louisiana, we have grown to 86 locations in Louisiana, Alabama, Arkansas, Mississippi and Texas as of December 31, 2004.
Segments
We operate in two segments for financial reporting purposes: home-based services and facility-based services. We derived 68.5% of our net service revenue during the nine months ended September 30, 2004 and 77.7% of our net service revenue for the year ended December 31, 2003 from our home-based services segment and derived the balance of our net service revenue for those periods from our facility-based services segment.
Through our home-based services segment we offer a wide range of services, including skilled nursing, private duty nursing, physical, occupational, and speech therapy, medically-oriented social services, and hospice care. As of December 31, 2004, we owned and operated 63 home nursing locations, of which 56 were Medicare-certified, and three Medicare-certified hospices. Of these 66 home-based services locations, 37 are wholly-owned by us and 29 are owned through joint ventures or controlled through other strategic relationships. We also manage the operations of four home nursing agencies and two hospices in which we have no ownership interest. We intend to increase the number of home nursing agencies that we operate through continued acquisition and development, primarily in underserved rural markets, as we implement our growth strategy. As we acquire and develop home nursing agencies, we anticipate the percentage of our net service revenue and operating income derived from our home-based services segment will increase.
We provide facility-based services principally through our long-term acute care hospitals and outpatient rehabilitation clinics. As of December 31, 2004, we owned and operated four long-term acute care hospitals with seven locations, all located within host hospitals, and one inpatient rehabilitation facility, which we intend to convert into a long-term acute care hospital. We also owned and operated five outpatient rehabilitation clinics and provided contract rehabilitation services to third parties. Of these 13 facility-based services locations, nine are wholly-owned by us and four are owned through joint ventures or controlled through other strategic relationships. We also manage the operations of one inpatient rehabilitation facility in which we have no ownership interest. Because of the recent changes in the regulations applicable to long-term acute care hospitals operated as hospitals within hospitals, we do not intend to expand the number of hospital within a hospital long-term acute care hospitals that we operate. As a result, we anticipate that the percentage of our net service revenue and operating income derived from our facility-based services segment will decline.
Development Activities
Since January 2001, we have acquired all or a majority of the economic interests in 26 home nursing agencies for a total consideration of approximately $2.7 million: 19 in Louisiana, one in Alabama,
28
Since January 2001, we have acquired all or a majority of the economic interests in two long-term acute care hospital locations and three outpatient rehabilitation clinics located in Louisiana for approximately $2.2 million since January 2001. During this same period, we internally developed six long-term acute care hospital locations, two inpatient rehabilitation facilities and two outpatient rehabilitation clinics located in Louisiana. Since January 2002, we have expanded the number of licensed beds at our long-term acute care hospital locations and inpatient rehabilitation facilities from 22 beds to 132 beds as of December 31, 2004.
In February 2004, we sold three hospices, two in Louisiana and one in Mississippi, and one home nursing agency in Louisiana for $500,000. Also in February 2004, we sold one inpatient rehabilitation facility located in Louisiana for $129,000 and closed one outpatient rehabilitation clinic and one long-term acute care hospital, both located in Louisiana. In October 2004, we closed one home nursing agency and one outpatient rehabilitation clinic. Typically, we sold or closed these locations because they were not performing according to our expectations.
The following table is a summary of our acquisitions, divestitures and internal development activities since 2001. This table does not include the seven management services agreements under which we manage the operations of four home nursing agencies, two hospices and one inpatient rehabilitation facility.
Long-Term Acute Care | Outpatient | ||||||||||||||||
Home Nursing | Hospitals and Inpatient | Rehabilitation | |||||||||||||||
Year | Agencies | Hospices | Rehabilitation Facilities | Clinics | |||||||||||||
|
|
|
|
|
|||||||||||||
Total at January 1, 2001
|
20 | 2 | | 2 | |||||||||||||
Developed
|
1 | | 1 | | |||||||||||||
Acquired
|
10 | 1 | | | |||||||||||||
|
|
|
|
||||||||||||||
Total at January 1, 2002
|
31 | 3 | 1 | 2 | |||||||||||||
Developed
|
1 | | 2 | | |||||||||||||
Acquired
|
7 | 1 | | | |||||||||||||
|
|
|
|
||||||||||||||
Total at January 1, 2003
|
39 | 4 | 3 | 2 | |||||||||||||
Developed
|
7 | 1 | 2 | 2 | |||||||||||||
Acquired
|
2 | 1 | 2 | | |||||||||||||
|
|
|
|
||||||||||||||
Total at January 1, 2004
|
48 | 6 | 7 | 4 | |||||||||||||
Developed
|
10 | | 3 | | |||||||||||||
Acquired
|
7 | | | 3 | |||||||||||||
Divested/ Closed
|
(2 | ) | (3 | ) | (2 | ) | (2 | ) | |||||||||
|
|
|
|
||||||||||||||
Total at December 31, 2004
|
63 | 3 | 8 | 5 |
Sources of Revenue by Payor
We receive payments for our services rendered to patients from Medicare, state Medicaid programs, commercial insurers and managed care organizations and from our patients directly. From all sources except Medicare, reimbursement is typically billed and recorded as services are rendered based upon discounts from established rates and revenue. We generally receive fixed payments from Medicare and Medicaid for our services based upon the level of care provided to our patients. Consequently, our net income largely depends upon our ability to manage the cost of providing these services. Reductions in
29
The following table sets forth the percentage of our net service revenue earned by category of payor for each of our last three fiscal years and during the nine months ended September 30, 2004:
Nine Months | |||||||||||||||||||||
Ended | |||||||||||||||||||||
Year Ended December 31, | September 30, | ||||||||||||||||||||
|
|
||||||||||||||||||||
Payor | 2001 | 2002 | 2003 | 2003 | 2004 | ||||||||||||||||
|
|
|
|
|
|
||||||||||||||||
Medicare
|
79.3 | % | 82.8 | % | 83.1 | % | 83.3 | % | 85.7 | % | |||||||||||
Medicaid
|
2.6 | 3.8 | 5.1 | 5.2 | 4.8 | ||||||||||||||||
Other
|
18.1 | 13.4 | 11.8 | 11.5 | 9.5 | ||||||||||||||||
|
|
|
|
|
|||||||||||||||||
Total net service revenue
|
100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | |||||||||||
|
|
|
|
|
Medicare |
Home Nursing. We are reimbursed for our home nursing services under the Medicare prospective payment system based on episodes of care. An episode of care is defined as a length of care up to 60 days with multiple continuous episodes allowed. A base episode payment is established by Medicare through federal legislation. The base episode payment is adjusted based on case mix, the applicable geographic wage index, high or low utilization (either expected or unexpected), intervening events and other factors. The base episode payment will remain constant regardless of the costs we incur to provide care and covers all aspects of service plus reimbursement for medical supplies, within the scope of the home health benefit received.
We recognize revenue when services are provided based on the number of days elapsed during the episode. We periodically perform payment variance analysis to verify that the models utilized in projecting total net service revenue accurately reflect the payments received.
A portion of reimbursement for each Medicare episode is billed, and cash is typically received, before all services are rendered. The estimated episode payment is billed at the commencement of the episode. At initial billing, 60.0% of the estimated reimbursement is received for the initial episode of care and 50.0% is received for subsequent episodes of care. The remaining reimbursement is received upon completion of the episode. It is important to note that although every effort is made to accurately report Medicare net reimbursement, Medicare rates are subject to change. Due to the length of our episodes of care, the situation may arise where Medicare rate changes affect a prior periods net service revenue.
The current base payment rate for Medicare home nursing is $2,264. Since the inception of the prospective payment system in October 2000, the base episode rate payment has varied due to both the impact of annual market basket based increases and Medicare-related legislation. The passage of the MMA resulted in two changes in Medicare reimbursement. First, for episodes ended on or after April 1, 2004 through December 31, 2006, the base episode rate increase has been reduced by 0.8%. Secondly, a 5.0% payment increase is provided for services furnished in a non-MSA setting for episodes ending on or after April 1, 2004 and before April 1, 2005. Based on the Medicare definition of a non-MSA setting, only a portion of our rural patients qualify for this payment increase. Approximately 36.1% of our net service revenue for the nine months ended September 30, 2004 was derived from patients who reside in a non-MSA.
Effective January 1, 2005, the market basket adjustment was increased by approximately 2.0% (net of the 0.8% reduction referred to above). The Medicare Payment Advisory Commission, or MedPAC, has recommended to Congress that the increase be eliminated. MedPAC is an independent federal body established to advise Congress on issues affecting the Medicare program. We cannot predict the timing or the magnitude of any changes recommended by MedPAC.
30
Hospice. Medicare reimburses for hospice care using a prospective payment system. Under that system, we receive one of four predetermined daily or hourly rates based upon the level of care we furnish to the beneficiary. These rates are subject to annual adjustments based on inflation and geographic wage considerations. We currently receive between $105.22 and $111.32 per day for routine home care, depending on the geographic location. On October 1, 2003 and October 1, 2004, the base Medicare payment rates for hospice increased by approximately 3.4% and 3.3%, respectively, over the base rate previously in effect. These rates were further adjusted geographically by the hospice wage index. Overall payments by Medicare to us for hospice services are subject to caps calculated by the Medicare fiscal intermediary at the end of the hospice cap period, which runs from November 1st of each year to October 31st of the following year. If one of our hospices were to exceed the caps, it could have an adverse impact on the net service revenue generated by our hospice operations. None of our hospice locations exceeded the caps during 2001, 2002, 2003 or 2004.
Long-Term Acute Care Hospitals. We are reimbursed for services rendered by our long-term acute care hospitals under a Medicare prospective payment system. Under this system, each discharged patient is assigned to a distinct long-term care diagnosis-related group, and our long-term acute care hospitals are generally paid a pre-determined, fixed amount applicable to the assigned long-term care diagnosis-related group (adjusted for area wage differences).
Effective for discharges on or after October 1, 2004, CMS has published the new relative weights applicable to the long-term care diagnosis-related group system. We have modeled our historical diagnosis-related group utilization and applied the new relative weights to determine the financial impact of this update. After conducting this analysis, and assuming that utilization remains the same, we have determined that the relative weight changes could increase our net service revenue by almost 2.0%.
In August 2004, CMS announced final regulatory changes applicable to long-term acute care hospitals operated as hospitals within hospitals. Effective October 1, 2004, the final rule, subject to certain exceptions, imposes lower rates of reimbursement on long-term acute care hospitals within hospitals whose Medicare admissions from their host hospitals are in excess of specified percentages. Our existing long-term acute care hospitals should be unaffected by the rule until October 1, 2005, when the limitation on Medicare host admissions drops to 75.0%. In order to minimize the more significant impact of the rule after October 1, 2006, when the limitation on Medicare host admissions drops to 50.0%, we intend, during the intervening period, to reevaluate our business plan in each of our markets where we have long-term acute care hospitals and develop appropriate strategies to adapt to the rule.
Outpatient Rehabilitation. Outpatient therapy services are reimbursed on a fee schedule, subject to annual limitations. Outpatient therapy service providers receive a fixed fee for each procedure performed, adjusted by the geographical area in which the outpatient rehabilitation clinic is located.
Medicaid |
Medicaid fee-for-service rates are published by the various state Medicaid programs. Net service revenue for our Medicaid population is recognized at the time that services are rendered. Because Medicaid applies a fee-for-service payment methodology, as opposed to the case rate payment methodology of the Medicare system, we are able to recognize the exact amount expected from the Medicaid program in any given reporting period at the time that services are rendered.
Other |
Other payor sources include commercial insurance, managed care organizations, private payors and patients. Similar to Medicaid, net service revenue from these payor sources is recognized at the time services are rendered because most of our commercial insurance and managed care payment arrangements are fee-for-service in nature.
31
Components of Expenses
Cost of Service Revenue |
Our cost of service revenue consists primarily of the following expenses incurred by our clinical and clerical personnel in our agencies and facilities:
| salaries and related benefits; | |
| transportation, primarily mileage reimbursement; and | |
| supplies and services, including payments to contract therapists. |
General and Administrative Expenses |
Our general and administrative expenses consist primarily of the following expenses incurred by our home office and administrative field personnel:
| Home office: |
| salaries and related benefits; | |
| insurance; | |
| costs associated with advertising and other marketing activities; and | |
| rent and utilities; |
| Supplies and services: |
| accounting, legal and other professional services; and | |
| office supplies; |
| Depreciation; and | |
| Provision for bad debts. |
Equity-Based Compensation Expense |
Under our KEEP Plan certain of our employees were granted KEEP Units. The KEEP Units, which have no exercise price, vest over a five-year period. The KEEP Units function as stock appreciation rights whereby an individual is entitled to receive, on a per unit basis, the increase in estimated fair value, as determined by us, of our units from the date of grant until the date upon which the employee dies, retires or is terminated for any reason other than cause. Accordingly, the KEEP Units are subject to variable accounting until such time as the obligation to the employee is settled. We will incur an equity-based compensation charge in respect of the quarter ended December 31, 2004 of $531,000. Assuming an initial public offering price of $13.00 per share, upon the completion of this offering all obligations relating to our KEEP Units will be settled by conversion into shares of our common stock and we will incur a final, non-recurring equity-based compensation charge in the amount of approximately $3.4 million, recorded in the reporting period the offering is completed.
In March 2001, an officer of the Company acquired 90,000 shares of our common stock from a significant stockholder in exchange for a non-recourse, prepayable interest bearing note. Under GAAP this transaction must be treated as though the shares were acquired from us. In March 2004, the 90,000 shares were returned to the significant stockholder and the note was cancelled. The officer then acquired 150,000 membership units directly from us pursuant to a non-recourse, prepayable interest bearing promissory note. We recorded equity-based compensation expense in relation to these transactions of $111,000 in 2001, $124,000 in 2002 and $665,000 in 2003, and approximately $600,000 as of September 30, 2004. In June 2004, the 150,000 shares were returned, the note was cancelled and we committed to issue 150,000 KEEP Units to replace these shares. Future equity-based compensation expense will be recognized to the extent the fair value of the KEEP Units varies from the cumulative compensation charge of $1.5 million recognized through September 30, 2004.
32
Our equity-based compensation expense is allocated to our home-based and facility-based services segments in accordance with our home office allocation, which is calculated based on the percentage of our net service revenue contributed by each segment during the applicable period.
Discontinued Operations |
During the nine months ended September 30, 2004, we sold our majority interest in three hospices, our majority interest in an inpatient rehabilitation facility and the rights to operate a home nursing agency in a specific area. In accordance with SFAS No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets , the results of operations of these entities, including the gain on sale and impairment loss, are presented as discontinued operations in the consolidated statement of income for all periods presented.
Consolidated Results of Operations
The following table sets forth, for the periods indicated, certain items included in our consolidated statement of income as a percentage of our net service revenue:
Nine Months | |||||||||||||||||||||
Ended | |||||||||||||||||||||
Year Ended December 31, | September 30, | ||||||||||||||||||||
|
|
||||||||||||||||||||
2001 | 2002 | 2003 | 2003 | 2004 | |||||||||||||||||
|
|
|
|
|
|||||||||||||||||
(unaudited) | |||||||||||||||||||||
Net service revenue
|
100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | |||||||||||
Cost of service revenue
|
47.7 | 47.9 | 51.3 | 50.3 | 51.6 | ||||||||||||||||
|
|
|
|
|
|||||||||||||||||
Gross margin
|
52.3 | 52.1 | 48.7 | 49.7 | 48.4 | ||||||||||||||||
General and administrative expenses
|
39.1 | 33.5 | 34.3 | 34.9 | 30.1 | ||||||||||||||||
Impairment loss
|
| | 0.0 | | | ||||||||||||||||
Equity-based compensation expense
|
0.4 | 0.3 | 1.2 | 0.3 | 1.4 | ||||||||||||||||
|
|
|
|
|
|||||||||||||||||
Operating income
|
12.8 | 18.3 | 13.2 | 14.5 | 16.9 | ||||||||||||||||
Interest expense
|
1.5 | 2.3 | 1.7 | 1.6 | 1.2 | ||||||||||||||||
Non-operating (income) loss, including gain on
sales of assets
|
(1.2 | ) | (0.3 | ) | (0.1 | ) | (0.1 | ) | 0.1 | ||||||||||||
Income tax expense
|
4.1 | 4.4 | 3.2 | 3.4 | 4.8 | ||||||||||||||||
Minority interest and cooperative endeavor
allocations
|
4.8 | 5.5 | 3.9 | 4.3 | 3.5 | ||||||||||||||||
|
|
|
|
|
|||||||||||||||||
Income from continuing operations
|
3.6 | % | 6.4 | % | 4.5 | % | 5.3 | % | 7.3 | % | |||||||||||
|
|
|
|
|
33
The following table sets forth, for the periods indicated, net service revenue, cost of service revenue, general and administrative expenses, equity-based compensation expense and operating income by segment. The table also includes data regarding total admissions and total Medicare admissions for our home-based services segment and patient days and average revenue per patient day for our facility-based services segment.
Nine Months Ended | |||||||||||||||||||||
Year Ended December 31, | September 30, | ||||||||||||||||||||
|
|
||||||||||||||||||||
2001 | 2002 | 2003 | 2003 | 2004 | |||||||||||||||||
|
|
|
|
|
|||||||||||||||||
(unaudited) | |||||||||||||||||||||
(in thousands, except for admissions and patient day data) | |||||||||||||||||||||
Home-Based Services Data:
|
|||||||||||||||||||||
Net service revenue
|
$ | 24,276 | $ | 42,443 | $ | 56,196 | $ | 38,914 | $ | 60,368 | |||||||||||
Cost of service revenue
|
11,328 | 19,745 | 27,567 | 18,671 | 29,962 | ||||||||||||||||
General and administrative expenses
|
9,365 | 13,388 | 17,642 | 12,616 | 17,969 | ||||||||||||||||
Equity-based compensation expense
|
78 | 87 | 605 | 109 | 880 | ||||||||||||||||
Operating income
|
3,505 | 9,223 | 10,351 | 7,518 | 11,557 | ||||||||||||||||
Total admissions
|
5,655 | 10,395 | 12,606 | 8,632 | 11,954 | ||||||||||||||||
Total Medicare admissions
|
3,957 | 7,150 | 8,267 | 6,069 | 8,768 | ||||||||||||||||
Facility-Based Services Data:
|
|||||||||||||||||||||
Net service revenue
|
$ | 3,932 | $ | 6,507 | $ | 16,169 | $ | 10,401 | $ | 27,590 | |||||||||||
Cost of service revenue
|
2,138 | 3,693 | 9,579 | 6,118 | 15,453 | ||||||||||||||||
General and administrative expenses
|
1,646 | 3,042 | 7,119 | 4,589 | 8,464 | ||||||||||||||||
Equity-based compensation expense
|
33 | 37 | 259 | 47 | 377 | ||||||||||||||||
Operating income (loss)
|
115 | (265 | ) | (788 | ) | (353 | ) | 3,296 | |||||||||||||
Patient days
|
3,782 | 4,510 | 15,368 | 9,928 | 26,066 | ||||||||||||||||
Outpatient visits
|
21,782 | 11,829 | 6,944 | 5,108 | 16,662 |
The following table shows net service revenue, cost of service revenue, general and administrative expenses, equity-based compensation expense and operating income by segment, expressed as a percentage of each segments net service revenue.
Nine Months Ended | |||||||||||||||||||||
Year Ended December 31, | September 30, | ||||||||||||||||||||
|
|
||||||||||||||||||||
2001 | 2002 | 2003 | 2003 | 2004 | |||||||||||||||||
|
|
|
|
|
|||||||||||||||||
(unaudited) | |||||||||||||||||||||
Home-Based Services:
|
|||||||||||||||||||||
Net service revenue
|
100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | |||||||||||
Cost of service revenue
|
46.7 | 46.5 | 49.1 | 48.0 | 49.6 | ||||||||||||||||
General and administrative expenses
|
38.6 | 31.5 | 31.4 | 32.4 | 29.8 | ||||||||||||||||
Impairment loss
|
| | 0.1 | | | ||||||||||||||||
Equity-based compensation expense
|
0.3 | 0.2 | 1.1 | 0.3 | 1.5 | ||||||||||||||||
Operating income
|
14.4 | 21.7 | 18.4 | 19.3 | 19.1 | ||||||||||||||||
Facility-Based Services:
|
|||||||||||||||||||||
Net service revenue
|
100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | |||||||||||
Cost of service revenue
|
54.4 | 56.8 | 59.2 | 58.8 | 56.0 | ||||||||||||||||
General and administrative expenses
|
41.9 | 46.7 | 44.0 | 44.1 | 30.7 | ||||||||||||||||
Equity-based compensation expense
|
0.8 | 0.6 | 1.6 | 0.5 | 1.4 | ||||||||||||||||
Operating income (loss)
|
2.9 | (4.1 | ) | (4.9 | ) | (3.4 | ) | 11.9 |
34
Nine Months Ended September 30, 2004 Compared to Nine Months Ended September 30, 2003
Net Service Revenue |
Net service revenue for the nine months ended September 30, 2004 was $88.0 million, an increase of $38.7 million, or 78.5%, from $49.3 million in 2003. For the nine months ended September 30, 2004 and 2003, 85.7% and 83.3%, respectively, of our net service revenue was derived from Medicare.
Home-Based Services. Net service revenue for the nine months ended September 30, 2004 was $60.4 million, an increase of $21.5 million, or 55.3%, from $38.9 million for the nine months ended September 30, 2003. The increase in net service revenue resulted in part from a 38.5% increase in total admissions from 8,632 in the nine months ended September 30, 2003 to 11,954 in the nine months ended September 30, 2004. Improvements in case mix and payor mix and an increase in therapy utilization within our home health episodes also contributed to the increase. Approximately $10.6 million of this increase was attributable to net service revenue generated from acquisition or internal development activity during 2003. An additional $2.4 million increase in net service revenue was attributable to acquisition or internal development activity during the period. The remaining increase of approximately $8.5 million reflects our internal growth.
Facility-Based Services. Net service revenue for the nine months ended September 30, 2004 was $27.6 million, an increase of $17.2 million, or 165.4%, from $10.4 million for the nine months ended September 30, 2003. The increase in net service revenue resulted in part from an increase in patient days of 162.6% from 9,928 in the nine months ended September 30, 2003 to 26,066 in the nine months ended September 30, 2004. Also contributing to our growth was a 98.6% increase in the aggregate number of licensed beds at our long-term acute care hospitals and inpatient rehabilitation facilities from 69 beds at September 30, 2003 to 137 beds at September 30, 2004. Of these 137 beds, 18 beds were licensed and became available for patient care in late September 2004. Approximately $6.0 million of this increase was attributable to net service revenue generated from acquisition activity during 2003. An additional $5.8 million increase in net service revenue was attributable to acquisition or internal development activity during the period. The remaining increase of approximately $5.4 million reflects our internal growth.
Cost of Service Revenue |
Cost of service revenue for the nine months ended September 30, 2004 was $45.4 million, an increase of $20.6 million, or 83.1%, from $24.8 million for the nine months ended September 30, 2003. Cost of service revenue represented approximately 51.6% and 50.3% of our net service revenue for the nine months ended September 30, 2004 and 2003, respectively.
Home-Based Services. Cost of service revenue for the nine months ended September 30, 2004 was $30.0 million, an increase of $11.3 million, or 60.4%, from $18.7 million for the nine months ended September 30, 2003. Approximately $10.3 million of this increase resulted from an increase in salaries and benefits, of which $5.2 million was incurred as a result of acquisition or development activity during 2003. The increase in salaries and benefits expense due to internal growth accounted for approximately $3.3 million of the increase in this category. The remaining increase in salaries and benefits expense was attributable to 2004 acquisitions of $1.8 million. Supplies and services expense and transportation expense contributed $500,000 and $500,000, respectively, to the increase in cost of service revenue. Cost of service revenue for the nine months ended September 30, 2004 represented 49.6% of our net service revenue compared to 48.0% during the nine months ended September 30, 2003.
Facility-Based Services. Cost of service revenue for the nine months ended September 30, 2004 was $15.5 million, an increase of $9.4 million, or 154.1%, from $6.1 million for the nine months ended September 30, 2003. Approximately $6.0 million of this increase resulted from an increase in salaries and benefits. Of this amount, $2.5 million was incurred as a result of acquisition and internal development activity during 2003. Of the remaining $3.5 million increase, $2.1 million resulted from acquisition and development activity during the period. The increase in salaries and benefits expense from internal growth within our facility-based services segment amounted to $1.4 million. Supplies and services expense
35
General and Administrative Expenses |
General and administrative expenses for the nine months ended September 30, 2004 were $26.4 million, an increase of $9.2 million, or 53.5%, from $17.2 million for the nine months ended September 30, 2003.
Home-Based Services. General and administrative expenses for the nine months ended September 30, 2004 were $18.0 million, an increase of $5.4 million, or 42.9%, from $12.6 million for the nine months ended September 30, 2003. Approximately $3.5 million of this increase was attributable to acquisition or internal development activity during 2003. The remaining $1.9 million of the increase in general and administrative expense was due to acquisition and internal development activity during the 2004 period.
Facility-Based Services. General and administrative expenses for the nine months ended September 30, 2004 were $8.5 million, an increase of $3.9 million, or 84.8%, from $4.6 million for the nine months ended September 30, 2003. The majority, or $3.0 million, of the increase was attributable equally to the increased acquisition and internal development activity during the 2003 and 2004 periods. Internal growth accounted for approximately $700,000 of the increase. The remaining increase in general and administrative expenses of $200,000 was related to increases in provision for bad debts expense and depreciation expense. Bad debt expense as a percentage of this segments revenue for the nine months ended September 30, 2004 was 1.0% compared to 0.7% for the same period in 2003. During the period ended September 30, 2004, we increased our allowance for uncollectible accounts due to identified collectibility issues with accounts receivable. We believe the additional bad debt expense recognized in the period relates to collectibility issues specific to a group of accounts receivable acquired in an acquisition and does not indicate a change in the trend of collections.
Equity-Based Compensation Expense |
Equity-based compensation expense for the nine months ended September 30, 2004 was $1.3 million, an increase of approximately $1.1 million from $156,000 for the nine months ended September 30, 2003. Approximately $600,000 of this increase was related to the mark-to-market valuation adjustment for the KEEP Units and $500,000 was attributable to the mark-to-market valuation adjustment related to shares of common stock held by one of our officers. Of the $1.3 million expense we incurred in the nine months ended September 30, 2004, approximately $31,000 was attributable to cost of service revenue with the remaining amount attributable to general and administrative expenses.
Income Tax Expense |
The effective tax rates for the nine months ended September 30, 2004 and 2003 were 39.4% and 39.2%, respectively.
Minority Interest and Cooperative Endeavor Allocations |
The minority interest and cooperative endeavor allocations expense for the nine months ended September 30, 2004 was $3.1 million, an increase of $1.0 million, compared to $2.1 million for the nine months ended September 30, 2003. The increase was attributable to an acquisition of a long-term acute care hospital in late 2003 with a significant minority interest position.
36
Year Ended December 31, 2003 Compared to Year Ended December 31, 2002
Net Service Revenue |
For the years ended December 31, 2003 and 2002, 83.1% and 82.8%, respectively, of our net service revenue was derived from Medicare. Net service revenue for the year ended December 31, 2003 was $72.4 million, an increase of $23.4 million, or 47.8%, from $49.0 million in 2002.
Home-Based Services. Net service revenue for the year ended December 31, 2003 was $56.2 million, an increase of $13.8 million, or 32.6%, from $42.4 million in 2002. The increase in net service revenue resulted in part from an 21.3% increase in total admissions from 10,395 in year ended December 31, 2002 to 12,606 in the year ended December 31, 2003. Improvements in case mix and payor mix and an increase in therapy utilization within our home health episodes also contributed to the increase. Approximately $10.4 million, or 75.4%, of this increase reflects internal growth. Acquisition and internal development activity during 2003 accounted for the remaining $3.4 million of the increased net service revenue over the comparable period in 2002.
Facility-Based Services. Net service revenue for the year ended December 31, 2003 was $16.2 million, an increase of $9.7 million, or 149.2%, from $6.5 million in 2002. The increase in net service revenue resulted in part from an increase in patient days of 240.8% from 4,510 in the year ended December 31, 2002 to 15,368 in the year ended December 31, 2003. Also contributing to our growth was an increase in the aggregate number of licensed beds at our long-term acute care hospitals and inpatient rehabilitation facilities from 28 beds at December 31, 2002 to 97 beds at December 31, 2003. Approximately $4.6 million of this increase reflects internal growth. Acquisition and internal development activity accounted for the remaining $5.1 million of the increased net service revenue over the comparable period in 2002.
Cost of Service Revenue |
Cost of service revenue for the year ended December 31, 2003 was $37.1 million, an increase of $13.7 million, or 58.5%, from $23.4 million in 2002. Cost of service revenue for the year ended December 31, 2003 represented 51.3% of our net service revenue compared to 47.9% during the year ended December 31, 2002.
Home-Based Services. Cost of service revenue for the year ended December 31, 2003 was $27.6 million, an increase of $7.9 million, or 40.1%, from $19.7 million in 2002. Approximately $7.5 million of this increase was attributable to salaries and benefits, of which approximately $5.2 million resulted from internal growth, with the remaining $2.3 million attributable to acquisition and internal development activity during 2003. Supplies and services expense of $400,000 accounted for the remaining increase in cost of service revenue. Cost of service revenue for the year ended December 31, 2003 represented 49.1% of our net service revenue compared to 46.5% during the year ended December 31, 2002.
Facility-Based Services. Cost of service revenue for the year ended December 31, 2003 was $9.6 million, an increase of $5.9 million, or 159.5%, from $3.7 million in 2002. Approximately $4.2 million of this increase was attributable to salaries and benefits, of which $1.8 million resulted from internal growth, the remaining $2.4 million attributable to acquisition and internal development activity during 2003. Supplies and services expense contributed approximately $1.5 million of the increase in cost of service revenue and was attributable to our acquisition and internal development activity during 2003. The remaining increase in cost of service revenue of $200,000 was related to increases in provision for bad debts expense and depreciation expense. Cost of service revenue for the year ended December 31, 2003 represented 59.2% of our net service revenue compared to 56.8% during the year ended December 31, 2002.
37
General and Administrative Expenses |
General and administrative expenses for the year ended December 31, 2003 were $24.8 million, an increase of $8.4 million, or 51.2%, from $16.4 million in 2002.
Home-Based Services. General and administrative expenses for the year ended December 31, 2003 were $17.6 million, an increase of $4.2 million, or 31.3%, from $13.4 million in 2002. Approximately $4.1 million of this increase was attributable to home office expenses, of which $2.8 million was attributable to internal growth, with the remaining $1.3 million attributable to our acquisition and internal development activity during 2003. The remaining increase in general and administrative expenses of $149,000 was related to increases in provision for bad debts expense and depreciation expense.
Facility-Based Services. General and administrative expenses for the year ended December 31, 2003 were $7.1 million, an increase of $4.1 million, or 136.7%, from $3.0 million in 2002. Approximately $3.8 million of this increase was attributable to home office expenses, of which $1.2 million was attributable to internal growth and the remaining $2.6 million was attributable to acquisition and internal development activity during 2003. The remaining increase in general and administrative expenses of $300,000 was related to increases in provision for bad debts expense and depreciation expense.
Equity-Based Compensation Expense |
Equity-based compensation expense for the year ended December 31, 2003 was $864,000, an increase of $740,000 from $124,000 in 2002. This increase was related to the mark-to-market valuation adjustment for the KEEP Units and the shares of common stock held by one of our officers. Of the $864,000 expense incurred in 2003, only $5,000 was attributable to cost of service revenue with the remaining amount attributable to general and administrative expenses.
Income Tax Expense |
The effective tax rates for the years ended December 31, 2003 and 2002 were 41.4% and 40.7%, respectively.
Minority Interest and Cooperative Endeavor Allocations |
The minority interest and cooperative endeavor allocations expense for the year ended December 31, 2003 was $2.8 million compared to $2.7 million for 2002. The increase of $138,000, or 5.1%, was attributable to internal growth of our facilities and agencies that have minority interests.
Year Ended December 31, 2002 Compared to Year Ended December 31, 2001
Net Service Revenue |
For the year ended December 31, 2002, 82.8% of our net service revenue was derived from Medicare, as compared to only 79.3% for the year ended December 31, 2001. Net service revenue for the year ended December 31, 2002 was $49.0 million, an increase of $20.8 million, or 73.8%, from $28.2 million in 2001.
Home-Based Services. Net service revenue for the year ended December 31, 2002 was $42.4 million, an increase of $18.1 million, or 74.5%, from $24.3 million in 2001. The increase in net service revenue resulted in part from a 83.8% increase in total admissions from 5,655 in the year ended December 31, 2001 to 10,395 in the year ended December 31, 2002. Improvements in case mix and payor mix and an increase in therapy utilization within our home health episodes also contributed to the increase. Of this increase, approximately $12.3 million was the result of acquisition and internal development activity. Internal growth during fiscal year 2002 amounted to approximately $5.8 million of the remaining increase.
Facility-Based Services. Net service revenue for the year ended December 31, 2002 was $6.5 million, an increase of $2.6 million, or 66.7%, from $3.9 million in 2001. The increase in net service revenue resulted in part from an increase in patient days of 19.2% from 3,782 in the year ended
38
Cost of Service Revenue |
Cost of service revenue for the year ended December 31, 2002 was $23.4 million, an increase of $9.9 million, or 73.3%, from $13.5 million in 2001. Cost of service revenue for the year ended December 31, 2002 represented 47.9% of our net service revenue compared to 47.7% during the year ended December 31, 2001.
Home-Based Services. Cost of service revenue for the year ended December 31, 2002 was $19.8 million, an increase of $8.5 million, or 75.2%, from $11.3 million in 2001. Approximately $7.3 million of this increase was attributable to salaries and benefits, with internal growth accounting for $2.6 million of the increase. Approximately $4.7 million of the salaries and benefits increase was the result of acquisition and internal development activity. Supplies and services expense contributed approximately $1.2 million of the increase in cost of service revenue, of which 50.0% was attributable to our acquisition and development activity during 2001. Cost of service revenue for the years ended December 31, 2002 and 2001 represented 46.5% and 46.7% of our net service revenue, respectively.
Facility-Based Services. Cost of service revenue for the year ended December 31, 2002 was $3.7 million, an increase of $1.6 million, or 76.2%, from $2.1 million in 2001. Approximately $1.1 million of this increase was attributable to salaries and benefits, of which $1.0 million was related to internal development activity during the period. Supplies and services expense contributed approximately $500,000 of the increase in cost of service revenue and was also attributable to new start-ups in fiscal year 2002. Cost of service revenue for the year ended December 31, 2002 represented 56.8% of our net service revenue compared to 54.4% during the year ended December 31, 2001.
General and Administrative Expenses |
General and administrative expenses for the year ended December 31, 2002 were $16.4 million, an increase of $5.4 million, or 49.1%, from $11.0 million in 2001.
Home-Based Services. General and administrative expenses for the year ended December 31, 2002 were $13.4 million, an increase of $4.0 million, or 42.6%, from $9.4 million in 2001. Approximately $3.5 million, or 87.5%, of this increase is attributable to home office expenses, of which $2.3 million was the result of our acquisition and development activity during 2001. An additional $1.0 million increase in home office expense was attributable to acquisition or internal development activity during the period. Internal growth of $300,000 accounted for the balance of the increase in home office expenses. The remaining increase in general and administrative expenses of $200,000 was related to increases in provision for bad debts expense and depreciation expense.
The substantial increase in home office expenses within our internal growth during 2002 is directly related to the implementation of our Regional Manager program, whereby experienced clinical managers were hired to oversee and manage all of the field locations. Additionally, our home office billing and collections staff was increased to keep pace with our growth.
Facility-Based Services. General and administrative expenses for the year ended December 31, 2002 were $3.0 million, an increase of $1.4 million, or 87.5%, from $1.6 million in 2001. Approximately $1.0 million, or 71.4%, of this increase is attributable to home office expenses, of which $600,000 was related to internal development activity during the period. The remaining increase in general and administrative expenses was primarily attributable to an increase in provision for bad debts expense and depreciation expense of $400,000.
39
Equity-Based Compensation Expense |
Equity-based compensation expense for the years ended December 31, 2002 and 2001 was $124,000 and $111,000, respectively. All of our equity-based compensation expense in 2002 was attributable to general and administrative expenses.
Income Tax Expense |
The effective tax rates for the years ended December 31, 2002 and 2001 were 40.7% and 52.8%, respectively. The provision for income taxes of 52.8% in 2001 is due to a nondeductible charge of $963,000 for an increase in the fair value of a warrant liability.
Minority Interest and Cooperative Endeavor Allocations |
The minority interest and cooperative endeavor allocation expense for the year ended December 31, 2002 was $2.7 million compared to $1.4 million for 2001. Approximately $1.0 million of the increase was attributable to internal growth in our facilities and agencies that have minority interests.
Unaudited Consolidated Quarterly Results of Operations
The following table presents our operating results for each of the last 11 fiscal quarters up to the period ended September 30, 2004. The information for each of these quarters is unaudited and has been prepared on the same basis as the audited consolidated financial statements included in this prospectus. In our opinion, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. This data should be read together with our consolidated financial statements and the related notes.
Three Months Ended | ||||||||||||||||
|
||||||||||||||||
March 31, | June 30, | September 30, | December 31, | |||||||||||||
2002 | 2002 | 2002 | 2002 | |||||||||||||
|
|
|
|
|||||||||||||
(unaudited) | ||||||||||||||||
(in thousands) | ||||||||||||||||
Net service revenue
|
$ | 10,139 | $ | 11,977 | $ | 12,768 | $ | 14,066 | ||||||||
Cost of service revenue
|
4,730 | 6,002 | 5,789 | 6,917 | ||||||||||||
|
|
|
|
|||||||||||||
Gross margin
|
5,409 | 5,975 | 6,979 | 7,149 | ||||||||||||
General and administrative expenses
|
3,493 | 3,823 | 4,540 | 4,574 | ||||||||||||
Impairment loss
|
| | | | ||||||||||||
Equity-based compensation expense
|
31 | 31 | 31 | 31 | ||||||||||||
|
|
|
|
|||||||||||||
Operating income
|
$ | 1,885 | $ | 2,121 | $ | 2,408 | $ | 2,544 | ||||||||
|
|
|
|
Three Months Ended | ||||||||||||||||
|
||||||||||||||||
March 31, | June 30, | September 30, | December 31, | |||||||||||||
2003 | 2003 | 2003 | 2003 | |||||||||||||
|
|
|
|
|||||||||||||
(unaudited) | ||||||||||||||||
(in thousands) | ||||||||||||||||
Net service revenue
|
$ | 14,708 | $ | 16,681 | $ | 17,926 | $ | 23,050 | ||||||||
Cost of service revenue
|
7,482 | 7,811 | 9,496 | 12,357 | ||||||||||||
|
|
|
|
|||||||||||||
Gross margin
|
7,226 | 8,870 | 8,430 | 10,693 | ||||||||||||
General and administrative expenses
|
5,466 | 5,862 | 5,877 | 7,556 | ||||||||||||
Impairment loss
|
| | | 31 | ||||||||||||
Equity-based compensation expense
|
32 | 88 | 36 | 708 | ||||||||||||
|
|
|
|
|||||||||||||
Operating income
|
$ | 1,728 | $ | 2,920 | $ | 2,517 | $ | 2,398 | ||||||||
|
|
|
|
40
Three Months Ended | ||||||||||||||||
|
||||||||||||||||
March 31, | June 30, | September 30, | ||||||||||||||
2004 | 2004 | 2004 | ||||||||||||||
|
|
|
||||||||||||||
(unaudited) | ||||||||||||||||
(in thousands) | ||||||||||||||||
Net service revenue
|
$ | 25,980 | $ | 29,599 | $ | 32,379 | ||||||||||
Cost of service revenue
|
13,911 | 14,852 | 16,652 | |||||||||||||
|
|
|
||||||||||||||
Gross margin
|
12,069 | 14,747 | 15,727 | |||||||||||||
General and administrative expenses
|
7,609 | 9,212 | 9,612 | |||||||||||||
Impairment loss
|
| | | |||||||||||||
Equity-based compensation expense
|
817 | 229 | 211 | |||||||||||||
|
|
|
||||||||||||||
Operating income
|
$ | 3,643 | $ | 5,306 | $ | 5,904 | ||||||||||
|
|
|
Liquidity and Capital Resources
Our principal source of liquidity for our operating activities is the collection of our accounts receivable, most of which are collected from governmental and third party commercial payors. Our reported cash flows from operating activities are impacted by various external and internal factors, including the following:
| Operating Results Our net income has a significant impact on our operating cash flows. Our net income has increased from $787,000 in 2001 to $2.8 million in 2003. Over this same period of time, our cash flow from operating activities changed from cash used in operating activities of $1,686,000 in 2001 to cash provided by operating activities of $830,000 in 2003. Any significant increase or decrease in our net income could have a material impact on our operating cash flows. | |
| Start Up Costs Following the completion of an acquisition, we generally incur substantial start up costs in order to implement our business strategy. There is generally a delay between our expenditure of these start up costs and the increase in net service revenue, and subsequent cash collections, which adversely effects our cash flows from operating activities. | |
| Timing of Payroll Our employees are paid bi-weekly on Fridays; therefore, operating cash flows decline in reporting periods that end on a Friday. Conversely, for those reporting periods ending on a day other than Friday, our cash flows are higher because we have not yet paid our payroll. | |
| Medical Insurance Plan Funding We are self funded for medical insurance purposes. Any significant changes in the amount of insurance claims submitted could have a direct impact on our operating cash flows. | |
| Medical Supplies A significant expense associated with our business is the cost of medical supplies. Any increase in the cost of medical supplies, or in the use of medical supplies by our patients, could have a material impact on our operating cash flows. | |
Cash used in investing activities is primarily for acquisitions of healthcare facilities and property and equipment, while cash provided by financing activities is derived from the proceeds from our revolving debt arrangement.
We are a holding company with no operations of our own. Accordingly, our ability to service our debt and pay dividends, if any, is dependent upon the earnings from the business conducted by our subsidiaries. The distributions of those earnings or advances or other distributions of funds by these subsidiaries to us are contingent upon the subsidiaries earnings and are subject to various business and legal considerations. If our subsidiaries are unable to make sufficient distributions or advances to us, we may not have the cash resources necessary to service our debt or pay dividends.
41
Nine months ended September 30, 2004 |
Operating activities during the nine months ended September 30, 2004, provided $5.6 million in cash while these activities provided $3.1 million in cash during the same nine-month period in 2003. For the nine months ended September 30, 2004, cash provided by operating activities was primarily attributable to net income of $6.7 million. Non-cash items such as depreciation and amortization, provision for bad debts, equity-based compensation, minority interest in the earnings of subsidiaries, deferred income taxes, and gain on sales of assets totaled $5.2 million. However, changes in our operating assets and liabilities, excluding cash, offset these non-cash charges including an increase in receivables of $7.7 million due primarily to an increase in operations and patient census. Accounts payable and accrued expenses increased $2.2 million, reflecting the additional payroll and benefits costs resulting from the 2004 acquisitions.
Days sales outstanding, or DSO, for our Medicare operations for the nine months ended September 30, 2004 was 43 days compared to 30 days for the same nine-month period in 2003. Our DSO at September 30, 2003 was unusually low due to a combination of events, including the implementation of weekly billings of requests for accelerated payment, or RAPs, which resulted in increased collections and a corresponding decrease in accounts receivable, and a decline in acquisition activity during the third quarter of 2003.
Investing activities used $4.1 million for the nine months ended September 30, 2004, whereas such activities used $1.8 million for the nine months ended September 30, 2003. Cash used in investing activities in 2004 is primarily attributed to purchases of property and equipment of $3.1 million and cash used in various 2004 acquisitions of $1.7 million which was partially offset by proceeds from sale of property and entities of $650,000.
Financing activities used $460,000 for the nine months ended September 30, 2004, whereas such activities used $2.2 million during the same period of 2003. Cash provided by financing activities in 2004 was primarily attributed to proceeds from issuance of debt, lines of credit and revolving debt arrangements of $4.1 million. These proceeds were partially offset by minority interest distributions of $2.0 million, principal payments on debt of $1.6 million, and offering costs of $631,000.
At September 30, 2004 we had working capital of $18.6 million compared to $10.7 million at December 31, 2003, an increase of $7.9 million. This improvement in our working capital position was due largely to the improved operating cash flows, which was partially offset by our 2004 acquisitions.
Year ended December 31, 2003 |
Operating activities during the year ended December 31, 2003, provided $830,000 in cash while these activities provided $174,000 in cash during the same period in 2002. For the year ended December 31, 2003, cash provided by operating activities was primarily attributable to net income of $2.8 million. Non-cash items such as depreciation and amortization, provision for bad debts, equity-based compensation, minority interest in the earnings of subsidiaries, deferred income taxes, and gain on sales of assets also totaled $2.8 million. However, changes in our operating assets and liabilities, excluding cash, offset these non-cash charges including an increase in receivables of $4.5 million and an increase in amounts due from governmental entities of $655,000 due primarily to an increase in operations and patient census. Accounts payable and accrued expenses increased $534,000 reflecting the additional payroll and benefits costs resulting from the 2003 acquisitions.
DSO for the years ended December 31, 2002 and 2003 was 49 days in each year.
Investing activities used $3.8 million for the year ended December 31, 2003, whereas such activities used $1.2 million for the year ended December 31, 2002. Cash used in investing activities in 2003 was primarily attributed to purchases of property and equipment of $2.0 million and cash used in various 2003 acquisitions of $1.9 million.
42
Financing activities provided $1.5 million for the year ended December 31, 2003, whereas such activities provided $4.1 million during the same period of 2002. Cash provided by financing activities in 2003 was primarily attributed to proceeds from issuance of debt, lines of credit, and revolving debt arrangements of $2.6 million. These proceeds were partially offset by principal payments on debt of $1.3 million.
At December 31, 2003 we had working capital of $10.7 million compared to $8.9 million at December 31, 2002, an increase of $1.8 million. This improvement in our working capital position was due largely to the improved operating cash flows, which was partially offset by our 2003 acquisitions.
Year ended December 31, 2002 |
Operating activities during the year ended December 31, 2002, provided $174,000 in cash while these activities used $1.7 million in cash during the same period in 2001. For the year ended December 31, 2002, cash provided by operating activities was primarily attributable to net income of $2.8 million. Non-cash items such as depreciation and amortization, provision for bad debts, equity-based compensation, minority interest in the earnings of subsidiaries, deferred income taxes, and gain on sales of assets totaled $1.0 million. However, changes in our operating assets and liabilities, excluding cash, offset these non-cash charges including an increase in receivables of $7.1 million due primarily to an increase in operations and patient census. Accounts payable and accrued expenses increased $3.7 million reflecting the additional payroll and benefits costs resulting from the 2002 acquisitions.
DSO for the year ended December 31, 2002 was 49 days compared to 46 days as of December 31, 2001. This increase was primarily attributable to increased acquisition activity during 2002.
Investing activities used $1.2 million for the year ended December 31, 2002, whereas such activities used $2.2 million for the year ended December 31, 2001. Cash used in investing activities in 2002 was primarily attributed to purchases of property and equipment of $871,000 and cash used in various 2002 acquisitions of $340,000.
Financing activities provided $4.1 million for the year ended December 31, 2002, whereas such activities provided $3.6 million during the same period of 2001. Cash provided by financing activities in 2002 was primarily attributed to proceeds from issuance of debt, lines of credit, and revolving debt arrangements of $5.3 million. These proceeds were partially offset by principal payments on debt of $1.1 million.
At December 31, 2002 we had working capital of $8.9 million compared to $2.4 million at December 31, 2001, an increase of $6.5 million. This improvement in our working capital position was due largely to the improved operating cash flows, which was partially offset by our 2002 acquisitions.
Year ended December 31, 2001 |
Operating activities during the year ended December 31, 2001, used $1.7 million in cash. For the year ended December 31, 2001, cash provided by operating activities was primarily attributable to net income of $787,000. Non-cash items such as depreciation and amortization, provision for bad debts, equity-based compensation, minority interest in the earnings of subsidiaries, deferred income taxes, and gain on sales of assets totaled $1.4 million. However, changes in our operating assets and liabilities, excluding cash, offset these non-cash charges including an increase in receivables of $4.6 million due primarily to an increase in operations and patient census. Accounts payable and accrued expenses increased $707,000, reflecting the additional payroll and benefits costs resulting from the 2001 acquisitions, and amounts due under cooperative endeavor agreements increased $297,000.
Investing activities used $2.2 million for the year ended December 31, 2001. Cash used in investing activities in 2001 was primarily attributed to purchases of property and equipment of $751,000 and cash used in various 2001 acquisitions of $1.5 million.
43
Financing activities provided $3.6 million for the year ended December 31, 2001. Cash provided by financing activities in 2001 was primarily attributed to proceeds from issuance of debt, lines of credit, and revolving debt arrangements of $6.3 million. These proceeds were partially offset by principal payments on debt of $2.6 million.
At December 31, 2001 we had working capital of $2.4 million. Our working capital position was due largely to the improved operating cash flows, which was partially offset by our 2001 acquisitions.
Indebtedness |
Our total long-term indebtedness, including the current portion of $2.4 million, was $12.3 million at December 31, 2003 and $15.2 million at September 30, 2004. Prior to the completion of this offering we intend to enter into a new senior secured credit facility. Under the terms of this new senior secured credit facility, we expect to have access to a revolving line of credit of approximately $25.0 million, as well as a term loan of approximately $5.0 million. Prior to the completion of this offering, we intend to borrow approximately $13.7 million under our new senior secured credit facility to satisfy the following obligations: (1) $12.0 million to repay in full our existing credit facility with Residential Funding Corporation; (2) $1.0 million to repay our outstanding obligations under our loan agreement with The Catalyst Fund, Ltd. and Southwest/Catalyst Capital, Ltd.; (3) $380,000 to repay our obligations under a subordinated promissory note bearing interest at 15.5% due February 1, 2006, which is collateralized by shares of our common stock that were repurchased by us in consideration for the promissory note; and (4) approximately $300,000 to repay indebtedness assumed by us in connection with acquisitions completed by us in 2004. As of December 31, 2004, none of our debt instruments restrict the ability of our subsidiaries and joint ventures to make distributions.
Future Funding Requirements |
We believe available borrowings under our new
senior secured credit facility, together with our cash flows
from operations and the net proceeds of this offering, will be
sufficient to fund our requirements for at least the next
12 months. To the extent available borrowings and cash
flows from operations are insufficient to fund future
requirements, we may be required to seek additional financing
through increases in our senior secured credit facility,
negotiate credit facilities with other lenders or institutions
or seek additional capital through private placements or public
offerings of equity or debt securities. No assurances can be
given that we will be able to extend or increase the existing
senior secured credit facility, secure additional bank
borrowings or complete additional debt or equity financings on
terms favorable to us or at all. Any such financing may be
dilutive in ownership, preferences, rights, or privileges to our
stockholders. If we are unable to obtain funds when needed, or
on acceptable terms, we may need to curtail our acquisition and
development programs. Our ability to meet our funding needs
could be adversely affected if we suffer adverse results of
operations, or if we violate the covenants and restrictions to
which we will be subject under our new senior secured credit
facility.
Commitments
The following table discloses aggregate
information about our contractual obligations and the periods in
which payments are due as of December 31, 2003:
Less Than
More Than
Contractual Cash Obligation
Total
1 Year
1-3 Years
3-5 Years
5 Years
(in thousands)
$
11,195
$
2,080
$
9,115
$
$
1,222
301
458
190
273
8,623
2,617
3,472
1,776
758
$
21,040
$
4,998
$
13,045
$
1,966
$
1,031
44
Off-Balance Sheet Arrangements
We do not currently have any off-balance sheet arrangements with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. In addition, we do not engage in trading activities involving non-exchange traded contracts. As such, we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in these relationships.
Quantitative and Qualitative Disclosures About Market Risk
As of September 30, 2004, we had cash and cash equivalents of $2.8 million, which consisted of highly liquid money market instruments with maturities less than 90 days. Because of the short maturities of these instruments, a sudden change in market interest rates would not have a material impact on the fair value of the portfolio. We would not expect our operating results or cash flows to be materially affected by the effect of a sudden change in market interest rates on our portfolio.
Our exposure to market risk relates to changes in interest rates for borrowings under the new senior secured credit facility we intend to enter into prior to the completion of this offering. These borrowings are expected to bear interest at variable rates.
Critical Accounting Policies
We prepare our consolidated financial statements in accordance with GAAP. Accordingly, we make estimates and assumptions that affect our reported amounts of assets, liabilities, revenues and expenses, as well as the disclosure of contingent assets and liabilities. In some cases, we could reasonably have used different accounting policies and estimates. Changes in the accounting estimates are reasonably likely to occur from period to period. Accordingly, actual results could differ materially from our estimates. To the extent that there are material differences between these estimates and actual results, our financial condition or results of operations will be affected. We base our estimates on past experience and other assumptions that we believe are reasonable under the circumstances, and we evaluate these estimates on an ongoing basis. We refer to accounting estimates of this type as critical accounting policies and estimates, which we discuss further below.
Principles of Consolidation |
Our consolidated financial statements include all subsidiaries and entities controlled by us. We define control as ownership of a majority of the voting interest of an entity. Our consolidated financial statements also include entities in which we absorb a majority of the entitys expected losses, receive a majority of the entitys expected residual returns, or both, as a result of ownership, contractual or other financial interests in the entity.
The decision to consolidate or not consolidate an entity would not impact our earnings, as we would include our portion of these entities profits and losses either through consolidation or the equity method of accounting if we did not consolidate.
All significant intercompany accounts and transactions have been eliminated in consolidation. Business combinations accounted for as purchases have been included in the consolidated financial statements from the respective dates of acquisition.
45
The following table summarizes the percentage of net service revenue earned by type of ownership or relationship we had with the operating entity:
Years Ended December 31, | |||||||||||||||||
|
Nine Months Ended | ||||||||||||||||
2001 | 2002 | 2003 | September 30, 2004 | ||||||||||||||
|
|
|
|
||||||||||||||
Wholly owned subsidiaries
|
51.3 | % | 48.9 | % | 50.8 | % | 44.1 | % | |||||||||
Equity joint ventures
|
4.1 | 5.0 | 9.7 | 37.7 | |||||||||||||
Cooperative endeavors
|
42.2 | 42.2 | 31.7 | 5.9 | |||||||||||||
License leasing arrangements
|
0.1 | 1.9 | 5.4 | 11.4 | |||||||||||||
Management services
|
2.3 | 1.9 | 2.4 | 1.0 | |||||||||||||
|
|
|
|
||||||||||||||
Total net service revenue
|
100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | |||||||||
|
|
|
|
The following discussion sets forth our consolidation policy with respect to our equity joint ventures, cooperative endeavors, license leasing arrangements and management services agreements.
Equity Joint Ventures |
Our joint ventures are structured as limited liability companies in which we typically own a majority equity interest ranging from 51.0% to 95.0%. Each member of all but one of our equity joint ventures participates in profits and losses in proportion to their equity interests. We have one joint venture partner whose participation in losses is limited. We consolidate these entities, as we absorb a majority of the entities expected losses, receive a majority of the entities expected residual returns and generally have voting control.
Cooperative Endeavors |
We have arrangements with certain partners that involve the sharing of profits and losses. Unlike our joint venture relationships, we own 100.0% of the equity interests in these joint ventures. In these cooperative endeavors, we possess interests in the net profits and losses ranging from 67.0% to 95.0%. We have one cooperative endeavor partner whose participation in losses is limited. We consolidate these entities, as we own 100.0% of the outstanding equity interests, absorb a majority of the entities expected losses and receive a majority of the entities expected residual returns.
License Leasing Arrangements |
We lease, through our wholly-owned subsidiaries, home health licenses necessary to operate certain of our home nursing agencies. As with our wholly owned subsidiaries, we own 100.0% of the equity interests of these entities and consolidate them based on such ownership, as well as our right to receive a majority of the entities expected residual returns and our obligation to absorb a majority of the entities expected losses.
Management Services |
We have various management services agreements under which we manage certain operations of agencies and facilities. We do not consolidate these agencies or facilities, as we do not have an equity interest and do not have a right to receive a majority of the agencies or facilities expected residual returns or an obligation to absorb a majority of the agencies or facilities expected losses.
Revenue Recognition |
We report net service revenue at the estimated net realizable amount due from Medicare, Medicaid, commercial insurance, managed care payors, patients, and others for services rendered. Under Medicare, our home nursing patients are classified into a home health resource group prior to the receipt of services. Based on this home health resource group we are entitled to receive a prospective Medicare payment for delivering care over a 60 day period. Medicare adjusts these prospective payments based on a variety of factors, such as low utilization, patient transfers, changes in condition and the level of services
46
Under Medicare, patients in our long-term acute care facilities are classified into long-term care diagnosis-related groups. Based on this classification, we are then entitled to receive a fixed payment from Medicare. This fixed payment is also subject to adjustment by Medicare due to factors such as short stays. In calculating our reported net service revenue for services provided in our long-term acute care hospitals, we reduce the prospective payment amounts by an estimate of the adjustments. We calculate the adjustment based on a historical average of these types of adjustments for claims paid during the preceding three months. For our long-term acute care hospitals we recognize revenue as services are provided.
For hospice services we are paid by Medicare under a prospective payment system. We receive one of four predetermined daily or hourly rates based upon the level of care we furnish. We record net service revenue from our hospice services based on the daily or hourly rate. We recognize revenue for hospice as services are provided.
Under Medicare we are reimbursed for our rehabilitation services based on a fee schedule for services provided adjusted by the geographical area in which the facility is located. We recognize revenue as these services are provided.
Our Medicaid reimbursement is based on a predetermined fee schedule applied to each service we provide. Therefore, we recognize revenue for Medicaid services as services are provided based on this fee schedule. Our managed care payors reimburse us in a manner similar to either Medicare or Medicaid. Accordingly, we recognize revenue from our managed care payors in the same manner as we recognize revenue from Medicare or Medicaid.
We record management services revenue as services are provided in accordance with the various management services agreements to which we are a party. The agreements generally call for us to provide billing, management, and other consulting services suited to and designed for the efficient operation of the applicable home nursing agency or inpatient rehabilitation facility. We are responsible for the costs associated with the locations and personnel required for the provision of the services. We are generally compensated based on a percentage of net billings or an established base fee. In addition, for certain of the management agreements, we may earn incentive compensation.
Accounts Receivable and Allowances for Uncollectible Accounts |
We report accounts receivable net of estimated allowances for uncollectible accounts and adjustments. Accounts receivable are uncollateralized and primarily consist of amounts due from third-party payors and patients who receive final bills once all documentation is completed. Using detailed accounts receivable aging reports produced by our billing system, our collections department monitors and pursues payment. We have adopted a charity care policy that provides the criteria a patient must meet in order to be considered indigent and his or her balance considered for write-off. All other accounts that are deemed uncollectible are turned over to an outside collection agency for further collection efforts. To provide for accounts receivable that could become uncollectible in the future, we establish an allowance for uncollectible accounts to reduce the carrying amount of such receivables to their estimated net realizable value. The credit risk for concentrations of receivables is limited due to the significance of Medicare as the primary payor. The amount of the provision for bad debts is based upon our assessment of historical and expected net collections, business and economic conditions, trends in government reimbursement and other collection indicators.
A portion of the estimated Medicare prospective payment system reimbursement from each submitted home nursing episode is received in the form of a RAP before all services are rendered. The estimated episodic payment is billed at the commencement of the episode. We receive a RAP for 60.0% of
47
At December 31, 2003, our allowance for doubtful accounts, as a percentage of patient accounts receivable, was approximately 2.5%. For the period ended September 30, 2004, the provision for doubtful accounts increased to 1.3% of net service revenue compared to 0.8% of net service revenue for the year ended December 31, 2003. We do not expect the provision for doubtful accounts, as a percentage of net service revenue, to decline from 2004 levels during 2005, based upon our net service revenue and trends at September 30, 2004. Adverse changes in general economic conditions, billing operations, payor mix, or trends in federal or state governmental coverage could affect our collection of accounts receivable, cash flows and results of operations.
The following table sets forth our aging of accounts receivable as of September 30, 2004:
Payor | 0-30 | 31-60 | 61-90 | 91-120 | 121-150 | 150+ | Total | ||||||||||||||||||||||
|
|
|
|
|
|
|
|
||||||||||||||||||||||
(in thousands) | |||||||||||||||||||||||||||||
Medicare
|
$ | 13,599 | $ | 1,939 | $ | 870 | $ | 449 | $ | 191 | $ | 608 | $ | 17,655 | |||||||||||||||
Medicaid
|
573 | 264 | 241 | 343 | 209 | 863 | 2,492 | ||||||||||||||||||||||
Other
|
2,244 | 697 | 358 | 219 | 168 | 543 | 4,229 | ||||||||||||||||||||||
|
|
|
|
|
|
|
|||||||||||||||||||||||
Total
|
$ | 16,416 | $ | 2,900 | $ | 1,469 | $ | 1,011 | $ | 567 | $ | 2,014 | $ | 24,376 | |||||||||||||||
|
|
|
|
|
|
|
Intangible Assets |
Goodwill represents substantially all of the intangible assets reflected on our consolidated balance sheet, included elsewhere in this prospectus. Goodwill is the excess purchase price over the estimated fair market value of the net assets we have acquired in business combinations. On June 29, 2001, the Financial Accounting Standards Board, or FASB, issued Statement of Financial Accounting Standards, or SFAS, No. 142, Goodwill and Other Intangible Assets, which changed the accounting for goodwill and intangible assets. Under SFAS No. 142, goodwill and indefinite lived intangible assets are no longer amortized but are reviewed annually, or more frequently if impairment indicators arise, for impairment. Prior to the adoption of SFAS No. 142, goodwill had been amortized on a straight-line basis over 25 years through December 31, 2001. We adopted SFAS No. 142 effective January 1, 2002.
We completed our transitional impairment test under SFAS No. 142 as of January 1, 2002, based on estimated fair value of the business and we determined that no impairment of goodwill existed. For the year ended December 31, 2003, we recorded an impairment loss of $357,000, of which $320,000 was related to the sale of a non-performing subsidiary subsequent to year-end and is included in loss from discontinued operations, net in the consolidated statement of income. We concluded no impairment indicators were present at September 30, 2004.
The Company has concluded that licenses to operate home-based and/or facility-based services have indefinite lives, as management has determined that there are no legal, regulatory, contractual, economic or other factors that would limit the useful life of the licenses and the Company intends to renew and operate the licenses indefinitely. Accordingly, the Company has elected to recognize the fair value of these indefinite-lived licences and goodwill as a single asset for financial reporting purposes, as permitted by SFAS No. 141, Business Combinations.
We estimate the fair value of our identified reporting units and compare those estimates against the related carrying value. For each of the reporting units, the estimated fair value is determined based on
48
Components of our home-based services segment are generally represented by individual subsidiaries or joint ventures with individual licenses to conduct specific operations within geographic markets as limited by the terms of each license. Components of our facility-based services are represented by individual operating entities. Effective January 1, 2004 we began aggregating the components of these two segments into two reporting units for purposes of evaluating impairment. Prior to January 1, 2004 we evaluated each operating entity separately for impairment. Modifications to our management of the segments and reporting provided us with a basis to change the reporting unit structure.
Recently Issued Accounting Pronouncements
In December 2003, the FASB published a revision to Interpretation 46, or FIN 46R, to clarify certain provisions of FASB Interpretation No. 46, Consolidation of Variable Interest Entities, and to exempt certain entities from its requirements. FIN No. 46R requires a company to consolidate a variable interest entity, or VIE, as defined, when the company will absorb a majority of the VIEs expected losses, receive a majority of the variable interest entitys expected residual returns, or both. FIN No. 46R also requires consolidation of existing, non-controlled affiliates if the VIE is unable to finance its operations without investor support, or where the other investors do not have exposure to the significant risks and rewards of ownership. FIN No. 46R is effective by the end of the first reporting period beginning after December 15, 2003. The Company does not expect the adoption of FIN No. 46R to have a material impact on the Companys consolidated financial statements.
49
BUSINESS
Overview
We provide post-acute healthcare services primarily to Medicare beneficiaries in rural markets in the southern United States. We provide these post-acute healthcare services through our home nursing agencies, hospices, long-term acute care hospitals and outpatient rehabilitation clinics. Since our founders began operations in 1994 with one home nursing agency in Palmetto, Louisiana, we have grown to 86 locations in Louisiana, Alabama, Arkansas, Mississippi and Texas as of December 31, 2004. We have grown our net service revenue from $28.2 million in 2001 to $72.4 million in 2003, representing a compound annual growth rate of 60.2%. During this same period, our net income grew from $787,000 in 2001 to $2.8 million in 2003. For the nine months ended September 30, 2004, we reported $88.0 million of net service revenue and $6.7 million of net income. Medicare accounted for 85.7% of our net service revenue for the nine months ended September 30, 2004. We have been profitable every year since 1999.
Our objective is to become the leading provider of post-acute healthcare services to Medicare patients in selected rural markets, which we define as counties that have between 10,000 and 100,000 residents. We believe these markets, which have a higher percentage of Medicare beneficiaries, are underserved relative to urban or suburban markets. We often enter a new market by forming a strategic relationship with a local hospital for, or by acquiring or assuming operation of, an existing hospital-owned home nursing agency that may be underperforming clinically or financially. Upon entering a new market, we implement our clinically-oriented business model that emphasizes improved patient care, strong relationships with local hospitals, physicians and other healthcare providers and an expansion in the range of healthcare services available to patients. Our model provides support and clinical guidelines to our local caregivers while promoting treatment flexibility that allows them to effectively address individual patient needs. This decentralized operating model also enhances our ability to expand efficiently into new markets and deliver high-quality care consistently on a cost-effective basis across multiple locations.
We provide home-based post-acute healthcare services through our home nursing agencies and hospices. We own and operate 63 home nursing locations, of which 56 are Medicare-certified. We also manage the operations of four home nursing locations in which currently have no ownership interest. Our home nursing locations offer a wide range of services, including skilled nursing, private duty nursing, physical, occupational, and speech therapy and medically-oriented social services. The nurses, home health aides and therapists in our home nursing agencies work closely with patients and their families to design and implement individualized treatment responsive to a physician-prescribed plan of care. We own and operate three Medicare-certified hospices and manage the operations of two hospices in which we currently have no ownership interest. Our hospices provide palliative care to patients with terminal illnesses through interdisciplinary teams of physicians, nurses, home health aides, counselors and volunteers. Of our 66 home-based services locations in which we maintain an ownership interest, 40 are wholly-owned by us and 26 are majority-owned by us through joint ventures or controlled through other strategic relationships. For the year ended December 31, 2003 and the nine months ended September 30, 2004, our home-based services provided $56.2 million and $60.4 million, respectively, of our net service revenue.
We provide facility-based post-acute healthcare services through our long-term acute care hospitals and outpatient rehabilitation clinics. We own and operate four long-term acute care hospitals with seven locations, with a total of 132 licensed beds, and one inpatient rehabilitation facility with 15 licensed beds. We plan to convert the inpatient rehabilitation facility into a long-term acute care hospital. Our long-term acute care hospitals, all of which are located within host hospitals, provide services primarily to patients who have transitioned out of a hospital intensive care unit with complex medical conditions that remain too severe for treatment in a non-acute setting. We provide outpatient rehabilitation services through physical therapists, occupational therapists and speech pathologists at our five outpatient rehabilitation clinics in which we maintain an ownership interest. We also provide outpatient rehabilitation services on a contract basis. In addition, we manage the operations of one inpatient rehabilitation facility in which we have no ownership interest. Of our facility-based services locations in which we maintain an ownership interest, nine are wholly-owned by us and four are majority-owned by us through joint ventures
50
Our founders began operations in September 1994 as St. Landry Home Health, Inc. in Palmetto, Louisiana. After several years of expansion, in June 2000, our founders reorganized their business and began operating as Louisiana Healthcare Group, Inc. In March 2001, Louisiana Healthcare Group, Inc. reorganized and became a wholly owned subsidiary of The Healthcare Group, Inc., also a Louisiana business corporation. Effective December 2002, The Healthcare Group, Inc. merged into LHC Group, LLC, a Louisiana limited liability company, with LHC Group, LLC being the surviving entity. In January 2005, LHC Group, LLC established a wholly owned Delaware subsidiary, LHC Group, Inc. Effective February 9, 2005, LHC Group, LLC merged into LHC Group, Inc.
Industry and Market Opportunity
According to MedPAC, an independent federal body established in 1997 to advise Congress on issues affecting the Medicare program, approximately one-third of all general acute care hospital patients require additional care following their discharge from the hospital. Some of these patients receive less intensive care in settings such as skilled nursing facilities, outpatient rehabilitation clinics or the home, while others receive continuing care in more intensive care settings such as inpatient rehabilitation facilities or long-term acute care hospitals that are either freestanding or co-located within general acute care facilities. According to MedPAC estimates, Medicare spending totaled $12.8 billion in 2003 for the two primary post-acute sectors in which we operate: home nursing and long-term acute care hospitals.
MedPAC estimates Medicare spending on home nursing services totaled $10.2 billion in 2003. CMS estimates that there are approximately 7,200 Medicare-certified home nursing agencies in the United States, the majority of which are operated by small local or regional providers. CMS also estimates that approximately 32.0% of these agencies are hospital-based or not-for-profit, freestanding agencies, and MedPAC estimates that approximately 34.0% are located in rural markets. CMS predicts that Medicare spending on home nursing will increase at an average annual growth rate of 7.6% between 2005 and 2009. Growth is being driven by:
| a U.S. population that is getting older and living longer; | |
| patient preference for less restrictive care settings; | |
| incentives for general acute care hospitals to discharge patients into less intensive treatment settings as quickly as medically appropriate; and | |
| higher incidences of chronic conditions and disease. |
Long-term acute care hospitals provide specialized medical and rehabilitative care to patients with complex medical conditions requiring higher intensity care and monitoring that cannot be provided effectively in other healthcare settings. These facilities typically serve as an intermediate step between the intensive care unit of a general acute care hospital and a less intensive treatment setting, such as a skilled nursing facility or the home. According to MedPAC estimates, Medicare spending for services provided by long-term acute care hospitals grew from $0.4 billion in 1993 to an estimated $2.6 billion in 2003.
According to the U.S. Census Bureau, rural areas have a higher percentage of residents over the age of 65, who account for 14.6% of the total population in rural markets compared to 11.8% in urban markets. Additionally, according to the American Public Health Association, or APHA, rural areas typically do not offer the range of post-acute healthcare services that are available in urban or suburban markets, patients in rural markets face challenges in accessing healthcare in a convenient and appropriate setting. For example, APHA estimates that although 20.0% of Americans live in rural areas, only 9.0% of the nations physicians practice in rural areas. According to APHA, individuals in rural areas may also have difficulty reaching healthcare facilities due to greater travel time required or a lack of public transportation. The economic characteristics and population dispersion of rural markets also make these
51
In our experience, because most rural areas have the population size to support only one or two general acute care hospitals, the local hospital often plays a significant role in rural market healthcare delivery systems. Rural patients who require home nursing frequently receive care from a small home care agency or an agency that, while owned and run by the hospital, is not an area of focus for that hospital. Similarly, patients in these markets who require services typically offered by long-term acute care hospitals are more likely to remain in the community hospital, as it is often the only local facility equipped to deal with severe, complex medical conditions. By entering these markets through affiliations with local hospitals, we usually face less competition for the services we provide. Therefore, we believe we are well positioned to foster community loyalty by building and maintaining long-term relationships with local hospitals, physicians and other healthcare providers and to become the highest quality post-acute provider in our markets.
Competitive Strengths
We believe the following competitive strengths have enabled us to grow our business and increase our net income while building strong market share:
| We have a proven track record of success in serving rural markets. Of our 86 locations, 72.7% are located in counties with fewer than 100,000 residents. Our strategic plan for entering new markets is specifically designed for rural markets with highly dispersed populations that are underserved by existing post-acute care alternatives. Our comprehensive plan includes: (1) building relationships with local hospitals, physicians and other healthcare providers; (2) expanding the breadth and quality of services provided; (3) recruiting qualified nurses and other healthcare professionals; and (4) transitioning acquired operations to our operating model and technology platform. We have generated significant increases in net service revenue and net income by focusing on internal growth in our existing markets, opening home-based and facility-based locations in new rural markets, and selectively acquiring home nursing agencies in rural markets. | |
| We have a clinically-oriented and patient-focused operating model. We have developed a decentralized, care management operating model that enhances our ability to deliver high-quality care on a consistent and cost-effective basis across multiple locations. Our operating model provides clinical guidelines at the agency and caregiver levels while promoting treatment flexibility to address patient-specific needs. We believe this approach allows us to allocate more resources to patient care, which enhances clinical outcomes and increases physician and patient satisfaction. Our operating model is supported by our Service Value Point system, a proprietary patient management information system that enables us to measure our clinical and financial performance across multiple locations. | |
| We incur low costs to enter new markets. Most of the hospitals with which we seek to establish strategic relationships have agencies that may be underperforming clinically or financially. We typically have acquired the assets of these agencies with limited capital investment. Upon acquiring these interests, we implement our standardized operating model, which generally leads to increased patient census, enhanced patient care and improved financial performance and provides us with high returns on our invested capital. | |
| We focus on maintaining strong employee relations. Critical to our success is our ability to attract and retain experienced and skilled employees and our recognition of the importance of good relations between us and our employees. Our care management operating model empowers our employees, giving them a high degree of autonomy by affording them treatment flexibility to meet |
52
patient-specific needs. This flexibility, combined with our emphasis on communication, education and competitive benefits, has allowed us to attract and retain highly skilled and experienced employees. As a result, we had an employee turnover rate for full-time employees of approximately 14.6% for the year ended December 31, 2004, which we believe is well below the comparable national average. | ||
| We have an experienced management team. Our ability to grow profitability, deliver high-quality service, and expand our operations has been due, in large part, to the experience of our senior management team. Our four executive officers have over 61 years of combined experience in the healthcare services industry, with extensive operational experience and an in-depth knowledge and understanding of the regulatory environments in which we operate. |
Growth Strategy
Our objective is to become the leading provider of post-acute services to Medicare beneficiaries in rural markets in the southern United States. To achieve this objective, we intend to:
| Drive internal growth in existing markets. We intend to drive internal growth in our existing markets by increasing the number of healthcare providers from whom we receive referrals and by increasing the breadth of home-based and facility-based post-acute healthcare services we provide. In order to achieve this growth, we will (1) continue to educate healthcare providers about the benefits of our services; (2) reinforce the position of our agencies as community assets; (3) maintain our emphasis on high-quality medical care for our patients; and (4) provide a superior work environment for our employees. | |
| Achieve margin improvement through the active management of costs. The majority of our net service revenue is generated under Medicare prospective payment systems through which we are paid pre-determined rates based upon the clinical condition and severity of the patients in our care. Because our profitability in a fixed payment system depends upon our ability to manage the costs of providing care, we continue to pursue initiatives to improve our margins and net income. One of these initiatives was the development of our Service Value Point system, which we believe effectively balances our dual objectives of clinical quality and effective financial management. | |
| Expand into new rural markets. We will continue expanding into new markets by developing new and acquiring existing Medicare-certified home nursing agencies in attractive markets. We currently plan to pursue expansion opportunities in underserved rural markets where we believe we can implement our operating model successfully. We employ a dedicated business development team of six people to identify and evaluate new market opportunities, with particular focus on 500 target markets in the following 14 contiguous states: Alabama, Arkansas, Florida, Georgia, Louisiana, Kentucky, Oklahoma, Mississippi, Missouri, North Carolina, South Carolina, Tennessee, Texas and West Virginia. | |
| Pursue strategic acquisitions. We will continue to identify and evaluate opportunities for strategic acquisitions in new and existing markets that will enhance our market position, increase our referral base and expand the breadth of services we offer. Due to historical capital constraints, our development activities have primarily focused on buying individual community-based home nursing agencies. We may use a portion of the proceeds of this offering to pursue acquisitions that would allow us to acquire market share in our target states through the purchase of larger home nursing operations. Our business development efforts have identified potential acquisitions in our target markets with which our long-term objectives and management philosophy align. |
Services
We provide post-acute healthcare services primarily to Medicare beneficiaries in rural markets in the southern United States. Our services can be broadly classified into two principal categories: (1) home-based services offered through our home nursing agencies and hospices; and (2) facility-based services
53
Home-Based Services |
Home Nursing. Our registered and licensed practical nurses provide a variety of medically necessary services to homebound patients who are suffering from acute or chronic illness, recovering from injury or surgery, or who otherwise require care or monitoring. These services include wound care and dressing changes, cardiac rehabilitation, infusion therapy, pain management, pharmaceutical administration, skilled observation and assessment, and patient education. We have also designed guidelines to treat chronic diseases and conditions including diabetes, hypertension, arthritis, Alzheimers disease, low vision, spinal stenosis, Parkinsons disease, osteoporosis, complex wound care and chronic pain. Our home health aides provide assistance with daily activities such as housekeeping, meal preparation, medication management, bathing, and walking. Through our medical social workers we counsel patients and their families with regard to financial, personal, and social concerns that arise from a patients health-related problems. We also provide skilled nursing, ventilator and tracheotomy services, extended care specialties, medication administration and management, and patient and family assistance and education on a private duty basis. Our nurses and home health aides are on call 24 hours a day, seven days a week, to provide private duty services that are affordable and designed to assist patients during their stay in a hospital or at home. We also provide management services to third party home nursing agencies, often as an interim solution until proper state and regulatory approvals for an acquisition can be obtained.
Our physical, occupational and speech therapists provide therapy services to patients in their home. Our therapists coordinate multi-disciplinary treatment plans with physicians, nurses and social workers to restore basic mobility skills such as getting out of bed, walking safely with crutches or a walker, and restoring range of motion to specific joints. As part of the treatment and rehabilitation process, a therapist will stretch and strengthen muscles, test balance and coordination abilities, and teach home exercise programs. Our therapists assist patients and their families with improving and maintaining a patients ability to perform functional activities of daily living, such as the ability to dress, cook, clean, and manage other activities safely in the home environment. Our speech and language therapists provide corrective and rehabilitative treatment to patients who suffer from physical or cognitive deficits or disorders that create difficulty with verbal communication or swallowing.
All of our home nursing agencies offer 24 hour personal emergency response and support services through LifeLine Systems, Inc. for patients who require close medical monitoring but who want to maintain an independent lifestyle. These services consist principally of a communicator that connects to the telephone line in the subscribers home and a personal help button that is worn or carried by the individual subscriber and that, when activated, initiates a telephone call from the subscribers communicator to Lifelines central monitoring facilities. Lifelines trained personnel identify the nature and extent of the subscribers particular need and notify the subscribers family members, neighbors, and/or emergency personnel, as needed. Our use of the Lifeline system increases customer satisfaction and loyalty by providing our patients a point of contact between our scheduled nursing visits. As a result, we offer our patients a more complete regimen of care management than our competitors in the markets in which we operate, particularly in Mississippi and Louisiana where we have an exclusive contract for these services with LifeLine.
Hospice. Our Medicare-certified hospice operations provide a full range of hospice services designed to meet the individual physical, spiritual, and psychosocial needs of terminally ill patients and their families. Our hospice services are primarily provided in a patients home but can also be provided in a nursing home, assisted living facility, or hospital. Key services provided include pain and symptom management accompanied by palliative medication; emotional and spiritual support; inpatient and respite care; homemaker services; dietary counseling; social worker visits; spiritual counseling; and bereavement counseling for up to 13 months after a patients death.
54
Facility-Based Services |
Long-term Acute Care Hospitals. Our long-term acute care hospitals treat patients with severe medical conditions who require high-level care along with frequent monitoring by physicians and other clinical personnel. Patients who receive our services in a long-term acute care hospital are too medically unstable to be treated in a non-acute setting. Examples of these medical conditions include respiratory failure, neuromuscular disorders, cardiac disorders, non-healing wounds, renal disorders, cancer, head and neck injuries, and mental disorders. These impairments often are associated with accidents, strokes, heart attacks and other serious medical conditions. We also treat patients diagnosed with musculoskeletal impairments that restrict their ability to perform normal activities of daily living. As part of our facility-based services, we operate an institutional pharmacy, which focuses on providing a full array of institutional pharmacy services to our long-term acute care hospitals and inpatient rehabilitation facility. We also provide management services to one critical access hospital.
Rehabilitation Services. We provide rehabilitation services in multiple settings, including both the inpatient and outpatient settings. In our facilities and through our contractual relationships, we provide physical, occupational and speech rehabilitation services. We also provide certain specialized services such as hand therapy or sports performance enhancement that treat sports and work related injuries, musculoskeletal disorders, chronic or acute pain and orthopedic conditions. Our patients are typically diagnosed with musculoskeletal impairments that restrict their ability to perform normal activities of daily living. These impairments are often associated with accidents, sports injuries, strokes, heart attacks and other medical conditions. Our rehabilitation services are designed to help these patients minimize physical and cognitive impairments and maximize functional ability. We also design services to prevent short-term disabilities from becoming chronic conditions. Our rehabilitation services are provided by our physical, occupational and respiratory therapists, and speech-language pathologists. We also provide management services to one inpatient rehabilitation facility and operate one health and wellness center located adjacent to one of our outpatient rehabilitation clinics.
Operations
Home-Based Services |
Each of our home nursing agencies is staffed with experienced clinical home health professionals who provide a wide range of patient care services. Our home nursing agencies are managed by a Director of Nursing or Branch Manager who is also a licensed registered nurse. Our Directors of Nursing and Branch Managers are overseen by Regional Managers. Our patient care operating model for our home nursing agencies is structured on a base model that requires a Medicare patient minimum census of 50 patients. At the base model level, one registered nurse is responsible for all aspects of the management of each patients plan of care. A home nursing agency based on this model is also staffed with an office manager, a field-registered nurse, a field-licensed professional nurse and a home health aide. All field staff are paid on a per visit basis. If needed, we contract with local community therapists as independent contractors to provide additional therapy services. As the size and patient census of a particular home nursing agency grows, these staffing patterns are increased appropriately.
Our home nursing agencies use our Service Value Point system, a proprietary clinical resource allocation model and cost management system. The system is a quantitative tool that assigns a target level of resource units to a group of patients based upon their initial assessment and estimated skilled nursing and therapy needs. The Service Value Point system allows the Director of Nursing or Branch Manager to allocate adequate resources throughout the group of patients assigned to his/her care, rather than focusing on the profitability of an individual patient.
Patient care is handled at the home nursing agency level. Functions that are centralized into the home office include payroll, accounting, financial reporting, billing, collections, regulatory and legal compliance, risk management, pharmacy, and general clinical oversight accomplished by periodic on-sight surveys. Each of our home nursing agencies is licensed and certified by the state and federal governments, and 29 of them also are accredited by the Joint Commission for Accreditation of Healthcare Organizations,
55
Facility-Based Services |
Long-Term Acute Care Hospitals. Each of our long-term acute care hospital locations is managed by a hospital administrator, while the clinical operations are directed by a Director of Nurses who is also a licensed registered nurse. The individual hospital administrators are responsible for managing the day-to-day operating activities of the hospital within appropriate budgetary constraints. Each administrator reports to the Chief Operating Officer of Facility-Based Services. Each Director of Nurses reports directly to his or her respective hospital administrator as well as indirectly to our Clinical Operations Officer responsible for the oversight of the quality of patient care services at the home office level. The medical management of each patient is overseen by a Medical Director, typically a physiatrist, who is responsible for ensuring the appropriateness of admissions, as well as leading weekly patient care conferences.
We follow a clinical approach under which each patient is discussed in weekly, multidisciplinary team meetings, at which patient progress is assessed compared to goals and future goals are set. Attendees at these meetings include a patients family and referring physician. We believe that this model results in higher quality care, predictable discharge patterns and the avoidance of unnecessary delays.
All coding, medical records, human resources, case management, utilization review, and medical staff credentialing are provided at the hospital level. Centralized functions that are provided by the home office include payroll, accounting, financial reporting, billing, collections, regulatory and legal compliance, risk management, pharmacy, and general clinical oversight accomplished by periodic on-sight surveys.
Rehabilitation Services. Our rehabilitation services are overseen by a home office based Director of Therapy Services, who is a licensed physical therapist. Each clinic also has an on-site therapist responsible for addressing staffing needs and concerns as well as managing the day-to-day operations of the outpatient rehabilitation clinic.
As with our long-term acute care hospitals, all coding, medical records, human resources, charge/data entry, front end collections, and marketing for our rehabilitation centers are provided at the individual center level. Centralized functions provided by the home office include payroll, accounting, financial reporting, billing, collections, regulatory and legal compliance, risk management, and general clinical oversight accomplished by periodic on-sight surveys.
Marketing
Our marketing efforts are directed primarily at physicians and hospital discharge planners. Marketing activities are coordinated locally by the individual location. Marketing activities are supplemented by a staff of six home office based sales and marketing associates, led by a Director of Sales and Marketing, who provide overall sales support, collateral materials and assistance in creative design. Many of our marketers are nurses or have other clinical experience. At each location we employ a dedicated marketing team, including a patient care representative who educates other healthcare providers about our services and monitoring closely the activities of our competitors. Our marketing efforts generally emphasize the benefits offered by our home nursing agencies or long-term acute care hospitals compared to other providers in the market. For our home-based services, these benefits typically include an emphasis on our decentralized, care management operating model that focuses on delivering personalized healthcare to our patients. For our facility-based services, we seek to differentiate our facilities by emphasizing our multidisciplinary approach to patient care, and our customized disease management programs.
Strategic Relationships
We have numerous strategic relationships with physicians, hospitals and other healthcare providers. Our strategic relationships include joint ventures, cooperative endeavors, license leasing
56
Our strategic relationships are generally subject to the Federal Anti-Kickback Statute. We have sought to satisfy as many safe harbor requirements under this statute as possible in structuring these arrangements. However, these arrangements may not meet all elements of a safe harbor. We believe that we have a reasonable basis for concluding that each of our strategic relationships complies with the Anti-Kickback Statute. Our strategic relationships with physicians and physician groups are also governed by the Stark Law. We believe we have structured these physician relationships in a way that meets applicable exceptions under the Stark Law and Anti-Kickback Statute. The Stark Law contains exceptions for certain physician ownership or investment interests in, and certain physician compensation arrangements with, entities, including ownership in an entire hospital and ownership in rural providers. We believe our compensation arrangements with referring physicians and our physician investment relationships meet the requirements for an exception under the Stark Law and that our operations comply with the Stark Law.
If our relationships with physicians, physician entities or hospitals were found to be in violation of the Anti-Kickback Statute or the Stark Law, we could be required to restructure them or refuse to accept referrals for designated health services from the physicians with whom we have a relationship. We also could be required to repay to Medicare or Medicaid amounts received as a result of these relationships pursuant to prohibited referrals, and we could be subject to monetary penalties as well as exclusion from participating in federal healthcare programs.
Equity Joint Ventures |
We have entered into 21 joint ventures for the ownership and operation of home nursing agencies, hospices, outpatient rehabilitation clinics and long-term acute care hospitals. Our joint ventures are structured as limited liability companies in which we typically own a majority equity interest and our joint venture partners own a minority equity interest ranging from 5.0% to 49.0%. At the time of formation, we and our joint venture partners each contribute capital to the joint venture in the form of cash or property. We believe that the amount contributed by each party to the joint venture represents their pro-rata portion of the fair market value of the joint venture entity.
Generally, we serve as the manager of our joint ventures and oversee their day-to-day operations. In two of our joint ventures with parties other than hospitals or physicians, our joint venture partners provide marketing services and, in one case, administrative services. The management of the joint venture is governed by a management committee, which is comparable to a board of directors. We generally possess a majority of the total votes available to be cast by the members of the management committee. However, in three of these joint ventures where we have partnered with not-for-profit hospitals, the hospital controls a majority of the total management committee votes. In such instances we possess the right to withdraw from the joint venture at any time upon notice to our joint venture partner in exchange for a payment from our partners in an amount calculated in accordance with a predetermined formula. Each member of all but one of our equity joint ventures participates in profits and losses in proportion to their equity interests. We have one joint venture partner whose participation in the losses of the venture is limited.
In addition to the 21 joint ventures, we also have two equity joint ventures that grant our joint venture partners the right to convert their equity interests in the joint venture into shares of our common stock upon the completion of this offering. We have entered into exchange agreements with our partners in each of these ventures, which provide that upon completion of this offering they will receive, in one instance, 450,000 shares of our common stock, valued at $5,850,000 million assuming an initial offering price of $13.00 per share, and cash consideration in an amount equal to the aggregate value of 230,658 shares of our common stock, or $2,998,554 assuming an initial offering price of $13.00 per share, and in the other instance, 68,036 shares of our common stock, valued at $884,468 assuming an initial
57
In addition to these conversion rights, several of our joint ventures grant a buy/sell option that will require us to either purchase or sell all of their membership interests in the joint venture within 30 days of the receipt of notice of the exercise of the buy/sell option. The purchase price under these buy/sell provisions is typically based on a multiple of the historical or future earnings before income taxes, depreciation and amortization of the joint venture at the time the buy/sell option is exercised.
Cooperative Endeavors |
We currently have three arrangements that involve the sharing of profits and losses, which we call cooperative endeavors. Unlike our joint venture relationships, our cooperative endeavor partners do not own an equity interest in the venture. Instead, our partners have only a contractual right to participate in the sharing of profits and losses. This right is part of the consideration we pay to acquire a home nursing agency from the entity that is a party to the cooperative endeavor. In these cooperative endeavors, we possess interests in the net profits and losses ranging from 67.0% to 95.0%. In one instance, there is a limit on the losses attributable to our cooperative endeavor partner. As with the equity joint ventures, we oversee the day-to-day operations of the arrangement, but the management of our cooperative endeavors is governed by a management committee, where we possess a majority of the total votes available to be cast.
License Leasing Arrangements |
We lease, through our wholly owned subsidiaries, the home health licenses necessary to operate certain of our home nursing agencies. These leases are entered into in instances where state law would otherwise prohibit the alienation and sale of the licenses of home nursing agencies we have targeted or the local hospital is reluctant to sell its home health license due to state imposed limits on the number of certificates of need or permits of approval issued. The leasing fees for one of these licenses is fixed for the initial term and the other provides for escalating fees over the initial term. These leasing arrangements provide for five-year terms with optional renewal periods. One of these leasing arrangements provides that if we choose not to renew, the lessor can require us to purchase the license. In the other leasing arrangement, we have a right of first refusal in the event that the lessor intends to sell the leased license to a third party.
Management Services Agreements |
As of December 31, 2004, we had seven management services agreements under which we managed the operations of four home nursing agencies, two hospices and one inpatient rehabilitation facility. We currently have no ownership interest in the agencies and facilities that are the subject of these management services agreements. In four of these arrangements, we are responsible for all direct and indirect costs associated with the operations and receive a management fee based on the profitability of those operations. Under the remaining three agreements we receive management fees, typically either a flat fee arrangement or a fee based on a percentage of net billings. The term of these arrangements is typically five years, with an option to renew for an additional five-year term. For two of these home nursing agencies and the hospice, these agreements are interim solutions with which to transfer control over day-
58
Competition
The home healthcare market is highly fragmented. According to CMS, there are approximately 7,200 Medicare-certified home nursing agencies in the United States, of which 32.0% are hospital-based or not-for-profit, freestanding agencies. MedPAC estimates that 34.0% of these home nursing agencies are located in rural markets. Although there are a small number of public home nursing companies with significant home nursing operations, they generally do not compete with us in the rural markets that we currently serve. As we expand into new markets, we may encounter public companies that have greater resources or greater access to capital. Competition in our markets comes primarily from small local and regional providers, many of which are undercapitalized. These providers include facility- and hospital-based providers, visiting nurse associations, and nurse registries. We are unaware of any competitor offering the breadth of services we offer that focuses on the needs of rural markets.
Although several public and private national and regional companies own or manage long-term acute care hospitals, they generally do not operate in the rural markets that we serve. If we elect to expand the number of long-term acute care hospitals that we operate, we may encounter national or regional companies that have greater resources or access to capital. Generally, the competition in our markets comes from local healthcare providers. We believe our principal competitive advantages over these local providers are our diverse service offerings, our collaborative approach to working with healthcare providers, our focus on rural markets and our patient-oriented operating model.
Compliance and Quality Control
We have had a Compliance Committee since 1996. Our Compliance Committee oversees a comprehensive company-wide compliance program. Our compliance program provides for:
| the appointment of a compliance officer and committee; | |
| adoption of codes of business conduct and ethics; | |
| employee education and training; | |
| monitoring of an internal system, including a toll-free hotline, for reporting concerns on a confidential, anonymous basis; | |
| ongoing internal auditing and monitoring programs; and | |
| means for enforcing the compliance programs policies. |
As part of our ongoing quality control, internal auditing and monitoring programs, at least annually we conduct internal regulatory audits and mock surveys at each of our agencies and facilities. If an agency or facility does not achieve a satisfactory rating, we require it to prepare and implement a plan of correction. We then perform a follow-up audit and survey to verify that all deficiencies identified in the initial audit and survey have been corrected.
As required under the Medicare conditions of participation, we have a continuous quality improvement program, which involves:
| ongoing education of staff and quarterly continuous quality improvement meetings at each of our agencies and facilities and at our home office; | |
| quarterly comprehensive audits of patient charts performed by each of our agencies and facilities; and | |
| at least once a year, a comprehensive audit of patient charts performed on each of our agencies and facilities by our home office staff. |
59
If an agency or facility fails to achieve a satisfactory rating on a patient chart audit, we require it to prepare and implement a plan of correction. We then conduct a follow-up patient chart audit to verify that appropriate action has been taken to prevent future deficiencies.
The effectiveness of our compliance program is directly related to the legal and ethical training that we provide to our employees. Compliance education for new hires is initiated immediately upon employment with corporate video training and subsequently reinforced through corporate orientation at which the Chief Compliance Officer conducts a comprehensive compliance training seminar. In addition, all of our employees are required to receive continuing compliance education and training each year.
We continually expand and refine our compliance and continuous quality improvement programs. Specific written policies, procedures, training and educational materials and programs, as well as auditing and monitoring activities, have been prepared and implemented to address the functional and operational aspects of our business. Our programs also address specific problem areas identified through regulatory interpretation and enforcement activities. Additionally, our policies, training, standardized documentation requirements, reviews and audits specifically address our financial arrangements with our referral sources, including fraud and abuse laws and physician self-referral laws. We believe our consistent focus on compliance and continuous quality improvement programs provide us with a competitive advantage in the market.
Technology and Intellectual Property
Our Service Value Point system is a proprietary information system that assists us in, among other things, monitoring use and other cost factors, supporting our healthcare management techniques, internal benchmarking, clinical analysis, outcomes monitoring and claims generation, revenue cycle management and revenue reporting. This proprietary home nursing clinical resource and cost management system is a quantitative tool that assigns a target level of resource units to each patient based upon their initial assessment and estimated skilled nursing and therapy needs. We designed this system to empower our direct care employees to make appropriate day-to-day clinical care decisions while also allowing us to manage the quality and delivery of care across our system and to monitor the cost of providing that care both on a patient-specific and agency-specific basis.
In addition to our Service Value Point system, our business is substantially dependent on other non-proprietary software. We have recently converted to a third-party software information system for our long-term acute care hospitals. Additionally, we are in the process of consolidating our various home health agency databases into an enterprise-wide system, which we expect to be fully implemented by the second quarter of 2005. These conversions are intended to improve the accuracy, reliability, and efficiency of processing and management reporting.
Further, we have two major patient billing systems that we use across the enterprise: one system for our home-based services and one for our facility-based services. Both of these systems are fully automated and contain functionality that allows us to calculate net service revenue at both the payor and patient level.
The software we use is based on client-server technology and is highly scalable. We believe our software and systems are flexible, easy-to-use, and allow us to accommodate growth without difficulty through development and acquisitions. Technology plays a key role in our organizations ability to expand operations and maintain effective managerial control. We believe that building and enhancing our information and software systems provides us with a competitive advantage that will allow us to grow our business in a more cost-efficient manner and will result in better patient care.
Reimbursement
Medicare |
The federal governments Medicare program, governed by the Social Security Act of 1965, reimburses healthcare providers for services furnished to Medicare beneficiaries. These beneficiaries
60
Home Nursing. The Medicare home nursing benefit is available to patients who need care following discharge from a hospital, as well as patients who suffer from chronic conditions that require ongoing but intermittent care. The services received need not be rehabilitative or of a finite duration; however, patients who require full-time skilled nursing for an extended period of time generally do not qualify for Medicare home nursing benefits. As a condition of coverage under Medicare, beneficiaries must: (1) be homebound in that they are unable to leave their home without considerable effort; (2) require intermittent skilled nursing, physical therapy, or speech therapy services that are covered by Medicare; and (3) receive treatment under a plan of care that is established and periodically reviewed by a physician. Qualifying patients also may receive reimbursement for occupational therapy, medical social services, and home health aide services if these additional services are part of a plan of care prescribed by a physician.
We receive a standard prospective Medicare payment for delivering care over a base 60-day period, or episode of care. There is no limit to the number of episodes a beneficiary may receive as long as he or she remains eligible. Most patients complete treatment within one payment episode. The base episode payment, established through federal legislation, is a flat rate that is adjusted upward or downward based upon differences in the expected resource needs of individual patients as indicated by clinical severity, functional severity, and service utilization. The magnitude of the adjustment is determined by each patients categorization into one of 80 payment groups, known as home health resource groups, and the costliness of care for patients in each group relative to the average patient. Our payment is also adjusted for differences in local prices using the hospital wage index.
We bill and are reimbursed for services in two stages: an initial request for advance payment when the episode commences and a final claim when it is completed. We receive 60.0% of the estimated payment for a patients initial episode up-front (after the initial assessment is completed and upon initial billing) and the remaining 40.0% upon completion of the episode and after all final treatment orders are signed by the physician. In the event of subsequent episodes, reimbursement timing is 50.0% up-front and 50.0% upon completion of the episode. Final payments may reflect one of five retroactive adjustments to ensure the adequacy and effectiveness of the total reimbursement: (1) an outlier payment if the patients care was unusually costly; (2) a low utilization adjustment if the number of visits was fewer than five; (3) a partial payment if the patient transferred to another provider before completing the episode; (4) a change-in-condition adjustment if the patients medical status changes significantly, resulting in the need for more or less care; or (5) a payment adjustment based upon the level of therapy services required in the population base. Because the applicability of a change is dependent upon the completion date of the episode, changes in reimbursement will impact our financial results up to 60 days in advance of the effective date. We submit all Medicare claims through a single fiscal intermediary for the federal government.
The current base payment rate for Medicare home nursing is $2,264. Since the inception of the prospective payment system in October 2000, the base episode rate payment has varied due to both the impact of annual market basket based increases and Medicare-related legislation. The passage of the MMA resulted in two changes in Medicare reimbursement. First, for episodes ended on or after April 1, 2004 through December 31, 2006, the base episode rate increase has been reduced by 0.8%. Secondly, a 5.0% payment increase is provided for services furnished in a non-MSA setting for episodes ending on or after April 1, 2004 and before April 1, 2005. Based on the Medicare definition of a non-MSA setting, only a portion of our rural patients qualify for this payment increase. Approximately 36.1% of our net service revenue for the nine months ended September 30, 2004 was derived from patients who reside in non-MSAs.
61
Effective January 1, 2005, the market basket adjustment was increased by approximately 2.0% (net of the 0.8% reduction referred to above). MedPAC has recommended to Congress that the increase be eliminated. We cannot predict the timing or the magnitude of any changes recommended by MedPAC.
CMS is expected in either 2005 or 2006 to review the case mix adjustments index as part of a previously scheduled process. We are unable to predict the timing or outcome of such a review.
The Office of Inspector General of HHS, or OIG, has a responsibility to report both to the Secretary of HHS and to Congress any program and management problems related to programs such as Medicare. The OIGs duties are carried out through a nationwide network of audits, investigations and inspections. The OIG has recently undertaken a study with respect to Medicare reimbursement rates. No estimate can be made at this time regarding the impact, if any, of the OIGs findings.
Hospice. In order for a Medicare beneficiary to qualify for the Medicare hospice benefit, two physicians must certify that, in the best judgment of the physician or medical director, the beneficiary has less than six months to live, assuming the beneficiarys disease runs its normal course. In addition, the Medicare beneficiary must affirmatively elect hospice care and waive any rights to other Medicare benefits related to his or her terminal illness. Each benefit period, a physician must recertify that the Medicare beneficiarys life expectancy is six months or less in order for the beneficiary to continue to qualify for and to receive the Medicare hospice benefit. The first two benefit periods are measured at 90-day intervals and subsequent benefit periods are measured at 60-day intervals. There is no limit on the number of periods that a Medicare beneficiary may be recertified. A Medicare beneficiary may revoke his or her election at any time and begin receiving traditional Medicare benefits. There is no limit on how long a Medicare beneficiary can receive hospice benefits and services, provided that the beneficiary continues to meet Medicare hospice eligibility criteria.
Medicare reimburses for hospice care using a prospective payment system. Under that system, we receive one of four predetermined daily or hourly rates based upon the level of care we furnish to the beneficiary. These rates are subject to annual adjustments based on inflation and geographic wage considerations. Our base Medicare rates effective October 1, 2004 depend upon which of the following four levels of care we provide:
| Routine Home Care. We receive between $105.22 and $111.32 per day for routine home care, depending on the geographic location. We are paid the routine home care rate for each day a patient is under our care and not receiving one of the other categories of hospice care. This rate is not adjusted for the volume or intensity of care provided on a given day. This rate is also paid when a patient is receiving hospital care for a condition unrelated to the terminal condition. | |
| General Inpatient Care. We receive between $473.15 and $498.43 per day for general inpatient care, depending on the geographic location. | |
| Continuous Home Care. We receive between $614.09 and $649.70 per day for continuous home care, depending on the geographic location. This daily continuous home care rate is divided by 24 in order to arrive at an hourly rate. The hourly rate is paid for every hour that continuous home care is furnished, up to 24 hours in a single day. A minimum of eight hours must be provided in a single day to qualify for this rate. | |
| Respite Care. We receive between $112.52 and $117.49 per day for respite care, depending on the geographic location. Respite care is provided when the family or caregiver of a patient requires temporary relief from his or her caregiving responsibilities for certain reasons. We can receive payment for respite care provided to a given patient for up to five consecutive days. Our payment for any additional days of respite care provided to the patient is limited to the routine home care rate. |
Medicare limits the reimbursement we may receive for inpatient care services. Under the so-called 80-20 rule, if the number of inpatient care days furnished by us to Medicare beneficiaries exceeds 20.0% of the total days of hospice care furnished by us to Medicare beneficiaries, Medicare payments to us for inpatient care days exceeding the inpatient cap will be reduced to the routine home care rate. This
62
Our Medicare hospice reimbursement is also subject to a cap amount calculated by the Medicare fiscal intermediary at the end of the hospice cap period, which runs from November 1st of each year through October 31st of the following year. Total Medicare payments to us during this period are compared to the cap amount for this period. Payments in excess of the cap amount must be returned by us to Medicare. The cap amount is calculated by multiplying the number of beneficiaries electing hospice care during the period by a statutory amount that is indexed for inflation annually. The cap amount for the twelve-month period ending October 31, 2004 was $19,636. Once published, the new cap amount will become effective retroactively for all initial hospice elections since October 1, 2004. The hospice cap amount is computed on a program-by-program basis. None of our hospices has exceeded the cap on per beneficiary limits during 2001, 2002, 2003 or 2004.
We are required to file annual cost reports with HHS on each of our hospices for informational purposes and to submit claims on the basis of the location where we actually furnish the hospice services. These requirements permit Medicare to adjust payment rates for regional differences in wage costs.
Long-term Acute Care Hospitals. We are reimbursed by Medicare for services provided by our long-term acute care hospitals under the long-term acute care hospital prospective payment system, which was implemented on October 1, 2002. Although CMS regulations allowed for a phase-in period, we have elected to be paid solely on the basis of the long-term care diagnosis-related groups established by the new system. As of December 31, 2004, all of our eligible long-term acute care hospitals had implemented the prospective payment system.
Under the prospective payment system, each patient discharged from our long-term acute care hospitals is assigned a long-term care diagnosis-related group. CMS establishes these long-term care diagnosis-related groups by grouping diseases by diagnosis, which group reflects the amount of resources needed to treat the diseases. We are paid a pre-determined fixed amount applicable to the particular long-term care diagnosis-related group to which that patient is assigned. This payment is intended to reflect the average cost of treating a Medicare patient classified in that particular long-term care diagnosis-related group. For select patients, the amount may be further adjusted based on length of stay and facility-specific costs, as well as in instances where a patient is discharged and subsequently readmitted, among other factors. Similar to other Medicare prospective payment systems, the rate is also adjusted for geographic wage differences. Effective for discharges on or after October 1, 2004, CMS has published the new relative weights applicable to the long-term care diagnosis-related group system. CMS has stated it intends to develop long-term acute care hospital patient-specific criteria to refine the definition of such facilities in its fiscal year 2006 rule-making that will be proposed in February 2005 and will become effective in July 2005.
In order to qualify for payment under the long-term acute care prospective payment system, a facility must be certified as a hospital by Medicare and have an average Medicare inpatient length of stay of greater than 25 days. Prior to qualifying under the prospective payment system, new long-term acute care hospitals initially receive lower payments under the general acute care hospital reimbursement system. New long-term acute care hospitals continue to be paid under this system for a minimum of six months while they establish their length-of-stay average and meet certain additional Medicare long-term acute care hospital requirements.
Effective July 2004, CMS published final regulations with regard to the prospective payment system for long-term acute care hospitals. The regulations provided for the following:
| the standard federal rate was increased by 3.1%; | |
| the average length of stay calculation was changed to consider discharge days instead of patient days as the denominator when calculating average length of stay; |
63
| the interrupted stay rule was expanded, bundling services sent to the host hospital within three days with the long-term acute care hospital costs incurred in providing care to that patient; | |
| the budget neutrality offset amount was increased from 94.0% to 99.5%; and | |
| the cost outlier fixed loss threshold was lowered to $17,864. |
Long-term acute care hospitals are typically operated either as stand-alone facilities or as separate provider units within traditional acute care hospitals. All of our long-term acute care hospitals are located within host hospitals. These hospitals within a hospital must satisfy additional standards. A hospital within a hospital must establish itself as a hospital separate from its host by, among other things, obtaining separate licensure and certification, not having common control with its host hospital or a common parent organization, and having a separate chief executive, chief medical officer and medical staff. Further, there are financial penalties associated with the failure to limit the number of total Medicare patients discharged to the host hospital and subsequently readmitted to the long-term acute care hospital to no greater than 5.0%. None of our long-term acute care hospitals exceeded this 5.0% limitation through December 31, 2004.
In August 2004, CMS announced final regulatory changes applicable to long-term acute care facilities operated as hospitals within hospitals. Effective October 1, 2004, the final rule, subject to certain exceptions, imposes lower rates of reimbursement on long-term acute care hospitals within hospitals whose Medicare admissions from their host hospitals are in excess of specified percentages. For new long-term acute care hospitals within hospitals, the Medicare admissions limitation will be 25.0% for hospitals located in an MSA and 50.0% for hospitals located in a non-MSA. For existing long-term acute care hospitals within hospitals and those under development that meet specified criteria, the Medicare admissions limitations are being phased-in over a four-year period that began October 1, 2004. The Medicare admissions limitations make distinctions between facilities in rural markets and facilities MSAs as follows:
Allowable Admissions from | ||||||||
Host Hospital Before | ||||||||
Payment Reduction | ||||||||
|
||||||||
Period | MSAs | Non-MSAs | ||||||
|
|
|
||||||
Until September 30, 2005
|
100.0% | 100.0% | ||||||
October 1, 2005
September 30, 2006
|
75.0% | 75.0% | ||||||
October 1, 2006
September 30, 2007
|
50.0% | 50.0% | ||||||
October 1, 2007 and thereafter
|
25.0% | 50.0% |
Of our seven long-term acute care hospital locations, five are physically located in non-MSAs and two are located in MSAs. Of the five locations in non-MSAs, two are satellite locations of a parent hospital that is located in a MSA. Based on our discussions with CMS, we believe these satellite locations will be viewed as being located in a non-MSA regardless of the location of their parent hospital and will be treated independently from their parent for purposes of calculating their compliance with the admissions limitations. For the nine months ended September 30, 2004, on an individual basis, four of our long-term acute care hospital locations admitted between 50.0% and 75.0% of their patients from their host hospitals and two of our long-term acute care hospital locations admitted more than 75.0% of their patients from their host hospitals. However, the admissions data for the nine months ended September 30, 2004 is not necessarily indicative of the admissions mix these facilities will experience in the future. Further, admissions data for this period ended September 30, 2004 includes long-term acute care hospital locations that were open only for a short time. In addition, we have recently commenced operations at one of our long-term acute care hospital locations and therefore do not have sufficient data to determine the percentage of referrals that will come from its host hospital at this time.
The new Medicare host admission limitations are scheduled to be phased in over a four-year period. Our existing long-term acute care hospitals should be unaffected by the rule until October 1, 2005, when the limitation on Medicare host admissions drops to 75.0%. Therefore, the rule should have no effect on our 2004 financial results. In order to minimize the more significant impact of the rule after October 1, 2006, when the limitation on Medicare host admissions drops to 50.0%, we intend, during the intervening
64
Outpatient Rehabilitation Services. Medicare requires that outpatient therapy services be reimbursed on a fee schedule, subject to annual limitations. Outpatient therapy providers receive a fixed fee for each procedure performed, adjusted by the geographical area in which the facility is located. Medicare also imposes annual per Medicare beneficiary caps that limited Medicare coverage to $1,500 for outpatient rehabilitation services (including both physical therapy and speech-language pathology services) and $1,500 for outpatient occupational health services, including deductible and co-insurance amounts. The caps were to be increased beginning in 2002 by application of an inflation index. Subsequent legislation imposed a moratorium on the application of these limits for the years 2000, 2001 and 2002. With the expiration of the moratorium, CMS implemented the caps beginning on September 2003. The MMA re-imposed the moratorium on the application of the therapy caps from the date of MMAs enactment through December 31, 2005. We cannot assure you that one or more of our outpatient rehabilitation clinics will not exceed the caps in the future.
Historically, outpatient rehabilitation services have been subject to scrutiny by the Medicare program for, among other things, medical necessity, appropriate documentation, supervision of therapy aides and students, and billing for group therapy. CMS has issued guidance to clarify that services performed by a student are not reimbursable even if provided under line of sight supervision of the therapist. Likewise, CMS has reiterated that Medicare does not pay for services provided by aides regardless of the level of supervision. CMS also has issued instructions that outpatient physical and occupational therapy services provided simultaneously to two or more individuals by a practitioner should be billed as group therapy services.
Inpatient Rehabilitation Facilities. Inpatient rehabilitation facilities are paid under a prospective payment system. Under this system, each patient discharged from an inpatient rehabilitation facility is assigned to a case mix group containing patients with similar clinical problems that are expected to require comparable resources. An inpatient rehabilitation facility is generally paid a predetermined, fixed amount applicable to the assigned case mix group (subject to certain case and facility level adjustments). The prospective payment system for inpatient rehabilitation facilities also includes special payment policies that adjust the payments for some patients based on length of stay, facility costs, whether the patient was discharged and subsequently readmitted, and other factors.
Medicaid |
Medicaid is a joint federal and state funded health insurance program for certain low-income individuals. Medicaid reimburses healthcare providers using a number of different systems, including cost-based, prospective payment, and negotiated rate systems. Rates are also subject to adjustment based on statutory and regulatory changes, administrative rulings, interpretations of policy by individual state agencies, and certain government funding limitations. Medicaid payments accounted for 5.1% of our net service revenue for the year ended December 31, 2003 and 4.8% of our net service revenue for the nine months ended September 30, 2004.
Non-Governmental Payors |
A portion of our net service revenue comes from private payor sources. These sources include insurance companies, workers compensation programs, health maintenance organizations, preferred provider organizations, other managed care companies, and employers, as well as patients directly. Patients are generally not responsible for any difference between customary charges for our services and amounts paid by Medicare and Medicaid programs and the non-governmental payors, but are responsible for services not covered by these programs or plans, as well as for deductibles and co-insurance obligations of their coverage. The amount of these deductibles and co-insurance obligations on patients has increased in recent years. Collection of amounts due from individuals is typically more difficult than collection of
65
Government Regulations
General |
The healthcare industry is highly regulated, and we are required to comply with federal, state and local laws, which significantly affect our business. These laws and regulations are extremely complex and, in many instances, the industry does not have the benefit of significant regulatory or judicial interpretation. Regulations and policies frequently change, and we monitor these changes through trade and governmental publications and associations. The significant areas of federal and state regulatory laws that could affect our ability to conduct our business include the following:
| Medicare and Medicaid participation and reimbursement; | |
| the federal Anti-Kickback Statute and similar state laws; | |
| the federal Stark Law and similar state laws; | |
| false and other improper claims; | |
| the Health Insurance Portability and Accountability Act of 1996, or HIPAA; | |
| civil monetary penalties; | |
| environmental health and safety laws; | |
| licensing; and | |
| certificates of need and permits of approval. |
If we fail to comply with these applicable laws and regulations, we could suffer civil or criminal penalties, including the loss of our licenses to operate and our ability to participate in federal and state healthcare programs. Although we believe we are in material compliance with all applicable laws, these laws are complex and a review of our practices by a court or law enforcement or regulatory authority could result in an adverse determination that could harm our business. Furthermore, the laws applicable to us are subject to change, interpretation and amendment, which could adversely affect our ability to conduct our business.
Medicare Participation |
During the year ended December 31, 2003 and the nine months ended September 30, 2004, 83.1% and 85.7%, respectively, of our net service revenue was received from Medicare. We expect to continue to receive the majority of our net service revenue from serving Medicare beneficiaries. Medicare is a federally funded and administered health insurance program, primarily for individuals entitled to social security benefits who are 65 or older or who are disabled. To participate in the Medicare program and receive Medicare payments, our agencies and facilities must comply with regulations promulgated by CMS. Among other things, these requirements, known as conditions of participation, relate to the type of
66
Under Medicare rules, the designation provider-based refers to circumstances in which a subordinate facility ( e.g. , a separately-certified Medicare provider, a department of a provider or a satellite facility) is treated as part of a provider for Medicare payment purposes. In these cases, the services of the subordinate facility are included in the main providers cost report and overhead costs of the main provider can be allocated to the subordinate facility, to the extent that they are shared. We operate three long-term acute care hospitals that are treated as provider-based satellites of certain of our other facilities. We also provide contract rehabilitation and management services to hospital rehabilitation departments that may be treated as provider-based. These facilities are required to satisfy certain operational standards in order to retain their provider-based status.
Anti-Kickback Statute |
Provisions of the Social Security Act of 1965, commonly referred to as the Anti-Kickback Statute, prohibit the payment or receipt of anything of value in return for the referral of patients or arranging for the referral of patients, or in return for the recommendation, arrangement, purchase, lease or order of items or services that are covered by a federal healthcare program such as Medicare and Medicaid. Violation of the Anti-Kickback Statute is a felony, and sanctions include imprisonment of up to five years, criminal fines of up to $25,000, civil monetary penalties of up to $50,000 per act plus three times the amount claimed or three times the remuneration offered, and exclusion from federal healthcare programs (including the Medicare and Medicaid programs). Many states have adopted similar prohibitions against payments that are intended to induce referrals of Medicaid and other third-party payor patients.
The OIG has published numerous safe harbors that exempt some practices from enforcement action under the federal Anti-Kickback Statute. These safe harbors exempt specified activities, including bona-fide employment relationships, contracts for the rental of space or equipment, and personal service arrangements and management contracts, so long as all of the requirements of the safe harbor are met. The OIG has recognized that the failure of an arrangement to satisfy all of the requirements of a particular safe harbor does not necessarily mean that the arrangement violates the Anti-Kickback statute. Nonetheless, we cannot assure you that arrangements that do not satisfy a safe harbor are not in violation of the Anti-Kickback Statute.
We are required under the Medicare conditions of participation and some state licensing laws to contract with numerous healthcare providers and practitioners, including physicians, hospitals and nursing homes, and to arrange for these individuals or entities to provide services to our patients. In addition, we have contracts with other suppliers, including pharmacies, ambulance services and medical equipment companies. We have also entered into various joint ventures and other relationships with hospitals and physicians for the ownership and management of home nursing agencies and long-term acute care hospitals. Some of these individuals or entities may refer, or be in a position to refer, patients to us, and we may refer, or be in a position to refer, patients to these individuals or entities. We attempt to structure these arrangements in a manner which meets a safe harbor. However, some of these arrangements may not meet all of the requirements of a safe harbor. We believe that our contracts and arrangements with providers, practitioners and suppliers do not violate the Anti-Kickback Statute or similar state laws. We cannot assure you, however, that these laws will ultimately be interpreted in a manner consistent with our practices.
From time to time, various federal and state agencies, such as HHS, issue pronouncements, including fraud alerts, that identify practices that may be subject to heightened scrutiny. For example, the OIGs 2004 Work Plan describes, among other things, the governments intention to examine beneficiary access to home nursing services, the quality of home healthcare since implementation of the prospective payment system, coding and billing processes for home nursing care, and arrangements where home nursing agencies are part of a comprehensive healthcare system.
67
In June 1995, the OIG issued a special fraud alert that focused on the home nursing industry and identified some of the illegal practices the OIG has uncovered. In March 1998, the OIG issued a special fraud alert titled, Fraud and Abuse in Nursing Home Arrangements with Hospices . This special fraud alert focused on payments received by nursing homes from hospices. We believe, but cannot assure you, that our operations comply with the principles expressed by the OIG in these special fraud alerts.
We endeavor to conduct our operations in compliance with federal and state healthcare fraud and abuse laws, including the Anti-Kickback Statute. However, our practices may be challenged in the future, and the fraud and abuse laws may be interpreted in a way that finds us in violation of these laws. If we are found to be in violation of the Anti-Kickback Statute we could be subject to civil and criminal penalties, and we could be excluded from participating in federal healthcare programs such as Medicare and Medicaid. The occurrence of any of these events could significantly harm our business and financial condition.
Stark Law |
Congress has also passed significant prohibitions against certain physician referrals of patients for healthcare services. These prohibitions are commonly known as the Stark Law. The Stark Law prohibits a physician from making referrals for particular healthcare services (called designated health services) to entities with which the physician, or an immediate family member of the physician, has a financial relationship.
The term financial relationship is defined very broadly to include most types of ownership or compensatory relationships. The Stark Law also prohibits the entity receiving the referral from seeking payment under the Medicare and Medicaid programs for services rendered pursuant to a prohibited referral. If an entity is paid for services rendered pursuant to a prohibited referral, it may incur civil penalties and could be excluded from participating in the Medicare or Medicaid programs. If an arrangement is covered by the Stark Law, the requirements of a Stark Law exception must be met for the physician to be able to make referrals to the entity for designated health services and for the entity to be able to bill for these services.
Designated health services under the Stark Law are defined to include clinical laboratory services; physical therapy services; occupational therapy services; radiology services, including magnetic resonance imaging, computerized axial tomography scans, and ultrasound services; radiation therapy services and supplies; durable medical equipment and supplies; parenteral and enteral nutrients, equipment, and supplies; prosthetics, orthotics, and prosthetic devices and supplies; home health services; outpatient prescription drugs; and inpatient and outpatient hospital services. The Stark Law defines a financial relationship to include: (1) a physicians ownership or investment interest in an entity and (2) a compensation relationship between a physician and an entity. Under the Stark Law, financial relationships include both direct and indirect relationships.
Physicians refer patients to us for several Stark Law designated health services, including home health services, inpatient and outpatient hospital services, and physical therapy services. We have compensation arrangements with some of these physicians or their professional practices in the form of medical director and consulting agreements. We also have operations owned by joint ventures in which physicians have an investment interest. In addition, other physicians who refer patients to our agencies and facilities may own our stock. As a result of these relationships, we could be deemed to have a financial relationship with physicians who refer patients to our facilities and agencies for designated health services. If so, the Stark Law would prohibit the physicians from making those referrals and would prohibit us from billing for the services unless a Stark Law exception applies.
The Stark Law contains exceptions for certain physician ownership or investment interests in and certain physician compensation arrangements with entities. If a compensation arrangement or investment relationship between a physician, or immediate family member, and an entity satisfies all requirements for a Stark Law exception, the Stark Law will not prohibit the physician from referring patients to the entity for designated health services. The exceptions for compensation arrangements cover employment
68
The Stark Law also includes an exception for a physicians ownership or investment interest in certain entities through the ownership of stock. If a physician owns stock in an entity, and the stock is listed on a national exchange or is quoted on Nasdaq and the ownership meets certain other requirements, the Stark Law will not apply to prohibit the physician from referring to the entity for designated health services. The requirements for this Stark Law exception include a requirement that the entity issuing the stock have at least $75.0 million in stockholders equity at the end of its most recent fiscal year or on average during the previous three fiscal years.
If an entity violates the Stark Law, it could be subject to civil penalties of up to $15,000 per prohibited claim and up to $100,000 for knowingly entering into certain prohibited referral schemes. The entity also may be excluded from participating in federal healthcare programs (including Medicare and Medicaid). If the Stark Law was found to apply to our relationships with referring physicians and no exceptions under the Stark Law were available, we would be required to restructure these relationships or refuse to accept referrals for designated health services from these physicians. If we were found to have submitted claims to Medicare or Medicaid for services provided pursuant to a referral prohibited by the Stark Law, we would be required to repay any amounts we received from Medicare for those services and could be subject to civil monetary penalties. Further, we could be excluded from participating in Medicare and Medicaid. If we were required to repay any amounts to Medicare, subjected to fines, or excluded from the Medicare and Medicaid Programs, our business and financial condition would be harmed significantly.
Many states have physician relationship and referral statutes that are similar to the Stark Law. These laws generally apply regardless of payor. We believe that our operations are structured to comply with applicable state laws with respect to physician relationships and referrals. However, any finding that we are not in compliance with these state laws could require us to change our operations or could subject us to penalties. This, in turn, could have a negative impact on our operations.
False and Improper Claims |
The submission of claims to a federal or state healthcare program for items and services that are not provided as claimed may lead to the imposition of civil monetary penalties, criminal fines and imprisonment, and/or exclusion from participation in state and federally funded healthcare programs, including the Medicare and Medicaid programs. These false claims statutes include the Federal False Claims Act. Under the Federal False Claims Act, actions against a provider can be initiated by the federal government or by a private party on behalf of the federal government. These private parties are often referred to as qui tam relators, and relators are entitled to share in any amounts recovered by the government. Both direct enforcement activity by the government and qui tam actions have increased significantly in recent years. This development has increased the risk that a healthcare company like us will have to defend a false claims action, pay fines or be excluded from the Medicare and Medicaid programs as a result of an investigation arising out of false claims laws. Many states have enacted similar laws providing for the imposition of civil and criminal penalties for the filing of fraudulent claims. Because of the complexity of the government regulations applicable to our industry, we cannot assure that we will not be the subject of an action under the Federal False Claims Act or similar state law.
Anti-fraud Provisions of the Health Insurance Portability and Accountability Act of 1996 |
In an effort to combat healthcare fraud, Congress included several anti-fraud measures in HIPAA. Among other things, HIPAA broadened the scope of certain fraud and abuse laws, extended criminal penalties for Medicare and Medicaid fraud to other federal healthcare programs, and expanded the authority of the OIG to exclude persons and entities from participating in the Medicare and Medicaid
69
Federal healthcare offenses under HIPAA include healthcare fraud and making false statements relating to healthcare matters. Under HIPAA, among other things, any person or entity that knowingly and willfully defrauds or attempts to defraud a healthcare benefit program is subject to a fine, imprisonment or both. Also under HIPAA, any person or entity that knowingly and willfully falsifies or conceals or covers up a material fact or makes any materially false or fraudulent statements in connection with the delivery of or payment of healthcare services by a healthcare benefit plan is subject to a fine, imprisonment or both. HIPAA applies not only to governmental plans but also to private payors.
Administrative Simplification Provisions of HIPAA |
HHSs final regulations governing electronic transactions involving health information are part of the administrative simplification provisions of HIPAA. These regulations are commonly referred to as the Transaction Standards rule. The rule establishes standards for eight of the most common healthcare transactions by reference to technical standards promulgated by recognized standards publishing organizations. Under the new standards, any party transmitting or receiving health transactions electronically must send and receive data in a single format, rather than the large number of different data formats currently used. This rule will apply to us in connection with submitting and processing health claims. The Transaction Standards rule also applies to many of our payors and to our relationships with those payors. Since many of our payors might not have been able to accept transactions in the format required by the Transaction Standards rule by the original compliance date, we filed a timely compliance extension plan with HHS. We believe that our operations materially comply with the Transaction Standards rule.
HHS also has final regulations implementing HIPAA that set forth standards for the privacy of individually-identifiable health information, referred to as protected health information. The regulations cover healthcare providers, healthcare clearinghouses and health plans. The privacy regulations require companies covered by the regulations to use and disclose protected health information only as allowed by the privacy regulations. Specifically, the privacy regulations require companies such as us to do the following, among other things:
| obtain patient authorization prior to certain uses or disclosures of protected health information; | |
| provide notice of privacy practices to patients and obtain an acknowledgement that the patient has received the notice; | |
| respond to requests from patients for access to or to obtain a copy of their protected health information; | |
| respond to patient requests for amendments of their protected health information; | |
| provide an accounting to patients of certain disclosure of their protected health information; | |
| enter into agreements with the companies business associates through which the business associates agree to use and disclose protected health information only as permitted by the agreement and the requirements of the privacy regulations; | |
| train the companies workforce in privacy compliance; | |
| designate a privacy officer; | |
| use and disclose only the minimum necessary information to accomplish a particular purpose; and | |
| establish policies and procedures with respect to uses and disclosures of protected health information. |
70
These regulatory requirements impose significant administrative and financial obligations on companies that use or disclose individually identifiable health information relating to the health of a patient. We have implemented new policies and procedures to maintain patient privacy and comply with HIPAAs privacy regulations. The privacy regulations are extensive, and we may need to change some of our practices to comply with them as they are interpreted and as we deal with issues that arise.
In February 2003, HHS published the final security regulations implementing HIPAA that govern the security of health information. The compliance date for the security regulations is April 21, 2005. The security regulations require the implementation of policies and procedures that establish administrative, physical, and technical safeguards for electronic protected health information. Companies covered by the security regulations are required to ensure the confidentiality, integrity, and availability of electronic protected health information. Specifically, among others things, companies are required to:
| conduct a thorough assessment of the potential risks and vulnerabilities to confidentiality, integrity, and availability of electronic protected health information and to reduce the risks and vulnerabilities to a reasonable and appropriate level as required by the security regulations; | |
| designate a security officer; | |
| establish policies relating to access by the companies workforce to electronic protected health information; | |
| enter into agreements with the companies business associates whereby business associates agree to establish administrative, physical, and technical safeguards for electronic protected health information received from or on behalf of the companies; | |
| create a disaster and contingency plan to ensure the availability of electronic protected health information; | |
| train the companies workforce in security compliance; | |
| establish physical controls for electronic devices and media containing or transmitting electronic protected health information; | |
| establish policies and procedures regarding the use of workstations with access to electronic protected health information; and | |
| establish technical controls for the information systems maintaining or transmitting electronic protected health information. |
These regulatory requirements impose significant administrative and financial obligations on companies like us that use or disclose electronic health information. We are in the process of assessing our systems, drafting the required policies and procedures, and implementing procedures to be in compliance with the security regulations by the compliance date.
Civil Monetary Penalties |
The Secretary of HHS may impose civil monetary penalties on any person or entity that presents, or causes to be presented, certain ineligible claims for medical items or services. The amount of penalties varies depending on the offense, from $2,000 to $50,000 per violation, plus treble damages for the amount at issue and exclusion from federal healthcare programs (including Medicare and Medicaid).
HHS also can impose penalties on a person or entity who offers inducements to beneficiaries for program services, who violates rules regarding the assignment of payments or who knowingly gives false or misleading information that could reasonably influence the discharge of patients from a hospital. Persons who have been excluded from a federal healthcare program and who retain ownership in a participating entity and persons who contract with excluded persons may be penalized.
71
HHS also can impose penalties for false or fraudulent claims and those that include services not provided as claimed. In addition, HHS may impose penalties on claims:
| for physician services that the person or entity knew or should have known were rendered by a person who was unlicensed, or misrepresented either (1) his or her qualifications in obtaining his or her license or (2) his or her certification in a medical specialty; | |
| furnished by a person who was, at the time the claim was made, excluded from the program to which the claim was made; or | |
| that show a pattern of medically unnecessary items or services. |
Penalties also are applicable in certain other cases, including violations of the federal Anti-Kickback Statute, payments to limit certain patient services and improper execution of statements of medical necessity.
Environmental Health and Safety Laws |
We are subject to federal, state and local regulations governing the storage, use and disposal of materials and waste products. Although we believe that our safety procedures for storing, handling and disposing of these hazardous materials comply with the standards prescribed by law and regulation, we cannot completely eliminate the risk of accidental contamination or injury from those hazardous materials. In the event of an accident, we could be held liable for any damages that result, and any liability could exceed the limits or fall outside the coverage of our insurance. We may not be able to maintain insurance on acceptable terms, or at all. We could incur significant costs and the diversion of our managements attention in order to comply with current or future environmental laws and regulations. We do not have any material estimated capital expenditures related to compliance with environmental, health and safety laws through calendar year 2005.
Licensing |
Our agencies and facilities are subject to state and local licensing regulations ranging from the adequacy of medical care to compliance with building codes and environmental protection laws. In order to assure continued compliance with these various regulations, governmental and other authorities periodically inspect our agencies and facilities. Additionally, healthcare professionals at our agencies and facilities are required to be individually licensed or certified under applicable state law. We take steps to ensure that our employees and agents possess all necessary licenses and certifications.
The institutional pharmacy operations within our facility-based services segment are subject to regulation by the various states in which business is conducted as well as by the federal government. The pharmacies are regulated under the Food, Drug and Cosmetic Act and the Prescription Drug Marketing Act, which are administered by the United States Food and Drug Administration. Under the Comprehensive Drug Abuse Prevention and Control Act of 1970, which is administered by the United States Drug Enforcement Administration, dispensers of controlled substances must register with the Drug Enforcement Administration, file reports of inventories and transactions and provide adequate security measures. Failure to comply with such requirements could result in civil or criminal penalties.
JCAHO is a nationwide commission that establishes standards relating to the physical plant, administration, quality of patient care and operation of medical staffs of hospitals. Currently, JCAHO accreditation of home nursing agencies is voluntary. However, managed care organizations use JCAHO accreditation as a minimum standard for regional and state contracts. As of December 31, 2004, JCAHO had accredited 29 of our home nursing agencies. Those not yet accredited are working towards achieving this accreditation, which can take up to six months.
72
Certificate of Need and Permit of Approval Laws |
In addition to state licensing laws, some states require a provider to obtain a certificate of need or permit of approval prior to establishing or expanding certain health services or facilities. States with certificate of need or permit of approval laws place limits on both the construction and acquisition of healthcare facilities and operations and the expansion of existing facilities and services. In these states, approvals are required for capital expenditures exceeding amounts that involve certain facilities or services, including home nursing agencies. In addition, the state of Louisiana has imposed a moratorium on the issuance of new licenses for home nursing agencies that is effective until July 1, 2008. Of the 14 states in which intend to pursue expansion opportunities, Alabama, Arkansas, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee and West Virginia have certificate of need or permit of approval laws. The certificate of need or permit of approval issued by the state determines the service areas for the applicable agency or program.
State certificate of need and permit of approval laws generally provide that, prior to the addition of new capacity, the construction of new facilities or the introduction of new services, a designated state health planning agency must determine that a need exists for those beds, facilities or services. The process is intended to promote comprehensive healthcare planning, assist in providing high quality healthcare at the lowest possible cost and avoid unnecessary duplication by ensuring that only those healthcare facilities and operations that are needed will be built and opened.
Insurance
We are subject to claims and legal actions in the ordinary course of our business. To cover claims that may arise, we maintain professional malpractice liability insurance, general liability insurance, automobile liability insurance, and workers compensation/employers liability in amounts that we believe are appropriate and sufficient for our operations. We maintain professional malpractice and general liability insurance that provide primary coverage on a claims-made basis of $1.0 million per incident and $3.0 million in annual aggregate amounts. We maintain workers compensation insurance that meets state statutory requirements with a primary employer liability limit of $1.0 million for Louisiana, Mississippi and Arkansas and $500,000 in Texas. We maintain Automobile Liability for all owned, hired, and non-owned autos with a primary limit of $1.0 million. In addition, we currently maintain multiple layers of umbrella coverage in the aggregate amount of $5.0 million that provides excess coverage for professional malpractice, general liability, automobile liability and employers liability. Directors and Officers liability insurance in the aggregate amount of $15.0 million will be in effect prior to the time this offering is completed. The cost and availability of such coverage has varied widely in recent years. While we believe that our insurance policies and coverage are adequate for a business enterprise of our type, we cannot assure you that our insurance coverage is sufficient to cover all future claims or that it will continue to be available in adequate amounts or at a reasonable cost.
Legal Proceedings
We are involved in litigation and proceedings in the ordinary course of our business. We do not believe that the outcome of any of the matters in which we are currently involved, individually or in the aggregate, will have a material adverse effect upon our business, financial condition, or results of operations.
Properties
As of December 31, 2004 we owned or managed 63 locations in Louisiana, one in Alabama, six in Arkansas, 12 in Mississippi, and four in Texas. Our home office is located in Lafayette, Louisiana in 19,159 square feet of leased office space, under a lease that commenced on March 1, 2004 and expires February 28, 2014. Typically, our home nursing agencies are located in leased facilities. Generally, the leases for our home nursing agencies have initial terms of one year, but range from one to five years. Most of the leases either contain multiple options to extend the lease period in one-year increments or convert to
73
Employees
As of December 31, 2004 we had 2,164 employees, of which 1,260 were full-time and 904 were part-time employees, and approximately 374 independent contractors. None of our employees is subject to a collective bargaining agreement. We consider our relationships with our employees and independent contractors to be good.
74
MANAGEMENT
Executive Officers and Directors
The following table sets forth, as of
February 14, 2005, information about our executive officers
and directors.
Keith G. Myers
is
our co-founder, and has served as Chairman of the Board of
Directors, President and Chief Executive Officer (or similar
positions in our predecessors) since 1994. Prior to joining us,
Mr. Myers founded, co-owned and operated Louisiana Premium
Seafoods, Inc., an international food processing, procurement
and distribution company. Mr. Myers received credentials in
1999 from the National Association for Home Care with regard to
the home/hospice care sector. Mr. Myers was named Business
Executive of the Year in 1999 by Louisiana Rural Health
Association and Entrepreneur of the Year in the healthcare
category by Ernst & Young LLP with respect to the
Texas, Louisiana and Mississippi Region.
R. Barr Brown
joined us in April 2000 as our Senior
Vice President and Chief Financial Officer and has served as a
director and Treasurer since August 2004. From 1994 to 1999,
Mr. Brown was employed with Equity Corporation
International, where he served as Managing Director of Corporate
Development for the southern United States. Mr. Brown has
also served as the Chief Financial and Administrative Officer
and as a member of the board of directors for the Kasler
Corporation. Mr. Brown, a Certified Public Accountant,
received his Bachelor of Science degree in Business
Administration, with a major in accounting, from Louisiana State
University and commenced his professional career with Arthur
Young & Co., where he was employed from 1979 to 1984.
John L. Indest
has
served as our Senior Vice President and Chief Operating Officer
of Home-Based Services since May 2001. Mr. Indest has
served as a director since June 2000 and as Secretary since
August 2004. From November 1998 to May 2001, Mr. Indest
served as our Vice President. Prior to joining us in November
1998, Mr. Indest served as President, Chief Executive
Officer and co-owner of Homebound Care, Inc., a regional home
health provider. Mr. Indest has testified before the United
States House of Representatives Ways and Means
Subcommittee on healthcare issues and currently serves as
co-chairman of the Louisiana Task Force on Ethics, overseeing
compliance issues applicable to home health and hospice in the
state of Louisiana. Mr. Indest is a registered nurse with a
Masters of Science in Health Services Administration from the
University of St. Francis.
75
Daryl J. Doise
has
served as our Senior Vice President and Chief Operating Officer
of Facility-Based Services since May 2002, with responsibility
for the management and business development of our
facility-based services segment. Prior to joining us,
Mr. Doise was employed for the previous four years by
Quorum Health Services where he served as President and Chief
Executive Officer of Opelousas General Hospital, a 200-bed
hospital with over 800 employees. Mr. Doise has also served
as an officer and member of the board of directors of the
Louisiana Hospital Association. Mr. Doise received a
Bachelor of Science degree from Louisiana State University, with
a major in accounting, and earned a Masters of Business
Administration from Tulane University.
W. Patrick
Mulloy, II
was appointed as a
director in January 2005. From September 2001 to November 2004,
Mr. Mulloy served as President and Chief Executive Officer
of LifeTrust America, a privately held senior housing company
which owns and operates assisted living communities in seven
states across the Southeast. In 2004, LifeTrust merged with Five
Star Quality Care, Inc., a publicly traded senior housing
company. From 1996 until 2000, Mr. Mulloy served as Chief
Executive Officer, President and as a director of Atria, Inc., a
publicly-traded operator of assisted and retirement living
facilities. Prior to joining Atria, Mr. Mulloy was a
partner at Greenebaum, Doll and McDonald, PLLC, a law firm
headquartered in Louisville, Kentucky, and, from 1992 to 1994,
he served as the Secretary of Finance to the Governor of
Kentucky. Mr. Mulloy received a Bachelor of Arts Degree in
1974 and a Juris Doctorate in 1977, each from Vanderbilt
University, where he was a member of the Phi Beta Kappa Society.
W.J. Billy
Tauzin
was appointed as our lead
independent director in January 2005. In December 2004,
Congressman Tauzin was named President and Chief Executive
Officer of the Pharmaceutical Research and Manufacturers of
America, a trade group that serves as one of the pharmaceutical
industrys top lobbying groups. He served 12 terms in the
U.S. House of Representatives, representing
Louisianas 3rd Congressional District since being first
sworn in 1980. From January 2001 through December 2004,
Congressman Tauzin served as Chairman of the House Committee on
Energy and Commerce. He also served as a senior member of the
House Resources Committee and Deputy Majority Whip. Prior to
being a member of Congress, Congressman Tauzin was a member of
the Louisiana State Legislature, where he served as Chairman of
the House Natural Resources Committee and Chief Administration
Floor Leader. Congressman Tauzin received a Bachelor of Arts
Degree from Nicholls State University in 1964 and a Juris
Doctorate from Louisiana State University in 1967.
Earline H. Bihm
has
served as a director since 1994 and served as our Secretary of
the Board of Directors from June 2002 to July 2004. Mayor Bihm
received a Bachelor of Arts degree from the University of
Louisiana, Lafayette and taught in the public school system of
St. Landry Parish for 33 years before retiring from
teaching in 1997. Mayor Bihm held the position of councilman for
the Village of Palmetto from 1969 to 2002 and has served as
Mayor of the Village of Palmetto from March 2002 to present.
Ronald T. Nixon
has
served as a director since July 2001. Mr. Nixon is a
founding principal of The Catalyst Group, formed in 1990, which
manages two small business investment companies, or SBICs, one
participating preferred SBIC and three private equity investment
funds. Prior to joining The Catalyst Group, Mr. Nixon
operated companies in the manufacturing, distribution and
service sectors. Mr. Nixon serves on numerous private
boards. Mr. Nixon holds a Bachelor of Science degree in
Mechanical Engineering that he received from the University of
Texas at Austin and is a registered Professional Engineer in the
State of Texas.
Ted W. Hoyt
has
served as a director since August 2004. Mr. Hoyt has
practiced corporate and tax law since 1977, counseling both
private and public corporations. Since January 1999,
Mr. Hoyt has served as the Managing General Manager of the
law firm of Hoyt, Hodge & Stanford, LLC. Mr. Hoyt
was the co-founder of Omni Geophysical Corporation, which later
became Omni Energy Services, a publicly traded company, for
which he served as a director and officer from 1986 to 1996.
Mr. Hoyt has also served as a tax attorney with the
National Office of the Internal Revenue Service. Mr. Hoyt
holds a Bachelor of Science degree in Business Administration
degree from the University of Louisiana, Lafayette,
76
George A. Lewis
has
served as a director since August 2004. Mr. Lewis commenced
his auditing career with Arthur Andersen & Co. in 1958.
In 1963, Mr. Lewis joined the firm of Broussard, Poche,
Lewis & Breaux, L.L.P., Certified Public Accountants,
where he served as an audit partner until his retirement in
1996. Since 1996, Mr. Lewis has primarily served as an
expert audit and accounting defense witness with respect to
litigation involving various nationally recognized accounting
firms. Mr. Lewis has served on various committees of the
American Institute of Certified Public Accountants, including as
a member of the Auditing Standards Board from 1990 to 1994, and
as a member of the Society of Louisiana Certified Public
Accountants. At present, Mr. Lewis serves as Chairman of
the AICPA/ CICA ElderCare/ PrimePlus Task Force and has authored
an education course to train CPAs to deal with issues of the
elderly. Mr. Lewis received a Bachelor of Accounting from
Louisiana State University.
Board of Directors
In accordance with the terms of our certificate
of incorporation, the terms of office of the directors are
divided into three classes:
The Class I directors will be
Messrs. Brown and Mulloy and Ms. Bihm, the
Class II directors will be Messrs. Nixon, Indest and
Tauzin, and the Class III directors will be
Messrs. Myers, Hoyt and Lewis. At each annual meeting of
stockholders, or special meeting in lieu thereof, after the
initial classification of the board of directors, the successors
to directors whose terms will then expire will be elected to
serve from the time of election and qualification until the
third annual meeting following election, or special meeting held
in lieu thereof. The number of directors may be changed only by
resolution of the board of directors or a super-majority vote of
the stockholders. Any additional directorships resulting from an
increase in the number of directors will be distributed among
the three classes so that, as nearly as possible, each class
will consist of one-third of the directors. This classification
of the board of directors may have the effect of delaying or
preventing changes in control of management.
Board Committees
Our audit committee consists of
Messrs. Lewis, Hoyt and Nixon. The purpose of the audit
committee is to assist our board of directors in its general
oversight of our financial reporting, internal controls and
audit functions. Among other functions, the audit committee has
direct responsibility for the appointment, compensation,
retention and oversight of the work of our independent auditors.
Each member of the audit committee satisfies the requirements
for membership established by Nasdaq and the Securities and
Exchange Commission, or SEC. The board of directors has
determined that Mr. Lewis is a financial expert
within the definition of that term set forth in the regulations
under the Securities Act. Mr. Lewis will serve as the
Chairman of the Audit Committee.
Our compensation committee consists of
Messrs. Hoyt, Lewis and Mulloy. The compensation committee
reviews and recommends to the board of directors the
compensation and benefits of our executive officers and
administers our stock plans and employee benefit plans. The
compensation committee is responsible for producing an annual
report on executive compensation for inclusion in the
Companys proxy statement for each annual meeting of
stockholders. Each member of the compensation
77
Our nominating and corporate governance committee
consists of Messrs. Tauzin and Nixon and Ms. Bihm. The
nominating and corporate governance committee is responsible for
identifying qualified individuals to serve on the board of
directors, developing and recommending to the board of directors
a set of corporate policies and principles, and overseeing an
annual evaluation of the board of directors. Each member of the
nominating and corporate governance committee satisfies the
requirements for membership established by Nasdaq.
Mr. Tauzin will serve as the Chairman of the Nominating and
Corporate Governance Committee and as our lead independent
director.
Name
Age
Position(s)
44
President and Chief Executive Officer, Chairman
of the Board of Directors
47
Senior Vice President, Chief Financial Officer,
Treasurer, Director
52
Senior Vice President, Chief Operating Officer of
Home-Based Services, Secretary, Director
46
Senior Vice President, Chief Operating Officer of
Facility-Based Services
61
Director
51
Director
64
Director
48
Director
50
Director
68
Director
(1)
Audit Committee member
(2)
Compensation Committee member
(3)
Nominating and Corporate Governance Committee
Table of Contents
Table of Contents
Class I, whose term will expire at the
annual meeting of stockholders to be held in 2005;
Class II, whose term will expire at the
annual meeting of stockholders to be held in 2006; and
Class III, whose term will expire at the
annual meeting of stockholders to be held in 2007.
Audit Committee
Compensation Committee
Table of Contents
Nominating and Corporate Governance
Committee
Independent Director Compensation
We have not yet paid any compensation to
independent directors. Our lead independent director will
receive compensation of $50,000 per year, plus an initial
restricted stock grant of 7,000 shares, which will vest
over a two year period, and annual option grants to acquire
3,500 shares of our common stock, which options will be
fully vested upon issuance. Our other independent directors will
receive compensation of $24,000 per year and an additional
$6,000 per year for each committee on which they serve.
Committee chairpersons will receive an additional $6,000 per
year for each committee they chair. Our current independent
directors will also receive an initial restricted stock grant of
3,500 shares upon the completion of this offering, which
will vest over a two year period, and annual option grants to
acquire 2,000 shares of our common stock, which options
will be fully vested upon issuance. All independent directors
will also receive $300 for each non-regularly scheduled board
meeting attended. All stock options granted to our non-employee
directors will be granted pursuant to our 2005 Director
Compensation Plan and will be governed by the terms of such
plan. The shares issued under our 2005 Director Compensation
Plan will be issued from the 1,000,000 shares reserved for
issuance under our 2005 Long-Term Incentive Plan. Subject to
customary exceptions, we intend to enter into agreements
restricting our independent directors from selling shares of our
common stock received in consideration for service as a director
during their tenure on our Board of Directors.
Compensation Committee Interlocks and Insider
Participation
Prior to establishing the compensation committee,
the board of directors as a whole performed the functions
delegated to the compensation committee. No member of the board
of directors or the compensation committee serves as a member of
the board of directors or compensation committee of any entity
that has one or more executive officers serving as a member of
our board of directors or compensation committee.
Code of Conduct and Ethics
Prior to the completion of this offering, our
board of directors will adopt a code of conduct and code of
ethics applicable to all our officers, directors and employees
in accordance with applicable rules and regulations of the SEC
and Nasdaq. Upon completion of the offering, our code of conduct
and code of ethics will be available on our website.
78
Table of Contents
Executive Compensation
The following table sets forth certain elements
of compensation for our chief executive officer and the four
additional most highly compensated executive officers for the
fiscal year ended December 31, 2004:
Summary Compensation Table
Employee Benefit Plans
Our 2003 KEEP Plan was adopted by our board of
directors on March 28, 2003. The KEEP Plan provides for the
grant of awards to employees and officers in the form of KEEP
Units which represent the right to receive a cash or stock
payment in the future, based on the future value of the company,
and subject to certain restrictions and to risk of forfeiture.
The value of the KEEP Units is based on the fair market value of
the Company, where 10.0 million KEEP Units equals 100.0% of
the Company. The KEEP Units are subject to a five-year vesting
schedule from the date of grant (10.0%, 15.0%, 25.0%, 25.0% and
25.0% per year, respectively). In addition, any unvested
KEEP Units will vest (i) upon a sale of the Company or an
initial public offering of a class of securities of the Company,
(ii) upon a
79
The cash value of vested KEEP Units will be paid
to a participant following his or her termination of employment
in five equal installments as follows: 20.0% to be paid within
90 days of termination and then 20.0% on each of the first
four anniversaries of the termination. In the event of a sale of
the Company, the KEEP Units would automatically vest and would
be redeemed for cash and/or stock (in the same proportion of
cash and stock as the consideration received by members of the
Company in the sale transaction). In the event of an initial
public offering of a class of securities of the Company, the
KEEP Units would automatically vest and would be converted into
shares of common stock.
In connection with this offering, all outstanding
KEEP Units will become fully vested and non-forfeitable, and
will convert to and be settled in shares of common stock of the
company on a one-for-one basis. The board of directors has
determined that no additional awards of KEEP Units will be
granted under the KEEP Plan.
Our 2005 Long-Term Incentive Plan was adopted by
our board of directors and stockholders on January 20,
2005. It will go into effect as of the closing of this offering.
The purpose of the incentive plan is to promote our success and
enhance our value by linking the personal interests of
participants to those of the stockholders, and by providing such
persons with an incentive for outstanding performance.
The incentive plan authorizes the granting of
awards to employees, officers, directors and consultants in the
following forms:
The number of shares reserved and available for
issuance under the incentive plan is 1,000,000 shares. Not
more than 1,000,000 shares of stock may be granted in the
form of incentive stock options. In the event that any
outstanding award for any reason is cancelled or forfeited,
terminates, expires, lapses or is settled in cash, any unissued
shares subject to the award will again be available for issuance
under the incentive plan. If a participant pays the exercise
price of an option by delivering to us previously owned shares,
only the number of shares we issue in excess of the surrendered
shares will count against the incentive plans share limit.
Also, if the full number of shares subject to an option is not
issued upon
80
The incentive plan will be administered by the
compensation committee of our board of directors. The
compensation committee has the authority to:
Our board of directors may at any time administer
the incentive plan. In the event that the board of directors
chooses to administer the incentive plan, it will have all the
powers of the compensation committee regarding administration of
the incentive plan.
All awards must be evidenced by a written award
certificate, which will include the provisions specified by the
compensation committee. The compensation committee will
determine the exercise price for nonstatutory stock options. The
exercise price for any option cannot be less than the fair
market value of our common stock as of the date of the grant.
Under Section 162(m) of the Code, a public
company generally may not deduct compensation in excess of
$1.0 million paid to its chief executive officer and the
four next most highly compensated executive officers. Until the
annual meeting of our stockholders in 2009, or until the
incentive plan is materially amended, if earlier, awards granted
under the incentive plan will be exempt from the deduction
limits of Section 162(m). In order for awards granted after
the expiration of such grace period to be exempt, the incentive
plan must be amended to comply with the exemption conditions and
be resubmitted for approval by our stockholders.
In the event of certain corporate transactions
(including any stock dividend, stock split, merger, spin-off, or
related transaction), the share authorization limits described
above will be adjusted proportionately, and the compensation
committee may adjust awards to preserve their benefits or
potential benefits.
Unless otherwise provided in an award
certificate, upon the death, disability or retirement of a
participant, all of his or her outstanding options, stock
appreciation rights and other awards in the nature of rights
that may be exercised, will become fully vested, time-based
vesting restrictions on outstanding awards will lapse, and any
performance-based criteria will be deemed to be satisfied at the
greater of target or actual performance as of the
date of termination. Unless otherwise provided in an award
certificate, if a participants employment is terminated
without cause or the participant resigns for good reason (as
such terms are defined in the incentive plan) within two years
after a change in control of the company, all of such
participants outstanding options, stock appreciation
rights and other awards in the nature of rights that may be
exercised will become fully vested, time-based vesting
restrictions on outstanding awards will lapse, and any
performance-based criteria will be deemed to be satisfied at the
greater of target or actual performance as of the
date of termination. In addition, an award certificate or plan
document may provide that all of a participants
outstanding options, stock appreciation rights and other awards
in the nature of rights that may be exercised will become fully
vested, time-based vesting restrictions on outstanding awards
will lapse, and any performance-based criteria will be deemed to
be satisfied at the greater of target or actual
performance upon the occurrence of a specified future event,
including, but not limited to, a change in control of our
company or the participants termination of employment in
connection with a change of control of our company. The
compensation committee may, in its discretion, accelerate the
vesting of an option, stock appreciation right, or any other
award in the nature of rights that may be exercised and/or may
determine that all or a part of the time-based vesting
restrictions on all or a portion of a participants
outstanding awards will lapse and/or that any performance-based
criteria with respect to any awards will be deemed to be wholly
or partially satisfied, in
81
Our board of directors or the compensation
committee may at any time terminate or amend the incentive plan
without stockholder approval, but any amendment would be subject
to stockholder approval if, in the reasonable opinion of the
board or the compensation committee, the amendment would:
No termination or amendment of the incentive plan
may reduce or diminish the value of an outstanding award
determined as if the award had been exercised, vested, cashed in
or otherwise settled on the date of such amendment or
termination. The compensation committee may amend or terminate
outstanding awards, but such amendments may require the consent
of the participant and, unless approved by our stockholders or
otherwise permitted by the antidilution provisions of the
incentive plan, the exercise price of an outstanding option may
not be reduced, directly or indirectly, and the original term of
an option may not be extended.
We estimate that, as of the date of the closing
of this offering, substantially all of our employees, officers
and directors will be eligible to participate in the incentive
plan. Any awards will be made at the discretion of the
compensation committee. Therefore, it is not presently possible
to determine the benefits or amounts that will be received by
any individuals or groups pursuant to the incentive plan in the
future.
LHC Group Profit Sharing 401(k) Plan
Since January 1, 1998, we have maintained
the LHC Group Profit Sharing 401(k) Plan, which is a
tax-qualified, defined contribution plan subject to regulation
under the Employee Retirement Income Security Act of 1974, or
ERISA. Eligible employees may generally begin participating in
the plan on the first day of the next calendar month after they
complete three consecutive months of service.
Participants may elect to defer up to the lesser
of 100.0% of their compensation or the Internal Revenue Service
limit in effect for a given plan year (e.g. $13,000 in 2004,
$14,000 in 2005, $15,000 in 2006). Catch-up contributions for
participants who have reached age 50 are also available
under the plan. Compensation for plan purposes generally means a
participants total compensation plus any salary deferrals
made to this plan, a Code Section 125 cafeteria plan, a
Code Section 457 plan and under any transportation fringe
benefit arrangement.
Each plan year, we may determine whether to make
an employer matching contribution to the plan. The amount of any
matching contribution will be a discretionary percentage of each
participants salary deferrals during the plan year up to a
maximum percentage determined by us. Any matching contribution
we decide to make will be allocated to those participants who
are employed on the last day of the plan year and who have at
least 1,000 hours of service during the year.
Each plan year, we also may contribute an
employer profit-sharing contribution to the plan. The amount of
this profit-sharing contribution is discretionary and is
determined by us each year. Participants, in order to receive a
portion of this profit-sharing contribution, must be employed on
the last day of the plan year and must have completed at least
1,000 hours of service during the year. A participant
generally vests in his employer matching contributions and
employer profit-sharing contributions on a six year graded
schedule.
82
Before a participant terminates employment, he
may receive a distribution of his vested account balance once he
reaches his normal retirement age (the later of age 65 or
the 5th anniversary of a participants participation in the
plan). A participant may also receive a distribution of amounts
attributable to his salary deferrals under the plan and his
rollover contributions in the event of a financial hardship.
Participant loans are also available under the plan. At
termination of employment, participants may receive
distributions in the form of a lump sum (either of their entire
account balance or of a portion of the account balance).
Participants may direct the investment of their
account balances in various investment options offered under the
plan.
Employment and Change of Control
Agreements
We have entered into employment agreements with
our named executive officers, to be effective upon the date of
this prospectus, that are expected to include substantially the
terms described below.
Term.
The named
executive officers employment agreements have an initial
term of three years, and thereafter each of the agreements will
be automatically extended for additional one-year periods unless
the company or the executive officer gives notice to the other
party at least 60 days prior to the then-current term.
Salary and Benefits.
Each of the named executive officers is entitled to a base
annual salary (subject to annual review and increases for merit
performance) and is entitled to participate in all incentive,
savings, retirement and welfare benefit plans generally made
available to our senior management personnel. The initial annual
salaries of the named executive officers are as follows:
Mr. Myers: $275,000; Mr. Indest: $250,000;
Mr. Brown: $250,000; and Mr. Doise: $200,000. Each of
the named executive officers is entitled to participate in our
executive bonus plan, pursuant to which he will have an
opportunity to earn an annual cash bonus based upon achievement
of performance goals established by the compensation committee
of our board of directors. In addition, each of the named
executive officers is entitled to fringe benefits generally made
available to our senior management personnel.
Termination.
The
employment agreements may be terminated by us at any time with
or without cause (as defined therein), or by the
executive with or without good reason (as defined
therein). The agreements will also be terminated upon the death,
disability or retirement of the executive. Depending on the
reason for the termination and when it occurs, the executive
will be entitled to certain severance benefits, as described
below.
If a named executive officer is terminated
without cause or resigns for good reason, he will be entitled to
unpaid base salary, prorated annual bonus and accrued benefits
through the termination date, plus a severance amount equal to a
multiple of his base salary and target annual bonus. We will
also provide the executive with welfare benefit plan coverage
following such termination for a specified number of years. In
addition, if a named executive officer is terminated without
cause or resigns for good reason, all stock options and other
equity awards will become immediately vested and exercisable.
If any of the named executive officers is
terminated for cause or if he resigns without good reason, he
will be entitled to his accrued salary and benefits through the
date of termination. If a named executive officers
employment is terminated by reason of his death, disability or
retirement, he (or his estate, as applicable) will be entitled
to his accrued salary, a prorated annual bonus, and any accrued
benefits and disability or retirement benefits that may apply.
Restrictive
Covenants.
The employment agreements
include a covenant not to disclose confidential information or
compete with us, and not to solicit our customers or recruit our
employees, for a period of two years following the termination
of employment.
Change of Control.
The employment agreements include change of control provisions.
If the officer is terminated without cause or resigns for good
reason (as defined) during the two year period following a
change of control, he will receive severance benefits in an
amount equal to a multiple of his
83
84
Long-Term
Compensation
Annual Compensation
Restricted
Stock,
All Other
Name and Principal Position
Year
Salary
Bonus
Award(s)(1)
Compensation(2)
2004
$
250,000
$
157,824
$
32,617
$
7,059
President, Chief Executive Officer and
Chairman of the Board
2004
225,000
109,940
1,169,694
7,661
Senior Vice President, Chief Financial
Officer, Treasurer and Director
2004
225,000
101,654
69,894
12,094
Senior Vice President, Chief Operating
Officer of Home-Based Services,
Secretary and Director
2004
165,000
71,170
117,049
3,529
Senior Vice President, Chief Operating Officer of
Facility-Based Services
(1)
Amounts in this column include the value of KEEP
Units granted under the KEEP Plan. The KEEP Units represent the
right to receive a cash or stock payment based on the future
value of the company, where 10.0 million KEEP Units equal
100.0% of the companys value. KEEP Units are subject to a
five year vesting schedule with accelerated vesting upon a sale
of the company or in the event of an initial public offering. In
connection with this offering, all outstanding KEEP Units will
become fully vested and non-forfeitable, and will convert to and
be settled in shares of common stock of the company on a
one-for-one basis. The number and aggregate value of the KEEP
Units held by the named executive officers as of
December 31, 2004 were as follows: Keith G.
Myers 21,000 KEEP Units for an aggregate value of
$273,000; John L. Indest 33,000 KEEP Units for an
aggregate value of $429,000; R. Barr Brown 258,000
KEEP Units for an aggregate value of $3,354,000; and Daryl J.
Doise 77,430 KEEP Units for an aggregate value of
$1,006,590.
(2)
Amounts in this column reflect 401(k) plan
matching contributions of $2,099 for Mr. Myers, $2,854 for
Mr. Indest, $2,701 for Mr. Brown, and $2,309 for
Mr. Doise; long-term disability premiums of $1,220 paid on
behalf of each of the named executive officers; and life
insurance premiums of $3,740 paid on behalf of Mr. Myers,
$8,020 for Mr. Indest and $3,740 for Mr. Brown.
2003 Key Employee Equity Participation
Plan
Table of Contents
2005 Long-Term Incentive Plan
options to purchase shares of our common stock,
which may be nonstatutory stock options or incentive stock
options under the Internal Revenue Code of 1986, as amended, or
the Code;
stock appreciation rights, which give the holder
the right to receive the difference between the fair market
value per share on the date of exercise over the grant price;
performance awards, which are payable in cash or
stock upon the attainment of specified performance goals;
restricted stock, which is subject to
restrictions on transferability and other restrictions set by
the compensation committee;
restricted stock units, which give the holder the
right to receive shares of stock, or the equivalent value in
cash or other property, in the future;
dividend equivalents, which entitle the
participant to payments equal to any dividends paid on the
shares of stock underlying an award;
performance-based cash awards, which give the
holder the right to a cash award to be paid upon achievement of
specified performance goals; and
other stock-based awards in the discretion of the
compensation committee, including unrestricted stock grants.
Table of Contents
designate participants;
determine the type or types of awards to be
granted to each participant and the number, terms and conditions
of awards;
establish, adopt or revise any rules and
regulations to administer the incentive plan; and
make all other decisions and determinations that
may be required under the incentive plan.
Table of Contents
materially increase the number of shares
available under the incentive plan;
expand the types of awards available under the
incentive plan;
materially expand the class of participants
eligible to participate in the incentive plan;
materially extend the term of the incentive
plan; or
otherwise constitute a material change requiring
stockholder approval under applicable laws or the applicable
requirements of Nasdaq.
Table of Contents
Table of Contents
Table of Contents
CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
We believe that we have executed all of the transactions set forth below on terms no less favorable to us than we could have obtained from unaffiliated third parties.
Catalyst Fund and Southwest/ Catalyst Capital Investments
In July 2001, we entered into a Loan Agreement with The Catalyst Fund, Ltd. and Southwest/ Catalyst Capital, Ltd., or the Catalyst Entities, involving an aggregate amount of $2.0 million. These loans were evidenced by individual promissory notes; each in the principal amount of $1.0 million, accruing interest at a rate of 12.0% per annum and payable in equal monthly installments of approximately $26,000 in principal and interest, due July 1, 2006. As of September 30, 2004, approximately $1.0 million in principal and interest remained outstanding under these promissory notes.
The terms of these promissory notes provide for prepayment penalties and fees in the amount of 3.0%, 2.0% and 1.0% of any amount prepaid during years one, two and three, respectively. In addition, any prepayment of principal must be in an amount equal to or exceeding $50,000. There are exceptions to these prepayment penalties where payments are made as a result of excess operating cash flow.
In order to guarantee repayment under these notes, the Catalyst Entities possess a security interest in our equipment, inventory, accounts receivable, general intangibles, chattel paper and instruments. Also serving as collateral is the assignment of a Key Employee Life Insurance Policy with regard to Keith G. Myers in the amount of $2.0 million, of which we are named beneficiary.
In connection with the Loan Agreement, we entered into a Consulting Agreement with the Catalyst Entities under which they agreed to provide assistance, advice and consultation with respect to our operations, marketing and financial structure and performance in consideration of the issuance of warrants to purchase up to the equivalent of an aggregate of 966,813 shares of our currently outstanding common stock. These warrants were exercised in their entirety in March 2002 for a total of $1,000. As a result of the exercise of these warrants, shares held by the Catalyst Entities represented an aggregate of approximately 8.0% of our issued and outstanding shares of common stock prior to this offering.
Ronald T. Nixon, one of our directors, serves as an executive officer of each of the Catalyst Entities. Mr. Nixon was elected to our board of directors as the Catalyst Entities nominee pursuant to the July 2001 Loan Agreement. No other investors participated in the July 2001 transactions. We intend to repay the amounts outstanding under the Catalyst Loan Agreement prior to the completion of this offering.
Sunset Clinic Lease Arrangement
In July 2003, one of our indirect, wholly owned subsidiaries, Louisiana Physical Therapy, LLC, entered into a Lease Agreement with Oak Shadows of Sunset, LLC for approximately 7,250 square feet of space located in Grand Coteau, Louisiana. The Lease Agreement has an initial 10-year term that expires in July 2013, with an option to extend for additional successive one-year periods on the same terms. The Lease Agreement grants no right of termination. The Lease Agreement requires monthly payments of approximately $3,500 for the initial term for the use of the space plus maintenance, taxes, insurance and other expenses. Currently, the property is used as an outpatient rehabilitation clinic.
At the time of the Lease Agreements execution, Keith G. Myers, our President, Chief Executive Officer and Chairman, held 100.0% of the membership interests in Oak Shadows. On December 1, 2004, pursuant to a Transfer and Assignment of LLC Membership Interest, Mr. Myers, as the sole member of Oak Shadows, transferred this membership interest, which included land and building with a net book value of $292,945, to us in exchange for our assumption of Mr. Myerss guarantee of mortgage indebtedness relating to the property, in the form of two note payables whose principal balances totaled $292,945. The acquisition of 100.0% interest in Oak Shadows of Sunset, LLC will be reflected in our fourth quarter reported results by recording the property and the note payables at the amounts stated above.
85
Repurchase of Common Stock from Certain Stockholders
In March 2001, Rebecca and Byron Briggs agreed to sell us the equivalent of an aggregate of 3,881,663 shares of our currently outstanding common stock. The purchase price was paid pursuant to a promissory note in the principal amount of approximately $1.0 million. The note bears interest at a rate of 15.5% and payments of approximately $25,000 are due on the first of each month, beginning March 1, 2001. As of September 30, 2004, approximately $380,000 in principal and accrued interest was outstanding under this note.
The repurchased shares are held in escrow as collateral for the payment of the purchase price. As we pay each monthly installment due under the promissory note, a proportion of the total repurchased shares is released to us. This proportion is determined by dividing the principal amount paid in the particular installment by a price per share of $0.4026. The sole and exclusive remedy available in the event of default under the promissory note is foreclosure on the remaining collateral. We intend to satisfy this note in full prior to the completion of this offering.
We are also contingently liable to pay Mr. and Mrs. Briggs approximately $337,500 related to an earn-out payment under a noncompete agreement, which is payable on or before March 31, 2006 if our gross collected revenues equal or exceed $225,693,359 between January 1, 2001 and December 31, 2005. We met the revenue earn-out threshold in the quarter ended December 31, 2004, and will record a compensation charge of $337,500 in that period.
Shareholders Agreement for Hebert, Thibodeaux, Albro and Touchet Therapy Group, Inc.
We and the shareholders of Hebert, Thibodeaux, Albro and Touchet Therapy Group, Inc., including two of our significant stockholders, Christopher B. Thibodeaux and David D. Hebert, entered into a shareholders agreement in April 2004 for the purpose of governing one of our joint ventures. Under the terms of this shareholders agreement, Messrs. Thibodeaux, Hebert, Albro and Touchet have the right to convert their equity interests in the joint venture into shares of our common stock upon the consummation of this offering. In November 2004, Messrs. Thibodeaux, Hebert, Albro and Touchet agreed to convert their equity interests in the joint venture into an aggregate of 68,036 shares of our common stock, of which an aggregate of 40,960 shares will be issued to Messrs. Hebert and Thibodeaux, respectively, effective upon the completion of this offering. In connection with their conversion, the shareholders agreement with respect to Hebert, Thibodeaux, Albro and Touchet Therapy Group, Inc. will be terminated and we will be released from any further obligations thereunder.
Indebtedness of Certain Officers
In October 2004, R. Barr Brown, who serves as our Senior Vice President, Chief Financial Officer and Treasurer and as a director, repaid in full a promissory note held by us in the principal amount of $90,000. The promissory note, which had an interest rate of 7.0% per annum, was formerly secured by 33,000 KEEP Units issued by our predecessor, LHC Group, LLC and held by Mr. Brown. In connection with its repayment by Mr. Brown, the promissory note was canceled and our security interest in Mr. Browns KEEP Units was terminated.
Mr. Brown was formerly the obligor under another promissory note in our favor in the principal amount of $123,401, which note had an interest rate of 6.0% per annum and was due on or before March 2010. Mr. Brown was entitled under the note to prepay all or any part of this obligation without penalty. This promissory note was intended to serve as payment of the purchase price for 150,000 membership units issued by our predecessor, LHC Group, LLC purchased by Mr. Brown pursuant to a Subscription Agreement in March 2004. As security for the repayment of the promissory note, Mr. Brown concurrently executed an Act of Pledge in which he granted us the right to sell any or all of his membership units in the event of default under or non-payment of the promissory note. In exchange for the return of the 150,000 membership units formerly issued to Mr. Brown, this promissory note was cancelled in June 2004.
86
We will not borrow from or provide loans to any of our directors, officers or stockholders in the future.
Indemnification Agreements with Certain Officers and Directors
We have entered into indemnification agreements with each of our executive officers and directors. See Description of Capital Stock Limitations of Liability and Indemnification Matters.
87
PRINCIPAL AND SELLING STOCKHOLDERS
The following table sets forth information regarding the beneficial ownership of our common stock, as of December 31, 2004, by the following individuals or groups: (1) each person, or group of affiliated persons, whom we know beneficially owns more than 5.0% of our outstanding stock; (2) each of our named executive officers; (3) each of our directors; (4) all of our directors and executive officers as a group; and (5) each of our stockholders selling shares in this offering.
Except as indicated by footnote, and except for community property laws where applicable, we believe, based on information provided to us, that the persons named in the table below have sole voting and investment power with respect to all shares of common stock shown as beneficially owned by them. Beneficial ownership is determined in accordance with the rules of the SEC. The percentage of beneficial ownership before the offering is based on 13,091,865 shares of common stock deemed outstanding as of December 31, 2004, which assumes conversion of the joint venture equity interests of two of our joint venture partners into 518,034 aggregate shares of our common stock in connection with this offering, gives effect to the issuance of 481,680 shares of our common stock upon conversion of outstanding KEEP Units and gives effect to the issuance of 7,000 shares of vested restricted common stock upon the completion of this offering.
Shares Beneficially | Shares Beneficially | ||||||||||||||||||||||||||||||||
Owned Prior to | Shares Beneficially | Shares to | Owned After Offering | ||||||||||||||||||||||||||||||
Offering | Shares to | Owned After Offering | be Sold in | with Over-Allotment | |||||||||||||||||||||||||||||
|
be Sold in |
|
Over- |
|
|||||||||||||||||||||||||||||
Name and Address of | Number | Percent | Offering | Number | Percent | Allotment | Number | Percent | |||||||||||||||||||||||||
Beneficial Owner (1) : |
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||
Named Executive Officers
|
|||||||||||||||||||||||||||||||||
Keith G. Myers
(2)
|
4,514,337 | 34.5 | % | 282,368 | 4,231,969 | 26.1 | % | 188,245 | 4,043,724 | 25.0 | % | ||||||||||||||||||||||
R. Barr Brown
(3)
|
258,000 | 2.0 | 17,054 | 240,946 | 1.5 | 11,369 | 229,577 | 1.4 | |||||||||||||||||||||||||
John L. Indest
(4)
|
649,137 | 5.0 | 41,461 | 607,676 | 3.8 | 27,640 | 580,036 | 3.6 | |||||||||||||||||||||||||
Daryl J. Doise
(5)
|
77,430 | * | | 77,430 | * | | 77,430 | * | |||||||||||||||||||||||||
Directors
|
|||||||||||||||||||||||||||||||||
Earline H. Bihm
(6)
|
1,301,280 | 9.9 | % | 82,154 | 1,219,126 | 7.5 | % | 54,770 | 1,164,356 | 7.2 | % | ||||||||||||||||||||||
Ted W. Hoyt
(7)
|
3,167 | * | | 3,167 | * | | 3,167 | * | |||||||||||||||||||||||||
George A. Lewis
(8)
|
3,167 | * | | 3,167 | * | | 3,167 | * | |||||||||||||||||||||||||
W. Patrick Mulloy, II
(9)
|
3,167 | * | | 3,167 | * | | 3,167 | * | |||||||||||||||||||||||||
Ronald T. Nixon
(10)
|
969,981 | 7.4 | 145,022 | 824,959 | 5.1 | 96,682 | 728,277 | 4.5 | |||||||||||||||||||||||||
W.J. Billy Tauzin
(11)
|
5,833 | * | | 5,833 | * | | 5,833 | * | |||||||||||||||||||||||||
All executive officers and directors as a group
(10 persons)
|
7,785,499 | 59.5 | % | 568,059 | 7,217,440 | 44.5 | % | 378,706 | 6,838,734 | 42.2 | % | ||||||||||||||||||||||
Beneficial Owners of 5% or More of the
Outstanding Common Stock of LHC Group
|
|||||||||||||||||||||||||||||||||
James Gravois
(12)
|
1,301,280 | 9.9 | % | 82,154 | 1,219,126 | 7.5 | % | 54,770 | 1,164,356 | 7.2 | % | ||||||||||||||||||||||
Harold Taylor
(13)
|
1,308,031 | 10.0 | 82,575 | 1,225,456 | 7.6 | 55,051 | 1,170,405 | 7.2 | |||||||||||||||||||||||||
David Hebert
(14)
|
699,654 | 5.3 | 44,613 | 655,041 | 4.0 | 29,742 | 625,299 | 3.9 | |||||||||||||||||||||||||
Chris Thibodeaux
(15)
|
699,655 | 5.3 | 44,613 | 655,042 | 4.0 | 29,742 | 625,300 | 3.9 | |||||||||||||||||||||||||
Denise Romano
(16)
|
658,175 | 5.0 | 42,025 | 616,150 | 3.8 | 28,016 | 588,134 | 3.6 | |||||||||||||||||||||||||
Other Selling Stockholders
|
|||||||||||||||||||||||||||||||||
The Catalyst Fund, Ltd.
(17)
|
483,407 | 3.7 | % | 72,511 | 410,896 | 2.5 | % | 48,341 | 362,555 | 2.2 | % | ||||||||||||||||||||||
Southwest/Catalyst Capital, Ltd.
(17)
|
483,407 | 3.7 | 72,511 | 410,896 | 2.5 | 48,341 | 362,555 | 2.2 | |||||||||||||||||||||||||
Beta Home Care, Inc.
(18)
|
450,000 | 3.4 | 28,080 | 421,920 | 2.6 | 18,720 | 403,200 | 2.5 | |||||||||||||||||||||||||
Victor Varisco
(19)
|
105,000 | * | 7,506 | 97,494 | * | 5,005 | 92,489 | * | |||||||||||||||||||||||||
Angie Begnaud
(20)
|
3,000 | * | 187 | 2,813 | * | 125 | 2,688 | * |
88
Shares Beneficially | Shares Beneficially | |||||||||||||||||||||||||||||||
Owned Prior to | Shares Beneficially | Shares to | Owned After Offering | |||||||||||||||||||||||||||||
Offering | Shares to | Owned After Offering | be Sold in | with Over-Allotment | ||||||||||||||||||||||||||||
|
be Sold in |
|
Over- |
|
||||||||||||||||||||||||||||
Name and Address of | Number | Percent | Offering | Number | Percent | Allotment | Number | Percent | ||||||||||||||||||||||||
Beneficial Owner (1) : |
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
Greg Ketchings
(21)
|
1,500 | * | 94 | 1,406 | * | 62 | 1,344 | * | ||||||||||||||||||||||||
Holly Rabalais
(22)
|
750 | * | 47 | 703 | * | 31 | 672 | * | ||||||||||||||||||||||||
Kelli Dore
(22)
|
750 | * | 47 | 703 | * | 31 | 672 | * |
(*) | Less than 1.0% of the outstanding common stock. | |
(1) | Unless otherwise noted below, the address of each beneficial owner listed in the table above is c/o LHC Group, Inc., 420 West Pinhook Rd., Suite A, LaFayette, LA 70503. | |
(2) | Includes 21,000 shares that will automatically be issued upon the completion of this offering in connection with the conversion of outstanding KEEP Units, 970,416 shares held by his wife, Ginger Myers, and 3,370,002 shares held by K & G Family, LLC, of which Mr. Myers is a Manager. Of the 470,613 aggregate shares shown on the table above as being sold by Mr. Myers in the offering, including those shares to be sold upon the exercise of the over-allotment option, 17,697 shares are being sold by Mr. Myers and 452,916 shares are being sold by his wife. | |
(3) | Includes 258,000 shares that will automatically be issued upon the completion of this offering in connection with the conversion of outstanding KEEP Units. | |
(4) | Includes 33,000 shares that will automatically be issued upon the completion of this offering in connection with the conversion of outstanding KEEP Units and 462,102 shares held by Duperier Avenue Investors, LLC, of which Mr. Indest is a Manager. | |
(5) | Includes 77,430 shares that will automatically be issued upon the completion of this offering in connection with the conversion of outstanding KEEP Units. | |
(6) | Includes 975,960 shares held by SKE Management, LLC, of which Mrs. Bihm is a Manager. | |
(7) | Includes 2,000 shares issuable upon the exercise of stock options exercisable within 60 days. The options and stock held by Mr. Hoyt were issued under our 2005 Director Compensation Plan. Although these options and stock will be issued upon the completion of this offering, the table above gives effect to such issuance as if it had occurred on December 31, 2004. | |
(8) | Includes 2,000 shares issuable upon the exercise of stock options exercisable within 60 days. The options and stock held by Mr. Lewis were issued under our 2005 Director Compensation Plan. Although these options and stock will be issued upon the completion of this offering, the table above gives effect to such issuance as if it had occurred on December 31, 2004. | |
(9) | Includes 2,000 shares issuable upon the exercise of stock options exercisable within 60 days. The options and stock held by Mr. Mulloy were issued under our 2005 Director Compensation Plan. Although these options and stock will be issued upon the completion of this offering, the table above gives effect to such issuance as if it had occurred on December 31, 2004. | |
(10) | Includes 483,407 shares owned by The Catalyst Fund, Ltd. and 483,407 shares owned by Southwest/Catalyst Capital, Ltd. Mr. Nixon is an executive officer of The Catalyst Fund, Ltd. and Southwest/Catalyst Capital, Ltd. Mr. Nixon and Rick Hermann, who is also an executive officer of The Catalyst Fund, Ltd. and Southwest/Catalyst Capital Ltd., exercise shared investment power over the shares of common stock owned by The Catalyst Fund Ltd. and Southwest/Catalyst Capital, Ltd. The address for Mr. Nixon is Two Riverway, Suite 1710, Houston, TX 77056. Mr. Nixons beneficial ownership also includes 2,000 shares issuable upon the exercise of stock options exercisable within 60 days. The options and stock held by Mr. Nixon were issued under our 2005 Director Compensation Plan. Although these options and stock will be issued upon the completion of this offering, the table above gives effect to such issuance as if it had occurred on December 31, 2004. Of the 241,704 aggregate shares shown on the table above as being sold by Mr. Nixon in the offering, including those shares to be sold upon the exercise of the over-allotment option, 120,852 shares are being sold by The Catalyst Fund, Ltd. and 120,852 shares are being sold by Southwest/Catalyst Capital, Ltd. |
89
(11) | Includes 3,500 shares issuable upon the exercise of stock options exercisable within 60 days. The options held by Mr. Tauzin were issued under our 2005 Director Compensation Plan. Although these options and stock will be issued upon the completion of this offering, the table above gives effect to such issuance as if it had occurred on December 31, 2004. |
(12) | Includes 975,960 shares held by Gravois Investments, LLC, of which Mr. Gravois is a Manager. |
(13) | Includes 6,750 shares that will automatically be issued upon the completion of this offering in connection with the conversion of outstanding KEEP Units, 490,511 shares held by Silver State Partners, LLC and 490,511 shares held by Bayou State Partners, LLC, in each of which Mr. Taylor is a Manager. |
(14) | Includes 20,480 shares that will automatically be issued upon the completion of this offering in connection with the conversion of Mr. Heberts equity interests in one of our joint ventures into shares of our common stock. |
(15) | Includes 20,480 shares that will automatically be issued upon the completion of this offering in connection with the conversion of Mr. Thibodeauxs equity interests in one of our joint ventures into shares of our common stock and 524,741 shares held by Thibodeaux Family Investors, LLC, of which Mr. Thibodeaux is a Manager. |
(16) | Includes 1,500 shares that will automatically be issued upon the completion of this offering in connection with the conversion of outstanding KEEP Units and 492,506 shares held by Bayou State Associates, LLC, of which Mrs. Romano is a Manager. |
(17) | The address for The Catalyst Fund, Ltd. and Southwest/Catalyst Capital, Ltd. is Two Riverway, Suite 1710, Houston, TX 77056. |
(18) | Includes 450,000 shares that will automatically be issued upon the completion of this offering in connection with the conversion of Beta Home Care, Inc.s equity interests in one of our joint ventures into shares of our common stock. The address for Beta Home Care, Inc. is 3201 Center Street, Lake Charles, LA 70601. Christopher Baggett and John Rudd exercise shared investment power over the shares of common stock held by Beta Home Care, Inc. |
(19) | Includes 15,000 shares that will automatically be issued upon the completion of this offering in connection with the conversion of outstanding KEEP Units. |
(20) | Includes 3,000 shares that will automatically be issued upon the completion of this offering in connection with the conversion of outstanding KEEP Units. |
(21) | Includes 1,500 shares that will automatically be issued upon the completion of this offering in connection with the conversion of outstanding KEEP Units. |
(22) | Includes 750 shares that will automatically be issued upon the completion of this offering in connection with the conversion of outstanding KEEP Units. |
90
DESCRIPTION OF OUR CAPITAL STOCK
Our authorized capital stock consists of 40,000,000 shares of common stock, $0.01 par value, and 5,000,000 shares of preferred stock, $0.01 par value. The following description summarizes important terms of our capital stock. Because it is only a summary, it does not contain all the information that may be important to you. For a complete description, you should refer to our certificate of incorporation and bylaws, copies of which have been filed as exhibits to the registration statement of which this prospectus is a part, as well as the relevant portions of the Delaware General Corporation Law.
Common Stock
General. As of December 31, 2004, there were 12,085,150 shares of common stock outstanding and 12 stockholders of record. After this offering, there will be 16,191,867 shares of our common stock outstanding.
Voting Rights. The holders of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders, including the election of directors, and do not have cumulative voting rights. Accordingly, the holders of a majority of the shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they so choose.
Dividends. Subject to preferences that may be applicable to any then outstanding preferred stock, holders of our common stock are entitled to receive ratably those dividends, if any, as may be declared by the board of directors out of legally available funds.
Liquidation, Dissolution and Winding Up. Upon our liquidation, dissolution or winding up, the holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the prior rights of any preferred stock then outstanding.
Preemptive Rights. Holders of our common stock have no preemptive or conversion rights or other subscription rights and there are no redemption or sinking funds provisions applicable to our common stock.
Assessment. All outstanding shares of our common stock are, and the shares of our common stock to be outstanding upon completion of this offering will be, fully paid and nonassessable.
Preferred Stock
A total of 5,000,000 shares of undesignated preferred stock is authorized, none of which is outstanding. The board of directors has the authority, without further action by the stockholders, to issue from time to time the undesignated preferred stock in one or more series and to fix the number of shares, designations, preferences, powers, and relative, participating, optional or other special rights and the qualifications or restrictions thereof. The preferences, powers, rights and restrictions of different series of preferred stock may differ with respect to dividend rates, amounts payable on liquidation, voting rights, conversion rights, redemption provisions, sinking fund provisions, purchase funds and other matters. The issuance of preferred stock could decrease the amount of earnings and assets available for distribution to holders of our common stock or adversely affect the rights and powers, including voting rights, of the holders of our common stock, and may have the effect of delaying, deferring or preventing a change in control of our company.
Anti-Takeover Effects of Provisions of our Certificate of Incorporation and Bylaws and Delaware Law
Some provisions of Delaware law and our certificate of incorporation and bylaws contain provisions that could make the following transactions more difficult: (1) acquisition of us by means of a tender offer; (2) acquisition of us by means of a proxy contest or otherwise; or (3) removal of our incumbent officers and directors. These provisions, summarized below, are intended to encourage persons seeking to acquire
91
Undesignated Preferred Stock. Our board of directors has the ability to authorize undesignated preferred stock, which allows the board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any unsolicited attempt to change control of our company. This ability may have the effect of deferring hostile takeovers or delaying changes in control or management of our company.
Stockholder Meetings. Our bylaws provide that a special meeting of stockholders may be called only by our President, our Chief Executive Officer or by a resolution adopted by a majority of our board of directors.
Requirements for Advance Notification of Stockholder Nominations and Proposals. Our bylaws establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of our board of directors or a committee thereof.
Elimination of Stockholder Action by Written Consent. Our certificate of incorporation eliminates the right of stockholders to act by written consent without a meeting.
Election and Removal of Directors. Our board of directors is divided into three classes. The directors in each class will serve for a three-year term, one class being elected each year by our stockholders. Once elected, directors may be removed only for cause and only by the affirmative vote of a majority of our outstanding common stock. For more information on the classified board, see the section entitled Management Board of Directors. This system of electing and removing directors may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us because it generally makes it more difficult for stockholders to replace a majority of the directors.
Delaware Anti-Takeover Statute. We are subject to Section 203 of the Delaware General Corporation Law which prohibits persons deemed interested stockholders from engaging in a business combination with a Delaware corporation for three years following the date these persons become interested stockholders. Generally, an interested stockholder is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15.0% or more of a corporations voting stock. Generally, a business combination includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors.
The provisions of Delaware law and our certificate of incorporation and bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. Such provisions may also have the effect of preventing changes in our management. It is possible that these provisions could make it more difficult to accomplish transactions which stockholders may otherwise deem to be in their best interests.
Limitations of Liability and Indemnification Matters
We have adopted provisions in our certificate of incorporation that limit the liability of our directors for monetary damages for breach of their fiduciary duties, except for liability that cannot be eliminated under the Delaware General Corporation Law. Delaware law provides that directors of a corporation will not be personally liable for monetary damages for breach of their fiduciary duties as directors, except liability for any of the following: (1) any breach of their duty of loyalty to the corporation or the stockholders; (2) acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; (3) unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the Delaware General Corporation Law; or (4) any transaction from which the director derived an improper personal benefit. This limitation of liability does not apply to
92
Our bylaws also provide that we will indemnify our directors and executive officers and we may indemnify our other officers and employees and other agents to the fullest extent permitted by law. We believe that indemnification under our bylaws covers at least negligence and gross negligence on the part of indemnified parties. Our bylaws also permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in such capacity, regardless of whether our bylaws would permit indemnification. We have entered into separate indemnification agreements with our directors and executive officers, in addition to the indemnification provided for in our charter documents. These agreements, among other things, provide for indemnification of our directors and executive officers for expenses, judgments, fines, and settlement amounts incurred by any such person in any action or proceeding arising out of such persons services as a director or executive officer or at our request.
Transfer Agent and Registrar
The transfer agent and registrar for the common stock is SunTrust Bank.
93
SHARES ELIGIBLE FOR FUTURE SALE
Prior to this offering there has been no public market for our common stock, and we cannot predict the effect that any future sales may have on the market price prevailing from time to time. As described below, only a limited number of shares will be available for sale shortly after this offering due to contractual and legal restrictions on resale. Nevertheless, sales of our common stock in the public market after these restrictions lapse, or the perception that such sales may occur, could adversely affect our stock price.
Sales of Restricted Shares
Upon the closing of this offering, we will have outstanding an aggregate of approximately 16,191,867 shares of common stock. Of these shares, 4,000,000 shares of common stock to be sold in this offering, or 4,600,000 shares if the underwriters exercise their over-allotment in full, will be freely tradable without restriction or further registration under the Securities Act, unless the shares are held by any of our affiliates, as that term is defined in Rule 144 of the Securities Act. All remaining shares were issued and sold by us in private transactions and are eligible for public sale only if registered under the Securities Act or sold in accordance with Rule 144, including Rule 144(k), or Rule 701, each of which is discussed below. In addition, upon completion of this offering, we will have (i) outstanding stock options held by employees, consultants and directors for the purchase of 11,500 shares of common stock; and (ii) 14,000 shares of unvested restricted common stock issued under our 2005 Director Compensation Plan.
All of our officers and directors and substantially all of our stockholders are subject to lock-up agreements under which they have agreed not to transfer or dispose of, directly or indirectly, any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock, for a period of 180 days after the date of this prospectus.
As a result of the lock-up agreements described below and the provisions of Rule 144, Rule 144(k) and Rule 701 under the Securities Act, the shares of our common stock (excluding the shares to be sold in this offering) will be available for sale in the public market as follows:
shares
will be eligible for sale on the date of this prospectus;
shares
will be eligible for sale under Rule 144 or Rule 701
ninety days after the date of this prospectus; and
shares
will be eligible for sale upon the expiration of the lock-up
agreements, as more particularly and except as described below,
beginning 180 days after the date of this prospectus
pursuant to Rule 144, Rule 144(k) or Rule 701.
We expect the remaining shares to become eligible for future sale in the public market pursuant to Rule 144 at varying times after one year from the date of this prospectus.
Rule 144 |
Rule 144 allows persons whose shares are subject to transfer restrictions, either because the person is an affiliate or because the shares have never been registered, to transfer the shares if they comply with the Rules requirements. In general, under Rule 144, a person (or group of persons whose shares are aggregated) who has beneficially owned restricted securities for at least one year (including, in some instances, the holding period of a previous owner if the previous owner was not an affiliate), and who files a Form 144 with respect to such sale, is entitled to sell within any three-month period commencing 90 days after the date of this prospectus a number of shares of common stock that does not exceed the greater of: (i) 1.0% of the then outstanding shares of our common stock, which would equal approximately 161,919 shares immediately after this offering, or (ii) the average weekly trading volume during the four calendar weeks preceding such sale. Sales under Rule 144 are also subject to restrictions relating to manner of sale and the availability of current public information about us. We cannot estimate the number
94
Rule 144(k) |
A person who is not deemed to have been our affiliate at any time during the 90 days immediately preceding a sale and who has beneficially owned his or her shares for at least two years, including the holding period of any prior owner who is not an affiliate, is entitled to sell these shares of common stock pursuant to Rule 144(k) without regard to the volume limitations, manner of sale provisions, public information or notice requirements of Rule 144. Affiliates are not eligible to sell under Rule 144(k) and must always meet all of the requirements discussed under Rule 144 above, even after the applicable holding periods have been satisfied.
Rule 701 |
Rule 701 may be relied upon with respect to the resale of securities originally acquired from us by our employees, directors, officers, consultants or advisers prior to the closing of this offering and pursuant to written compensatory benefit plans or written contracts relating to the compensation of such persons. In addition, the SEC has indicated that Rule 701 will apply to stock options granted by us before this offering, along with the shares acquired upon exercise of such options. Securities issued in reliance on Rule 701 are deemed to be restricted shares and, beginning 90 days after the date of this prospectus, may be sold by persons other than affiliates subject only to the manner of sale provisions of Rule 144 and by affiliates under Rule 144 without compliance with the holding period requirements.
Lock-up Agreements
We, our executive officers and directors and all of our stockholders have each signed a lock-up agreement which prevents each of us, subject to limited exceptions, from offering, selling, contracting to sell, pledging or otherwise disposing of any shares of our common stock or securities or other rights convertible into or exchangeable or exercisable for any shares of our common stock either owned as of the date of this prospectus or thereafter acquired or publicly announcing an intention to do any of the foregoing, for a period of 180 days after the date of this prospectus without the prior written consent of the underwriters. This 180 day period may be extended if (1) during the last 17 days of the 180 day period we issue an earning release or material news or a material event relating to us occurs or (2) prior to the expiration of the 180 day period, we announce that we will release earnings results during the 16 day period beginning on the last day of the 180 day period. The period of such extension will be 18 days, beginning on the issuance of the earnings release or the occurrence of the material news or material event.
Stock Options
We intend to file a registration statement under the Securities Act covering up to 1,000,000 shares of common stock reserved for issuance under our 2005 Long-Term Incentive Plan. This registration statement is expected to be filed soon after the date of this prospectus and will automatically become effective upon filing. Accordingly, shares registered under such registration statement will be available for sale in the open market, unless such shares are subject to vesting restrictions with us or are otherwise subject to the lock-up agreements described above.
95
FEDERAL INCOME TAX CONSEQUENCES TO
General
The following is a general discussion of the U.S. federal income and estate tax consequences of the ownership and disposition of our common stock that may be relevant to you if you are a non-U.S. holder that acquires our common stock pursuant to this offering. This discussion is limited to non-U.S. holders who hold our common stock as a capital asset within the meaning of Section 1221 of the Code.
This discussion does not address all aspects of U.S. federal income and estate taxation that may be relevant to you in light of your particular circumstances, and does not address any foreign, state or local tax consequences. Furthermore, this discussion does not consider specific facts and circumstances that may be relevant to a particular non-U.S. holders tax position, specific rules that may apply to certain non-U.S. holders, including banks, insurance companies, partnerships or other pass-through entities, U.S. expatriates, dealers and traders in securities, or special tax rules that may apply to a non-U.S. holder that holds our common stock as part of a straddle, hedge or conversion transaction. This discussion is based on provisions of the Code, Treasury Regulations and administrative and judicial interpretations as of the date of this prospectus. All of these are subject to change, possibly with retroactive effect, or different interpretations. If you are considering buying our common stock, you should consult your own tax advisor about current and possible future tax consequences of holding and disposing of our common stock in your particular situation.
For purposes of this discussion, a non-U.S. holder is a beneficial owner of common stock if that individual is any of the following for U.S. federal income tax purposes:
| a nonresident alien individual within the meaning of Section 7701(b) of the Code; | |
| a foreign corporation or other foreign entity taxable as a corporation under U.S. federal income tax law; or | |
| a foreign estate or trust within the meaning of Section 7701(a) of the Code. |
If an entity treated as a partnership for U.S. federal income tax purposes holds shares of common stock, the tax treatment of a partner generally will depend on the status of the partner and upon the activities of the partnership. If you are a partner of a partnership holding shares of our common stock, we suggest you consult your own tax advisor.
Distributions
If distributions are paid on the shares of our common stock, these distributions generally will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles, and then will constitute a return of capital that is applied against your tax basis in the common stock to the extent these distributions exceed those earnings and profits. Distributions in excess of our current and accumulated earnings and profits and your tax basis in the common stock (determined on a share by share basis) will be treated as a gain from the sale or exchange of the common stock, the treatment of which is discussed below. Dividends paid to a non-U.S. holder that are not effectively connected with the conduct of a U.S. trade or business of the non-U.S. holder will be subject to U.S. federal withholding tax at a 30.0% rate or, if an income tax treaty applies and certain information reporting requirements are satisfied, a lower rate specified by the treaty. Non-U.S. holders should consult their tax advisors regarding their entitlement to benefits under a relevant tax treaty.
The U.S. federal withholding tax generally is imposed on the gross amount of a distribution, regardless of whether we have sufficient earnings and profits to cause the distribution to be a dividend for U.S. federal income tax purposes. However, we may elect to withhold on less than the gross amount of the
96
A non-U.S. holder eligible for a reduced rate of U.S. federal withholding tax under a tax treaty may establish entitlement to the benefit of a reduced rate of withholding under such tax treaty by timely filing a properly completed Form W-8BEN with us prior to the payment of a dividend. A non-U.S. holder eligible for a reduced rate of U.S. federal withholding tax under a tax treaty may obtain a refund of any excess amounts withheld by filing an appropriate claim for a refund together with the required information with the Internal Revenue Service.
Dividends that are effectively connected with a non-U.S. holders conduct of a trade or business within the U.S. and, if a tax treaty applies, attributable to a non-U.S. holders U.S. permanent establishment, are exempt from U.S. federal withholding tax if the non-U.S. holder furnishes to us or our paying agent a properly completed IRS Form W-8ECI (or successor form) containing the non-U.S. holders taxpayer identification number. However, dividends exempt from U.S. federal withholding tax because they are effectively connected or attributable to a U.S. permanent establishment under an applicable tax treaty are subject to U.S. federal income tax on a net income basis at the regular graduated U.S. federal income tax rates. Any such effectively connected dividends received by a foreign corporation may, under certain circumstances, be subject to an additional branch profits tax at a 30.0% rate or a lower rate specified by an applicable tax treaty.
Gain on Disposition of Common Stock
A non-U.S. holder generally will not be subject to U.S. federal income tax with respect to gain recognized on a sale or other disposition of common stock unless one of the following applies:
| The gain is effectively connected with a non-U.S. holders conduct of a trade or business within the United States and, if a tax treaty applies, the gain is attributable to a non-U.S holders U.S. permanent establishment. In such a case, unless an applicable tax treaty provides otherwise, the non-U.S. holder generally will be taxed on its net gain derived from the sale at regular graduated U.S. federal income tax rates, and in the case of a foreign corporation, may also be subject to an additional branch profits tax as described above. | |
| A non-U.S. holder who is an individual holds our common stock as a capital asset and is present in the United States for 183 or more days in the taxable year of the sale or other disposition, and certain other conditions are met. In such a case, the non-U.S. holder will be subject to a flat 30.0% tax on the gain derived from the sale, which may be offset by certain U.S. capital losses. | |
| At any time during the 5 year period ending on the date of a sale or other disposition of our stock, our company is classified as a United States Real Property Holding Corporation, generally defined as a corporation, the fair market value of whose real property interests equals or exceeds 50.0% of the fair market value of its U.S. real property interests, its interests in real property located outside the United States and any other of its assets used or held for use in a trade or business. Our company believes it is not and does not anticipate becoming a United States Real Property Holding Corporation for United States federal income tax purposes. |
Information Reporting and Backup Withholding Tax
We must report annually to the Internal Revenue Service and to each non-U.S. holder the amount of dividends paid to that holder and the tax withheld with respect to those dividends. These information reporting requirements apply even if withholding was not required. Pursuant to an applicable tax treaty or other agreement, copies of the information returns reporting those dividends and withholding may also be made available to the tax authorities in the country in which the non-U.S. holder resides.
Under certain circumstances, Treasury regulations require information reporting and backup withholding (currently at a rate of 28.0%), on certain payments on common stock. A non-U.S. holder of common stock that fails to certify its non-U.S. holder status in accordance with applicable Treasury
97
Payment of the proceeds of a sale of our common stock by or through a U.S. office of a broker is subject to both information reporting and backup withholding unless the non-U.S. holder certifies to the payor in the manner required as to its non-U.S. status under penalties of perjury or otherwise establishes an exemption. As a general matter, information reporting and backup withholding will not apply to a payment of the proceeds of a sale of our common stock by or through a foreign office of a foreign broker effected outside the United States. However, information reporting requirements, but not backup withholding, will apply to payment of the proceeds of a sale of our common stock by or through a foreign office of a broker effected outside the United States if that broker is:
| a U.S. person, | |
| a foreign person that derives 50.0% or more of its gross income for specified periods from the conduct of a trade or business in the United States, | |
| a controlled foreign corporation as defined in the Code, or | |
| a foreign partnership that at any time during its tax year either (i) has one or more U.S. persons that, in the aggregate, own more than 50.0% of the income or capital interests in the partnership or (ii) is engaged in the conduct of a trade or business in the United States. |
Information reporting requirements will not apply to the payment of the proceeds of a sale of our common stock if the broker receives a statement from the owner, signed under penalty of perjury, certifying such owners non-U.S. status or an exemption is otherwise established. Non-U.S. holders should consult their own tax advisors regarding the application of the information reporting and backup withholding rules to them.
Amounts withheld under the backup withholding rules do not constitute a separate U.S. federal income tax. Rather, any amounts withheld under the backup withholding rules will be refunded or allowed as a credit against the holders U.S. federal income tax liability, if any, provided the required information and appropriate claim for refund is filed with the Internal Revenue Service.
Federal Estate Tax
Common stock owned or treated as owned by an individual who is not a citizen or resident, as defined for U.S. federal estate tax purposes, of the United States at the time of death will be included in that individuals gross estate for U.S. federal estate tax purposes and may be subject to U.S. federal estate tax, unless an applicable estate tax treaty provides otherwise.
The foregoing discussion is a summary of the material federal tax consequences of the ownership, sale or other disposition of our common stock by non-U.S. holders for U.S. federal income and estate tax purposes. You are urged to consult your own tax advisor with respect to the particular tax consequences to you of ownership and disposition of our common stock, including the effect of any state, local, non-U.S. or other tax laws.
98
UNDERWRITING
Subject to the terms and conditions stated in the
underwriting agreement among us, the selling stockholders and
the underwriters, each of the underwriters named below has
severally agreed to purchase, and we and the selling
stockholders have agreed to sell to each named underwriter, the
number of shares set forth opposite the name of each underwriter.
Number of
Underwriters
Shares
4,000,000
The underwriting agreement provides that the obligations of the several underwriters to purchase the shares offered by us and the selling stockholders are subject to some conditions. The underwriters are obligated to purchase all of the shares offered by us and the selling stockholders, other than those covered by the over-allotment option described below, if any of the shares are purchased. The underwriting agreement also provides that, in the event of a default by an underwriter, in some circumstances the purchase commitments of non-defaulting underwriters may be increased or the underwriting agreement may be terminated.
The underwriters propose to offer the common stock directly to the public at the public offering price indicated on the cover page of this prospectus and to some dealers at that price less a concession not in excess of $ per share. The underwriters may allow, and those dealers may reallow, a discount not in excess of $ per share to other dealers. After this offering, the public offering price, the concession to selected dealers and re-allowance to other dealers may be changed by the underwriters.
The selling stockholders have granted to the underwriters an option, exercisable not later than 30 days after the date of this prospectus, to purchase, in whole or in part, up to an aggregate of 600,000 additional shares at the public offering price less the underwriting discount set forth on the cover of this prospectus. The underwriters may exercise the options only to cover over-allotments, if any, made in connection with the sale of the shares of common stock offered by the selling stockholders. To the extent the options are exercised, each underwriter will be obligated, subject to some conditions, to purchase a number of additional shares approximately proportionate to that underwriters initial purchase commitment as indicated in the table above.
The following table shows the per share and total
underwriting discounts and commissions to be paid to the
underwriters by us and the selling stockholders. Such amounts
are shown assuming both no exercise and full exercise of the
underwriters options to purchase 600,000 additional
shares.
Paid by Us
Paid by the Selling Stockholders
Without Exercise
With Full Exercise
Without Exercise
With Full Exercise
of Over-allotment
of Over-allotment
of Over-allotment
of Over-allotment
We estimate that the total expenses of this offering, excluding the underwriting discounts and commissions, will be approximately $2,285,000, which will be paid by us.
At our request, the underwriters have reserved for sale at the initial public offering price up to 200,000 shares of our common stock being sold in this offering for our employees, family members of employees, and other third parties. The number of shares of our common stock available for the sale to the general public will be reduced to the extent these reserved shares are purchased. Any reserved shares not purchased by these persons will be offered by the underwriters to the general public on the same basis as the other shares in this offering.
This offering of shares of our common stock is made for delivery when, as and if accepted by the underwriters and subject to prior sale and to withdrawal, cancellation or modification of this offering
99
We and the selling stockholders have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act, and to contribute to payments the underwriters may be required to make because of any of those liabilities.
We, our executive officers and directors and all of our stockholders have agreed, subject to limited exceptions, for a period of 180 days, after the date of this prospectus, that we and they will not offer, sell, contract to sell, pledge or otherwise dispose of any shares of our common stock or securities or other rights convertible into or exchangeable or exercisable for any shares of our common stock either owned as of the date of this prospectus or thereafter acquired without the prior written consent of Jefferies & Company, Inc. This 180 day period may be extended if (1) during the last 17 days of the 180 day period we issue an earning release or material news or a material event relating to us occurs or (2) prior to the expiration of the 180 day period, we announce that we will release earnings results during the 16 day period beginning on the last day of the 180 day period. The period of such extension will be 18 days, beginning on the issuance of the earnings release or the occurrence of the material news or material event.
We have been advised by the underwriters that, in accordance with Regulation M under the Securities Act, some persons participating in this offering may engage in transactions, including syndicate covering transactions, stabilizing bids or the imposition of penalty bids, that may have the effect of stabilizing or maintaining the market price of the shares at a level above that which might otherwise prevail in the open market.
A syndicate covering transaction is a bid for or the purchase of shares on behalf of the underwriters to reduce a syndicate short position incurred by the underwriters in connection with this offering. The underwriters may create a syndicate short position by making short sales of our shares and may purchase our shares in the open market to cover syndicate short positions created by short sales. Short sales involve the sale by the underwriters of a greater number of shares than they are required to purchase in this offering. Short sales can be either covered or naked. Covered short sales are sales made in an amount not greater than the underwriters over-allotment option to purchase additional shares from the selling stockholders in this offering. Naked short sales are sales in excess of the over-allotment option. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the shares in the open market after pricing that could adversely affect investors who purchase in this offering. If the underwriters create a syndicate short position, they may choose to reduce or cover this position by either exercising all or part of the over-allotment option to purchase additional shares from the selling stockholders or by engaging in syndicate covering transactions. The underwriters may close out any covered short position by either exercising their over-allotment option or purchasing shares in the open market. The underwriters must close out any naked short position by purchasing shares in the open market. In determining the source of shares to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase shares through the over-allotment option.
A stabilizing bid is a bid for or the purchase of shares on behalf of the underwriters for the purpose of fixing or maintaining the price of our common stock. A penalty bid is an arrangement that permits the representatives to reclaim the selling concession from an underwriter or a syndicate member when shares sold by such underwriter or syndicate members are purchased by the representatives in a syndicate covering transaction and, therefore, have not been effectively placed by the underwriter or syndicate member.
We have been advised by the representatives that these transactions may be effected on Nasdaq or otherwise and, if commenced, may be discontinued at any time. Similar to other purchase activities, these activities may have the effect of raising or maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market.
100
The representatives of the underwriters have advised us that the underwriters do not intend to confirm sales to any account over which they exercise discretionary authority.
A prospectus in electronic format may be available on sites maintained on the Internet or through other online services maintained by the underwriters or selling group members participating in this offering, or by their affiliates. In those cases, prospective investors may view the preliminary prospectus and the final prospectus online. In addition, the underwriters participating in this offering may distribute prospectuses electronically. Other than the prospectus in electronic format, the information on these websites is not a part of this prospectus or the registration statement of which this prospectus forms a part, has not been approved or endorsed by us or any underwriter in its capacity as underwriter, and should not be relied upon by investors.
Prior to this offering, there has been no public market for our common stock. The initial public offering price for the shares of our common stock offered by this prospectus was determined through negotiations among us, the selling stockholders and the representatives. The principal factors in determining the initial public offering price included:
| the information presented in this prospectus and otherwise available to the representatives; | |
| the history of and the prospects for our industry; | |
| the abilities of our management; | |
| our past and present operations; | |
| our historical results of operations; | |
| our anticipated operational results in 2005 and beyond; | |
| the recent market prices of, and the demand for, publicly traded common stock of generally comparable companies; | |
| market conditions for initial public offerings; and | |
| the general condition of the securities markets at the time of this offering. |
We cannot be sure that the initial public offering price will correspond to the price at which the common stock will trade in the public market following this offering or that an active trading market for the common stock will develop and continue after this offering.
101
LEGAL MATTERS
The legality of the shares of common stock to be issued in this offering will be passed upon by Alston & Bird LLP, Atlanta, Georgia. Morrison & Foerster LLP, New York, New York, will pass upon certain matters in connection with this offering on behalf of the underwriters.
EXPERTS
The consolidated financial statements of LHC Group, Inc. at December 31, 2002 and 2003 and June 30, 2004 and for each of the three years in the period ended December 31, 2003 and the six months ended June 30, 2004, appearing in this prospectus and registration statement have been audited by Ernst & Young LLP, independent registered public accounting firm, as set forth in their report thereon appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing.
WHERE YOU CAN FIND ADDITIONAL INFORMATION
We have filed with the SEC through its Electronic Data Gathering and Retrieval System a registration statement on Form S-1 under the Securities Act with respect to the offer and sale of common stock pursuant to this prospectus. This prospectus, filed as a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits and schedules thereto in accordance with the rules and regulations of the SEC and reference is hereby made to such omitted information. Statements made in this prospectus concerning the contents of any contract, agreement, or other document filed as an exhibit to the registration statement are summaries of the terms of such contracts, agreements, or documents. Reference is made to each such exhibit for a more complete description of the matters involved. The registration statement and the exhibits and schedules thereto filed with the SEC may be inspected, without charge, and copies may be obtained at prescribed rates at the public reference facility maintained by the SEC at Judiciary Plaza, 450 Fifth Street, NW, Washington, D.C. 20549 and at the regional office of the SEC located at 175 W. Jackson Boulevard, Suite 900, Chicago, Illinois 60604. The public may obtain additional information regarding the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The registration statement and other information filed by LHC Group, Inc. with the SEC via EDGAR are also available at the web site maintained by the SEC on the World Wide Web at http://www.sec.gov.
102
LHC GROUP, INC. AND SUBSIDIARIES
CONTENTS
F-1
REPORT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM
The Board of Directors
We have audited the accompanying consolidated
balance sheets of LHC Group, Inc. and subsidiaries as of
December 31, 2002 and 2003, and June 30, 2004, and the
related consolidated statements of income, changes in
stockholders equity, and cash flows for each of the three
years in the period ended December 31, 2003, and the six
months ended June 30, 2004. These financial statements are
the responsibility of the Companys management. Our
responsibility is to express an opinion on these financial
statements based on our audits.
We conducted our audits in accordance with the
Standards of the Public Company Accounting Oversight Board
(United States). Those standards require that we plan and
perform the audit to obtain reasonable assurance about whether
the financial statements are free of material misstatement. An
audit includes consideration of internal control over financial
reporting as a basis for designing audit procedures that are
appropriate in the circumstances, but not for purposes of
expressing an opinion on the effectiveness of the Companys
internal control over financial reporting. Accordingly, we
express no such opinion. An audit also includes examining, on a
test basis, evidence supporting the amounts and disclosures in
the financial statements, assessing the accounting principles
used and significant estimates made by management, and
evaluating the overall financial statement presentation. We
believe that our audits provide a reasonable basis for our
opinion.
In our opinion, the financial statements referred
to above present fairly, in all material respects, the
consolidated financial position of LHC Group, Inc. and
subsidiaries at December 31, 2002 and 2003, and
June 30, 2004, and the consolidated results of their
operations and their cash flows for each of the three years in
the period ended December 31, 2003, and the six months
ended June 30, 2004, in conformity with U.S. generally
accepted accounting principles.
As discussed in Note 2 to the consolidated
financial statements, effective January 1, 2002, the
Company changed its method of accounting for goodwill and
intangible assets.
/s/ ERNST & YOUNG LLP
New Orleans, Louisiana
F-2
LHC GROUP, INC. AND SUBSIDIARIES
See accompanying notes.
F-3
LHC GROUP, INC. AND SUBSIDIARIES
F-4
See accompanying notes.
F-5
LHC GROUP, INC. AND SUBSIDIARIES
See accompanying notes.
F-6
LHC GROUP, INC. AND SUBSIDIARIES
See accompanying notes.
F-7
LHC GROUP, INC. AND SUBSIDIARIES
LHC Group, LLC (Company) is a
healthcare provider specializing in the post-acute continuum of
care primarily for Medicare beneficiaries in rural markets in
the southern United States. The Company provides home-based
services, primarily through home nursing agencies and hospices,
and facility-based services, primarily through long-term acute
care hospitals and outpatient rehabilitation clinics. The
Company, through its wholly and majority-owned subsidiaries,
equity joint ventures, and controlled affiliate, currently
operates in Louisiana, Mississippi, and Texas.
The Company operated as Louisiana Health Care
Group, Inc. (LHCG), until March 2001, when the
shareholders of LHCG transferred to The Health Care Group, Inc.
(THCG), all of the issued and outstanding shares of
common stock of LHCG in exchange for shares in THCG. On
January 1, 2003, the Company began operating as LHC Group,
LLC, a Louisiana limited liability company. The THCG
shareholders exchanged their shares for membership interests in
the Company (units).
The Company operates under the terms of an
operating agreement which provides that the Company does not
have a finite life and that the members personal liability
is limited to his or her capital contribution. There is only one
class of member interest.
In 2004, the Company sold its majority interest
in three hospices, its majority interest in an inpatient
rehabilitation facility and the rights to operate a home nursing
agency in a specific area. In accordance with SFAS No. 144,
Accounting for the Impairment or Disposal of Long-Lived
Assets,
the results of operations of these entities,
including the gain on sale and impairment loss are presented as
discontinued operations in all periods presented.
In March 2004, the Company engaged in initial
discussions with potential underwriters regarding our initial
public offering. In June 2004, the Companys Board of
Directors authorized the Company to proceed with an initial
public offering.
Plan of Merger and Recapitalization
In January 2005, LHC Group, LLC established a
wholly-owned Delaware subsidiary, LHC Group, Inc. Effective
February 9, 2005, LHC Group, LLC merged into LHC Group,
Inc. In connection with the merger, each outstanding membership
unit in LHC Group, LLC was converted into shares of the $0.01
par value common stock of LHC Group, Inc. based on an exchange
ratio of three-for-two. Each KEEP unit will also be convertible
upon the initial public offering into shares of common stock of
LHC Group, Inc. pursuant to the same three-for-two ratio. LHC
Group, Inc. has 40,000,000 shares of $0.01 par value common
stock authorized and 5,000,000 shares of $0.01 par value
preferred stock authorized. All references to common stock,
share, and per share amounts have been retroactively restated to
reflect the merger and recapitalization as if the merger and
recapitalization had taken place as of the beginning of the
earliest period presented.
As used herein, the Company includes
LHC Group, Inc. and all predecessor entities.
Use of Estimates
The preparation of financial statements in
conformity with accounting principles generally accepted in the
United States requires management to make estimates and
assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities
at the date of the financial statements and the reported revenue
and expenses during the reported period. Actual results could
differ from those estimates.
F-8
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (Continued)
Critical Accounting Policies
The most critical accounting policies relate to
the principles of consolidation, revenue recognition, accounts
receivable and allowances for uncollectible accounts, and
accounting for goodwill.
The consolidated financial statements include all
subsidiaries and entities controlled by the Company.
Control is generally defined by the Company as
ownership of a majority of the voting interest of an entity. The
consolidated financial statements include entities in which the
Company absorbs a majority of the entitys expected losses,
receives a majority of the entitys expected residual
returns, or both, as a result of ownership, contractual or other
financial interests in the entity.
All significant intercompany accounts and
transactions have been eliminated in consolidation. Business
combinations accounted for as purchases have been included in
the consolidated financial statements from the respective dates
of acquisition.
The following describes the Companys
consolidation policy with respect to its various ventures
excluding wholly owned subsidiaries:
Equity Joint Ventures
The Companys joint ventures are structured
as limited liability companies in which the Company typically
owns a majority equity interest ranging from 51% to 95%. Each
member of all but one of the Companys equity joint
ventures participates in profits and losses in proportion to
their equity interests. We have one joint venture partner whose
participation in losses is limited. The Company consolidates
these entities as the Company absorbs a majority of the
entities expected losses, receives a majority of the
entities expected residual returns and generally has
voting control.
Cooperative Endeavors
The Company has arrangements with certain
partners that involve the sharing of profits and losses. Unlike
the joint venture relationships the Company owns 100% of the
equity in these ventures. In these cooperative endeavors, the
Company possesses interests in the net profits and losses
ranging from 67% to 95%. The Company has one cooperative
endeavor partner whose participation in losses is limited. The
Company consolidates these entities as the Company owns 100% of
the outstanding equity and the Company absorbs a majority of the
entities expected losses and receives a majority of the
entities expected residual returns.
License Leasing Arrangements
The Company, through wholly-owned subsidiaries,
leases home health licenses necessary to operate certain of its
home nursing agencies. As with wholly owned subsidiaries, the
Company owns 100% of the equity of these entities and
consolidates them based on such ownership as well as the
Companys right to receive a majority of the entities
expected residual returns and the Companys obligation to
absorb a majority of the entities expected losses.
F-9
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (Continued)
Management Services
The Company has various management services
agreements under which the Company manages certain operations of
agencies and facilities. The Company does not consolidate these
agencies or facilities, as the Company does not have an
ownership interest and does not have a right to receive a
majority of the agencies or facilities expected
residual returns or an obligation to absorb a majority of the
agencies or facilities expected losses.
The following table summarizes the percentage of
net service revenue earned by type of ownership or relationship
the Company had with the operating entity:
The Company reports net service revenue at the
estimated net realizable amount due from Medicare, Medicaid,
commercial insurance, managed care payors, patients, and others
for services rendered. Under Medicare, the Companys home
nursing patients are classified into a home health resource
group prior to the receipt of services. Based on this home
health resource group the Company is entitled to receive a
prospective Medicare payment for delivering care over a 60 day
period. Medicare adjusts these prospective payments based on a
variety of factors, such as low utilization, patient transfers,
changes in condition and the level of services provided. In
calculating the Companys reported net service revenue from
home nursing services, the Company adjusts the prospective
Medicare payments by an estimate of the adjustments. The Company
calculates the adjustments based on a rolling average of these
types of adjustments for claims paid during the preceding three
months. For home nursing services, the Company recognizes
revenue based on the number of days elapsed during the episode
of care.
Under Medicare, patients in the Companys
long-term acute care facilities are classified into long-term
diagnosis-related groups. Based on this classification, the
Company is then entitled to receive a fixed payment from
Medicare. This fixed payment is also subject to adjustment by
Medicare due to factors such as short stays. In calculating
reported net service revenue for services provided in the
Companys long-term acute care hospitals, the Company
reduces the prospective payment amounts by an estimate of the
adjustments. The Company calculates the adjustment based on a
historical average of these types of adjustments for claims paid
during the preceding three months. For the Companys
long-term acute care hospitals revenue is recognized as services
are provided.
For hospice services the Company is paid by
Medicare under a prospective payment system. The Company
receives one of four predetermined daily or hourly rates based
upon the level of care the Company furnished. The Company
records net service revenue from hospice services based on the
daily or hourly rate. The Company recognizes revenue for hospice
as services are provided
Under Medicare the Company is reimbursed for
rehabilitation services based on a fee schedule for services
provided adjusted by the geographical area in which the facility
is located. The Company recognizes revenue as these services are
provided.
F-10
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (Continued)
The Companys Medicaid reimbursement is
based on a predetermined fee schedule applied to each service
provided. Therefore, revenue is recognized for Medicaid services
as services are provided based on this fee schedule. The
Companys managed care payors reimburse the Company in a
manner similar to either Medicare or Medicaid. Accordingly, the
Company recognizes revenue from managed care payors in the same
manner as the Company recognizes revenue from Medicare or
Medicaid.
The Company records management services revenue
as services are provided in accordance with the various
management services agreements to which the Company is a party.
The agreements generally call for the Company to provide
billing, management, and other consulting services suited to and
designed for the efficient operation of the applicable home
nursing agency or inpatient rehabilitation facility. The Company
is responsible for the costs associated with the locations and
personnel required for the provision of the services. The
Company is generally compensated based on a percentage of net
billings or an established base fee. In addition, for certain of
the management agreements, the Company may earn incentive
compensation.
Net service revenue was comprised of the
following:
The following table sets forth the percentage of
net service revenue earned by category of payor:
Home Nursing
Services.
The Company receives a
standard prospective Medicare payment for delivering care over a
base 60-day period, or episode of care. The base payment,
established through federal legislation, is a flat rate that is
adjusted upward or downward based upon differences in the
expected resource needs of individual patients as indicated by
clinical severity, functional severity, and service utilization.
The magnitude of the adjustment is determined by each
patients categorization into one of 80 payment groups,
known as home health resource groups, and the costliness of care
for patients in each group relative to the average patient. The
Companys payment is also adjusted for differences in local
prices using the hospital wage index. The Company recognizes
revenue when services are provided based on the number of days
elapsed during the episode. The Company performs payment
variance analysis to verify the models utilized in projecting
total net service revenue are accurately reflecting the payments
received.
Medicare rates are subject to change. Due to the
length of the Companys episodes of care, a situation may
arise where Medicare rate changes affect prior periods net
service revenue. In the event that
F-11
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (Continued)
Medicare rates experience change, the net effect
of that change will be reflected in the current reporting period.
Final payments from Medicare may reflect one of
five retroactive adjustments to ensure the adequacy and
effectiveness of the total reimbursement: (a) an outlier
payment if the patients care was unusually costly;
(b) a low utilization adjustment if the number of visits
was fewer than five; (c) a partial payment if the patient
transferred to another provider before completing the episode;
(d) a change-in-condition adjustment if the patients
medical status changes significantly, resulting in the need for
more or less care; or (e) a payment adjustment based upon
the level of therapy services required in the population base.
Management estimates the impact of these payment adjustments
based on historical experience and records this estimate during
the period the services are rendered.
Hospice Services.
Medicare reimburses for hospice care using a prospective payment
system. Under that system, the Company receives one of four
predetermined daily or hourly rates based upon the level of care
furnished to the beneficiary. These rates are subject to annual
adjustments based on inflation and geographic wage
considerations. The Company recognizes revenue as the services
are provided.
The Companys Medicare hospice reimbursement
is subject to two caps. One cap relates to individual programs
receiving more than 20% of its total Medicare reimbursement from
inpatient care services. The second cap relates to individual
programs receiving reimbursements in excess of a cap
amount, calculated by multiplying the number of
beneficiaries during the period by a statutory amount that is
indexed for inflation. The determination for each cap is made
annually based on the 12-month period ending on October 31
of each year. This limit is computed on a program-by-program
basis. None of the Companys hospices exceeded either cap
during 2001, 2002, 2003, or the 2004 period.
Long-Term Acute Care
Services.
The Company is reimbursed by
Medicare for services provided under the long-term acute care
hospital prospective payment system, which was implemented on
October 1, 2002. The Company is paid solely on the basis of
the long-term acute care hospital diagnosis-related groups. The
Company recognizes revenue as the services are provided.
Each patient discharged from the Companys
long-term acute care hospitals is assigned a long-term care
diagnosis-related group. The Company is paid a predetermined
fixed amount applicable to that particular group. This payment
is intended to reflect the average cost of treating a Medicare
patient classified in that particular long-term care
diagnosis-related group. For selected patients, the amount may
be further adjusted based on length of stay and
facility-specific costs, as well as in instances where a patient
is discharged and subsequently readmitted, among other factors.
Similar to other Medicare prospective payment systems, the rate
is also adjusted for geographic wage differences.
Outpatient Rehabilitation
Services.
Outpatient therapy services
are reimbursed on a fee schedule, subject to annual limitations.
Outpatient therapy providers receive a fixed fee for each
procedure performed, adjusted by the geographical area in which
the facility is located. The Company recognizes revenue as the
services are provided. There are also annual per Medicare
beneficiary caps that limit Medicare coverage for outpatient
rehabilitation services.
The Company reports accounts receivable net of
estimated allowances for uncollectible accounts and adjustments.
Accounts receivable are uncollateralized and primarily consist
of amounts due from third-party payors and patients. To provide
for accounts receivable that could become uncollectible in the
future, the Company establishes an allowance for uncollectible
accounts to reduce the carrying amount of such receivables to
their estimated net realizable value. The credit risk for other
concentrations of
F-12
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (Continued)
receivables is limited due to the significance of
Medicare as the primary payor. The Company does not believe that
there are any other significant concentrations of receivables
from any particular payor that would subject it to any
significant credit risk in the collection of accounts receivable.
The amount of the provision for bad debts is
based upon the Companys assessment of historical and
expected net collections, business and economic conditions, and
trends in government reimbursement.
A portion of the estimated Medicare prospective
payment system reimbursement from each submitted home nursing
episode is received in the form of a request for accelerated
payment (RAP) before all services are rendered. The
estimated episodic payment is billed at the commencement of the
episode. The Company receives a RAP for 60% of the estimated
reimbursement at the initial billing for the initial episode of
care per patient and the remaining reimbursement is received
upon completion of the episode. For any subsequent episodes of
care contiguous with the first episode of care for the patient,
the Company receives a RAP for 50% of the estimated
reimbursement at initial billing. The remaining 50%
reimbursement is received upon completion of the episode.
Amounts billed and received in advance of actual services
performed are recorded as amounts due to the Medicare program.
These amounts are recorded as a reduction to accounts receivable
in the accompanying consolidated balance sheets. These amounts
were $4,829,000, $4,986,000, and $7,189,000 at December 31,
2002 and 2003, and June 30, 2004, respectively. Conversely,
the Company has earned net service revenue in excess of billings
rendered to Medicare. Thus, only a nominal portion of the
amounts due to the Medicare program represent cash collected in
advance of providing services.
Goodwill
Effective January 1, 2002, the Company
adopted the provisions of Statement of Financial Accounting
Standards (SFAS) No. 142,
Goodwill and Other
Intangible Assets.
Under SFAS No. 142, goodwill
and other intangible assets with indefinite lives are no longer
subject to periodic amortization but are instead reviewed
annually, or more frequently if circumstances indicate
impairment may have occurred. Principally all of the
Companys intangible assets are goodwill.
The Company estimates the fair value of its
identified reporting units and compares those estimates against
the related carrying value. For each of the reporting units, the
estimated fair value is determined based on a multiple of
earnings before interest, taxes, depreciation, and amortization
or on the estimated fair value of assets in situations when it
is readily determinable.
The Company has concluded that licenses to
operate home-based and/or facility-based services have
indefinite lives, as management has determined that there are no
legal, regulatory, contractual, economic or other factors that
would limit the useful life of the licenses and the Company
intends to renew and operate the licenses indefinitely.
Accordingly, the Company has elected to recognize the fair value
of these indefinite-lived licences and goodwill as a single
asset for financial reporting purposes, as permitted by SFAS
No. 141,
Business Combinations.
Components of the Companys home nursing
operating segment are generally represented by individual
subsidiaries or joint ventures with individual licenses to
conduct specific operations within geographic markets as limited
by the terms of each license. Components of the Companys
facility-based services are represented by individual operating
entities. Effective January 1, 2004, management began
aggregating the components of these two segments into two
reporting units for purposes of evaluating impairment. Prior to
January 1, 2004, management evaluated each operating entity
separately for impairment. Modifications to the Companys
management of the segments and reporting provided management
with a basis to change the reporting unit structure.
F-13
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (Continued)
Through December 31, 2001, goodwill was
amortized on a straight-line basis over the estimated useful
life of 40 years. The following table reconciles previously
reported net income as if the provisions of
SFAS No. 142 were in effect for 2001 (in thousands).
As a result of this change, there would have been
no change in the reported basic or fully diluted earnings per
share amounts for 2001.
Other Significant Accounting
Policies
Cash equivalents are defined as short-term,
highly liquid investments both readily convertible to known
amounts of cash or so near maturity at acquisition that there is
an insignificant risk of change in value because of changes in
interest rates. Cash equivalents are stated at cost.
Prior to October 1, 2000, the Company
recorded Medicare home nursing services revenues at the lower of
actual costs, the per visit cost limit, or a per beneficiary
cost limit on an individual provider basis. Final reimbursement
was determined based on submission of annual cost reports and
audits by the fiscal intermediary. Adjustments were accrued on
an estimated basis in the period the related services were
rendered and further adjusted as final settlements are
determined. These adjustments are accounted for as changes in
estimates. There have been no significant changes in estimates
during 2001, 2002, 2003, or the 2004 period.
Property, building, and equipment are stated at
cost. Depreciation is computed using the straight-line method
over the estimated useful lives of the individual assets,
generally ranging from three to ten years.
Capital leases, primarily consisting of
transportation equipment, are included in equipment. Capital
leases are recorded at the present value of the future rentals
at lease inception and are amortized over the shorter of the
applicable lease term or the useful life of the equipment.
Amortization of assets under the capital lease obligations is
included in depreciation and amortization expense.
The Company reviews the realizability of
long-lived assets whenever events or circumstances occur which
indicate recorded costs may not be recoverable. If the expected
future cash flows (undiscounted) are less than the carrying
amount of such assets, the Company recognizes an impairment loss
for the difference between the carrying amount of the assets and
their estimated fair value.
The Company has elected to be taxed as a
C corporation and accounts for income taxes using the
liability method. Under the liability method, deferred taxes are
determined based on differences between the financial reporting
and tax bases of assets and liabilities, and are measured using
the enacted tax laws that will be in effect when the differences
are expected to reverse. Management provides a valuation
F-14
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (Continued)
allowance for any net deferred tax assets when it
is more likely than not that a portion of such net deferred tax
assets will not be recovered.
The interest held by third parties in
subsidiaries owned or controlled by the Company is reported on
the consolidated balance sheets as minority interest. Minority
interest reported in the consolidated statements of income
reflects the respective interests in the income or loss of the
subsidiaries attributable to the other parties, the effect of
which is removed from the Companys consolidated results of
operations.
Several of the Companys home health
agencies have cooperative endeavor agreements with third parties
that allow the third parties to be paid or recover a fee based
on the profits or losses of the respective agencies. The Company
accrues for the settlement of the third partys profits or
losses during the period the amounts are earned. Under the
agreements, the Company has incurred net amounts due to the
third parties of $1,355,000 in 2001, $2,699,000 in 2002,
$2,638,000 in 2003, and $415,000 in 2004. The cooperative
endeavor agreements have terms expiring through
December 31, 2005.
For agreements where the third party is a
healthcare institution, the agreements typically require the
Company to lease building and equipment and receive housekeeping
and maintenance from the healthcare institutions. Ancillary
services related to these arrangements are also typically
provided by the healthcare institution.
During 2003, certain subsidiaries operating under
cooperative endeavor agreements were converted to limited
liability companies in which the third parties contributed
capital for ownership rights. The third parties retained the
right to their share of the profits or losses. These entities
are accounted for as majority-owned subsidiaries.
Cost of service revenue consists primarily of the
following expenses incurred by clinical and clerical personnel
in the Companys agencies and facilities:
General and administrative expenses consist
primarily of the following expenses incurred by home office and
administrative field personnel:
F-15
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (Continued)
The Company expenses all advertising and
marketing costs as incurred, which approximated $423,000 in
2001, $1,033,000 in 2002, $1,248,000 in 2003, and $565,000 in
2004 of which $29,000, $107,000, $88,000, and 7,000,
respectively, related to discontinued operations and is
classified accordingly.
During 2003, the Company began sponsoring a Key
Employee Equity Participation (KEEP) Plan whereby
certain individuals are granted participation equity units
(KEEP Units). The KEEP Plan functions as a stock
appreciation rights plan whereby an individual is entitled to
receive, on a per KEEP Unit basis, the increase in estimated
fair value of the Companys common stock from the date of
grant until the date that the employee dies, retires, or is
terminated for other than cause. Accordingly, the KEEP Units are
subject to variable accounting until such time as the obligation
to the employee is settled. The Company has a call right, under
which, it can purchase all or portion of the KEEP Units. The
individuals receiving KEEP Units vest in those rights in a
graded manner over a five-year period and, accordingly, the
Company records compensation expense for the vested portion of
the KEEP Units. The KEEP Units have no exercise price.
Compensation expense, and a corresponding
increase in paid-in capital, is also recognized each period for
any change in value associated with certain shares held by an
officer of the Company.
Basic net income per unit is computed by dividing
net income by the weighted-average number of units outstanding
during the period. Diluted earnings per share is computed by
dividing net income by the weighted-average number of shares
outstanding plus dilutive potential shares.
The following table sets forth shares used in the
computation of basic and diluted net income per share for the
years ended December 31, 2001, 2002, and 2003 and for the
six months ended June 30, 2004.
Financial instruments that potentially expose the
Company to concentration of credit risk primarily consist of
cash balances and accounts receivable. The Company invests its
excess cash with a large bank. At December 31, 2001, 2002,
and 2003, and June 30, 2004, accounts receivable due from
the
F-16
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (Continued)
Medicare program represented approximately 66%,
74%, 78%, and 61%, respectively, of total patient accounts
receivable.
The accompanying 2003, 2002, and 2001 financial
statements have been reclassified to conform to the 2004
financial statement presentation.
Recently Issued Accounting
Pronouncements
In December 2003, the FASB published a revision
to Interpretation 46, or FIN 46R, to clarify certain
provisions of FASB Interpretation No. 46,
Consolidation of Variable Interest Entities,
and to exempt certain entities from its requirements. FIN
No. 46R requires a company to consolidate a variable
interest entity, or VIE, as defined, when the company will
absorb a majority of the VIEs expected losses, receive a
majority of the variable interest entitys expected
residual returns, or both. FIN No. 46R also requires
consolidation of existing, non-controlled affiliates if the VIE
is unable to finance its operations without investor support, or
where the other investors do not have exposure to the
significant risks and rewards of ownership.
FIN No. 46R is effective by the end of the first
reporting period beginning after December 15, 2003. The
Company does not expect the adoption of FIN No. 46R to
have a material impact on the Companys consolidated
financial statements.
The following acquisitions were completed
pursuant to the Companys strategy of becoming the leading
provider of post-acute healthcare services to Medicare patients
in selected rural markets in the southern United States. The
purchase price of each acquisition was determined based on the
Companys analysis of comparable acquisitions and target
markets potential cash flows. Goodwill generated from the
acquisitions was recognized based on the expected contributions
of each acquisition to the overall corporate strategy and is
expected to be fully tax deductible. The Company has concluded
that licenses to operate home-based and/or facility-based
services have indefinite lives, as management has determined
that there are no legal, regulatory, contractual, economic or
other factors that would limit the useful life of the licenses
and the Company intends to renew and operate the licenses
indefinitely. Accordingly, the Company has elected to recognize
the fair value of these indefinite-lived licenses and goodwill
as a single asset for financial reporting purposes, as permitted
by SFAS No. 141,
Business Combinations
. Each of the
acquisitions completed was accounted for as a purchase and is
included in the Companys financial statements based on its
respective acquisition date.
The Company made five acquisitions during the six
months ended June 30, 2004 for $390,000 in cash. These
acquisitions were primarily the purchase of the entities
existing operations. Goodwill of $370,000 was assigned to the
home-based services segment and goodwill of $20,000 was assigned
to the facility-based segment.
The Company also acquired a 70% interest in an
outpatient rehabilitation facility through a stock purchase
agreement for $207,000 in cash. Goodwill of $54,000 was assigned
to the facility-based segment.
Additionally, the Company acquired a portion of
the minority interest in a majority-owned home nursing joint
venture by issuing a $300,000 promissory note. A $300,000
increase in the home-based segments goodwill was
recognized in connection with this transaction.
F-17
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (Continued)
The Company sold its majority interest in three
hospice subsidiaries to the majority interest holder. The
Company received $300,000 and recognized a gain on the sale of
$347,000. The Company also sold its minority interest in a
rehabilitation facility to another owner in the facility for
$129,000, receiving cash of $45,000 and a promissory note for
$85,000. The Company recognized a loss on the sale of $40,000.
The Company sold the rights to operate a home
care facility in a specific area to an unrelated party for
$200,000. The Company received $125,000 in cash and a promissory
note for the balance. The Company recognized a gain on the sale
of $200,000.
In connection with the planned divestiture of
certain entities in 2004, management recognized an impairment
loss on two operating entities in 2003.
The following results of these divestitures have
been presented as loss from discontinued operations in the
accompanying consolidated statement of income:
The Company made four acquisitions during 2003
for $2,100,000. These acquisitions were primarily the purchase
of the entities existing operations. The Company paid
$1,600,000 in cash and issued a promissory note for $500,000.
Goodwill of $126,000 was assigned to the home-based services
segment and goodwill of $1,950,000 was assigned to the
facility-based segment.
Additionally, the Company increased ownership in
a home-nursing operation by paying $315,000 in cash and
recognized an increase in goodwill of $315,000 in the home-based
services segment.
The Company made five acquisitions during 2002
for $340,000 in cash. These acquisitions were primarily the
purchase of the entities existing operations. Goodwill of
$340,000 was assigned to the home-based services segment.
The Company made eight acquisitions during 2001
for $1,470,000 in cash. These acquisitions were primarily the
purchase of the entities existing operations. Goodwill of
$1,360,000 was assigned to the home-based services segment.
F-18
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (Continued)
The changes in recorded goodwill by segment for
the years ended December 31, 2002 and 2003, and the six
months ended June 30, 2004, were as follows (in thousands):
The above transactions were considered to be
immaterial individually and in the aggregate. Accordingly, no
supplemental pro forma information is considered required.
Significant components of the Companys
deferred tax assets and liabilities were as follows:
F-19
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (Continued)
The components of the Companys income tax
expense from continuing operations were as follows:
A reconciliation of the differences between
income taxes computed at the federal statutory rate and
provisions for income taxes for each period are as follows:
F-20
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (Continued)
Long-Term Debt
Long-term debt consisted of the following:
The Companys loan agreement with the
Catalyst Entities bears interest at 12% per annum, and
monthly installments of $53,000 are due through July 1,
2006. (See Note 7.)
The Companys subordinated promissory note
is being repaid in equal installments of $25,000, bearing
interest at 15.5% through February 1, 2006. (See
Note 7.)
Certain of the Companys loan agreements
contain certain restrictive covenants, including limitations on
indebtedness and the maintenance of certain financial ratios. At
December 31, 2002 and 2003, and June 30, 2004, the
Company was in compliance with all covenants.
The scheduled principal payments on long-term
debt are as follows for each of the next two years following
June 30, 2004 (in thousands):
Other Credit Arrangements
The Company maintains a revolving-debt
arrangement with Residential Funding Corporation. Under the
terms of this arrangement, the Company may be advanced funds up
to a defined limit of eligible accounts receivable not to exceed
the borrowing limit. At December 31, 2002 and 2003, and
June 30, 2004, the borrowing limit was $7,000,000,
$15,000,000, and $15,000,000, respectively, and the amounts
outstanding were $6,628,000, $7,867,000, and $11,032,000,
respectively. Interest accrues on outstanding amounts at a
varying rate and is based on the Wells Fargo Bank, N.A. prime
rate plus 2%. Payments are made on the outstanding balance as
accounts receivables are collected. The arrangement matures on
April 30, 2006.
F-21
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (Continued)
The Company, through certain subsidiaries, has
lines of credit outstanding with a bank. These arrangements
provide these subsidiaries with aggregate borrowings of up to
$1,050,000. Balances outstanding at December 31, 2002 and
2003, were $881,000 and $803,000, respectively. There were no
amounts outstanding under these arrangements at June 30,
2004. The interest rates on these borrowings range from 8.3% to
8.6%. These credit arrangements have no stated expiration dates.
The Company, through a subsidiary, has another line of credit
outstanding with a bank. The arrangement provides for borrowings
up to $300,000 with a stated interest rate of 6.5%. The
arrangement expires on January 27, 2005. The balance
outstanding at June 30, 2004, was $140,000.
The Company has reserved up to 6.5% of the value
of the Companys stock for issuance under the KEEP Plan. A
summary of the changes in the KEEP Units outstanding is as
follows:
The outstanding unvested KEEP Units vest
according to the following schedule:
Upon the occurrence of certain events, as defined
in the KEEP Plan, including an initial public offering, the
outstanding KEEP Units fully vest and the Company can convert
the KEEP Units to common stock, pay out the liability as
estimated as of that date, or settle the awards in any other way
deemed appropriate.
The KEEP Units are accounted for at their
estimated fair value. Accordingly, no pro forma net income or
per share information is required.
Catalyst Fund, Ltd. and Southwest/ Catalyst
Capital, Ltd. Investments
In July 2001, the Company entered into a loan
agreement with the Catalyst Fund, Ltd., and Southwest/ Catalyst
Capital, Ltd. (Catalyst Entities), involving an
aggregate amount of $2,000,000. These loans were evidenced by
individual promissory notes, each in the principal amount of
$1,000,000, accruing interest at a rate of 12.0% per annum
and payable in equal monthly installments of approximately
F-22
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (Continued)
$26,000 in principal and interest, due through
July 1, 2006. As of June 30, 2004, $1,119,000 in
principal remained outstanding under these promissory notes.
The Catalyst Entities possess a security interest
in the Companys equipment, inventory, accounts receivable,
general intangibles, chattel paper, and instruments. Also
serving as collateral is the assignment of a key man life
insurance policy with regard to a Company officer of which the
Company is named beneficiary.
In connection with the loan agreement with the
Catalyst Entities, the Company entered into a consulting
agreement with the Catalyst Entities under which they agreed to
provide assistance, advice, and consultation with respect to
operations, marketing, and financial structure and performance
in consideration for the issuance of two warrants (the
Warrants) to purchase up to the equivalent of an
aggregate of 966,813 shares of the Companys currently
outstanding common stock. Management estimated the value of the
Warrants to be $229,000 at the date of issuance and recognized
this amount as prepaid consulting fees to be amortized over the
life of the arrangements. The Company applied variable
accounting to the Warrants and recognized subsequent changes in
the estimated fair value of the Warrants as consulting expense.
This resulted in a charge of $963,000 in 2001. The Warrants were
exercised in their entirety in March 2002 for a total of $1,000.
The fair value of the Warrants was recognized as a capital
contribution at the date of exercise.
Under the terms of the Warrant agreements under
which these shares of common stock were issued to the Catalyst
Entities, they were originally granted the right, at any time
after the period beginning on July 3, 2006, or upon the
occurrence of a change in control, to compel the Company to
purchase their shares of common stock. However, these put rights
were terminated on March 18, 2002, by the mutual agreement
of the parties.
Repurchase of Common Stock from Certain
Stockholders
In March 2001, certain stockholders agreed to
sell the equivalent of an aggregate of 3,881,663 shares of
the Companys currently outstanding common stock to the
Company. The purchase price was paid pursuant to a promissory
note in the principal amount of approximately $1,000,000. The
note bears interest at a rate of 15.5%, and payments of
approximately $25,000 are due each month. At June 30, 2004,
$439,000 in principal was outstanding under this note.
The repurchased shares are held in escrow as
collateral for the payment of the purchase price. As payments
under the promissory note are made, a proportion of the total
repurchased shares is released. This proportion is determined by
dividing the principal amount paid in the particular installment
by a price per share of $0.268. The sole and exclusive remedy
available in the event of default under the promissory note is
foreclosure on the remaining collateral. At June 30, 2004,
1,636,479 treasury units are considered restricted under the
terms of this agreement.
Indebtedness of Officer of the
Company
In October 2004, an officer repaid in full a
promissory note held by the Company at June 30, 2004, in
the principal amount of $90,000. The promissory note, which had
an interest rate of 7% per annum, was formerly secured by
33,000 KEEP Units held by the officer. In connection with its
repayment by the officer, the promissory note was canceled and
the Companys security interest in the officers KEEP
Units was terminated.
The officer was the obligor under another
promissory note in the Companys favor in the principal
amount of $123,000, which note had an interest rate of
6% per annum and was due on or before March 3, 2010.
The officer was entitled under the note to prepay all or any
part of this obligation without penalty. This promissory note
was intended to serve as payment of the purchase price for
150,000 shares of
F-23
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (Continued)
common stock purchased by the officer under a
subscription agreement, dated March 3, 2004. The Company
recognized a compensation charge of $600,000 in connection with
the issuance of these shares of common stock. As security for
the repayment of the promissory note, the officer concurrently
executed an Act of Pledge in which he granted the Company the
right to sell any or all of his shares of common stock in the
event of default under or nonpayment of the promissory note. In
exchange for the return of the 150,000 shares of common
stock formerly issued to the officer, this promissory note was
canceled on June 30, 2004.
The Company has committed to issue to this
officer 150,000 KEEP Units in connection with the return of the
150,000 shares of common stock described above. Future
compensation expense will be recognized only to the extent the
estimated fair value of the 150,000 KEEP Units varies from the
cumulative compensation charge of $1,500,000 for the
150,000 shares of common stock that were returned.
Sunset Clinic Lease Agreement
In July 2003, one of the Companys indirect,
wholly owned subsidiaries, Louisiana Physical Therapy, LLC,
entered into a lease agreement with Oak Shadows of Sunset, LLC
(Oak Shadows). The lease agreement had an initial
ten-year term that expired in July 2013. The lease agreement
granted no right of termination. The lease agreement required
monthly payments of approximately $4,000 for the initial term.
Currently, the property is used as an outpatient rehabilitation
facility. At the time of the lease agreements execution,
an officer of the Company held 100% of the membership interests
in Oak Shadows. On December 1, 2004, pursuant to a Transfer
and Assignment of LLC Membership Interest, the officer, as the
sole member of Oak Shadows, transferred his membership interest,
which included land and building with a net book value of
$292,945, to the Company in exchange for the Companys
assumption of the officers guarantee of mortgage
indebtedness relating to the property, in the form of two note
payables whose principal balances totaled $292,945. The
acquisition of 100.0% interest in Oak Shadows of
Sunset, LLC will be reflected in our fourth quarter
reported results by recording the property and the note payables
at the amounts stated above.
The Company, through two of its wholly owned
subsidiaries, entered into one lease agreement in 2001 and
another in 2003 for a Medicare and a Medicaid license and the
associated provider numbers. The agreements are for an initial
term of five years and will be automatically extended for a
consecutive five-year term unless the lessee gives written
notice to the lessor 180 days prior to the expiration date
of the initial term. The initial lease terms expire in 2006 and
2008. Expense related to these leases was $6,000 in 2001,
$73,000 in 2002, $166,000 in 2003, and $363,000 in 2004.
Payments due under these leases are $182,000 for the remainder
of 2004, $393,000 in 2005, $393,000 in 2006, $243,000 in 2007,
and $182,000 in 2008.
The Company leases office space and equipment at
its various locations. Total rental expense was approximately
$808,000 in 2001, $1,856,000 in 2002, $3,649,000 in 2003, and
$2,326,000 in 2004 of which $71,000, $196,000, $222,000, and
$40,000, respectively, relate to discontinued operations and is
classified
F-24
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (Continued)
accordingly. Future minimum rental commitments
under noncancelable operating leases, are as follows for the
periods ending December 31 (in thousands):
Future minimum payments by year and in the
aggregate, under noncancelable capital leases with initial terms
of one year or more, consisted of the following:
The cost of assets held under capital leases was
$163,000, $1,227,000 and $2,051,000 at December 31, 2002
and 2003, and June 30, 2004, respectively. The related
accumulated amortization was $25,000, $81,000 and $200,000 at
December 31, 2002 and 2003, and June 30, 2004,
respectively.
The Company sponsors a profit-sharing 401(k) plan
that covers substantially all eligible full-time employees. The
plan allows participants to contribute up to 15% of their
compensation and discretionary Company contributions as
determined by the Companys board of directors.
Discretionary contributions authorized to the plan during the
years ended December 31, 2001, 2002 and 2003, and the
period ended June 30, 2004, were $141,000, $163,000,
$201,000, and $177,000, respectively.
Contingencies
In the event the Company makes an initial public
offering, the terms of certain majority owned subsidiaries
operating agreements require the Company to offer to purchase
the minority interests. The terms of the operating agreements
for two majority owned subsidiaries require the Company to offer
to purchase the minority interests in the event the Company
makes an initial public offering. The Company has executed
agreements with the minority interest owners of two of these
subsidiaries to stipulate the
F-25
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (Continued)
terms of the exchange upon consummation of an
initial public offering. Based on the terms of these exchange
agreements, the estimated contingent liability, which will be
satisfied through cash and the issuance of equity, was
approximately $5,760,000 at June 30, 2004. (See
Note 15.)
The terms of several joint venture operating
agreements grant a buy/sell option that would require the
Company to either purchase or sell the existing membership
interest in the joint venture within 30 days of the receipt
of the notice to exercise the provision. Either the Company or
its joint venture partner has the right to exercise the buy/sell
option. The party receiving the exercise notice has the right to
either purchase the interests held by the other party or sell
its interests to the other party. The purchase price formula for
the interests is set forth in the joint venture agreement and is
typically based on a multiple of the earnings before income
taxes, depreciation and amortization of the joint venture. Total
revenue earned by the Company from joint ventures subject to
these arrangements was $11,158,000, $16,127,000, $17,385,000 and
$12,396,000 during the years ended December 31, 2001, 2002,
and 2003, and the period ended June 30, 2004, respectively.
The Company has not received notice from any joint venture
partners of their intent to exercise the buy/sell option nor has
the Company notified any joint venture partners of any intent to
exercise the buy/sell option.
The Company is contingently liable to certain
former stockholders related to an earnout payment under a
noncompete agreement, which is payable on or before
March 31, 2006 if the gross collected revenues of the
Company equal or exceed $225,693,359 between January 1,
2001 and December 31, 2005. Pursuant to the terms of the
earn-out agreement, the amount of the payment to the former
stockholders will not exceed $337,500. The revenue earn-out
threshold was met in the fourth quarter ending December 31,
2004. Accordingly, the Company will record a compensation charge
of $337,500 in the fourth quarter.
The Company is involved in various legal
proceedings arising in the ordinary course of business. Although
the results of litigation cannot be predicted with certainty,
management believes the outcome of pending litigation will not
have a material adverse effect, after considering the effect of
the Companys insurance coverage, on the Companys
consolidated financial statements.
Compliance
The laws and regulations governing the
Companys operations, along with the terms of participation
in various government programs, regulate how the Company does
business, the services offered, and interactions with patients
and the public. These laws and regulations, and their
interpretations, are subject to frequent change. Changes in
existing laws or regulations, or their interpretations, or the
enactment of new laws or regulations could materially and
adversely affect the Companys operations and financial
condition.
The Company is subject to various routine and
nonroutine governmental reviews, audits, and investigations. In
recent years, federal and state civil and criminal enforcement
agencies have heightened and coordinated their oversight efforts
related to the healthcare industry, including with respect to
referral practices, cost reporting, billing practices, joint
ventures, and other financial relationships among healthcare
providers. Violation of the laws governing the Companys
operations, or changes in the interpretation of those laws,
could result in the imposition of fines, civil or criminal
penalties, the termination of the Companys rights to
participate in federal and state-sponsored programs, and the
suspension or revocation of the Companys licenses.
If the Companys long-term acute care
hospitals fail to meet or maintain the standards for Medicare
certification as long-term acute care hospitals, such as average
minimum length of patient stay, they will receive payments under
the prospective payment system applicable to general acute care
hospitals rather than payment under the system applicable to
long-term acute care hospitals. Payments at rates
F-26
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (Continued)
applicable to general acute care hospitals would
likely result in the Company receiving less Medicare
reimbursement than currently received for patient services.
Moreover, all of the Companys long-term acute care
hospitals are subject to additional Medicare criteria because
they operate as separate hospitals located in space leased from,
and located in, a general acute care hospital, known as a host
hospital. This is known as a hospital within a
hospital model. These additional criteria include
requirements concerning financial and operational separateness
from the host hospital.
The Company anticipates there may be changes to
the standard episode-of-care payment from Medicare in the
future. Due to the uncertainty of the revised payment amount,
the Company cannot estimate the impact that changes in the
payment rate, if any, will have on its future financial
statements. In August 2004, the Centers for Medicare and
Medicaid Services, or CMS, adopted new regulations that
implement significant changes affecting long-term acute care
hospitals. Among other things, these new regulations, which will
be effective in October 2004, implemented new rules that provide
long-term acute care hospitals operating in the hospital within
a hospital model with lower rates of reimbursement for Medicare
admissions from their host hospitals that are in excess of
specified percentages.
These new rules also reclassified certain
long-term acute care hospital diagnosis related groups, which
could result in a decrease in reimbursement rates. Further, the
new rules kept in place the financial penalties associated with
the failure to limit to no greater than 5% the total number of
Medicare patients discharged to the host hospital and
subsequently readmitted to a long-term acute care hospital
located within the host hospital.
The Company believes that it is in compliance
with all applicable laws and regulations and is not aware of any
pending or threatened investigations involving allegations of
potential wrongdoing. While no such regulatory inquiries have
been made, compliance with such laws and regulations can be
subject to future government review and interpretation as well
as significant regulatory action, including fines, penalties,
and exclusion from the Medicare program.
The Companys Louisiana facilities accounted
for approximately 100%, 92%, 89%, and 83% of net service revenue
during the years ended December 31, 2001, 2002, and 2003,
and the six months ended June 30, 2004, respectively. Any
material change in the current economic, or competitive
conditions in Louisiana could have a disproportionate effect on
the Companys overall business results.
F-27
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (Continued)
The Companys segments consist of
(a) home-based services and (b) facility-based
services. Home-based services include home nursing services and
hospice services. Facility-based serviced include long-term
acute care services and outpatient rehabilitation services. The
accounting policies of the segments are the same as those
described in the summary of significant accounting policies.
F-28
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (Continued)
The following table summarizes the fair value of
the Companys financial instruments:
F-29
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (Continued)
The carrying amounts of the Companys cash
and cash equivalents, receivables, accounts payable, and accrued
liabilities approximate their fair value because of their short
maturity.
The carrying amount of the Companys lines
of credit and capital lease obligations approximate their fair
value because of the interest rates are considered to be at
market rates. The fair value of the long-term debt is based on
the current interest rates on the Companys variable debt.
The following table summarizes the activity and
ending balances in the allowance for uncollectible accounts:
The following table describes the components of
property, building, and equipment:
Acquisitions
Effective October 1, 2004, the Company
acquired, through a stock purchase a 100% ownership interest in
an outpatient rehabilitation facility, for $1,400,000. The
consideration paid included cash of $750,000 and promissory
notes of $650,000. Additionally, effective October 1, 2004,
the Company acquired the operations of another home nursing
agency for $300,000 in cash.
The Company is in the process of allocating the
purchase price.
Exchange Agreements
The Company and the shareholders of one of the
Companys equity joint ventures were parties to a
shareholders agreement governing that venture. This
agreement granted these shareholders the right to convert their
equity interests in the joint venture into shares of the
Companys common stock upon the
F-30
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (Continued)
consummation of an initial public offering. These
shareholders have agreed to convert their equity interests in
the joint venture into 68,034 shares, effective upon the
completion of an initial public offering.
On September 14, 2004, the Company executed
an exchange agreement with the minority interest owner of one of
the Companys equity joint ventures. The agreement allows
the minority interest owner, upon the occurrence of certain
triggering events, including, but not limited to the closing of
an initial public offering, to exchange all of their membership
interests in the majority-owned subsidiary for
450,000 shares of the Companys common stock and cash
consideration in an amount equal to the value of
230,658 shares of the Companys stock based on the per
share public offering price.
F-31
LHC GROUP, INC. AND SUBSIDIARIES
See accompanying notes.
F-32
LHC GROUP, INC. AND SUBSIDIARIES
(1) Equity-based compensation expense is
allocated as follows:
F-33
LHC GROUP, LLC AND SUBSIDIARIES
See accompanying notes.
F-34
LHC GROUP, INC. AND SUBSIDIARIES
LHC Group, LLC (Company) is a
healthcare provider specializing in the post-acute continuum of
care primarily to Medicare patients in rural markets in the
southern United States. The Company provides home-based
services, primarily through home nursing agencies and hospices,
and facility-based services, primarily through long-term acute
care hospitals and outpatient rehabilitation clinics. The
Company, through its wholly and majority-owned subsidiaries,
equity joint ventures, and controlled affiliate, currently
operates in Louisiana, Arkansas, Mississippi, and Texas.
The Company operates under the terms of an
operating agreement which provides that the Company does not
have a finite life and that the members personal liability
is limited to his or her capital contribution. There is only one
class of member interest.
In March 2004, the Company engaged in initial
discussions with potential underwriters regarding our initial
public offering. In June 2004, the Companys Board of
Directors authorized the Company to proceed with an initial
public offering of its common stock.
Plan of Merger and Recapitalization
In January 2005, LHC Group, LLC established a
wholly-owned Delaware subsidiary, LHC Group, Inc. Effective
February 9, 2005, LHC Group, LLC merged into LHC Group,
Inc. In connection with the merger, each outstanding membership
unit in LHC Group, LLC was converted into shares of the $0.01
par value common stock of LHC Group, Inc. based on an exchange
ratio of three-for-two. Each KEEP unit will also be convertible
upon the initial public offering into shares of common stock of
LHC Group, Inc. pursuant to the same three-for-two ratio. LHC
Group, Inc. has 40,000,000 shares of $0.01 par value common
stock authorized and 5,000,000 shares of $0.01 par value
preferred stock authorized. All references to common stock,
share, and per share amounts have been retroactively restated to
reflect the merger and recapitalization as if the merger and
recapitalization had taken place as of the beginning of the
earliest period presented.
As used herein, the Company includes
LHC Group, Inc. and all predecessor entities.
Interim Financial Statements
In the opinion of management, all adjustments
(consisting of normal recurring accruals) considered necessary
for a fair presentation in accordance with accounting principles
generally accepted in the United States have been included.
Operating results for the nine months ended September 30,
2004 are not necessarily indicative of the results that may be
expected for the year ending December 31, 2004.
Use of Estimates
The preparation of financial statements in
conformity with accounting principles generally accepted in the
United States requires management to make estimates and
assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities
at the date of the financial statements and the reported revenue
and expenses during the reported period. Actual results could
differ from those estimates.
F-35
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Principles of Consolidation
The consolidated financial statements include the
accounts of LHC Group, Inc., its wholly owned and majority-owned
subsidiaries, and those entities where the Company has a
controlling financial interest. The Company has a joint venture
in which the Company shares in the majority of the operating
profits and losses. The joint venture partner is a
not-for-profit entity who has majority voting rights only in
matters impacting the joint venture partners tax-exempt
status. Management has determined that the Company is the
primary beneficiary of this entity due to its controlling
financial interest.
In 2004, the Company sold its majority interest
in three hospices, its minority interest in an inpatient
rehabilitation facility and the rights to operate a home nursing
agency in a specific area. In accordance with SFAS No. 144,
Accounting for the Impairment or Disposal of Long-Lived
Assets,
the results of operations of these entities,
including the gain on sale and impairment loss are presented as
discontinued operations in all periods presented.
All significant intercompany accounts and
transactions have been eliminated in consolidation. Business
combinations accounted for as purchases have been included in
the consolidated financial statements from the respective dates
of acquisition.
Revenue Recognition
The Company reports net service revenue at the
estimated net realizable amount due from Medicare, Medicaid,
commercial insurance, managed care payors, patients, and others
for services rendered. Under Medicare, the Companys home
nursing patients are classified into a home health resource
group prior to the receipt of services. Based on this home
health resource group the Company is entitled to receive a
prospective Medicare payment for delivering care over a 60 day
period. Medicare adjusts these prospective payments based on a
variety of factors, such as low utilization, patient transfers,
changes in condition and the level of services provided. In
calculating reported net service revenue from the Companys
home nursing services, the Company adjusts the prospective
Medicare payments by an estimate of the adjustments. The Company
calculates the adjustments based on a rolling average of these
types of adjustments for claims paid during the preceding three
months. For home nursing services, revenue is recognized based
on the number of days elapsed during the episode of care.
Under Medicare, patients in the Companys
long-term acute care facilities are classified into long-term
diagnosis-related groups. Based on this classification, the
Company is then entitled to receive a fixed payment from
Medicare. This fixed payment is also subject to adjustment by
Medicare due to factors such as short stays. In calculating
reported net service revenue for services provided in the
Companys long-term acute care hospitals, the Company
reduces the prospective payment amounts by an estimate of the
adjustments. The Company calculates the adjustment based on a
historical average of these types of adjustments for claims paid
during the preceding three months. For the Companys
long-term acute care hospitals revenue is recognized as services
are provided.
For hospice services the Company is paid by
Medicare under a prospective payment system. The Company
receives one of four predetermined daily or hourly rates based
upon the level of care furnished. The Company records net
service revenue from hospice services based on the daily or
hourly rate. The Company recognizes revenue for hospice as
services are provided
Under Medicare the Company is reimbursed for
rehabilitation services based on a fee schedule for services
provided adjusted by the geographical area in which the facility
is located. The Company recognizes revenue as these services are
provided.
The Companys Medicaid reimbursement is
based on a predetermined fee schedule applied to each service
provided. Therefore, the Company recognizes revenue for Medicaid
services as services are
F-36
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
provided based on this fee schedule. The
Companys managed care payors reimburse the Company in a
manner similar to either Medicare or Medicaid. Accordingly, the
Company recognizes revenue from managed care payors in the same
manner as the Company recognizes revenue from Medicare or
Medicaid.
The Company records management services revenue
as services are provided in accordance with the various
management services agreements to which the Company is a party.
The agreements generally call for the Company to provide
billing, management, and other consulting services suited to and
designed for the efficient operation of the applicable home
nursing agency or inpatient rehabilitation facility. The Company
is responsible for the costs associated with the locations and
personnel required for the provision of the services. The
Company is generally compensated based on a percentage of net
billings or an established base fee. In addition, for certain of
the management agreements, the Company may earn incentive
compensation.
Net service revenue was comprised of the
following:
The following table sets forth the percentage of
net service revenue earned by category of payor:
Home Nursing
Services.
The Company receives a
standard prospective Medicare payment for delivering care over a
base 60-day period, or episode of care. The base payment,
established through federal legislation, is a flat rate that is
adjusted upward or downward based upon differences in the
expected resource needs of individual patients as indicated by
clinical severity, functional severity, and service utilization.
The magnitude of the adjustment is determined by each
patients categorization into one of 80 payment groups,
known as home health resource groups, and the costliness of care
for patients in each group relative to the average patient. The
Companys payment is also adjusted for differences in local
prices using the hospital wage index. The Company recognizes
revenue when services are provided based on the number of days
elapsed during the episode. The Company performs payment
variance analysis to verify the models utilized in projecting
total net service revenue are accurately reflecting the payments
received.
Medicare rates are subject to change. Due to the
length of the Companys episodes of care, a situation may
arise where Medicare rate changes affect prior periods net
service revenue. In the event that
F-37
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Medicare rates experience change, the net effect
of that change will be reflected in the current reporting period.
Final Medicare payments may reflect one of five
retroactive adjustments to ensure the adequacy and effectiveness
of the total reimbursement: (a) an outlier payment if the
patients care was unusually costly; (b) a low
utilization adjustment if the number of visits was fewer than
five; (c) a partial payment if the patient transferred to
another provider before completing the episode; (d) a
change-in-condition adjustment if the patients medical
status changes significantly, resulting in the need for more or
less care; or (e) a payment adjustment based upon the level
of therapy services required in the population base. Management
estimates the impact of these payment adjustments based on
historical experience and records this estimate during the
period the services are rendered.
A portion of the estimated Medicare prospective
payment system reimbursement from each submitted home nursing
episode is received in the form of a request for accelerated
payment, (RAP) before all services are rendered. The
estimated episodic payment is billed at the commencement of the
episode. The Company receives a RAP for 60% of the estimated
reimbursement at the initial billing for the initial episode of
care per patient and the remaining reimbursement is received
upon completion of the episode. For any subsequent episodes of
care contiguous with the first episode of care for a patient the
Company receives a RAP for 50% of the estimated reimbursement at
initial billing. The remaining 50% reimbursement is received
upon completion of the episode. Amounts billed and received in
advances of actual services performed are recorded as amounts
due to the Medicare program. Amounts billed and received in
advance of services being performed are recorded as reductions
to accounts receivable. The amounts were $4,986 and $6,994 at
December 31, 2003 and September 30, 2004,
respectively. At December 31, 2003 and September 30,
2004, accounts receivable due from the Medicare program
represented approximately 78% and 62%, respectively, of total
patient accounts receivable.
Hospice Services.
Medicare reimburses for hospice care using a prospective payment
system. Under that system, the Company receives one of four
predetermined daily or hourly rates based upon the level of care
furnished to the beneficiary. These rates are subject to annual
adjustments based on inflation and geographic wage
considerations. The Company recognizes revenue as the services
are provided.
The Companys Medicare hospice reimbursement
is subject to two caps. One cap relates to individual programs
receiving more than 20% of its total Medicare reimbursement from
inpatient care services. The second cap relates to individual
programs receiving reimbursements in excess of a cap
amount, calculated by multiplying the number of
beneficiaries during the period by a statutory amount that is
indexed for inflation. The determination for each cap is made
annually based on the 12-month period ending on October 31
of each year. This limit is computed on a program-by-program
basis. None of the Companys hospices exceeded either cap
during 2001, 2002, 2003, or the 2004 period.
Long-Term Acute Care
Services.
The Company is reimbursed by
Medicare for services provided under the long-term acute care
hospital prospective payment system, which was implemented on
October 1, 2002. The Company is paid solely on the basis of
the long-term acute care hospital diagnosis-related groups. The
Company recognizes revenue as the services are provided.
Each patient discharged from the Companys
long-term acute care hospitals is assigned a long-term care
diagnosis-related group. The Company is paid a predetermined
fixed amount applicable to that particular group. This payment
is intended to reflect the average cost of treating a Medicare
patient classified in that particular long-term care
diagnosis-related group. For selected patients, the amount may
be further adjusted based on length of stay and
facility-specific costs, as well as in instances where a
F-38
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
patient is discharged and subsequently
readmitted, among other factors. Similar to other Medicare
prospective payment systems, the rate is also adjusted for
geographic wage differences.
Outpatient Rehabilitation
Services.
Outpatient therapy services
are reimbursed on a fee schedule, subject to annual limitations.
Outpatient therapy providers receive a fixed fee for each
procedure performed, adjusted by the geographical area in which
the facility is located. The Company recognizes revenue as the
services are provided. There are also annual per Medicare
beneficiary caps that limit Medicare coverage for outpatient
rehabilitation services.
Due to/from Governmental Entities
Prior to October 1, 2000, the Company
recorded Medicare home nursing services revenues at the lower of
actual costs, the per visit cost limit, or a per beneficiary
cost limit on an individual provider basis. Final reimbursement
was determined based on submission of annual cost reports and
audits by the fiscal intermediary. Adjustments were accrued on
an estimated basis in the period the related services were
rendered and further adjusted as final settlements are
determined. These adjustments are accounted for as changes in
estimates. There have been no significant changes in estimates
during the 2003 or 2004 periods.
The Company sponsors a Key Employee Equity
Participation (KEEP) Plan whereby certain
individuals are granted participation equity units (KEEP
Units). The KEEP Plan functions as a stock appreciation
rights plan whereby an individual is entitled to receive, on a
per KEEP Unit basis, the increase in estimated fair value of the
Companys common stock from the date of grant until the
date that the employee dies, retires, or is terminated for other
than cause. Accordingly, the KEEP Units are subject to variable
accounting until such time as the obligation to the employee is
settled. The Company has a call right, under which, it can
purchase all or portion of the KEEP units. The individuals
receiving KEEP Units vest in those rights in a graded manner
over a five-year period and, accordingly, the Company records
compensation expense for the vested portion of the KEEP Units.
The KEEP Units have no exercise price.
Compensation expense, and a corresponding
increase in paid-in capital, is also recognized each period for
any change in value associated with certain shares held by an
officer of the Company.
Basic net income per share is computed by
dividing net income by the weighted-average number of shares
outstanding during the period. Diluted earnings per share is
computed by dividing net income by the weighted-average number
of shares outstanding plus dilutive potential shares.
The following table sets forth shares used in the
computation of basic and diluted net income per share for the
nine months ended September 30, 2003 and 2004.
F-39
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The KEEP Units are accounted for at their
estimated fair value. Accordingly, no pro forma net income or
per share information is required.
Recently Issued Accounting
Pronouncements
In December 2003, the FASB published a revision
to Interpretation 46, or FIN 46R, to clarify certain
provisions of FASB Interpretation No. 46,
Consolidation
of Variable Interest Entities,
and to exempt certain
entities from its requirements. FIN No. 46R requires a
company to consolidate a variable interest entity, or VIE, as
defined, when the company will absorb a majority of the
VIEs expected losses, receive a majority of the variable
interest entitys expected residual returns, or both.
FIN No. 46R also requires consolidation of existing,
non-controlled affiliates if the VIE is unable to finance its
operations without investor support, or where the other
investors do not have exposure to the significant risks and
rewards of ownership. FIN No. 46R is effective by the
end of the first reporting period beginning after
December 15, 2003. The Company does not expect the adoption
of FIN No. 46R to have a material impact on the
Companys consolidated financial statements.
The following acquisitions were completed
pursuant to the Companys strategy of becoming the leading
provider of post-acute healthcare services to Medicare patients
in selected rural markets in the southern United States. The
purchase price of each acquisition was determined based on the
Companys analysis of comparable acquisitions and target
markets potential cash flows. Goodwill generated from the
acquisitions was recognized based on the expected contributions
of each acquisition to the overall corporate strategy and is
expected to be fully tax deductible. The Company has concluded
that licenses to operate home-based and/or facility-based
services have indefinite lives, as management has determined
that there are no legal, regulatory, contractual, economic or
other factors that would limit the useful life of the licenses
and the Company intends to renew and operate the licenses
indefinitely. Accordingly, the Company has elected to recognize
the fair value of these indefinite-lived licences and goodwill
as a single asset for financial reporting purposes, as permitted
by SFAS No. 141,
Business Combinations.
Each of the
acquisitions completed was accounted for as a purchase and is
included in the Companys financial statements based on its
respective acquisition date.
2004 Acquisitions
The Company made six acquisitions during the nine
months ended September 30, 2004 for $520,000 in cash. These
acquisitions were primarily the purchase of the entities
existing operations. Goodwill of $370,000 was assigned to the
home-based services segment and goodwill of $35,000 was assigned
to the facility-based segment.
The Company also acquired a 70% interest in an
outpatient rehabilitation facility through a stock purchase
agreement for $207,000 in cash. Goodwill of $54,000 was assigned
to the facility-based segment.
Additionally, the Company acquired a portion of
the minority interest in a majority-owned home nursing joint
venture by issuing a $300,000 promissory note. A $300,000
increase in the home-based segments goodwill was
recognized in connection with this transaction.
2004 Divestitures
The Company sold the rights in three hospice
subsidiaries to the minority interest holder. The Company
received $300,000 and recognized a gain on the sale of $347,000.
The Company also sold its majority interest in a rehabilitation
facility to another owner in the facility for $129,000,
receiving cash of $45,000 and a promissory note for $85,000. The
Company recognized a loss on the sale of $40,000.
F-40
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The Company sold the rights to operate a home
care facility in a specific area to an unrelated party for
$200,000. The Company received $125,000 in cash and a promissory
note for the balance. The Company recognized a gain on the sale
of $200,000.
In connection with the planned divestiture of
certain entities in 2004, management recognized an impairment
loss on two operating entities in 2003.
The following results of these divestitures have
been presented as a loss from discontinued operations in the
accompanying unaudited consolidated statement of income:
2003 Acquisitions
The Company made four acquisitions during 2003
for $2,100,000. These acquisitions were primarily the purchase
of the entities existing operations. The Company paid
$1,600,000 in cash and issued a promissory note for $500,000.
Goodwill of $126,000 was assigned to the home-based services
segment and goodwill of $1,950,000 was assigned to the
facility-based segment.
Additionally, the Company increased ownership in
a home-nursing operation by paying $315,000 in cash and
recognized an increase in goodwill of $315,000 in the home-based
services segment.
The changes in recorded goodwill by segment for
the period ended September 30, 2004, were as follows (in
thousands):
The above transactions were considered to be
immaterial individually and in the aggregate. Accordingly, no
supplemental pro forma information is considered required.
F-41
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The following table summarizes the activity in
stockholders equity for the nine months ended
September 30, 2004 (in thousands except share and per share
data).
The Company has reserved up to 6.5% of the value
of the Companys stock for issuance under the KEEP Plan. A
summary of the changes in the KEEP Units outstanding is as
follows:
The outstanding unvested KEEP Units vest
according to the following schedule:
Upon the occurrence of certain events, as defined
in the KEEP Plan, including an initial public offering, the
outstanding KEEP Units fully vest.
The Companys Louisiana facilities accounted
for approximately 88% and 83% of net service revenue during the
nine months ended September 30, 2004 and 2003,
respectively. Any material change in the current economic, or
competitive conditions in Louisiana could have a
disproportionate effect on the Companys overall business
results.
F-42
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The Companys segments consist of
(a) home-based services and (b) facility-based
services. Home-based services include home nursing and hospice
services. Facility-based services include long-term acute care
service and outpatient rehabilitation services. The accounting
policies for the segments are the same as those described in the
summary of accounting policies.
Effective October 1, 2004, the Company
acquired, through a stock purchase, a 100% ownership interest in
an outpatient rehabilitation facility for $1,400,000. The
consideration to be paid included cash of $750,000 and
promissory notes of $650,000. The Company is in the process of
allocating the purchase price. The $750,000 cash payment was
made prior to September 30, 2004 and has been included in
other assets in the accompanying consolidated balance sheets.
Additionally, effective October 31, 2004, the Company
acquired the operations of another home nursing agency for
$300,000 in cash.
F-43
F-2
F-3
F-4
F-6
F-7
F-8
F-32
F-33
F-34
F-35
Table of Contents
Table of Contents
Table of Contents
Year Ended December 31,
Six Months
Ended
2001
2002
2003
June 30, 2004
(in thousands, except share and per share data)
$
28,208
$
48,950
$
72,365
$
55,579
13,466
23,438
37,146
28,763
14,742
25,512
35,219
26,816
11,011
16,430
24,761
16,821
31
111
124
864
1,046
3,620
8,958
9,563
8,949
411
1,135
1,226
698
(325
)
(124
)
(106
)
124
3,534
7,947
8,443
8,127
1,151
2,139
2,320
2,466
1,355
2,699
2,837
1,985
1,028
3,109
3,286
3,676
(241
)
(267
)
(443
)
(13
)
303
$
787
$
2,842
$
2,843
$
3,966
$
0.09
$
0.26
$
0.27
$
0.30
(0.02
)
(0.02
)
(0.03
)
0.03
$
0.07
$
0.24
$
0.24
$
0.33
$
0.08
$
0.26
$
0.26
$
0.30
(0.02
)
(0.02
)
(0.03
)
(0.0
)
0.03
$
0.06
$
0.24
$
0.23
$
0.33
11,756,419
11,926,222
12,085,150
12,085,150
12,241,908
12,084,534
12,114,671
12,184,454
Table of Contents
(1)
Equity-based compensation is allocated as follows:
Year Ended December 31,
Six Months
Ended
2001
2002
2003
June 30, 2004
(in thousands)
$
$
$
5
$
19
111
124
859
1,027
$
111
$
124
$
864
1,046
Table of Contents
Common Stock
Notes
Issued
Treasury
Additional
Receivable
Paid-In
From
Retained
Amount
Shares
Amount
Shares
Capital
Officer
Earnings
Total
(in thousands, except share and per share data)
$
121
15,000,000
$
$
268
$
$
(547
)
$
(158
)
787
787
111
111
(1,042
)
3,881,663
(1,042
)
(101
)
(101
)
121
15,000,000
(1,042
)
3,881,663
379
139
(403
)
2,842
2,842
260
(966,813
)
1,193
(260
)
1,193
124
124
(163
)
(163
)
121
15,000,000
(782
)
2,914,850
1,696
2,558
3,593
2,843
2,843
665
665
(192
)
(192
)
121
15,000,000
(782
)
2,914,850
2,361
5,209
6,909
3,966
3,966
40
(150,000
)
683
(123
)
600
(1,500
)
150,000
1,377
123
(224
)
(224
)
$
121
15,000,000
$
(2,242
)
2,914,850
$
4,421
$
$
8,951
$
11,251
Table of Contents
Year Ended December 31,
Six Months
Ended
2001
2002
2003
June 30, 2004
(in thousands)
$
787
$
2,842
$
2,843
$
3,966
98
230
441
407
484
461
604
684
351
963
111
124
864
1,046
241
1,578
(168
)
157
310
(295
)
(89
)
(10
)
(365
)
(4,574
)
(7,086
)
(4,476
)
(5,384
)
(299
)
(330
)
(221
)
(120
)
707
3,686
534
2,205
297
(168
)
4
(276
)
(3
)
258
(655
)
(236
)
(1,686
)
174
830
3,210
(751
)
(871
)
(2,046
)
(2,011
)
150
180
470
(1,470
)
(340
)
(1,891
)
(597
)
(2,221
)
(1,211
)
(3,787
)
(1,958
)
1
(58
)
(153
)
(184
)
(160
)
(2,566
)
(1,083
)
(1,331
)
(1,223
)
4,168
251
1,405
762
2,089
5,069
1,161
2,362
452
(1,150
)
(62
)
3,571
4,085
1,503
591
(336
)
3,048
(1,454
)
1,843
467
131
3,179
1,725
$
131
$
3,179
$
1,725
$
3,568
$
400
$
1,066
$
1,304
$
729
$
820
$
1,994
$
1,922
$
2,456
Table of Contents
1.
Organization
2.
Significant Accounting Policies
Table of Contents
Principles of Consolidation
Table of Contents
Year Ended December 31,
Six Months
Ended
2001
2002
2003
June 30, 2004
51.3
%
48.9
%
50.8
%
48.7
%
4.1
5.0
9.7
30.7
42.2
42.3
3.17
8.6
0.1
1.9
5.4
11.4
2.3
1.9
2.4
0.6
100.0
%
100.0
%
100.0
%
100.0
%
Revenue Recognition
Table of Contents
Year Ended December 31,
Six Months
Ended
2001
2002
2003
June 30, 2004
86.1
%
86.7
%
77.7
%
68.6
%
13.9
13.3
22.3
31.4
100.0
%
100.0
%
100.0
%
100.0
%
Year Ended December 31,
Six Months
Ended
2001
2002
2003
June 30, 2004
79.3
%
82.8
%
83.1
%
86.3
%
2.6
3.8
5.1
4.9
18.1
13.4
11.8
8.8
100.0
%
100.0
%
100.0
%
100.0
%
Home-Based Services
Table of Contents
Facility-Based Services
Accounts Receivable and Allowances for
Uncollectible Accounts
Table of Contents
Table of Contents
$
787
24
$
811
Cash and Cash Equivalents
Due to/from Governmental
Entities
Property, Building, and
Equipment
Long-Lived Assets
Income Taxes
Table of Contents
Minority Interest and Cooperative Endeavor
Agreements
Cost of Service Revenue
Salaries and related benefits expense;
Transportation, primarily mileage reimbursement;
and
Supplies and services, including payments to
contract therapists.
General and Administrative
Expenses
Home office:
Salaries and related benefits expense;
Costs associated with advertising and other
marketing activities; and
Rent and utilities.
Supplies and services:
Accounting, legal, and other professional
services;
Office supplies;
Table of Contents
Depreciation; and
Provision for bad debts.
Advertising and Marketing
Costs
Equity-Based Compensation
Expense
Earnings Per Share
Year Ended December 31,
Six Months
Ended
2001
2002
2003
June 30, 2004
11,756,419
11,926,222
12,085,150
12,085,150
29,521
99,304
485,489
158,312
12,241,908
12,084,534
12,114,671
12,184,454
Concentration of Credit Risk
Table of Contents
Reclassification
3.
Acquisitions and Divestitures
2004 Acquisitions
Table of Contents
2004 Divestitures
December 31,
June 30,
2001
2002
2003
2004
(in thousands)
$
728
$
4,828
$
5,532
$
763
1,108
5,278
6,288
784
(380
)
(450
)
(756
)
(21
)
139
183
313
8
$
(241
)
$
(267
)
$
(443
)
$
(13
)
2003 Acquisitions
2002 Acquisitions
2001 Acquisitions
Table of Contents
Year Ended
December 31,
Six Months
Ended
2002
2003
June 30, 2004
$
1,604
$
1,944
$
2,034
340
441
670
(351
)
$
1,944
$
2,034
$
2,704
$
127
$
127
$
2,077
1,950
74
$
127
$
2,077
$
2,151
4.
Income Taxes
December 31,
June 30,
2002
2003
2004
(in thousands)
$
(186
)
$
(93
)
$
(46
)
(47
)
(70
)
(231
)
(115
)
(264
)
(462
)
(260
)
(247
)
(226
)
(174
)
(174
)
(574
)
(861
)
(1,160
)
189
131
229
119
78
214
76
245
191
308
285
879
$
(266
)
$
(576
)
$
(281
)
Table of Contents
Year Ended December 31,
Six Months
Ended
2001
2002
2003
June 30, 2004
(in thousands)
$
1,021
$
1,772
$
1,777
$
2,481
298
210
233
280
1,319
1,982
2,010
2,761
(150
)
141
277
(264
)
(18
)
16
33
(31
)
(168
)
157
310
(295
)
$
1,151
$
2,139
$
2,320
$
2,466
Year Ended December 31,
Six Months
Ended
2001
2002
2003
June 30, 2004
(in thousands)
$
741
$
1,784
$
1,906
$
2,088
213
214
243
259
197
141
171
119
$
1,151
$
2,139
$
2,320
$
2,466
Table of Contents
5.
Credit Arrangements
December 31,
June 30,
2002
2003
2004
(in thousands)
$
1,798
$
1,359
$
1,119
749
551
439
500
300
331
115
20
2,878
2,525
1,878
617
1,277
938
$
2,261
$
1,248
$
940
$
938
940
$
1,878
Table of Contents
6.
Key Employee Equity Participation
Plan
Year Ended
Six Months
December 31,
Ended
2003
June 30, 2004
106,500
106,500
140,430
106,500
246,930
19,745
64,344
40,457
63,194
44,152
24,717
9,883
183
182,586
7.
Related Party Transactions
Table of Contents
Table of Contents
8.
Leases
Table of Contents
$
1,992
3,039
2,241
1,444
932
1,811
$
11,459
December 31,
June 30,
2003
2004
(in thousands)
$
301
$
301
256
445
202
377
95
172
95
168
273
283
1,222
1,746
140
163
1,082
1,583
292
506
$
790
$
1,077
9.
Employee Benefit Plan
10.
Commitments and Contingencies
Table of Contents
Table of Contents
11.
Concentration of Risk
Table of Contents
12.
Segment Information
Year Ended December 31, 2001
Home-Based
Facility-Based
Services
Services
Total
(in thousands)
$
24,276
$
3,932
$
28,208
11,328
2,138
13,466
9,365
1,646
11,011
78
33
111
3,505
115
3,620
288
123
411
3,477
57
3,534
1,355
1,355
2,122
57
2,179
8,223
1,603
9,826
514
237
751
Year Ended December 31, 2002
Home-Based
Facility-Based
Services
Services
Total
(in thousands)
$
42,443
$
6,507
$
48,950
19,745
3,693
23,438
13,388
3,042
16,430
87
37
124
9,223
(265
)
8,958
807
328
1,135
8,522
(575
)
7,947
2,699
2,699
5,823
(575
)
5,248
18,153
3,332
21,485
267
604
871
Table of Contents
Year Ended December 31, 2003
Home-Based
Facility-Based
Services
Services
Total
(in thousands)
$
56,196
$
16,169
$
72,365
27,567
9,579
37,146
17,642
7,119
24,761
605
259
864
10,351
(788
)
9,563
872
354
1,226
9,571
(1,128
)
8,443
2,855
(18
)
2,837
6,716
(1,110
)
5,606
22,232
5,683
27,915
850
1,196
2,046
Six Months Ended June 30, 2004
Home-Based
Facility-Based
Services
Services
Total
(in thousands)
$
38,083
$
17,496
$
55,579
19,103
9,660
28,763
11,573
5,248
16,821
732
314
1,046
6,675
2,274
8,949
496
202
698
6,099
2,028
8,127
1,282
703
1,985
4,817
1,325
6,142
26,749
10,807
37,556
987
1,024
2,011
13.
Fair Value of Financial Instruments
December 31,
2002
2003
June 30, 2004
Carrying
Fair
Carrying
Fair
Carrying
Fair
Value
Value
Value
Value
Value
Value
(in thousands)
$
3,179
$
3,179
$
1,725
$
1,725
$
3,568
$
3,568
13,552
13,552
17,630
17,630
23,105
23,105
7,084
7,084
7,261
7,261
9,131
9,131
881
881
803
803
140
140
155
155
1,082
1,082
1,583
1,583
9,506
9,814
10,392
10,556
12,910
13,016
Table of Contents
14.
Allowance for Uncollectible Accounts and
Property, Building, and Equipment
Beginning
End of
of Period
Costs and
Period
Balance
Expenses
Deductions
Balance
(in thousands)
$
418
$
684
$
336
$
766
496
604
682
418
439
461
404
496
97
484
142
439
December 31,
June 30,
2002
2003
2004
(in thousands)
$
10
$
$
485
582
845
389
896
676
1,322
2,623
3,739
2,206
4,101
5,260
423
860
898
$
1,783
$
3,241
$
4,362
15.
Subsequent Events
Table of Contents
Table of Contents
Table of Contents
Nine Months Ended
September 30,
2003
2004
(unaudited)
(in thousands, except share and
per share data)
$
49,315
$
87,958
24,789
45,415
24,526
42,543
17,205
26,433
156
1,257
7,165
14,853
806
1,048
(52
)
109
6,411
13,696
1,694
4,173
2,113
3,066
2,604
6,457
(200
)
(18
)
308
$
2,404
$
6,747
$
0.22
$
0.53
(0.02
)
0.03
$
0.20
$
0.56
$
0.22
$
0.53
(0.02
)
0.02
$
0.20
$
0.55
12,085,150
12,085,150
12,100,682
12,201,531
$
.011
$
.031
Nine Months Ended
September 30,
2003
2004
$
$
31
156
1,226
$
156
$
1,257
Table of Contents
Nine Months Ended
September 30,
2003
2004
(unaudited)
(in thousands)
$
2,404
$
6,747
283
688
512
1,186
156
1,257
2,651
(232
)
(2
)
(365
)
728
(7,656
)
(103
)
(283
)
(1,519
)
2,212
769
(457
)
(83
)
(104
)
3,145
5,644
(503
)
(3,062
)
180
470
(1,325
)
(1,663
)
(1,828
)
(4,075
)
(149
)
(288
)
(777
)
(1,601
)
56
762
(1,537
)
3,340
(631
)
176
(2,042
)
(2,231
)
(460
)
(914
)
1,109
3,179
1,725
$
2,265
$
2,834
Table of Contents
1.
Organization
2.
Significant Accounting Policies
Table of Contents
Table of Contents
Nine Months Ended
September 30,
2003
2004
78.9
%
68.5
%
21.1
31.5
100.0
%
100.0
%
Nine Months Ended
September 30,
2003
2004
83.3
%
85.7
%
5.2
4.8
11.5
9.5
100.0
%
100.0
%
Home-Based Services
Table of Contents
Facility-Based Services
Table of Contents
Equity-Based Compensation Expense
Earnings Per Share
Nine Months Ended
September 30,
2003
2004
12,085,150
12,085,150
15,532
116,381
12,100,682
12,201,531
Table of Contents
3.
Acquisitions and Divestitures
Table of Contents
Nine Months
Ended
September 30, 2003
September 30, 2004
$
3,973
$
770
4,302
799
(329
)
(29
)
129
11
$
(200
)
$
(18
)
Nine Months
Ended
September 30, 2004
$
2,034
670
$
2,704
$
2,077
89
$
2,166
Table of Contents
4.
Stockholders Equity
Common Stock
Notes
Issued
Treasury
Addition
Receivable
Paid-In
From
Retained
Amount
Shares
Amount
Shares
Capital
Officer
Earnings
Total
$
121
15,000,000
$
(782
)
2,914,850
$
2,361
$
$
5,209
$
6,909
6,747
6,747
40
(150,000
)
683
(123
)
600
(1,500
)
150,000
1,377
123
(377
)
(377
)
$
121
15,000,000
$
(2,242
)
2,914,850
$
4,421
$
$
11,579
$
13,879
Nine Months
Ended
September 30, 2004
106,500
150,180
256,680
85,476
21,132
66,078
46,243
26,018
10,467
1,266
171,204
5.
Concentration of Risk
Table of Contents
6.
Segment Information.
Nine Months Ended September 30, 2004
Home-Based
Facility-Based
Services
Services
Total
(in thousands)
$
60,368
$
27,590
$
87,958
29,962
15,453
45,415
17,969
8,464
26,433
880
377
1,257
11,557
3,296
14,853
741
307
1,048
10,741
2,955
13,696
2,187
879
3,066
8,554
2,076
10,630
32,043
9,050
41,093
1,746
1,404
3,150
Nine Months Ended September 30, 2003
Home-Based
Facility-Based
Services
Services
Total
(in thousands)
$
38,914
$
10,401
$
49,315
18,671
6,118
24,789
12,616
4,589
17,205
109
47
156
7,518
(353
)
7,165
576
230
806
6,983
(572
)
6,411
2,113
2,113
4,870
(572
)
4,298
16,357
3,636
19,993
184
281
465
7.
Subsequent Events
Table of Contents
Table of Contents
PART II
The following table sets forth all fees and
expenses payable in connection with the issuance and
distribution of the securities being registered hereby. All
amounts except the SEC registration fee, the NASD filing fee and
the Nasdaq listing fee are estimated.
Section 145 of the Delaware General
Corporation Law permits a corporation to include in its
corporate documents, and in agreements between the corporation
and its directors and officers, provisions expanding the scope
of indemnification beyond that specifically provided by the
current law. Our certificate of incorporation provides for the
indemnification of directors to the fullest extent permissible
under Delaware law. In addition, our bylaws provide for the
indemnification of officers, directors and third parties acting
on our behalf if such person acted in good faith and in a manner
reasonably believed to be in and not opposed to our best
interests, and, with respect to any criminal action or
proceeding, the indemnified party had no reason to believe his
or her conduct was unlawful. We have entered into
indemnification agreements with our directors and executive
officers in addition to indemnification provided for in our
charter documents, and we intend to enter into indemnification
agreements with any new directors and executive officers in the
future. We intend to purchase and maintain insurance on behalf
of any person who is or was a director or officer against any
loss arising from any claim asserted against him or her and
incurred by him or her in any such capacity, subject to certain
exclusions.
In the three years preceding the filing of this
registration statement, we have sold and issued the following
unregistered securities:
The following information relates to all
securities issued or sold by us in the last three years that
were not registered under the Securities Act. Each of the
transactions described below was conducted in reliance upon the
exemptions from registration provided under Rule 701
promulgated under Section 3(b) of the Securities Act, and
Section 4(2) of the Securities Act and the rules and
regulations promulgated thereunder. Each of the stock
certificates we issued in such transactions contains a
restrictive legend permitting transfer of the securities only
upon registration under the Securities Act or pursuant to an
exemption from registration.
In May 2001, we issued 1,515,849 shares of
Louisiana Health Care Group, Inc. to the shareholders of The
Health Care Group, Inc. in connection with a stock exchange and
reorganization in consideration of their shares in the Health
Care Group, Inc.
In May 2002, we issued the equivalent of
966,813 shares of our currently outstanding common stock in
shares of Louisiana Health Care Group, Inc. in consideration of
a cash payment of $1,000 and a
II-1
In March 2004, we issued 150,000 shares to
an officer in consideration of a promissory note in the amount
of $123,401. This promissory note was secured by a pledge of the
shares. This promissory note has been cancelled and the shares
are no longer issued and outstanding.
Upon completion of this offering, we will issue
an aggregate of 518,036 aggregate shares to two of our joint
venture partners upon the exercise of their rights to convert
their joint venture equity interests into shares of our common
stock, and will issue 481,680 shares of our common stock upon
conversion of outstanding KEEP units.
(a)
Exhibits.
The list of exhibits is
set forth beginning on page II-4 of this Registration
Statement and is incorporated herein by reference.
(b)
Financial Statement Schedules.
Not applicable.
*(f) We hereby undertake to provide to the
underwriters at the closing specified in the underwriting
agreement certificates in such denominations and registered in
such names as required by the underwriters to permit prompt
delivery to each purchaser.
*(h) Insofar as indemnification for liabilities
arising under the Securities Act of 1933 may be permitted to
directors, officers and controlling persons of us pursuant to
the foregoing provisions, or otherwise, we have been advised
that in the opinion of the Securities and Exchange Commission
such indemnification is against public policy as expressed in
the Act and is, therefore, unenforceable. In the event that a
claim for indemnification against such liabilities (other than
the payment by us of expenses incurred or paid by a director,
officer or controlling person of us in the successful defense of
any action, suit or proceeding) is asserted by such director,
officer or controlling person in connection with the securities
being registered, we will, unless in the opinion of our counsel
the matter has been settled by controlling precedent, submit to
a court of appropriate jurisdiction the question whether such
indemnification by us is against public policy as expressed in
the Act and will be governed by the final adjudication of such
issue.
*(i) We hereby undertake that:
II-2
Item 13.
Other Expenses of Issuance and
Distribution
$
7,602
6,500
105,000
300,000
750,000
1,000,000
7,500
7,500
100,898
$
2,285,000
Item 14.
Indemnification of Directors and
Officers
Item 15.
Recent Sales of Unregistered
Securities
Table of Contents
Item 16.
Exhibits and Financial Statement
Schedules
Item 17.
Undertakings
For purposes of determining any liability under
the Securities Act of 1933, the information omitted from the
form of prospectus filed as part of this Registration Statement
in reliance upon Rule 430A and contained in a form of
prospectus filed by the Registrant pursuant to
Rule 424(b)(1) or (4) or 497(h) under the Securities
Act shall be deemed to be part of this Registration Statement as
of the time it was declared effective.
For the purpose of determining any liability
under the Securities Act of 1933, each post-effective amendment
that contains a form of prospectus shall be deemed to be a new
Registration Statement relating to the securities offered
therein, and the offering of such securities at that time shall
be deemed to be the initial
bona fide
offering
thereof.
*
Paragraph references correspond to those of
Regulation S-K, Item 512.
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Lafayette, State of Louisiana, as of February 14, 2005.
LHC GROUP, INC. |
By: | /s/ R. BARR BROWN |
|
|
R. Barr Brown | |
Senior Vice President, Chief Financial | |
Officer and Treasurer | |
POWER OF ATTORNEY
KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints R. Barr Brown and Keith G. Myers, or any of them, his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including pre-effective and post-effective amendments) to this registration statement and to sign any registration statement (and any post-effective amendments thereto) effective upon filing pursuant to Rule 462(b) under the Securities Act of 1933, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the SEC, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact, agent, or their substitutes may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed below by the following persons in the capacities and on the dates listed.
Signature | Title | Date | ||||
|
|
|
||||
*
Keith G. Myers |
President, Chief Executive Officer and Chairman of the Board of Directors (Principal Executive Officer and Director) | February 14, 2005 | ||||
/s/ R. BARR BROWN
R. Barr Brown |
Senior Vice President, Chief Financial Officer, Treasurer and Director (Principal Financial and Accounting Officer) | February 14, 2005 | ||||
*
John L. Indest |
Senior Vice President, Chief Operating Officer, Secretary and Director | February 14, 2005 | ||||
*
Earline H. Bihm |
Director | February 14, 2005 | ||||
*
Ronald T. Nixon |
Director | February 14, 2005 |
II-3
Signature | Title | Date | ||||
|
|
|
||||
*
Ted W. Hoyt |
Director | February 14, 2005 | ||||
*
George A. Lewis |
Director | February 14, 2005 | ||||
/s/ W. PATRICK MULLOY, II
W. Patrick Mulloy, II |
Director | February 14, 2005 | ||||
/s/ W.J. BILLY TAUZIN
W.J. Billy Tauzin |
Director | February 14, 2005 | ||||
*/s/ R. BARR BROWN
R. Barr Brown Attorney-in-fact |
II-4
EXHIBIT INDEX
Exhibit
Number
Description
1
.1
Form of Underwriting Agreement*
3
.1
Certificate of Incorporation of LHC Group, Inc.
3
.2
Bylaws of LHC Group, Inc.
4
.1
Specimen Stock Certificate of LHCs Common
Stock, par value $0.01 per share
4
.2
Reference is made to Exhibits 3.1 and 3.2
5
.1
Opinion of Alston & Bird LLP*
10
.1
Exchange Agreement between Louisiana Healthcare
Group, LLC, LHC Group, LLC and Beta HomeCare, Inc., dated
September 14, 2004
10
.2
Exchange Agreement between Louisiana Healthcare
Group, LLC, LHC Group, LLC and Hebert, Thibodeaux, Albro and
Touchet Therapy Group, dated November 23, 2004.
10
.3
LHC 2003 Key Employee Equity Participation
Plan
10
.4
LHC Group, Inc. 2005 Long-Term Incentive Plan
10
.5
Form of Award under LHC Group, Inc.
2005 Director Compensation Plan
10
.6
Employment Agreement between LHC Group, Inc. and
Keith G. Myers
10
.7
Employment Agreement between LHC Group, Inc. and
R. Barr Brown
10
.8
Employment Agreement between LHC Group, Inc. and
John L. Indest
10
.9
Employment Agreement between LHC Group, Inc. and
Daryl J. Doise
10
.10
Form of Indemnity Agreement between LHC Group and
directors and certain officers
10
.11
LHC Group, Inc. 2005 Director Compensation Plan
21
.1
Subsidiaries of the Registrant*
23
.1
Consent of Alston & Bird LLP (Included
in Exhibit 5.1)
23
.2
Consent of Ernst & Young LLP
24
.1
Power of Attorney (included in Part II of
this registration statement)
*
To be filed by amendment.
Previously filed.
II-5
EXHIBIT 3.1
CERTIFICATE OF INCORPORATION OF
LHC GROUP, INC.
A DELAWARE CORPORATION
I, the undersigned, for the purposes of incorporating and organizing a corporation under the General Corporation Law of the State of Delaware, do execute this Certificate of Incorporation and do hereby certify as follows:
ARTICLE I
The name of the corporation is LHC Group, Inc. (the "Corporation").
ARTICLE II
The address of the corporation's registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street, in the City of Wilmington, County of New Castle, 19801. The name of its registered agent at such address is The Corporation Trust Company.
ARTICLE III
The nature of the business or purposes to be conducted or promoted is to engage in any lawful act or activity for which corporations may be organized under the Delaware General Corporation Law.
ARTICLE IV
The Corporation is authorized to issue two classes of stock to be designated common stock ("Common Stock") and preferred stock ("Preferred Stock"). The number of shares of Common Stock authorized to be issued is forty million (40,000,000), par value $0.01 per share, and the number of shares of Preferred Stock authorized to be issued is five million (5,000,000), par value $0.01 per share.
The Preferred Stock may be issued from time to time in one or more series, without further stockholder approval. The Board of Directors is hereby authorized, in the resolution or resolutions adopted by the Board of Directors providing for the issue of any wholly unissued series of Preferred Stock, within the limitations and restrictions stated in this Certificate of Incorporation, to fix the designations, preferences and relative, participating, optional, or other special rights, and qualifications, limitations or restrictions thereof, including, without limitation, the authority to fix or alter the dividend rights, dividend rate, conversion rights, voting rights, rights and terms of redemption (including sinking fund provisions), the redemption price or prices, and the liquidation preferences of any wholly unissued series of Preferred Stock, and the number of shares constituting any such series and the designation thereof, or any of them, and to increase or decrease the number of shares of any series subsequent to the issue of shares of that series, but not below the number of shares of such series then outstanding. In case the number of shares of any series shall be so decreased, the shares constituting such decrease shall resume the
status that they had prior to the adoption of the resolution originally fixing the number of shares of such series.
ARTICLE V
The following provisions are inserted for the management of the business and the conduct of the affairs of the Corporation and for further definition, limitation and regulation of the powers of the Corporation and of its directors and stockholders:
A. The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors. In addition to the powers and authority expressly conferred upon them by statute or by this Certificate of Incorporation or the Bylaws of the Corporation, the directors are hereby empowered to exercise all such powers and do all such acts and things as may be exercised or done by the Corporation.
B. The directors of the Corporation need not be elected by written ballot unless the Bylaws so provide.
C. Following the effective date of the Corporation's registration statement filed pursuant to the Securities Act of 1933, as amended, and prepared in connection with the Corporation's initial public offering (the "IPO Date"), any action required or permitted to be taken by the stockholders of the Corporation must be effected at a duly called annual or special meeting of stockholders of the Corporation and may not be effected by any consent in writing by such stockholders.
ARTICLE VI
The number of directors of the Corporation shall be fixed from time to time by the Board of Directors pursuant to a resolution adopted by a majority of the Whole Board. For purposes of this Certificate of Incorporation, the term "Whole Board" shall mean the total number of authorized directors whether or not there exist any vacancies in previously authorized directorships.
Following the IPO Date, the Board of Directors shall be divided into three classes: Class I, Class II and Class III. Such classes shall be as nearly equal in number of directors as possible. Each director shall serve for a term ending on the third annual meeting of stockholders following the annual meeting of stockholders at which such director was elected; provided, however, that the directors first elected to Class I shall serve for a term ending on the Corporation's first annual meeting of stockholders following the effectiveness of this Article, the directors first elected to Class II shall serve for a term ending on the Corporation's second annual meeting of stockholders following the effectiveness of this Article and the directors first elected to Class III shall serve for a term ending on the Corporation's third annual meeting of stockholders following the effectiveness of this Article. The foregoing notwithstanding, each director shall serve until such director's successor shall have been duly elected and qualified, or until such director's prior death, resignation, retirement, disqualification or other removal.
At each annual election, directors chosen to succeed those whose terms then expire shall be of the same class as the directors they succeed unless, by reason of any intervening changes in the authorized number of directors, the Board of Directors shall designate one or more directorships whose term then expires as directorships of another class in order more nearly to achieve equality of number of directors among the classes.
Notwithstanding the rule that the three classes shall be as nearly equal in number of directors as possible, in the event of any change in the authorized number of directors, each director then continuing to serve as such shall nevertheless continue as a director of the class of which such director is a member until the expiration of such director's current term, or such director's prior death, resignation, retirement, disqualification or other removal. If any newly created directorship may, consistently with the rule that the three classes shall be as nearly equal in number of directors as possible, be allocated to more than one class, the Board of Directors shall allocate it to that of the available class whose term of office is due to expire at the earliest date following such allocation.
Subject to the rights of the holders of any series of Preferred Stock then outstanding, any directors, or the entire Board of Directors, may be removed from office at any time, but only for cause and only by the affirmative vote of the holders of at least a majority of the voting power of all of the then-outstanding shares of capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class.
ARTICLE VII
A director of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (i) for any breach of the director's duty of loyalty to the Corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) under Section 174 of the Delaware General Corporation Law, or (iv) for any transaction from which the director derived any improper personal benefit. If the Delaware General Corporation Law is amended after approval by the stockholders of this Article VIII to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the Delaware General Corporation Law as so amended.
Any repeal or modification of the foregoing provisions of this Article VII by the stockholders of the Corporation shall not adversely affect any right or protection of a director of the Corporation existing at the time of, or increase the liability of any director of this Corporation with respect to any acts or omissions of such director occurring prior to, such repeal or modification.
ARTICLE VIII
The Board of Directors is expressly empowered to adopt, amend or repeal any or all of the Bylaws of the Corporation. Any adoption, amendment or repeal of the Bylaws of the Corporation by the Board of Directors shall require the approval of a majority of the Whole Board. The stockholders shall also have power to adopt, amend or repeal the Bylaws of the
Corporation; provided, however, that, in addition to any vote of the holders of any class or series of stock of the Corporation required by law or by this Certificate of Incorporation, the affirmative vote of the holders of at least sixty-six and two-thirds percent (66-2/3%) of the voting power of all of the then-outstanding shares of the capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required to adopt, amend or repeal any provision of the Bylaws of the Corporation.
ARTICLE IX
In addition to any vote of the holders of any class or series of the stock of this Corporation required by law or by this Certificate of Incorporation, the affirmative vote of the holders of a majority of the voting power of all of the then outstanding shares of capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required to amend or repeal the provisions of Article I, Article II, Article III and Article IV of this Certificate of Incorporation. Notwithstanding any other provision of this Certificate of Incorporation or any provision of law which might otherwise permit a lesser vote or no vote, but in addition to any vote of the holders of any class or series of the stock of this Corporation required by law or by this Certificate of Incorporation, the affirmative vote of the holders of at least sixty-six and two-thirds percent (66-2/3%) of the voting power of all of the then outstanding shares of the capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required to amend or repeal any provision of this Certificate of Incorporation not specified in the preceding sentence.
ARTICLE X
The incorporator of the corporation is Peter C. November, II, whose mailing address is Alston & Bird, LLP, 1201 West Peachtree Street, Atlanta, Georgia 30309.
ARTICLE XI
The powers of the incorporator are to terminate upon the filing of this Certificate of Incorporation with the Secretary of State of the State of Delaware. The name and mailing address of the person who shall serve as the initial director of the corporation until his successor is duly elected and qualified is Keith G. Myers, LHC Group, Inc., 420 West Pinhook Rd., Suite A, Lafayette, LA 70503.
IN WITNESS WHEREOF, this Certificate of Incorporation has been executed by the undersigned this 20th day of January, 2005.
/s/ Peter C. November II ---------------------------------- Peter C. November II, Incorporator |
EXHIBIT 3.2
BYLAWS OF
LHC GROUP, INC.
A DELAWARE CORPORATION
TABLE OF CONTENTS
Page ARTICLE I OFFICE AND RECORDS.....................................................................................1 Section 1.1 Delaware Office.............................................................................1 Section 1.2 Other Offices...............................................................................1 Section 1.3 Books and Records...........................................................................1 ARTICLE II STOCKHOLDERS..........................................................................................1 Section 2.1 Annual Meeting..............................................................................1 Section 2.2 Special Meeting.............................................................................1 Section 2.3 Place of Meeting............................................................................1 Section 2.4 Notice of Meeting...........................................................................1 Section 2.5 Quorum and Adjournment......................................................................2 Section 2.6 Proxies.....................................................................................2 Section 2.7 Notice of Stockholder Business and Nominations..............................................2 Section 2.8 Procedure for Election of Directors.........................................................5 Section 2.9 Inspectors of Elections.....................................................................5 Section 2.10 Conduct of Meetings........................................................................5 Section 2.11 Consent of Stockholders in Lieu of Meeting.................................................6 ARTICLE III BOARD OF DIRECTORS...................................................................................6 Section 3.1 General Powers..............................................................................6 Section 3.2 Number, Tenure and Qualifications...........................................................6 Section 3.3 Regular Meetings............................................................................6 Section 3.4 Special Meetings............................................................................6 Section 3.5 Action by Unanimous Consent of Directors....................................................7 Section 3.6 Notice......................................................................................7 Section 3.7 Conference Telephone Meetings...............................................................7 Section 3.8 Quorum......................................................................................7 Section 3.9 Vacancies...................................................................................7 Section 3.10 Committee..................................................................................8 Section 3.11 Removal....................................................................................8 ARTICLE IV OFFICERS..............................................................................................8 Section 4.1 Elected Officers............................................................................8 Section 4.2 Election and Term of Office.................................................................9 Section 4.3 Chairman of the Board.......................................................................9 Section 4.4 President and Chief Executive Officer.......................................................9 Section 4.5 Secretary...................................................................................9 Section 4.6 Treasurer...................................................................................9 Section 4.7 Removal....................................................................................10 Section 4.8 Vacancies..................................................................................10 |
ARTICLE V STOCK CERTIFICATES AND TRANSFERS......................................................................10 Section 5.1 Stock Certificates and Transfers...........................................................10 ARTICLE VI INDEMNIFICATION......................................................................................10 Section 6.1 Right to Indemnification...................................................................10 Section 6.2 Right to Advancement of Expenses...........................................................11 Section 6.3 Right of Indemnitee to Bring Suit..........................................................11 Section 6.4 Non-Exclusivity of Rights..................................................................12 Section 6.5 Insurance..................................................................................12 ARTICLE VII MISCELLANEOUS PROVISIONS............................................................................12 Section 7.1 Fiscal Year................................................................................12 Section 7.2 Dividends..................................................................................12 Section 7.3 Seal.......................................................................................12 Section 7.4 Waiver of Notice...........................................................................12 Section 7.5 Audits.....................................................................................12 Section 7.6 Resignations...............................................................................13 Section 7.7 Contracts..................................................................................13 Section 7.8 Proxies....................................................................................13 ARTICLE VIII AMENDMENTS.........................................................................................13 |
ARTICLE I
OFFICES AND RECORDS
Section 1.1 Delaware Office. The registered office of the Corporation in the State of Delaware shall be located in the City of Wilmington, County of New Castle.
Section 1.2 Other Offices. The Corporation may have such other offices, either within or without the State of Delaware, as the Board of Directors may designate or as the business of the Corporation may from time to time require.
Section 1.3 Books and Records. The books and records of the Corporation may be kept at the Corporation's headquarters in Lafayette, Louisiana or at such other locations outside the State of Delaware as may from time to time be designated by the Board of Directors.
ARTICLE II
STOCKHOLDERS
Section 2.1 Annual Meeting. The annual meeting of the stockholders of the Corporation shall be held at such date, place and/or time as may be fixed by resolution of the Board of Directors.
Section 2.2 Special Meeting. Special meetings of stockholders of the Corporation may be called only by the Chairman of the Board or the President or by the Board of Directors acting pursuant to a resolution adopted by a majority of the Whole Board. For purposes of these Bylaws, the term "Whole Board" shall mean the total number of authorized directors whether or not there exist any vacancies in previously authorized directorships.
Section 2.3 Place of Meeting. The Board of Directors may designate the place of meeting for any meeting of the stockholders. If no designation is made by the Board of Directors, the place of meeting shall be the principal office of the Corporation. Notwithstanding the foregoing, the Board of Directors may, in its sole discretion, determine that the meeting shall not be held at any place, but shall be held solely by means of remote communication, subject to such guidelines and procedures as the Board of Directors may adopt, as permitted by applicable law.
Section 2.4 Notice of Meeting. Except as otherwise required by law,
written, printed or electronic notice stating the place, day and hour of the
meeting and the purposes for which the meeting is called shall be prepared and
delivered by the Corporation not less than ten (10) days nor more than sixty
(60) days before the date of the meeting, either personally, by mail, or in the
case of stockholders who have consented to such delivery, by electronic
transmission (as such term is defined in the Delaware General Corporation Law),
to each stockholder of record entitled to vote at such meeting. If mailed, such
notice shall be deemed to be delivered when deposited in the U.S. mail with
postage thereon prepaid, addressed to the stockholder at his address as it
appears on the stock transfer books of the Corporation. Notice given by
electronic transmission shall be effective (A) if by facsimile, when faxed to a
number where the
stockholder has consented to receive notice; (B) if by electronic mail, when mailed electronically to an electronic mail address at which the stockholder has consented to receive such notice; (C) if by posting on an electronic network together with a separate notice of such posting, upon the later to occur of (1) the posting or (2) the giving of separate notice of the posting; or (D) if by other form of electronic communication, when directed to the stockholder in the manner consented to by the stockholder. Meetings may be held without notice if all stockholders entitled to vote are present (except as otherwise provided by law), or if notice is waived by those not present. Any previously scheduled meeting of the stockholders may be postponed and (unless the Corporations's Certificate of Incorporation (the "Certificate of Incorporation") otherwise provides) any special meeting of the stockholders may be cancelled, by resolution of the Board of Directors upon public notice given prior to the time previously scheduled for such meeting of stockholders.
Section 2.5 Quorum and Adjournment. Except as otherwise provided by law or by the Certificate of Incorporation, the holders of a majority of the voting power of the outstanding shares of the Corporation entitled to vote generally in the election of directors (the "Voting Stock"), represented in person or by proxy, shall constitute a quorum at a meeting of stockholders, except that when specified business is to be voted on by a class or series voting separately as a class or series, the holders of a majority of the voting power of the shares of such class or series shall constitute a quorum for the transaction of such business for the purposes of taking action on such business. In the absence of a quorum, any meeting of stockholders may be adjourned, from time to time, by vote of the holders of a majority of the shares represented thereat, but no other business shall be transacted at such meeting. At such adjourned meeting at which a quorum is present or represented, any business may be transacted which might have been transacted at the original meeting. The stockholders present at a duly called or convened meeting at which a quorum is present may continue to transact business until adjournment, notwithstanding the withdrawal of enough stockholders to leave less than a quorum. No notice of the time and place of adjourned meetings need be given provided such adjournment is for less than thirty (30) days and further provided that no new record date is fixed for the adjourned meeting.
Section 2.6 Proxies. At all meetings of stockholders, a stockholder may vote by proxy executed in writing by the stockholder or as may be permitted by law, or by his duly authorized attorney-in-fact. Such proxy must be filed with the Secretary of the Corporation or his representative, or otherwise delivered telephonically or electronically as set forth in the applicable proxy statement, at or before the time of the meeting.
Section 2.7 Notice of Stockholder Business and Nominations.
A. Nominations of persons for election to the Board of Directors and the
proposal of business to be transacted by the stockholders may be made at an
annual meeting of stockholders (1) pursuant to the Corporation's notice with
respect to such meeting, (2) by or at the direction of the Board of Directors or
(3) by any stockholder of record of the Corporation who was a stockholder of
record at the time of the giving of the notice provided for in the following
paragraph, who is entitled to vote at the meeting and who has complied with the
notice procedures set forth in this Section 2.7.
B. For nominations or other business to be properly brought before an annual meeting by a stockholder pursuant to paragraph (A)(3) of this Section 2.7, (1) the stockholder must have given timely notice thereof in writing to the Secretary of the Corporation, (2) such business must be a proper matter for stockholder action under the Delaware General Corporation Law, (3) if the stockholder, or the beneficial owner on whose behalf any such proposal or nomination is made, has provided the Corporation with a Solicitation Notice, as that term is defined in subclause (c)(iii) of this paragraph, such stockholder or beneficial owner must, in the case of a proposal, have delivered prior to the meeting a proxy statement and form of proxy to holders of at least the percentage of the Corporation's voting shares required under applicable law to carry any such proposal, or, in the case of a nomination or nominations, have delivered prior to the meeting a proxy statement and form of proxy to holders of a percentage of the Corporation's voting shares reasonably believed by such stockholder or beneficial holder to be sufficient to elect the nominee or nominees proposed to be nominated by such stockholder, and must, in either case, have included in such materials the Solicitation Notice and (4) if no Solicitation Notice relating thereto has been timely provided pursuant to this section, the stockholder or beneficial owner proposing such business or nomination must not have solicited a number of proxies sufficient to have required the delivery of such a Solicitation Notice under this section. To be timely, a stockholder's notice shall be delivered to the Secretary at the principal executive offices of the Corporation not less than sixty (60) or more than ninety (90) days prior to the first anniversary (the "Anniversary") of the date on which the Corporation first mailed its proxy materials for the preceding year's annual meeting of stockholders (for purposes of the first annual meeting of stockholders of the Corporation held after its initial public offering pursuant to an effective registration statement under the Securities Act of 1933 (the "Registration Statement"), as amended, covering the offer and sale of Common Stock of the Corporation to the public, the Anniversary of such annual meeting shall be January 15 of the following year); provided, however, that if no proxy materials were mailed by the Corporation in connection with the preceding year's annual meeting, or if the date of the annual meeting is advanced more than thirty (30) days prior to or delayed by more than thirty (30) days after the anniversary of the preceding year's annual meeting, notice by the stockholder to be timely must be so delivered not later than the close of business on the later of (x) the 90th day prior to such annual meeting or (y) the 10th day following the day on which public announcement of the date of such meeting is first made. Such stockholder's notice shall set forth (a) as to each person whom the stockholder proposes to nominate for election or reelection as a director all information relating to such person as would be required to be disclosed in solicitations of proxies for the election of such nominees as directors pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and such person's written consent to serve as a director if elected; (b) as to any other business that the stockholder proposes to bring before the meeting, a brief description of such business, the reasons for conducting such business at the meeting and any material interest in such business of such stockholder and the beneficial owner, if any, on whose behalf the proposal is made; and (c) as to the stockholder giving the notice and the beneficial owner, if any, on whose behalf the nomination or proposal is made (i) the name and address of such stockholder, as they appear on the Corporation's books, and of such beneficial owner, (ii) the class and number of shares of the Corporation that are owned beneficially and of record by such stockholder and such beneficial owner, and (iii) whether either such stockholder or beneficial owner intends to deliver a proxy statement and form of proxy to holders of, in the case of a proposal, at least the percentage of the Corporation's voting shares required under
applicable law to carry the proposal or, in the case of a nomination or nominations, a sufficient number of holders of the Corporation's voting shares to elect such nominee or nominees (an affirmative statement of such intent, a "Solicitation Notice").
C. Notwithstanding anything in the second sentence of paragraph (B) of this
Section 2.7 to the contrary, in the event that the number of directors to be
elected to the Board of Directors is increased and there is no public
announcement naming all of the nominees for director or specifying the size of
the increased Board made by the Corporation at least fifty-five (55) days prior
to the Anniversary, a stockholder's notice required by this Bylaw shall also be
considered timely, but only with respect to nominees for any new positions
created by such increase, if it shall be delivered to the Secretary at the
principal executive offices of the Corporation not later than the close of
business on the 10th day following the day on which such public announcement is
first made by the Corporation.
D. Only persons nominated in accordance with the procedures set forth in
this Section 2.7 shall be eligible to serve as directors and only such business
shall be conducted at an annual meeting of stockholders as shall have been
brought before the meeting in accordance with the procedures set forth in this
Section 2.7. The chair of the meeting shall have the power and the duty to
determine whether a nomination or any business proposed to be brought before the
meeting has been made in accordance with the procedures set forth in these
Bylaws and, if any proposed nomination or business is not in compliance with
these Bylaws, to declare that such defective proposed business or nomination
shall not be presented for stockholder action at the meeting and shall be
disregarded.
E. Only such business shall be conducted at a special meeting of
stockholders as shall have been brought before the meeting pursuant to the
Corporation's notice of meeting. Nominations of persons for election to the
Board of Directors may be made at a special meeting of stockholders at which
directors are to be elected pursuant to the Corporation's notice of meeting (1)
by or at the direction of the Board of Directors or (2) by any stockholder of
record of the Corporation who is a stockholder of record at the time of giving
of notice provided for in this paragraph, who shall be entitled to vote at the
meeting and who complies with the notice procedures set forth in this Section
2.7. Nominations by stockholders of persons for election to the Board of
Directors may be made at such a special meeting of stockholders if the
stockholder's notice required by paragraph (B) of this Section 2.7 shall be
delivered to the Secretary at the principal executive offices of the Corporation
not later than the close of business on the later of the 90th day prior to such
special meeting or the 10th day following the day on which public announcement
is first made of the date of the special meeting and of the nominees proposed by
the Board to be elected at such meeting.
F. For purposes of this Section 2.7, "public announcement" shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press or a comparable national news service or in a document publicly filed by the Corporation with the Securities and Exchange Commission pursuant to Section 13, 14 or 15(d) of the Exchange Act.
G. Notwithstanding the foregoing provisions of this Section 2.7, a stockholder shall also comply with all applicable requirements of the Exchange Act and the rules and regulations thereunder with respect to matters set forth in this Section 2.7. Nothing in this
Section 2.7 shall be deemed to affect any rights of stockholders to request inclusion of proposals in the Corporation's proxy statement pursuant to Rule 14a-8 under the Exchange Act.
Section 2.8 Procedure for Election of Directors. Election of directors at all meetings of the stockholders at which directors are to be elected need not be by written ballot, and, except as otherwise set forth in the Certificate of Incorporation with respect to the right of the holders of any series of Preferred Stock or any other series or class of stock to elect additional directors under specified circumstances, a plurality of the votes cast thereat shall elect directors. Except as otherwise provided by law, the Certificate of Incorporation or these Bylaws, all matters other than the election of directors submitted to the stockholders at any meeting shall be decided by the affirmative vote of a majority of the voting power of the outstanding Voting Stock present in person or represented by proxy at the meeting and entitled to vote thereon.
Section 2.9 Inspectors of Elections:
The Board of Directors by resolution shall appoint one or more inspectors, which inspector or inspectors may include individuals who serve the Corporation in other capacities, including, without limitation, as officers, employees, agents or representatives of the Corporation, to act at the meeting and make a written report thereof. One or more persons may be designated as alternate inspectors to replace any inspector who fails to act. If no inspector or alternate has been appointed to act, or if all inspectors or alternates who have been appointed are unable to act, at a meeting of stockholders, the chairman of the meeting shall appoint one or more inspectors to act at the meeting. Each inspector, before discharging his or her duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of his or her ability. The inspectors shall have the duties prescribed by the Delaware General Corporation Law.
Section 2.10 Conduct of Meetings.
A. The President and Chief Executive Officer shall preside at all meetings of the stockholders. In the absence of the President and Chief Executive Officer, the Chairman of the Board shall preside at a meeting of the stockholders. In the absence of both the President and Chief Executive Officer and the Chairman of the Board, the Secretary shall preside at a meeting of the stockholders. In the anticipated absence of all officers designated to preside over the meetings of stockholders, the Board of Directors may designate an individual to preside over a meeting of the stockholders.
B. The chairman of the meeting shall fix and announce at the meeting the date and time of the opening and the closing of the polls for each matter upon which the stockholders will vote at a meeting.
C. The Board of Directors may, to the extent not prohibited by law, adopt by resolution such rules and regulations for the conduct of the meeting of stockholders as it shall deem appropriate. Except to the extent inconsistent with such rules and regulations as adopted by the Board of Directors, the chairman of any meeting of stockholders shall have the right and authority to prescribe such rules, regulations and procedures and to do all such acts as,
in the judgment of such chairman, are appropriate for the proper conduct of the
meeting. Such rules, regulations or procedures, whether adopted by the Board of
Directors or prescribed by the chairman of the meeting, may to the extent not
prohibited by law include, without limitation, the following: (i) the
establishment of an agenda or order of business for the meeting; (ii) rules and
procedures for maintaining order at the meeting and the safety of those present;
(iii) limitations on attendance at or participation in the meeting to
stockholders of record of the Corporation, their duly authorized and constituted
proxies or such other persons as the chairman of the meeting shall determine;
(iv) restrictions on entry to the meeting after the time fixed for the
commencement thereof and (v) limitations on the time allotted to questions or
comments by participants. Unless, and to the extent, determined by the Board of
Directors or the chairman of the meeting, meetings of stockholders shall not be
required to be held in accordance with the rules of parliamentary procedure.
Section 2.11 Consent of Stockholders in Lieu of Meeting. Following the date the Registration Statement is declared effective by the Securities and Exchange Commission, any action required or permitted to be taken by the stockholders of the Corporation must be effected at a duly called annual or special meeting of stockholders of the Corporation and may not be effected by any consent in writing by such stockholders.
ARTICLE III
BOARD OF DIRECTORS
Section 3.1 General Powers. The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors. In addition to the powers and authority expressly conferred upon them by statute or by the Certificate of Incorporation or by these Bylaws, the directors are hereby empowered to exercise all such powers and do all such acts and things as may be exercised or done by the Corporation.
Section 3.2 Number, Tenure and Qualifications. Subject to the rights of the holders of any series of Preferred Stock to elect additional directors under specified circumstances, the number of directors shall be fixed from time to time exclusively by the Board of Directors pursuant to a resolution adopted by a majority of the Whole Board, and each director elected shall hold office until his successor is elected and qualified. The directors, other than those who may be elected by the holders of any series of Preferred Stock under specified circumstances, shall be divided into three classes pursuant to the Certificate of Incorporation. At each annual meeting of stockholders, directors elected to succeed those directors whose terms expire shall be elected for a term of office to expire at the third succeeding annual meeting of stockholders after their election.
Section 3.3 Regular Meetings. The Board of Directors may, by resolution, provide the time and place for the holding of regular meetings of the Board of Directors.
Section 3.4 Special Meetings. Special meetings of the Board of Directors shall be called at the request of the Chairman of the Board, the Chief Executive Officer or a majority of the Board of Directors. The person or persons authorized to call special meetings of the Board of Directors may fix the place and time of the meetings.
Section 3.5 Action By Unanimous Consent of Directors. The Board of Directors may take action without the necessity of a meeting by unanimous consent of directors. Such consent may be in writing or given by electronic transmission, as such term is defined in the Delaware General Corporation Law.
Section 3.6 Notice. Notice of any special meeting shall be given to each director at his business or residence in writing, or by telegram, facsimile transmission, telephone communication or electronic transmission (provided, with respect to electronic transmission, that the director has consented to receive the form of transmission at the address to which it is directed). If mailed, such notice shall be deemed adequately delivered when deposited in the United States mails so addressed, with postage thereon prepaid, at least five (5) days before such meeting. If by telegram, such notice shall be deemed adequately delivered when the telegram is delivered to the telegraph company at least twenty-four (24) hours before such meeting. If by facsimile transmission or other electronic transmission, such notice shall be transmitted at least twenty-four (24) hours before such meeting. If by telephone, the notice shall be given at least twelve (12) hours prior to the time set for the meeting. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the Board of Directors need be specified in the notice of such meeting, except for amendments to these Bylaws as provided under Section 8.1 of Article VIII hereof. A meeting may be held at any time without notice if all the directors are present (except as otherwise provided by law) or if those not present waive notice of the meeting in writing, either before or after such meeting.
Section 3.7 Conference Telephone Meetings. Members of the Board of Directors, or any committee thereof, may participate in a meeting of the Board of Directors or such committee by means of conference telephone or similar communications equipment by means of which all persons participating in the meeting can hear each other, and such participation in a meeting shall constitute presence in person at such meeting.
Section 3.8 Quorum. A whole number of directors equal to at least a majority of the Whole Board shall constitute a quorum for the transaction of business, but if at any meeting of the Board of Directors there shall be less than a quorum present, a majority of the directors present may adjourn the meeting from time to time without further notice. The act of the majority of the directors present at a meeting at which a quorum is present shall be the act of the Board of Directors.
Section 3.9 Vacancies. Subject to the rights of the holders of any series of Preferred Stock then outstanding, newly created directorships resulting from any increase in the authorized number of directors or any vacancies in the Board of Directors resulting from death, resignation, retirement, disqualification, removal from office or other cause shall, unless otherwise provided by law or by resolution of the Board of Directors, be filled only by a majority vote of the directors then in office, though less than a quorum, and directors so chosen shall hold office until their successor is elected and qualified. No decrease in the authorized number of directors shall shorten the term of any incumbent director.
Section 3.10 Committees.
A. The Board of Directors may designate one or more committees, each committee to consist of one or more of the directors of the Corporation. The Board of Directors may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of a member of the committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not he or they constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in place of any such absent or disqualified member. Any such committee, to the extent permitted by law and to the extent provided in the resolution of the Board of Directors, shall have and may exercise all the powers and authority of the Board of Directors in the management of the business and affairs of the Corporation, and may authorize the seal of the Corporation to be affixed to all papers which may require it; provided, however, that no committee shall have power or authority in reference to the following matters: (1) approving, adopting or recommending to stockholders any action or matter required by law to be submitted to stockholders for approval or (2) adopting, amending or repealing any bylaw.
B. Unless the Board of Directors otherwise provides, each committee designated by the Board of Directors may make, alter and repeal rules for the conduct of its business. In the absence of such rules each committee shall conduct its business in the same manner as the Board of Directors conducts its business pursuant to these Bylaws.
Section 3.11 Removal. Subject to the rights of the holders of any series of Preferred Stock then outstanding, any directors, or the entire Board of Directors, may be removed from office at any time, but only for cause and only by the affirmative vote of the holders of at least sixty-six and two-thirds percent (66-2/3%) of the voting power of all of the then-outstanding shares of capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class.
Section 3.12 Compensation of Directors. Directors may receive such compensation, if any, for their services, and such reimbursement for expenses, as may be fixed or determined by resolution of the Board of Directors.
ARTICLE IV
OFFICERS
Section 4.1 Elected Officers. The elected officers of the Corporation shall be a Chairman of the Board, a President, a Secretary, a Treasurer, and such other officers as the Board of Directors from time to time may deem proper. The Chairman of the Board shall be chosen from the directors. All officers chosen by the Board of Directors shall each have such powers and duties as generally pertain to their respective offices, subject to the specific provisions of this Article IV. Such officers shall also have powers and duties as from time to time may be conferred by the Board of Directors or by any committee thereof.
Section 4.2 Election and Term of Office. The elected officers of the Corporation shall be elected annually by the Board of Directors at the regular meeting of the Board of Directors held after each annual meeting of the stockholders. If the election of officers shall not be held at such meeting, such election shall be held as soon thereafter as convenient. Subject to Section 4.7 of these Bylaws, each officer shall hold office until his successor shall have been duly elected and shall have qualified or until his death or until he shall resign.
Section 4.3 Chairman of the Board. The Chairman of the Board shall preside at all meetings of the Board and perform such other duties and have such other powers as the Board of Directors shall designate from time to time.
Section 4.4 President and Chief Executive Officer. The President and Chief
Executive Officer shall be the general manager of the Corporation, subject to
the control of the Board of Directors, and as such shall, subject to Section
2.10 (A) hereof, preside at all meetings of shareholders, shall have general
supervision of the affairs of the Corporation, shall sign or countersign or
authorize another officer to sign all certificates, contracts, and other
instruments of the Corporation as authorized by the Board of Directors, shall
make reports to the Board of Directors and shareholders, and shall perform all
such other duties as are incident to such office or are properly required by the
Board of Directors. If the Board of Directors creates the office of Chief
Executive Officer as a separate office from President, the President shall be
the chief operating officer of the corporation and shall be subject to the
general supervision, direction, and control of the Chief Executive Officer
unless the Board of Directors provides otherwise.
Section 4.5 Secretary. The Secretary shall give, or cause to be given, notice of all meetings of stockholders and directors and all other notices required by law or by these Bylaws, and in case of his absence or refusal or neglect so to do, any such notice may be given by any person thereunto directed by the Chairman of the Board or the President, or by the Board of Directors, upon whose request the meeting is called as provided in these Bylaws. He shall record all the proceedings of the meetings of the Board of Directors, any committees thereof and the stockholders of the Corporation in a book to be kept for that purpose, and shall perform such other duties as may be assigned to him by the Board of Directors, the Chairman of the Board or the President. He shall have custody of the seal of the Corporation and shall affix the same to all instruments requiring it, when authorized by the Board of Directors, the Chairman of the Board or the President, and attest to the same.
Section 4.6 Treasurer. The Treasurer shall have the custody of the corporate funds and securities and shall keep full and accurate receipts and disbursements in books belonging to the Corporation. The Treasurer shall deposit all moneys and other valuables in the name and to the credit of the Corporation in such depositaries as may be designated by the Board of Directors. The Treasurer shall disburse the funds of the Corporation as may be ordered by the Board of Directors the Chairman of the Board, or the President, taking proper vouchers for such disbursements. The Treasurer shall render to the Chairman of the Board, the President and the Board of Directors, whenever requested, an account of all his transactions as Treasurer and of the financial condition of the Corporation. If required by the Board of Directors, the Treasurer shall give the Corporation a bond for the faithful discharge of his duties in such amount and with such surety as the Board of Directors shall prescribe. The Treasurer shall also perform such other
duties as may be assigned to him by the Board of Directors, the President or Chief Executive Officer.
Section 4.7 Removal. Any officer elected by the Board of Directors may be removed by the Board of Directors whenever, in their judgment, the best interests of the Corporation would be served thereby. No elected officer shall have any contractual rights against the Corporation for compensation by virtue of such election beyond the date of the election of his successor, his death, his resignation or his removal, whichever event shall first occur, except as otherwise provided in an employment contract or an employee plan.
Section 4.8 Vacancies. A newly created office and a vacancy in any office because of death, resignation, or removal may be filled by the Board of Directors for the unexpired portion of the term at any meeting of the Board of Directors.
ARTICLE V
STOCK CERTIFICATES AND TRANSFERS
Section 5.1 Stock Certificates and Transfers.
A. The interest of each stockholder of the Corporation shall be evidenced by certificates for shares of stock in such form as the appropriate officers of the Corporation may from time to time prescribe. The shares of the stock of the Corporation shall be transferred on the books of the Corporation by the holder thereof in person or by his attorney, upon surrender for cancellation of certificates for the same number of shares, with an assignment and power of transfer endorsed thereon or attached thereto, duly executed, and with such proof of the authenticity of the signature as the Corporation or its agents may reasonably require.
B. The certificates of stock shall be signed, countersigned and registered in such manner as the Board of Directors may by resolution prescribe, which resolution may permit all or any of the signatures on such certificates to be in facsimile. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate has ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if he were such officer, transfer agent or registrar at the date of issue.
ARTICLE VI
INDEMNIFICATION
Section 6.1 Right to Indemnification. Each person who was or is made a party or is threatened to be made a party to or is otherwise involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative (hereinafter a "proceeding"), by reason of the fact that he or she is or was a director or officer of the Corporation or, while a director or officer of the Corporation, is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust or other enterprise, including service with respect to an employee benefit plan (hereinafter an
"indemnitee"), where the basis of such proceeding is alleged action in an official capacity as a director, officer, employee or agent, shall be indemnified and held harmless by the Corporation to the fullest extent authorized by the Delaware General Corporation Law, as the same exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the Corporation to provide broader indemnification rights than permitted prior thereto), against all expense, liability and loss (including attorneys' fees, judgments, fines, ERISA excise taxes or penalties and amounts paid in settlement) reasonably incurred or suffered by such indemnitee in connection therewith and such indemnification shall continue as to an indemnitee who has ceased to be a director, officer, employee or agent and shall inure to the benefit of the indemnitee's heirs, executors and administrators; provided, however, that, except as provided in Section 6.3 hereof with respect to proceedings to enforce rights to indemnification, the Corporation shall indemnify any such indemnitee in connection with a proceeding (or part thereof) initiated by such indemnitee only if such proceeding (or part thereof) was authorized by the Board of Directors of the Corporation.
Section 6.2 Right to Advancement of Expenses. The right to indemnification
conferred in Section 6.1 shall include the right to be paid by the Corporation
the expenses incurred in defending any proceeding for which such right to
indemnification is applicable in advance of its final disposition (hereinafter
an "advancement of expenses"); provided, however, that, if the Delaware General
Corporation Law requires, an advancement of expenses incurred by an indemnitee
in his or her capacity as a director or officer (and not in any other capacity
in which service was or is rendered by such indemnitee, including, without
limitation, service to an employee benefit plan) shall be made only upon
delivery to the Corporation of an undertaking (hereinafter an "undertaking"), by
or on behalf of such indemnitee, to repay all amounts so advanced if it shall
ultimately be determined by final judicial decision from which there is no
further right to appeal (hereinafter a "final adjudication") that such
indemnitee is not entitled to be indemnified for such expenses under this
Section or otherwise.
Section 6.3 Right of Indemnitee to Bring Suit. The rights to
indemnification and to the advancement of expenses conferred in Section 6.1 and
Section 6.2, respectively, shall be contract rights. If a claim under Section
6.1 or Section 6.2 is not paid in full by the Corporation within sixty days
after a written claim has been received by the Corporation, except in the case
of a claim for an advancement of expenses, in which case the applicable period
shall be twenty days, the indemnitee may at any time thereafter bring suit
against the Corporation to recover the unpaid amount of the claim. If successful
in whole or in part in any such suit, or in a suit brought by the Corporation to
recover an advancement of expenses pursuant to the terms of an undertaking, the
indemnitee shall be entitled to be paid also the expense of prosecuting or
defending such suit. In (A) any suit brought by the indemnitee to enforce a
right to indemnification hereunder (but not in a suit brought by the indemnitee
to enforce a right to an advancement of expenses) it shall be a defense that,
and (B) in any suit by the Corporation to recover an advancement of expenses
pursuant to the terms of an undertaking the Corporation shall be entitled to
recover such expenses upon a final adjudication that, the indemnitee has not met
any applicable standard for indemnification set forth in the Delaware General
Corporation Law. Neither the failure of the Corporation (including its Board of
Directors, independent legal counsel, or its stockholders) to have made a
determination prior to the commencement of such suit that indemnification of the
indemnitee is proper in the circumstances because the indemnitee has met the
applicable standard of conduct set forth in the Delaware General Corporation
Law,
nor an actual determination by the Corporation (including its Board of Directors, independent legal counsel, or its stockholders) that the indemnitee has not met such applicable standard of conduct, shall create a presumption that the indemnitee has not met the applicable standard of conduct or, in the case of such a suit brought by the indemnitee, be a defense to such suit. In any suit brought by the indemnitee to enforce a right to indemnification or to an advancement of expenses hereunder, or by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the burden of proving that the indemnitee is not entitled to be indemnified, or to such advancement of expenses, under this Section or otherwise shall be on the Corporation.
Section 6.4 Non-Exclusivity of Rights. The rights to indemnification and to the advancement of expenses conferred in this Section shall not be exclusive of any other right which any person may have or hereafter acquire under the Certificate of Incorporation, these Bylaws, or any statute, agreement, vote of stockholders or disinterested directors or otherwise.
Section 6.5 Insurance. The Corporation may maintain insurance, at its expense, to protect itself and any director, officer, employee or agent of the Corporation or another corporation, partnership, joint venture, trust or other enterprise against any expense, liability or loss, whether or not the Corporation would have the power to indemnify such person against such expense, liability or loss under the Delaware General Corporation Law.
ARTICLE VII
MISCELLANEOUS PROVISIONS
Section 7.1 Fiscal Year. The fiscal year of the Corporation shall begin on the first day of January and end on the thirty-first day of December of each year.
Section 7.2 Dividends. The Board of Directors may from time to time declare, and the Corporation may pay, dividends on its outstanding shares in the manner and upon the terms and conditions provided by law and its Certificate of Incorporation.
Section 7.3 Seal. The corporate seal shall have inscribed the name of the Corporation thereon and shall be in such form as may be approved from time to time by the Board of Directors.
Section 7.4 Waiver of Notice. Whenever any notice is required to be given to any stockholder or director of the Corporation under the provisions of the Delaware General Corporation Law, a waiver thereof in writing, signed by the person or persons entitled to such notice, whether before or after the time stated therein, shall be deemed equivalent to the giving of such notice. Neither the business to be transacted at, nor the purpose of, any annual or special meeting of the stockholders of the Board of Directors need be specified in any waiver of notice of such meeting.
Section 7.5 Audits. The accounts, books and records of the Corporation shall be audited upon the conclusion of each fiscal year by an independent certified public accountant
selected by the Board of Directors, and it shall be the duty of the Board of Directors to cause such audit to be made annually.
Section 7.6 Resignations. Any director or any officer, whether elected or appointed, may resign at any time by serving written notice of such resignation on the Chairman of the Board, the Chief Executive Officer or the Secretary, or by submitting such resignation by electronic transmission (as such term is defined in the Delaware General Corporation Law), and such resignation shall be deemed to be effective as of the close of business on the date said notice is received by the Chairman of the Board, the Chief Executive Officer, or the Secretary or at such later date as is stated therein. No formal action shall be required of the Board of Directors or the stockholders to make any such resignation effective.
Section 7.7 Contracts. Except as otherwise required by law, the Certificate of Incorporation or these Bylaws, any contracts or other instruments may be executed and delivered in the name and on the behalf of the Corporation by such officer or officers of the Corporation as the Board of Directors may from time to time direct. Such authority may be general or confined to specific instances as the Board may determine. The Chairman of the Board, the Chief Executive Officer, the President or any Vice President may execute bonds, contracts, deeds, leases and other instruments to be made or executed for or on behalf of the Corporation. Subject to any restrictions imposed by the Board of Directors or the Chairman of the Board, the Chief Executive Officer, the President or any Vice President of the Corporation may delegate contractual powers to others under his jurisdiction, it being understood, however, that any such delegation of power shall not relieve such officer of responsibility with respect to the exercise of such delegated power.
Section 7.8 Proxies. Unless otherwise provided by resolution adopted by the Board of Directors, the Chairman of the Board, the Chief Executive Officer, the President or any Vice President may from time to time appoint any attorney or attorneys or agent or agents of the Corporation, in the name and on behalf of the Corporation, to cast the votes which the Corporation may be entitled to cast as the holder of stock or other securities in any other corporation or other entity, any of whose stock or other securities may be held by the Corporation, at meetings of the holders of the stock and other securities of such other corporation or other entity, or to consent in writing, in the name of the Corporation as such holder, to any action by such other corporation or other entity, and may instruct the person or persons so appointed as to the manner of casting such votes or giving such consent, and may execute or cause to be executed in the name and on behalf of the Corporation and under its corporate seal or otherwise, all such written proxies or other instruments as he may deem necessary or proper in the premises.
ARTICLE VIII
AMENDMENTS
Section 8.1 Amendments. Subject to the provisions of the Certificate of Incorporation, these Bylaws may be adopted, amended or repealed at any meeting of the Board of Directors by a resolution adopted by a majority of the Whole Board, provided notice of the proposed change was given in the notice of the meeting in a notice given no less than twenty-
four (24) hours prior to the meeting. Subject to the provisions of the Certificate of Incorporation, the stockholders shall also have power to adopt, amend or repeal these Bylaws, provided that notice of the proposed change was given in the notice of the meeting and provided further that, in addition to any vote of the holders of any class or series of stock of the Corporation required by law or by the Certificate of Incorporation, the affirmative vote of the holders of at least sixty-six and two-thirds percent (66-2/3%) of the voting power of all of the then-outstanding shares of the capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required to adopt, amend or repeal any provision of these Bylaws.
.
.
.
EXHIBIT 4.1
NUMBER LHC GROUP, INC. SHARES LHC INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP This certifies that is the record holder of FULLY PAID AND NON-ASSESSABLE SHARES OF THE COMMON STOCK PAR VALUE OF $0.01 OF LHC GROUP, INC transferable on the books of the Corporation by the holder hereof in person or by duly authorized attorney upon the surrender of this Certificate properly endorsed. This Certificate is not valid until countersigned by the Transfer Agent and registered by the Registrar. WITNESS the facsimile Corporate Seal of this Corporation and the facsimile signatures of its duly authorized officers. Dated: SIGNATURE TO COME [LHC GROUP, INC DELAWARE CORPORATE SEAL] SIGNATURE TO COME Chief Financial Officer President Countersigned and Registered: SUNTRUST BANK By Transfer Agent and Registrar, Authorized Signature --------------------------------------------------------------------------------------------------------- AMERICAN BANK NOTE COMPANY PRODUCTION COORDINATOR: MIKE PETERS 931-490-1714 711 ARMSTRONG LANE PROOF OF JANUARY 10, 2005 COLUMBIA, TENNESSEE 38401 LHC GROUP, INC. (931) 388-3003 TSB 18344 FC --------------------------------------------------------------------------------------------------------- SALES: J. DICKINSON 708-385-9112 Operator: Ron --------------------------------------------------------------------------------------------------------- / ETHER 19 / LIVE JOBS / L / LHC GROUP 18344 FC New --------------------------------------------------------------------------------------------------------- PLEASE INITIAL THE APPROPRIATE SELECTION FOR THIS PROOF: ___ OK AS IS ___ OK WITH CHANGES ___ MAKE CHANGES AND SEND ANOTHER PROOF COLORS SELECTED FOR PRINTING: INTAGLIO PRINTS IN SC-3 DARK GREEN. COLOR: THIS PROOF WAS PRINTED FROM A DIGITAL FILE OR ARTWORK ON A GRAPHICS QUALITY, COLOR LASER PRINTER. IT IS A GOOD REPRESENTATION OF THE COLOR AS IT WILL APPEAR ON THE FINAL PRODUCT. HOWEVER, IT IS NOT AN EXACT COLOR RENDITION, AND THE FINAL PRINTED PRODUCT MAY APPEAR SLIGHTLY DIFFERENT FROM THE PROOF DUE TO THE DIFFERENCE BETWEEN THE DYES AND PRINTING INK. |
THE CORPORATION WILL FURNISH WITHOUT CHARGE TO EACH STOCKHOLDER WHO SO REQUESTS, A STATEMENT OF THE POWERS, DESIGNATIONS, PREFERENCES AND RELATIVE, PARTICIPATING, OPTIONAL OR OTHER SPECIAL RIGHTS OF EACH CLASS OF STOCK OR SERIES THEREOF AND THE QUALIFICATIONS, LIMITATIONS OR RESTRICTIONS OF SUCH PREFERENCES AND/OR RIGHTS.
The following abbreviations, when used in the inscription on the face of this certificate, shall be construed as though they were written out in full according to applicable laws or regulations:
TEN COM - as tenants in common UNIF GIFT MIN ACT - _________ Custodian _________ TEN ENT - as tenants by the entireties (Cust) (Minor) JT TEN - as joint tenants with right of under Uniform Gifts to Minors survivorship and not as tenants Act _________________________ in common (State) |
Additional abbreviations may also be used though not in the above list.
For Value Received, _______________ hereby sell, assign and transfer unto
PLEASE INSERT SOCIAL SECURITY OR OTHER
IDENTIFYING NUMBER OF ASSIGNEE
--------------------------------------------------------------------------------------------------------- AMERICAN BANK NOTE COMPANY PRODUCTION COORDINATOR: MIKE PETERS 931-490-1714 711 ARMSTRONG LANE PROOF OF JANUARY 10, 2005 COLUMBIA, TENNESSEE 38401 LHC GROUP, INC. (931) 388-3003 TSB 18344 BK --------------------------------------------------------------------------------------------------------- SALES: J. DICKINSON 708-385-9112 Operator: Ron --------------------------------------------------------------------------------------------------------- / ETHER 19 / LIVE JOBS / L / LHC GROUP 18344 BK New --------------------------------------------------------------------------------------------------------- PLEASE INITIAL THE APPROPRIATE SELECTION FOR THIS PROOF: ___ OK AS IS ___ OK WITH CHANGES ___ MAKE CHANGES AND SEND ANOTHER PROOF |
.
.
.
EXHIBIT 10.4
LHC GROUP, INC.
2005 INCENTIVE PLAN
TABLE OF CONTENTS
ARTICLE 1 PURPOSE........................................................................................1 1.1 General.................................................................................1 ARTICLE 2 DEFINITIONS....................................................................................1 2.1 Definitions.............................................................................1 ARTICLE 3 TERM OF PLAN ..................................................................................7 3.1 Effective Date..........................................................................7 3.2 Termination Of Plan.....................................................................7 ARTICLE 4 ADMINISTRATION.................................................................................8 4.1 Committee...............................................................................8 4.2 Action and Interpretations by the Committee.............................................8 4.3 Authority of Committee..................................................................8 4.4 Award Certificates......................................................................10 ARTICLE 5 SHARES SUBJECT TO THE PLAN.....................................................................10 5.1 Number of Shares........................................................................10 5.2 Share Counting..........................................................................10 5.3 Stock Distributed.......................................................................10 ARTICLE 6 ELIGIBILITY....................................................................................10 6.1 General.................................................................................10 ARTICLE 7 STOCK OPTIONS..................................................................................11 7.1 General.................................................................................11 7.2 Incentive Stock Options.................................................................11 ARTICLE 8 STOCK APPRECIATION RIGHTS......................................................................12 8.1 Grant of Stock Appreciation Rights......................................................12 ARTICLE 9 PERFORMANCE AWARDS.............................................................................13 9.1 Grant of Performance Awards.............................................................13 9.2 Performance Goals.......................................................................13 9.3 Right to Payment........................................................................13 9.4 Other Terms.............................................................................14 ARTICLE 10 RESTRICTED STOCK AND RESTRICTED STOCK UNIT AWARDS.............................................14 10.1 Grant of Restricted Stock and Restricted Stock Units....................................14 10.2 Issuance and Restrictions...............................................................14 10.3 Forfeiture..............................................................................14 10.4 Delivery of Restricted Stock............................................................14 |
ARTICLE 11 DEFERRED STOCK UNITS..........................................................................15 11.1 Grant of Deferred Stock Units...........................................................15 ARTICLE 12 DIVIDEND EQUIVALENTS..........................................................................15 12.1 Grant of Dividend Equivalents...........................................................15 ARTICLE 13 STOCK OR OTHER STOCK-BASED AWARDS.............................................................15 13.1 Grant of Stock or Other Stock-Based Awards..............................................15 ARTICLE 14 PROVISIONS APPLICABLE TO AWARDS...............................................................15 14.1 Stand-Alone, Tandem, and Substitute Awards..............................................15 14.2 Term of Award...........................................................................15 14.3 Form of Payment for Awards..............................................................16 14.4 Limits on Transfer......................................................................16 14.5 Beneficiaries...........................................................................16 14.6 Compliance with Laws....................................................................16 14.7 Acceleration upon Death or Disability or Retirement.....................................16 14.8 Acceleration Upon a change in Control...................................................17 14.9 Acceleration for other Reasons..........................................................17 14.10 Termination of Employment...............................................................17 ARTICLE 15 CHANGES IN CAPITAL STRUCTURE..................................................................17 15.1 General.................................................................................17 ARTICLE 16 AMENDMENT, MODIFICATION AND TERMINATION.......................................................18 16.1 Amendment, Modification and Termination.................................................18 16.2 Awards Previously Granted...............................................................18 ARTICLE 17 GENERAL PROVISIONS 17.1 No Rights to Awards; Non-Uniform Determinations.........................................19 17.2 No Stockholder Rights...................................................................19 17.3 Withholding.............................................................................19 17.4 No Right to Continued Service...........................................................19 17.5 Unfunded Status of Awards...............................................................19 17.6 Indemnification.........................................................................20 17.7 Relationship to other Benefits..........................................................20 17.8 Expenses................................................................................20 17.9 Titles and Headings.....................................................................20 17.10 Gender and Number.......................................................................20 17.11 Fractional Shares.......................................................................20 17.12 Government and other Regulations........................................................20 17.13 Governing Law...........................................................................21 17.14 Additional provisions...................................................................21 17.15 No Limitations on Rights of Company.....................................................21 |
LHC GROUP, INC.
2005 INCENTIVE PLAN
ARTICLE 1
PURPOSE
1.1 GENERAL. The purpose of the LHC Group, Inc. 2005 Incentive Plan (the "Plan") is to promote the success, and enhance the value, of LHC Group, Inc. (the "Company"), by linking the personal interests of employees, officers, directors and consultants of the Company or any Affiliate (as defined below) to those of Company stockholders and by providing such persons with an incentive for outstanding performance. The Plan is further intended to provide flexibility to the Company in its ability to motivate, attract, and retain the services of employees, officers, directors and consultants upon whose judgment, interest, and special effort the successful conduct of the Company's operation is largely dependent. Accordingly, the Plan permits the grant of incentive awards from time to time to selected employees, officers, directors and consultants of the Company and its Affiliates.
ARTICLE 2
DEFINITIONS
2.1 DEFINITIONS. When a word or phrase appears in this Plan with the
initial letter capitalized, and the word or phrase does not commence a sentence,
the word or phrase shall generally be given the meaning ascribed to it in this
Section or in Section 1.1 unless a clearly different meaning is required by the
context. The following words and phrases shall have the following meanings:
(a) "Affiliate" means (i) any Subsidiary or Parent, or (ii) an entity that directly or through one or more intermediaries controls, is controlled by or is under common control with, the Company, as determined by the Committee.
(b) "Award" means any Option, Stock Appreciation Right, Restricted Stock or Restricted Stock Unit Award, Deferred Stock Unit Award, Performance Award, Dividend Equivalent Award, Other Stock-Based Award, Performance-Based Cash Awards or any other right or interest relating to Stock or cash, granted to a Participant under the Plan.
(c) "Award Certificate" means a written document, in such form as the Committee prescribes from time to time, setting forth the terms and conditions of an Award. Award Certificates may be in the form of individual award agreements or certificates or a program document describing the terms and provisions of an Awards or series of Awards under the Plan.
(d) "Board" means the Board of Directors of the Company.
(e) "Cause" as a reason for a Participant's termination of employment shall have the meaning assigned such term in the employment agreement, if any, between such Participant and the Company or an Affiliate, provided, however that if there is no such employment agreement in which such term is defined, and unless otherwise defined in the applicable Award Certificate, "Cause" shall mean any of the following acts by the Participant, as determined by the Board: gross neglect of duty, prolonged absence from
revenue rulings issued by the Secretary of the United States Treasury applicable to such plans.
(k) "Deferred Stock Unit" means a right granted to a Participant under Article 11.
(l) "Disability" or "Disabled" has the same meaning as provided in the
long-term disability plan or policy maintained by the Company or if
applicable, most recently maintained, by the Company or if applicable, an
Affiliate, for the Participant, whether or not such Participant actually
receives disability benefits under such plan or policy. If no long-term
disability plan or policy was ever maintained on behalf of Participant or
if the determination of Disability relates to an Incentive Stock Option,
Disability means Permanent and Total Disability as defined in Section
22(e)(3) of the Code. In the event of a dispute, the determination whether
a Participant is Disabled will be made by the Committee and may be
supported by the advice of a physician competent in the area to which such
Disability relates. Notwithstanding the foregoing, for any Awards that
constitute a nonqualified deferred compensation plan within the meaning of
Section 409A(d) of the Code, Disability shall have the same meaning as set
forth in any regulations, revenue procedure or revenue rulings issued by
the Secretary of the United States Treasury applicable to such plans.
(m) "Dividend Equivalent" means a right granted to a Participant under Article 12.
(n) "Effective Date" has the meaning assigned such term in Section 3.1.
(o) "Eligible Participant" means an employee, officer, consultant or director of the Company or any Affiliate.
(p) "Exchange" means the New York Stock Exchange or any other national securities exchange or, if applicable, the Nasdaq National Market on which the Stock may from time to time be listed or traded.
(q) "Fair Market Value", on any date, means (i) if the Stock is listed on a securities exchange or is traded over the Nasdaq National Market, the closing sales price on the immediately preceding date on which sales were reported, or (ii) if the Stock is not listed on a securities exchange or traded over the Nasdaq National Market, the mean between the bid and offered prices as quoted by Nasdaq for such immediately preceding trading date, provided that if it is determined that the fair market value is not properly reflected by such Nasdaq quotations, Fair Market Value will be determined by such other method as the Committee determines in good faith to be reasonable.
(r) "Good Reason" has the meaning assigned such term in the employment agreement, if any, between a Participant and the Company or an Affiliate, provided, however that if there is no such employment agreement in which such term is defined, and unless otherwise defined in the applicable Award Certificate, "Good Reason" shall mean any of the following acts by the Company or an Affiliate without the consent of the Participant (in each case, other than an isolated, insubstantial and inadvertent action not taken in bad faith and which is remedied by the Company or an Affiliate promptly after receipt of notice thereof given by the Participant): (i) the assignment to the Participant of
duties materially inconsistent with, or a material diminution in, the Participant's position, authority, duties or responsibilities as in effect immediately prior to a Change of Control, (ii) a reduction by the Company or an Affiliate in the Participant's base salary, (iii) the Company or an Affiliate requiring the Participant, without his or her consent, to be based at any office or location more than 35 miles from the location at which the Participant was stationed immediately prior to a Change of Control, or (iv) the continuing material breach by the Company or an Affiliate of any employment agreement between the Participant and the Company or an Affiliate after the expiration of any applicable period for cure.
(s) "Grant Date" means the date an Award is made by the Committee.
(t) "Incentive Stock Option" means an Option that is intended to be an incentive stock option and meets the requirements of Section 422 of the Code or any successor provision thereto.
(u) "Non-Employee Director" means a director of the Company who is not a common law employee of the Company or any Affiliate.
(v) "Nonstatutory Stock Option" means an Option that is not an Incentive Stock Option.
(w) "Option" means a right granted to a Participant under Article 7 of the Plan to purchase Stock at a specified price during specified time periods. An Option may be either an Incentive Stock Option or a Nonstatutory Stock Option.
(x) "Other Stock-Based Award" means a right, granted to a Participant under Article 13, that relates to or is valued by reference to Stock or other Awards relating to Stock.
(y) "Parent" means a corporation, limited liability company, partnership or other entity which owns or beneficially owns a majority of the outstanding voting stock or voting power of the Company. Notwithstanding the above, with respect to an Incentive Stock Option, Parent shall have the meaning set forth in Section 424(e) of the Code.
(z) "Participant" means a person who, as an employee, officer, director or consultant of the Company or any Affiliate, has been granted an Award under the Plan; provided that in the case of the death of a Participant, the term "Participant" refers to a beneficiary designated pursuant to Section 14.5 or the legal guardian or other legal representative acting in a fiduciary capacity on behalf of the Participant under applicable state law and court supervision.
(aa) "Performance Award" means Performance Shares, Performance Units or Performance-Based Cash Awards granted pursuant to Article 9.
(bb) "Performance-Based Cash Award" means a right granted to a Participant under Article 9 to a cash award to be paid upon achievement of such performance goals as the Committee establishes with regard to such Award.
(cc) "Performance Share" means any right granted to a Participant under Article 9 to a unit to be valued by reference to a designated number of Shares to be paid upon achievement of such performance goals as the Committee establishes with regard to such Performance Share.
(dd) "Performance Unit" means a right granted to a Participant under Article 9 to a unit valued by reference to a designated amount of cash or property other than Shares to be paid to the Participant upon achievement of such performance goals as the Committee establishes with regard to such Performance Unit.
(ee) "Person" means any individual, entity or group, within the meaning of Section 13(d)(3) or 14(d)(2) of the 1934 Act.
(ff) "Plan" means this 2005 Incentive Plan, as amended from time to time.
(gg) "Public Offering" shall occur on the closing date of a public offering of any class or series of the Company's equity securities pursuant to a registration statement filed by the Company under the 1933 Act.
(hh) "Restricted Stock Award" means Stock granted to a Participant under Article 10 that is subject to certain restrictions and to risk of forfeiture.
(ii) "Restricted Stock Unit Award" means the right to receive shares of Stock (or the equivalent value in cash or other property if the committee so provides) in the future, granted to a Participant under Article 10.
(jj) "Retirement" means a Participant's termination of employment with the Company or an Affiliate (i) after attaining age 62, or (ii) after attaining age 55 and having at least 10 years of service with the Company or an Affiliate.
(kk) "Shares" means shares of the Company's Stock. If there has been
an adjustment or substitution pursuant to Section 15.1, the term "Shares"
shall also include any shares of stock or other securities that are
substituted for Shares or into which Shares are adjusted pursuant to
Section 15.1.
(ll) "Stock" means the $0.01 par value common stock of the Company and such other securities of the Company as may be substituted for Stock pursuant to Article 15.
(mm) "Stock Appreciation Right" or "SAR" means a right granted to a Participant under Article 8 to receive a payment equal to the difference between the Fair Market Value of a Share as of the date of exercise of the SAR over the grant price of the SAR, all as determined pursuant to Article 8.
(nn) "Subsidiary" means any corporation, limited liability company, partnership or other entity of which a majority of the outstanding voting stock or voting power is beneficially owned directly or indirectly by the Company. Notwithstanding the above, with respect to an Incentive Stock Option, Subsidiary shall have the meaning set forth in Section 424(f) of the Code.
(oo) "1933 Act" means the Securities Act of 1933, as amended from time to time.
(pp) "1934 Act" means the Securities Exchange Act of 1934, as amended from time to time.
ARTICLE 3
TERM OF PLAN
3.1 EFFECTIVE DATE. The Plan was originally adopted by the Board on January __, 2005. The Plan was approved by the stockholders of the Company on _________, 2005 and became effective as of that date (the "Effective Date").
3.2 TERMINATION OF PLAN. The Plan shall terminate on ______, 2015, which is ten (10) years after the Effective Date. The termination of the Plan on such date shall not affect the validity of any Award outstanding on the date of termination.
ARTICLE 4
ADMINISTRATION
4.1. COMMITTEE. The Plan shall be administered by a Committee appointed by the Board (which Committee shall consist of at least two directors) or, at the discretion of the Board from time to time, the Plan may be administered by the Board. It is intended that at least two of the directors appointed to serve on the Committee shall be "non-employee directors" (within the meaning of Rule 16b-3 promulgated under the 1934 Act) and that any such members of the Committee who do not so qualify shall abstain from participating in any decision to make or administer Awards that are made to Eligible Participants who at the time of consideration for such Award (i) are persons subject to the short-swing profit rules of Section 16 of the 1934 Act, or (ii) are reasonably anticipated to become Covered Employees during the term of the Award. However, the mere fact that a Committee member shall fail to qualify under the foregoing requirements or shall fail to abstain from such action shall not invalidate any Award made by the Committee which Award is otherwise validly made under the Plan. The members of the Committee shall be appointed by, and may be changed at any time and from time to time in the discretion of, the Board. The Board may reserve to itself any or all of the authority and responsibility of the Committee under the Plan or may act as administrator of the Plan for any and all purposes. To the extent the Board has reserved any authority and responsibility or during any time that the Board is acting as administrator of the Plan, it shall have all the powers of the Committee hereunder, and any reference herein to the Committee (other than in this Section 4.1) shall include the Board. To the extent any action of the Board under the Plan conflicts with actions taken by the Committee, the actions of the Board shall control.
4.2 ACTION AND INTERPRETATIONS BY THE COMMITTEE. For purposes of administering the Plan, the Committee may from time to time adopt rules, regulations, guidelines and procedures for carrying out the provisions and purposes of the Plan and make such other determinations, not inconsistent with the Plan, as the Committee may deem appropriate. The Committee's interpretation of the Plan, any Awards granted under the Plan, any Award Certificate and all decisions and determinations by the Committee with respect to the Plan are final, binding, and conclusive on all parties. Each member of the Committee is entitled to, in good faith, rely or act upon any report or other information furnished to that member by any officer or other employee of the Company or any Affiliate, the Company's or an Affiliate's
independent certified public accountants, Company counsel or any executive compensation consultant or other professional retained by the Company to assist in the administration of the Plan.
4.3 AUTHORITY OF COMMITTEE. Except as provided below, the Committee has the exclusive power, authority and discretion to:
(a) Grant Awards;
(b) Designate Participants;
(c) Determine the type or types of Awards to be granted to each Participant;
(d) Determine the number of Awards to be granted and the number of Shares to which an Award will relate;
(e) Determine the terms and conditions of any Award granted under the Plan, including but not limited to, the exercise price, grant price, or purchase price, any restrictions or limitations on the Award, any schedule for lapse of forfeiture restrictions or restrictions on the exercisability of an Award, and accelerations or waivers thereof, based in each case on such considerations as the Committee in its sole discretion determines;
(f) Accelerate the vesting, exercisability or lapse of restrictions of any outstanding Award, in accordance with Article 14, based in each case on such considerations as the Committee in its sole discretion determines;
(g) Determine whether, to what extent, and under what circumstances an Award may be settled in, or the exercise price of an Award may be paid in, cash, Stock, other Awards, or other property, or an Award may be canceled, forfeited, or surrendered;
(h) Prescribe the form of each Award Certificate, which need not be identical for each Participant;
(i) Decide all other matters that must be determined in connection with an Award;
(j) Establish, adopt or revise any rules, regulations, guidelines or procedures as it may deem necessary or advisable to administer the Plan;
(k) Make all other decisions and determinations that may be required under the Plan or as the Committee deems necessary or advisable to administer the Plan;
(l) Amend the Plan or any Award Certificate as provided herein; and
(m) Adopt such modifications, procedures, and subplans as may be necessary or desirable to comply with provisions of the laws of non-U.S. jurisdictions in which the Company or any Affiliate may operate, in order to assure the
viability of the benefits of Awards granted to participants located in such other jurisdictions and to meet the objectives of the Plan.
Notwithstanding the foregoing, grants of Awards to Non-Employee Directors hereunder shall be made only in accordance with the terms, conditions and parameters of a formula program for equity awards to Non-Employee Directors as approved by the Board from time to time, and the Committee may not make discretionary grants hereunder to Non-Employee Directors.
Notwithstanding the above, the Board or the Committee may expressly delegate to a special committee consisting of one or more officers of the Company some or all of the Committee's authority under subsections (a) through (i) above, except that no delegation of its duties and responsibilities may be made to officers of the Company with respect to Awards to Eligible Participants who are, or who are anticipated to become, subject to the short-swing profit rules of Section 16 of the 1934 Act. The acts of such delegates shall be treated hereunder as acts of the Committee and such delegates shall report to the Committee regarding the delegated duties and responsibilities.
4.4. AWARD CERTIFICATES. Each Award shall be evidenced by an Award Certificate. Each Award Certificate shall include such provisions, not inconsistent with the Plan, as may be specified by the Committee.
ARTICLE 5
SHARES SUBJECT TO THE PLAN
5.1. NUMBER OF SHARES. Subject to adjustment as provided in Section 15.1 and 5.2, the aggregate number of Shares reserved and available for issuance pursuant to Awards granted under the Plan shall be 1,000,000. The maximum number of Shares that may be issued pursuant to the exercise of Incentive Stock Options shall be 1,000,000.
5.2. SHARE COUNTING.
(a) To the extent that an Award is canceled, terminates, expires, is forfeited or lapses for any reason, any unissued Shares subject to the Award will again be available for issuance pursuant to Awards granted under the Plan.
(b) Shares subject to Awards settled in cash will again be available for issuance pursuant to Awards granted under the Plan.
(c) Only the number of Shares issued and delivered upon exercise of a Stock Appreciation Right shall be considered for purposes of determining the number of Shares remaining available for issuance pursuant to Awards granted under the Plan.
(d) If the exercise price of an Option (but not the resulting tax obligation) is satisfied by delivering Shares to the Company (by either actual delivery or attestation), only the number of Shares issued in excess of the delivery or attestation shall be considered for purposes of determining the number of Shares remaining available for issuance pursuant to Awards granted under the Plan.
(e) To the extent that the full number of Shares subject to an Option is not issued upon exercise of the Option for any reason (other than Shares used to satisfy an applicable tax withholding obligation), only the number of Shares issued and delivered
upon exercise of the Option shall be considered for purposes of determining the number of Shares remaining available for issuance pursuant to Awards granted under the Plan. Nothing in this subsection shall imply that any particular type of cashless exercise of an Option is permitted under the Plan, that decision being reserved to the Committee.
5.3. STOCK DISTRIBUTED. Any Stock distributed pursuant to an Award may consist, in whole or in part, of authorized and unissued Stock, treasury Stock, or Stock purchased on the open market.
ARTICLE 6
ELIGIBILITY
6.1. GENERAL. Awards may be granted only to Eligible Participants; except that Incentive Stock Options may not be granted to Eligible Participants who are not employees of the Company or a Parent or Subsidiary as defined in Section 424(e) and (f) of the Code.
ARTICLE 7
STOCK OPTIONS
7.1. GENERAL. The Committee is authorized to grant Options to Participants on the following terms and conditions:
(a) EXERCISE PRICE. The exercise price per Share under an Option shall be determined by the Committee, subject to Section 7.2(a) with respect to an Incentive Stock Option.
(b) TIME AND CONDITIONS OF EXERCISE. The Committee shall determine the time or times at which an Option may be exercised in whole or in part, subject to Section 7.1(d). The Committee shall also determine the performance or other conditions, if any, that must be satisfied before all or part of an Option may be exercised or vested. The Committee may waive any exercise or vesting provisions at any time in whole or in part based upon factors as the Committee may determine in its sole discretion so that the Option becomes exercisable or vested at an earlier date. The Committee may permit an arrangement whereby receipt of Stock upon exercise of an Option is delayed until a specified future date.
(c) PAYMENT. The Committee shall determine the methods by which the exercise price of an Option may be paid, the form of payment, including, without limitation, cash, Shares, or other property (including "cashless exercise" arrangements), and the methods by which Shares shall be delivered or deemed to be delivered to Participants; provided, however, that if Shares are used to pay the exercise price of an Option, such Shares must have been held by the Participant for such period of time, if any, as necessary to avoid variable accounting for the Option.
(d) EXERCISE TERM. In no event may any Option be exercisable for more than ten years from the Grant Date.
7.2. INCENTIVE STOCK OPTIONS. The terms of any Incentive Stock Options granted under the Plan must comply with the following additional rules:
(a) EXERCISE PRICE. The exercise price of an Incentive Stock Option shall not be less than the Fair Market Value as of the Grant Date.
(b) LAPSE OF OPTION. Subject to any earlier termination provision
contained in the Award Certificate, an Incentive Stock Option shall lapse
upon the earliest of the following circumstances; provided, however, that
the Committee may, prior to the lapse of the Incentive Stock Option under
the circumstances described in subsections (3), (4) and (5) below, provide
in writing that the Option will extend until a later date, but if an Option
is so extended and is exercised after the dates specified in subsections
(3) and (4) below or more than three months after termination of employment
for any other reason, it will automatically become a Nonstatutory Stock
Option:
(1) The expiration date set forth in the Award Certificate.
(2) The tenth anniversary of the Grant Date.
(3) Three months after termination of the Participant's Continuous Status as a Participant for any reason other than the Participant's Disability or death.
(4) One year after the termination of the Participant's Continuous Status as a Participant by reason of the Participant' s Disability.
(5) One year after the Participant's death if the Participant dies while employed, or during the three-month period described in paragraph (3) or during the one-year period described in paragraph (4) and before the Option otherwise lapses.
Unless the exercisability of the Incentive Stock Option is accelerated as provided in Article 14, if a Participant exercises an Option after termination of employment, the Option may be exercised only with respect to the Shares that were otherwise vested on the Participant's termination of employment. Upon the Participant's death, any exercisable Incentive Stock Options may be exercised by the Participant's beneficiary, determined in accordance with Section 14.5.
(c) INDIVIDUAL DOLLAR LIMITATION. The aggregate Fair Market Value (determined as of the Grant Date) of all Shares with respect to which Incentive Stock Options are first exercisable by a Participant in any calendar year may not exceed $100,000.00.
(d) TEN PERCENT OWNERS. No Incentive Stock Option shall be granted to any individual who, at the Grant Date, owns stock possessing more than ten percent of the total combined voting power of all classes of stock of the Company or any Parent or Subsidiary unless the exercise price per Share of such Option is at least 110% of the Fair Market Value per Share at the Grant Date and the Option expires no later than five years after the Grant Date.
(e) EXPIRATION OF AUTHORITY TO GRANT INCENTIVE STOCK OPTIONS. No Incentive Stock Option may be granted pursuant to the Plan after the day immediately prior to the tenth anniversary of date the Plan was adopted by the Board, or the termination of the Plan, if earlier.
(f) RIGHT TO EXERCISE. During a Participant's lifetime, an Incentive Stock Option may be exercised only by the Participant or, in the case of the Participant's Disability, by the Participant's guardian or legal representative.
(g) ELIGIBLE GRANTEES. The Committee may not grant an Incentive Stock Option to a person who is not at the Grant Date an employee of the Company or a Parent or Subsidiary.
ARTICLE 8
STOCK APPRECIATION RIGHTS
8.1. GRANT OF STOCK APPRECIATION RIGHTS. The Committee is authorized to grant Stock Appreciation Rights to Participants on the following terms and conditions:
(a) RIGHT TO PAYMENT. Upon the exercise of a Stock Appreciation Right, the Participant to whom it is granted has the right to receive the excess, if any, of:
(1) The Fair Market Value of one Share on the date of exercise; over
(2) The grant price of the Stock Appreciation Right as determined by the Committee, which shall not be less than the Fair Market Value of one Share on the Grant Date in the case of any Stock Appreciation Right related to an Incentive Stock Option.
(b) OTHER TERMS. All awards of Stock Appreciation Rights shall be evidenced by an Award Certificate. The terms, methods of exercise, methods of settlement, form of consideration payable in settlement, and any other terms and conditions of any Stock Appreciation Right shall be determined by the Committee at the time of the grant of the Award and shall be reflected in the Award Certificate.
ARTICLE 9
PERFORMANCE AWARDS
9.1. GRANT OF PERFORMANCE AWARDS. The Committee is authorized to grant Performance Shares, Performance Units or Performance-Based Cash Awards to Participants on such terms and conditions as may be selected by the Committee. The Committee shall have the complete discretion to determine the number of Performance Awards granted to each Participant and to designate the provisions of such Performance Awards as provided in Section 4.3. All Performance Awards shall be evidenced by an Award Certificate or a written program established by the Committee, pursuant to which Performance Awards are awarded under the Plan under uniform terms, conditions and restrictions set forth in such written program.
9.2. PERFORMANCE GOALS. The Committee may establish performance goals for Performance Awards which may be based on any criteria selected by the Committee. Such performance goals may be described in terms of Company-wide objectives or in terms of objectives that relate to the performance of an Affiliate or a division, region, department or function within the Company or an Affiliate. If the Committee determines that a change in the business, operations, corporate structure or capital structure of the Company or the manner in which the Company or an Affiliate conducts its business, or other events or circumstances render performance goals to be unsuitable, the Committee may modify such performance goals in whole
or in part, as the Committee deems appropriate. If a Participant is promoted, demoted or transferred to a different business unit or function during a performance period, the Committee may determine that the performance goals or performance period are no longer appropriate and may (i) adjust, change or eliminate the performance goals or the applicable performance period as it deems appropriate to make such goals and period comparable to the initial goals and period, or (ii) make a cash payment to the participant in amount determined by the Committee.
9.3. RIGHT TO PAYMENT. The grant of a Performance Share to a Participant will entitle the Participant to receive at a specified later time a specified number of Shares, or the equivalent cash value, if the performance goals established by the Committee are achieved and the other terms and conditions thereof are satisfied. The grant of a Performance Unit to a Participant will entitle the Participant to receive at a specified later time a specified dollar value in cash or other property, including Shares, variable under conditions specified in the Award, if the performance goals in the Award are achieved and the other terms and conditions thereof are satisfied. The Committee shall set performance goals and other terms or conditions to payment of the Performance Awards in its discretion which, depending on the extent to which they are met, will determine the number and value of the Performance Awards that will be paid to the Participant.
9.4. OTHER TERMS. Performance Awards may be payable in cash, Stock, or other property, and have such other terms and conditions as determined by the Committee and reflected in the Award Certificate. For purposes of determining the number of Shares to be used in payment of a Performance Award denominated in cash but payable in whole or in part in Shares or Restricted Stock, the number of Shares to be so paid will be determined by dividing the cash value of the Award to be so paid by the Fair Market Value of a Share on the date of determination by the Committee of the amount of the payment under the Award, or, if the Committee so directs, the date immediately preceding the date the Award is paid.
ARTICLE 10
RESTRICTED STOCK AND RESTRICTED STOCK UNIT AWARDS
10.1. GRANT OF RESTRICTED STOCK AND RESTRICTED STOCK UNITS. The Committee is authorized to make Awards of Restricted Stock or Restricted Stock Units to Participants in such amounts and subject to such terms and conditions as may be selected by the Committee. An Award of Restricted Stock or Restricted Stock Units shall be evidenced by an Award Certificate setting forth the terms, conditions, and restrictions applicable to the Award.
10.2. ISSUANCE AND RESTRICTIONS. Restricted Stock or Restricted Stock Units shall be subject to such restrictions on transferability and other restrictions as the Committee may impose (including, without limitation, limitations on the right to vote Restricted Stock or the right to receive dividends on the Restricted Stock). These restrictions may lapse separately or in combination at such times, under such circumstances, in such installments, upon the satisfaction of performance goals or otherwise, as the Committee determines at the time of the grant of the Award or thereafter. Except as otherwise provided in an Award Certificate, the Participant shall have all of the rights of a stockholder with respect to the Restricted Stock, and the Participant shall have none of the rights of a stockholder with respect to Restricted Stock Units until such time as Shares of Stock are paid in settlement of the Restricted Stock Units.
10.3. FORFEITURE. Except as otherwise determined by the Committee at the time of the grant of the Award or thereafter, upon termination of Continuous Status as a Participant during the applicable restriction period or upon failure to satisfy a performance goal during the
applicable restriction period, Restricted Stock or Restricted Stock Units that are at that time subject to restrictions shall be forfeited; provided, however, that the Committee may provide in any Award Certificate that restrictions or forfeiture conditions relating to Restricted Stock or Restricted Stock Units will be waived in whole or in part in the event of terminations resulting from specified causes, and the Committee may in other cases waive in whole or in part restrictions or forfeiture conditions relating to Restricted Stock or Restricted Stock Units.
10.4. DELIVERY OF RESTRICTED STOCK. Shares of Restricted Stock shall be
delivered to the Participant at the time of grant either by book-entry
registration or by delivering to the Participant, or a custodian or escrow agent
(including, without limitation, the Company or one or more of its employees)
designated by the Committee, a stock certificate or certificates registered in
the name of the Participant. If physical certificates representing shares of
Restricted Stock are registered in the name of the Participant, such
certificates must bear an appropriate legend referring to the terms, conditions,
and restrictions applicable to such Restricted Stock.
ARTICLE 11
DEFERRED STOCK UNITS
11.1 GRANT OF DEFERRED STOCK UNITS . The Committee is authorized to grant Deferred Stock Units to Participants subject to such terms and conditions as may be selected by the Committee. Deferred Stock Units shall entitle the Participant to receive Shares of Stock (or the equivalent value in cash or other property if so determined by the Committee) at a future time as determined by the Committee, or as determined by the Participant within guidelines established by the Committee in the case of voluntary deferral elections. An Award of Deferred Stock Units shall be evidenced by an Award Certificate setting forth the terms and conditions applicable to the Award.
ARTICLE 12
DIVIDEND EQUIVALENTS
12.1 GRANT OF DIVIDEND EQUIVALENTS. The Committee is authorized to grant Dividend Equivalents to Participants subject to such terms and conditions as may be selected by the Committee. Dividend Equivalents shall entitle the Participant to receive payments equal to dividends with respect to all or a portion of the number of Shares of Stock subject to an Award, as determined by the Committee. The Committee may provide that Dividend Equivalents be paid or distributed when accrued or be deemed to have been reinvested in additional Shares of Stock, or otherwise reinvested.
ARTICLE 13
STOCK OR OTHER STOCK-BASED AWARDS
13.1. GRANT OF STOCK OR OTHER STOCK-BASED AWARDS. The Committee is authorized, subject to limitations under applicable law, to grant to Participants such other Awards that are payable in, valued in whole or in part by reference to, or otherwise based on or related to Shares, as deemed by the Committee to be consistent with the purposes of the Plan, including without limitation Shares awarded purely as a "bonus" and not subject to any restrictions or conditions, convertible or exchangeable debt securities, other rights convertible or exchangeable into Shares, and Awards valued by reference to book value of Shares or the value of securities of or the performance of specified Parents or Subsidiaries. The Committee shall determine the terms and conditions of such Awards.
ARTICLE 14
PROVISIONS APPLICABLE TO AWARDS
14.1. STAND-ALONE, TANDEM, AND SUBSTITUTE AWARDS. Awards granted under the Plan may, in the discretion of the Committee, be granted either alone or in addition to, in tandem with, or (subject to Section 16.2(c)) in substitution for, any other Award granted under the Plan. If an Award is granted in substitution for another Award, the Committee may require the surrender of such other Award in consideration of the grant of the new Award. Awards granted in addition to or in tandem with other Awards may be granted either at the same time as or at a different time from the grant of such other Awards.
14.2. TERM OF AWARD. The term of each Award shall be for the period as
determined by the Committee, provided that in no event shall the term of any
Incentive Stock Option or a Stock Appreciation Right granted in tandem with the
Incentive Stock Option exceed a period of ten years from its Grant Date (or, if
Section 7.2(d) applies, five years from its Grant Date).
14.3. FORM OF PAYMENT FOR AWARDS. Subject to the terms of the Plan and any applicable law or Award Certificate, payments or transfers to be made by the Company or an Affiliate on the grant or exercise of an Award may be made in such form as the Committee determines at or after the Grant Date, including without limitation, cash, Stock, other Awards, or other property, or any combination, and may be made in a single payment or transfer, in installments, or on a deferred basis, in each case determined in accordance with rules adopted by, and at the discretion of, the Committee.
14.4. LIMITS ON TRANSFER. No right or interest of a Participant in any unexercised or restricted Award may be pledged, encumbered, or hypothecated to or in favor of any party other than the Company or an Affiliate, or shall be subject to any lien, obligation, or liability of such Participant to any other party other than the Company or an Affiliate. No unexercised or restricted Award shall be assignable or transferable by a Participant other than by will or the laws of descent and distribution or, except in the case of an Incentive Stock Option, pursuant to a domestic relations order that would satisfy Section 414(p)(1)(A) of the Code if such Section applied to an Award under the Plan; provided, however, that the Committee may (but need not) permit other transfers where the Committee concludes that such transferability (i) does not result in accelerated taxation, (ii) does not cause any Option intended to be an Incentive Stock Option to fail to be described in Code Section 422(b), and (iii) is otherwise appropriate and desirable, taking into account any factors deemed relevant, including without limitation, state or federal tax or securities laws applicable to transferable Awards.
14.5 BENEFICIARIES. Notwithstanding Section 14.4, a Participant may, in the manner determined by the Committee, designate a beneficiary to exercise the rights of the Participant and to receive any distribution with respect to any Award upon the Participant's death. A beneficiary, legal guardian, legal representative, or other person claiming any rights under the Plan is subject to all terms and conditions of the Plan and any Award Certificate applicable to the Participant, except to the extent the Plan and Award Certificate otherwise provide, and to any additional restrictions deemed necessary or appropriate by the Committee. If no beneficiary has been designated or survives the Participant, payment shall be made to the Participant's estate. Subject to the foregoing, a beneficiary designation may be changed or revoked by a Participant at any time provided the change or revocation is filed with the Committee.
14.6. COMPLIANCE WITH LAWS. All Stock issuable under the Plan is subject to any stop-transfer orders and other restrictions as the Committee deems necessary or advisable to comply with federal or state securities laws, rules and regulations and the rules of any national securities exchange or automated quotation system on which the Stock is listed, quoted, or traded. The Committee may place legends on any Stock certificate or issue instructions to the transfer agent to reference restrictions applicable to the Stock.
14.7 ACCELERATION UPON DEATH OR DISABILITY OR RETIREMENT. Except as otherwise provided in the Award Certificate, upon the Participant's death or Disability during his or her Continuous Status as a Participant, or upon the Participant's Retirement, all of such Participant' s outstanding Options, SARs, and other Awards in the nature of rights that may be exercised shall become fully exercisable, all time-based vesting restrictions on his or her outstanding Awards shall lapse, and any performance-based criteria shall be deemed to be satisfied at the greater of "target" or actual performance as of the date of such termination. Any exercisable Awards shall thereafter continue or lapse in accordance with the other provisions of the Plan and the Award Certificate. To the extent that this provision causes Incentive Stock Options to exceed the dollar limitation set forth in Section 7.2(c), the excess Options shall be deemed to be Nonstatutory Stock Options.
14.8 ACCELERATION UPON A CHANGE OF CONTROL. Except as otherwise provided in the Award Certificate or special plan document governing an Award, if a Participant's employment is terminated without Cause or the Participant resigns for Good Reason within two years after the effective date of a Change of Control, all of that Participant's outstanding Options, SARs and other Awards in the nature of rights that may be exercised shall become fully exercisable, all time-based vesting restrictions on his or her outstanding Awards shall lapse, and any performance-based criteria with respect to any Award held by that Participant shall be deemed to be satisfied at the greater of "target" or actual performance as of the date of such termination.
14.9. ACCELERATION FOR OTHER REASONS. Regardless of whether an event has occurred as described in Section 14.7 or 14.8 above, the Committee may in its sole discretion at any time determine that all or a portion of a Participant's Options, SARs and other Awards in the nature of rights that may be exercised shall become fully or partially exercisable, that all or a part of the time-based vesting restrictions on all or a portion of a Participant's outstanding Awards shall lapse, and/or that any performance-based criteria with respect to any Awards shall be deemed to be wholly or partially satisfied, in each case, as of such date as the Committee may, in its sole discretion, declare. The Committee may discriminate among Participants and among Awards granted to a Participant in exercising its discretion pursuant to this Section 14.9.
14.10. TERMINATION OF EMPLOYMENT. Whether military, government or other service or other leave of absence shall constitute a termination of employment shall be determined in each case by the Committee at its discretion, and any determination by the Committee shall be final and conclusive. A Participant's Continuous Status as a Participant shall not be deemed to terminate (i) in a circumstance in which a Participant transfers from the Company to an Affiliate, transfers from an Affiliate to the Company, or transfers from one Affiliate to another Affiliate, or (ii) in the discretion of the Committee as specified at or prior to such occurrence, in the case of a spin-off, sale or disposition of the Participant's employer from the Company or any Affiliate. To the extent that this provision causes Incentive Stock Options to extend beyond three months from the date a Participant is deemed to be an employee of the Company, a Parent or Subsidiary for purposes of Sections 424(e) and 424(f) of the Code, the Options held by such Participant shall be deemed to be Nonstatutory Stock Options.
ARTICLE 15
CHANGES IN CAPITAL STRUCTURE
15.1. GENERAL. In the event of a corporate event or transaction involving
the Company (including, without limitation, any stock dividend, stock split,
extraordinary cash dividend, recapitalization, reorganization, merger,
consolidation, split-up, spin-off, combination or exchange of shares), the
authorization limits under Section 5.1 shall be adjusted proportionately, and
the Committee may adjust the Plan and Awards to preserve the benefits or
potential benefits of the Awards. Action by the Committee may include: (i)
adjustment of the number and kind of shares which may be delivered under the
Plan; (ii) adjustment of the number and kind of shares subject to outstanding
Awards; (iii) adjustment of the exercise price of outstanding Awards or the
measure to be used to determine the amount of the benefit payable on an Award;
and (iv) any other adjustments that the Committee determines to be equitable. In
addition, the Committee may, in its sole discretion, provide (i) that Awards
will be settled in cash rather than Stock, (ii) that Awards will become
immediately vested and exercisable and will expire after a designated period of
time to the extent not then exercised, (iii) that Awards will be assumed by
another party to a transaction or otherwise be equitably converted or
substituted in connection with such transaction, (iv) that outstanding Awards
may be settled by payment in cash or cash equivalents equal to the excess of the
Fair Market Value of the underlying Stock, as of a specified date associated
with the transaction, over the exercise price of the Award, (v) that performance
targets and performance periods for Performance Awards will be modified, or (vi)
any combination of the foregoing. The Committee's determination need not be
uniform and may be different for different Participants whether or not such
Participants are similarly situated. Without limiting the foregoing, in the
event of a subdivision of the outstanding Stock (stock-split), a declaration of
a dividend payable in Shares, or a combination or consolidation of the
outstanding Stock into a lesser number of Shares, the authorization limits under
Section 5.1 shall automatically be adjusted proportionately, and the Shares then
subject to each Award shall automatically be adjusted proportionately without
any change in the aggregate purchase price therefor.
ARTICLE 16
AMENDMENT, MODIFICATION AND TERMINATION
16.1. AMENDMENT, MODIFICATION AND TERMINATION. The Board or the Committee may, at any time and from time to time, amend, modify or terminate the Plan without stockholder approval; provided, however, that if an amendment to the Plan would, in the reasonable opinion of the Board or the Committee, (i) materially increase the number of Shares available under the Plan, (ii) expand the types of awards available under the Plan, (iii) materially expand the class of participants eligible to participate in the Plan, (iv) materially extend the term of the Plan, or (iv) otherwise constitute a material change requiring stockholder approval under applicable laws, policies or regulations or the applicable listing or other requirements of an Exchange, then such amendment shall be subject to stockholder approval; and provided further, that the Board or Committee may condition any other amendment or modification on the approval of stockholders of the Company for any reason, including by reason of such approval being necessary or deemed advisable to (i) permit Awards made hereunder to be exempt from liability under Section 16(b) of the 1934 Act, (ii) to comply with the listing or other requirements of an Exchange, or (iii) to satisfy any other tax, securities or other applicable laws, policies or regulations.
16.2. AWARDS PREVIOUSLY GRANTED. At any time and from time to time, the Committee may, without additional consideration, amend, modify or terminate any outstanding Award without approval of the Participant; provided, however:
(a) Subject to the terms of the applicable Award Certificate, such amendment, modification or termination shall not, without the Participant's consent, reduce or diminish the value of such Award determined as if the Award had been exercised, vested, cashed in or otherwise settled on the date of such amendment or termination (with the per-share value of an Option or Stock Appreciation Right for this purpose being calculated as the excess, if any, of the Fair Market Value as of the date of such amendment or termination over the exercise or base price of such Award);
(b) The original term of an Option may not be extended without the prior approval of the stockholders of the Company;
(c) Except as otherwise provided in Article 15, the exercise price of an Option may not be reduced, directly or indirectly, without the prior approval of the stockholders of the Company; and
(d) No termination, amendment, or modification of the Plan shall adversely affect any Award previously granted under the Plan, without the written consent of the Participant affected thereby. An outstanding Award shall not be deemed to be "adversely affected" by a Plan amendment if such amendment would not reduce or diminish the value of such Award determined as if the Award had been exercised, vested, cashed in or otherwise settled on the date of such amendment (with the per-share value of an Option or Stock Appreciation Right for this purpose being calculated as the excess, if any, of the Fair Market Value as of the date of such amendment over the exercise or base price of such Award).
ARTICLE 17
GENERAL PROVISIONS
17.1. NO RIGHTS TO AWARDS; NON-UNIFORM DETERMINATIONS. No Participant or any Eligible Participant shall have any claim to be granted any Award under the Plan. Neither the Company, its Affiliates nor the Committee is obligated to treat Participants or Eligible Participants uniformly, and determinations made under the Plan may be made by the Committee selectively among Eligible Participants who receive, or are eligible to receive, Awards (whether or not such Eligible Participants are similarly situated).
17.2. NO STOCKHOLDER RIGHTS. No Award gives a Participant any of the rights of a stockholder of the Company unless and until Shares are in fact issued to such person in connection with such Award.
17.3. WITHHOLDING. The Company or any Affiliate shall have the authority and the right to deduct or withhold, or require a Participant to remit to the Company, an amount sufficient to satisfy federal, state, and local taxes (including the Participant's FICA obligation) required by law to be withheld with respect to any exercise, lapse of restriction or other taxable event arising as a result of the Plan. If Shares are surrendered to the Company to satisfy withholding obligations in excess of the minimum withholding obligation, such Shares must have been held by the Participant as fully vested shares for such period of time, if any, as necessary to avoid variable accounting for the Award. With respect to withholding required upon any taxable
event under the Plan, the Committee may, at the time the Award is granted or thereafter, require or permit that any such withholding requirement be satisfied, in whole or in part, by withholding from the Award Shares having a Fair Market Value on the date of withholding equal to the minimum amount (and not any greater amount) required to be withheld for tax purposes, all in accordance with such procedures as the Committee establishes.
17.4. NO RIGHT TO CONTINUED SERVICE. Nothing in the Plan, any Award Certificate or any other document or statement made with respect to the Plan, shall interfere with or limit in any way the right of the Company or any Affiliate to terminate any Participant 's employment or status as an officer, director or consultant at any time, nor confer upon any Participant any right to continue as an employee, officer, director or consultant of the Company or any Affiliate, whether for the duration of a Participant's Award or otherwise.
17.5. UNFUNDED STATUS OF AWARDS. The Plan is intended to be an "unfunded" plan for incentive and deferred compensation. With respect to any payments not yet made to a Participant pursuant to an Award, nothing contained in the Plan or any Award Certificate shall give the Participant any rights that are greater than those of a general creditor of the Company or any Affiliate. This Plan is not intended to be subject to ERISA.
17.6. INDEMNIFICATION. To the extent allowable under applicable law, each member of the Committee shall be indemnified and held harmless by the Company from any loss, cost, liability, or expense (including, but not limited to, attorneys fees) that may be imposed upon or reasonably incurred by such member in connection with or resulting from any claim, action, suit, or proceeding to which such member may be a party or in which he may be involved by reason of any action or failure to act under the Plan and against and from any and all amounts paid by such member in satisfaction of judgment in such action, suit, or proceeding against him provided he gives the Company an opportunity, at its own expense, to handle and defend the same before he undertakes to handle and defend it on his own behalf. The foregoing right of indemnification shall not be exclusive of any other rights of indemnification to which such persons may be entitled under the Company's Certificate of Incorporation or Bylaws, as a matter of law, or otherwise, or any power that the Company may have to indemnify them or hold them harmless.
17.7. RELATIONSHIP TO OTHER BENEFITS. No payment under the Plan shall be taken into account in determining any benefits under any pension, retirement, savings, profit sharing, group insurance, welfare or benefit plan of the Company or any Affiliate unless provided otherwise in such other plan.
17.8. EXPENSES. The expenses of administering the Plan shall be borne by the Company or its Affiliates.
17.9. TITLES AND HEADINGS. The titles and headings of the Sections in the Plan are for convenience of reference only, and in the event of any conflict, the text of the Plan, rather than such titles or headings, shall control.
17.10. GENDER AND NUMBER. Except where otherwise indicated by the context, any masculine term used herein also shall include the feminine; the plural shall include the singular and the singular shall include the plural.
17.11. FRACTIONAL SHARES. No fractional Shares shall be issued and the Committee shall determine, in its discretion, whether cash shall be given in lieu of fractional Shares or whether such fractional Shares shall be eliminated by rounding up or down.
17.12. GOVERNMENT AND OTHER REGULATIONS.
(a) Notwithstanding any other provision of the Plan, no Participant who acquires Shares pursuant to the Plan may, during any period of time that such Participant is an affiliate of the Company (within the meaning of the rules and regulations of the Securities and Exchange Commission under the 1933 Act), sell such Shares, unless such offer and sale is made (i) pursuant to an effective registration statement under the 1933 Act, which is current and includes the Shares to be sold, or (ii) pursuant to an appropriate exemption from the registration requirements of the 1933 Act, such as that set forth in Rule 144 promulgated under the 1933 Act.
(b) Notwithstanding any other provision of the Plan, if at any time the Committee shall determine that the registration, listing or qualification of the Shares covered by an Award upon any Exchange or under any foreign, federal, state or local law or practice, or the consent or approval of any governmental regulatory body, is necessary or desirable as a condition of, or in connection with, the granting of such Award or the purchase or receipt of Shares thereunder, no Shares may be purchased, delivered or received pursuant to such Award unless and until such registration, listing, qualification, consent or approval shall have been effected or obtained free of any condition not acceptable to the Committee. Any Participant receiving or purchasing Shares pursuant to an Award shall make such representations and agreements and furnish such information as the Committee may request to assure compliance with the foregoing or any other applicable legal requirements. The Company shall not be required to issue or deliver any certificate or certificates for Shares under the Plan prior to the Committee' s determination that all related requirements have been fulfilled. The Company shall in no event be obligated to register any securities pursuant to the 1933 Act or applicable state or foreign law or to take any other action in order to cause the issuance and delivery of such certificates to comply with any such law, regulation or requirement.
17.13. GOVERNING LAW. To the extent not governed by federal law, the Plan and all Award Certificates shall be construed in accordance with and governed by the laws of the State of Delaware.
17.14 ADDITIONAL PROVISIONS. Each Award Certificate may contain such other terms and conditions as the Committee may determine; provided that such other terms and conditions are not inconsistent with the provisions of the Plan.
17.15. NO LIMITATIONS ON RIGHTS OF COMPANY. The grant of any Award shall not in any way affect the right or power of the Company to make adjustments, reclassification or changes in its capital or business structure or to merge, consolidate, dissolve, liquidate, sell or transfer all or any part of its business or assets. The Plan shall not restrict the authority of the Company, for proper corporate purposes, to grant or assume awards, other than under the Plan, to or with respect to any person. If the Committee so directs, the Company may issue or transfer Shares to an Affiliate, for such lawful consideration as the Committee may specify, upon the condition or understanding that the Affiliate will transfer such Shares to a Participant in accordance with the terms of an Award granted to such Participant and specified by the Committee pursuant to the provisions of the Plan.
****************************************
The foregoing is hereby acknowledged as being the LHC Group, Inc. 2005 Incentive Plan as adopted by the Board and approved by the stockholders as of January 20, 2005.
LHC GROUP, INC.
By: /s/ R. Barr Brown ----------------------------- Its: Senior Vice President and Chief Financial Officer |
EXHIBIT 10.5
RESTRICTED STOCK CERTIFICATE
Non-transferable
GRANT TO
by LHC Group, Inc. (the "Company") of
shares of its common stock, $0.01 par value (the "Shares")
pursuant to and subject to the provisions of the LHC Group, Inc. 2005 Non-Employee Directors Compensation Plan, which is a sub-plan of the LHC Group, Inc. 2005 Incentive Plan (the "Plan") and to the terms and conditions set forth on the following page (the "Terms and Conditions"). By accepting the Shares, Grantee shall be deemed to have agreed to the terms and conditions set forth in this Certificate and the Plan.
Unless sooner vested in accordance with Section 3 of the Terms and Conditions, the restrictions imposed under Section 2 of the Terms and Conditions will expire as to one-third of the Shares awarded hereunder on each of the first three anniversaries of the Grant Date, provided that Grantee is then still serving as a director of the Company:
IN WITNESS WHEREOF, LHC Group, Inc., acting by and through its duly authorized officers, has caused this Certificate to be executed as of the Grant Date.
LHC GROUP, INC.
TERMS AND CONDITIONS
1. Grant of Shares. The Company hereby grants to the Grantee named on page 1 hereof ("Grantee"), subject to the restrictions and the other terms and conditions set forth in the Plan and in this award certificate (this "Certificate"), the number of shares indicated on page 1 hereof of the Company's $0.01 par value common stock (the "Shares"). Capitalized terms used herein and not otherwise defined shall have the meanings assigned to such terms in the Plan.
2. Restrictions. The Shares are subject to each of the following restrictions. "Restricted Shares" mean those Shares that are subject to the restrictions imposed hereunder which restrictions have not then expired or terminated. Restricted Shares may not be sold, transferred, exchanged, assigned, pledged, hypothecated or otherwise encumbered. If Grantee's service as a director of the Company or any Affiliate terminates for any reason other than as set forth in paragraph (b) of Section 3 hereof, then Grantee shall forfeit all of Grantee's right, title and interest in and to the Restricted Shares as of the date of termination of service, and such Restricted Shares shall revert to the Company immediately following the event of forfeiture. The restrictions imposed under this Section shall apply to all shares of the Company's common stock or other securities issued with respect to Restricted Shares hereunder in connection with any merger, reorganization, consolidation, recapitalization, stock dividend or other change in corporate structure affecting the common stock of the Company.
3. Expiration and Termination of Restrictions. The restrictions imposed under
Section 2 will expire on the earliest to occur of the following (the period
prior to such expiration being referred to herein as the "Restricted Period"):
(a) as to one-third of the Shares specified on page 1 hereof, on the first three anniversaries of the Grant Date, provided that Grantee is then still serving as a director of the Company; or
(b) the date of termination of Grantee's service as a director of the Company due to his or her death, Disability or Retirement.
4. Delivery of Shares. The Shares will be registered in the name of Grantee as of the Grant Date and may be held by the Company during the Restricted Period in certificated or uncertificated form. If a certificate for Restricted Shares is issued during the Restricted Period with respect to such Shares, such certificate shall be registered in the name of Grantee and shall bear a legend in substantially the following form (in addition to any legend required under applicable state securities laws): "This certificate and the shares of stock represented hereby are subject to the terms and conditions (including forfeiture and restrictions against transfer) contained in a Restricted Stock Certificate between the registered owner of the shares represented hereby and LHC Group, Inc. Release from such terms and conditions shall be made only in accordance with the provisions of such Certificate, copies of which are on file in the offices of LHC Group, Inc." Stock certificates for the Shares, without the first above legend, shall be delivered to Grantee or Grantee's designee upon request of Grantee after the expiration of the Restricted Period, but delivery may be postponed for such period as may be required for the Company with reasonable diligence to comply, if deemed advisable by the Company, with registration requirements under the 1933 Act, listing requirements under the rules of any stock exchange or the Nasdaq national market, and requirements under any other law or regulation applicable to the issuance or transfer of the Shares.
5. Voting and Dividend Rights. Grantee, as beneficial owner of the Shares, shall have full voting and dividend rights with respect to the Shares during and after the Restricted Period. If Grantee forfeits any rights he may have under this Certificate, Grantee shall no longer have any rights as a stockholder with respect to the Restricted Shares or any interest therein and Grantee shall no longer be entitled to receive dividends on such stock. In the event that for any reason Grantee shall have received dividends upon such stock after such forfeiture, Grantee shall repay to the Company any amount equal to such dividends.
6. Changes in Capital Structure. The provisions of the Plan shall apply in the case of a change in the capital structure of the Company. Without limiting the foregoing, in the event of a subdivision of the outstanding Stock (stock-split), a declaration of a dividend payable in Stock, or a combination or consolidation of the outstanding Stock into a lesser number of shares, the Shares then subject to this Certificate shall automatically be adjusted proportionately.
7. Payment of Taxes. Upon issuance of the Shares hereunder, Grantee may make an election to be taxed upon such award under Section 83(b) of the Code. To effect such election, Grantee may file an appropriate election with Internal Revenue Service within thirty (30) days after award of the Shares and otherwise in accordance with applicable Treasury Regulations. Grantee will, no later than the date as of which any amount related to the Shares first becomes includable in Grantee's gross income for federal income tax purposes, pay to the Company, or make other arrangements satisfactory to the Committee regarding payment of, any federal, state and local taxes of any kind required by law to be withheld with respect to such amount. The obligations of the Company under this Certificate will be conditional on such payment or arrangements, and the Company, and, where applicable, its Affiliates will, to the extent permitted by law, have the right to deduct any such taxes from the award or any payment of any kind otherwise due to Grantee.
8. Amendment. The Committee may amend, modify or terminate this Certificate without approval of Grantee; provided, however, that such amendment, modification or termination shall not, without Grantee's consent, reduce or diminish the value of this award determined as if it had been fully vested on the date of such amendment or termination.
9. Plan Controls. The terms contained in the Plan are incorporated into and made a part of this Certificate and this Certificate shall be governed by and construed in accordance with the Plan. In the event of any actual or alleged conflict between the provisions of the Plan and the provisions of this Certificate, the provisions of the Plan shall be controlling and determinative.
10. Severability. If any one or more of the provisions contained in this Certificate is deemed to be invalid, illegal or unenforceable, the other provisions of this Certificate will be construed and enforced as if the invalid, illegal or unenforceable provision had never been included.
11. Notice. Notices and communications under this Certificate must be in writing and either personally delivered or sent by registered or certified United States mail, return receipt requested, postage prepaid. Notices to the Company must be addressed to LHC Group, Inc., 420 West Lafayette, LA 70503; Attn: Secretary, or any other address designated by the Company in a written notice to Grantee. Notices to Grantee will be directed to the address of Grantee then currently on file with the Company, or at any other address given by Grantee in a written notice to the Company.
EXHIBIT 10.6
EMPLOYMENT AGREEMENT
BETWEEN KEITH G. MYERS
AND LHC GROUP, INC.
EMPLOYMENT AGREEMENT
1. Effective Date....................................................1 2. Employment and Directorship.......................................1 (a) Employment........................................1 (a) Directorship......................................1 3. Employment Period.................................................1 4. Extent of Service.................................................1 5. Compensation and Benefits.........................................2 (a) Base Salary.......................................2 (b) Incentive, Savings and Retirement Plans...........2 (c) Welfare Benefit Plans.............................2 (d) Expenses..........................................2 (e) Fringe Benefits...................................3 (f) Vacation..........................................3 (g) Office and Support Staff..........................3 6. Change of Control..................................................3 7. Termination of Employment..........................................4 (a) Death or Retirement...............................4 (b) Disability........................................4 (c) Termination by the Company........................5 (d) Termination by Executive..........................5 (e) Notice of Termination.............................5 (f) Date of Termination...............................6 8. Obligations of the Company upon Termination........................6 (a) Termination by Executive for Good Reason; Termination by the Company Other Than for Cause or Disability......................................6 (b) Death, Disability or Retirement....................8 (c) Cause or Voluntary Termination without Good Reason.............................................8 (d) Expiration of Employment Period....................8 (e) Resignations.......................................8 |
9. Non-exclusivity of Rights..........................................8
10. Full Settlement; No Obligation to Mitigate.......................8 11. Certain Additional Payments by the Company.......................9 12. Costs of Enforcement............................................11 13. Representations and Warranties..................................11 14. Restrictions on Conduct of Executive............................11 (a) General.........................................11 (b) Definitions.....................................12 (c) Restrictive Covenants...........................13 (d) Enforcement of Restrictive Covenants............15 15. Arbitration.....................................................16 |
16. Assignment and Successors.......................................16
17. Miscellaneous...................................................16
EMPLOYMENT AGREEMENT
THIS EMPLOYMENT AGREEMENT (this "Agreement") is made and entered into this ____ day of January, 2005 by and between LHC Group, Inc., a Delaware corporation (the "Company"), and Keith G. Myers ("Executive"), to be effective as of the Effective Date, as defined in Section 1.
BACKGROUND
Executive currently serves as President and Chief Executive Officer of the Company. The Company desires to continue to engage Executive in such capacity from and after the Effective Date, in accordance with the terms of this Agreement. Executive is willing to serve as such in accordance with the terms and conditions of this Agreement.
NOW, THEREFORE, in consideration of the foregoing and of the mutual covenants and agreements set forth herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:
1. Effective Date. The effective date of this Agreement (the "Effective Date") shall be the effective date of a registration statement on Form S-1 for the initial public offering of the common stock of the Company.
2. Employment and Directorship.
(a) Employment. Executive is hereby employed on the Effective Date as President and Chief Executive Officer of the Company. In his capacity as President and Chief Executive Officer of the Company, Executive shall have the duties, responsibilities and authority commensurate with such position as shall be assigned to him by the Board of Directors of the Company. In his capacity as President and Chief Executive Officer of the Company, Executive will report directly to the Board of Directors.
(b) Directorship. The Company will cause Executive to be nominated to the Board of Directors of the company for a term of at least three years (or three one year terms) and shall recommend to the stockholders of the Company Executive's election to the Board.
3. Employment Period. Unless earlier terminated herein in accordance with Section 7 hereof, Executive's employment shall be for a three year term, beginning on the Effective Date and ending on the third anniversary of the Effective Date (the "Employment Period"). Beginning on the third anniversary of the Effective Date and on each subsequent anniversary of the Effective Date, the Employment Period shall, without further action by Executive or the Company, be extended by an additional one-year period; provided, however, that either the Company or the Executive may, by notice to the other given at least sixty (60) days prior to the scheduled expiration of the Employment Period, cause the Employment Period to cease to extend automatically. Upon such notice, the Employment Period shall terminate upon the expiration of the then-current term, including any prior extensions.
4. Extent of Service. During the Employment Period, and excluding any periods of vacation, holiday, sick leave and Company-approved leave of absence to which Executive is entitled in accordance with Company policies, Executive agrees to devote substantially all of his business time, attention, skill and efforts exclusively to the faithful performance of his duties hereunder. It shall not be a violation of this Agreement for Executive to (i) devote reasonable
1.
time to charitable or community activities, (ii) serve on corporate, civic,
educational or charitable boards or committees, subject to the Company's
standards of business conduct or other code of ethics, (iii) deliver lectures or
fulfill speaking engagements from time to time on an infrequent basis, and/or
(iv) manage personal business interests and investments, subject to the
Company's standards of business conduct or other code of ethics, and so long as
such activities do not interfere in a material manner or on a routine basis with
the performance of Executive's responsibilities under this Agreement.
5. Compensation and Benefits.
(a) Base Salary. During the Employment Period, the Company will pay to Executive base salary at the rate of U.S. $275,000 per year ("Base Salary"), less normal withholdings, payable in approximately equal bi-weekly or other installments as are or become customary under the Company's payroll practices for its employees from time to time. The compensation committee of the Board of Directors of the Company (or the full Board, if there is no compensation committee) shall review Executive's Base Salary annually and may increase (but not decrease) Executive's Base Salary from year to year. Such adjusted salary then shall become Executive's Base Salary for purposes of this Agreement. The annual review of Executive's salary by the Board will consider, among other things, Executive's own performance, and the Company's performance.
(b) Incentive, Savings and Retirement Plans. During the Employment Period, Executive shall be entitled to participate in all incentive, savings and retirement plans, practices, policies and programs available to senior executive officers of the Company ("Peer Executives"), and on the same basis as such Peer Executives. Without limiting the foregoing, the following shall apply:
(i) during the Employment Period, Executive will be entitled to participate in the Company's executive bonus plan, pursuant to which he will have an opportunity to receive an annual cash bonus based upon the achievement of performance goals established from year to year by the compensation committee of the Board of Directors of the Company (such bonus earned at the stated "goal" level of achievement being referred to herein as the "Target Bonus"); and
(ii) during the Employment Period, Executive will be eligible for grants, under the Company's long-term incentive plan or plans, of stock options and/or restricted stock awards (or such other stock-based awards as the Company makes to Peer Executives), having terms and determined in the same manner as awards to other Peer Executives, unless the Executive consents to a different type of award or different terms of such award than are applicable to other Peer Executives. Nothing herein requires the Board of Directors to make grants of options or other awards in any year.
(c) Welfare Benefit Plans. During the Employment Period, Executive and Executive's eligible dependents shall be eligible for participation in, and shall receive all benefits under, the welfare benefit plans, practices, policies and programs provided by the Company (including, without limitation, medical, prescription drug, dental, disability, employee life, dependent life, accidental death and travel accident insurance plans and programs) ("Welfare Plans") to the extent available to other Peer Executives.
(d) Expenses. During the Employment Period, Executive shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by Executive in the course of
performing his duties and responsibilities under this Agreement, in accordance with the policies, practices and procedures of the Company to the extent available to other Peer Executives with respect to travel, entertainment and other business expenses.
(e) Fringe Benefits. During the Employment Period, Executive shall be entitled to fringe benefits in accordance with the plans, practices, programs and policies of the Company available to other Peer Executives.
(f) Vacation. During the Employment Period, Executive will be entitled to such paid vacation time as may be provided from time to time under any plans, practices, programs and policies of the Company available to other Peer Executives.
(g) Office and Support Staff. During the Employment Period, Executive will be entitled to office, furnishings and equipment of similar type and quality made available to other Peer Executives. During the Employment Period, Executive will be entitled to secretarial and other assistance reasonably necessary for the performance of his duties and responsibilities.
6. Change of Control. For the purposes of this Agreement, a "Change of Control" shall mean the occurrence of any of the following events:
(a) individuals who, on the Effective Date, constitute the Board of Directors of the Company (the "Incumbent Directors") cease for any reason to constitute at least a majority of such Board, provided that any person becoming a director after the Effective Date and whose election or nomination for election was approved by a vote of at least a majority of the Incumbent Directors then on the Board shall be an Incumbent Director; provided, however, that no individual initially elected or nominated as a director of the Company as a result of an actual or threatened election contest with respect to the election or removal of directors ("Election Contest") or other actual or threatened solicitation of proxies or consents by or on behalf of any "person" (such term for purposes of this Section 6 being as defined in Section 3(a)(9) of the Securities Exchange Act of 1934 (the "Exchange Act") and as used in Section 13(d)(3) and 14(d)(2) of the Exchange Act) other than the Board ("Proxy Contest"), including by reason of any agreement intended to avoid or settle any Election Contest or Proxy Contest, shall be deemed an Incumbent Director; or
(b) any person is or becomes a "beneficial owner" (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of either (i) 35% or more of the then-outstanding shares of common stock of the Company ("Company Common Stock") or (ii) securities of the Company representing 35% or more of the combined voting power of the Company's then outstanding securities eligible to vote for the election of directors (the "Company Voting Securities"); provided, however, that for purposes of this paragraph (b), the following acquisitions of Company Common Stock or Company Voting Securities shall not constitute a Change of Control: (A) an acquisition directly from the Company, (B) an acquisition by the Company or a subsidiary of the Company, (C) an acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any subsidiary of the Company, or (D) an acquisition pursuant to a Non-Qualifying Transaction (as defined in paragraph (c) below); or
(c) the consummation of a recapitalization, reorganization, merger, consolidation, statutory share exchange or similar form of transaction involving the Company or a
subsidiary of the Company (a "Reorganization"), or the sale or other disposition of all or substantially all of the Company's assets (a "Sale") or the acquisition of assets or stock of another entity (an "Acquisition"), unless immediately following such Reorganization, Sale or Acquisition: (A) all or substantially all of the individuals and entities who were the beneficial owners, respectively, of the outstanding Company Common Stock and outstanding Company Voting Securities immediately prior to such Reorganization, Sale or Acquisition beneficially own, directly or indirectly, more than 50% of, respectively, the then outstanding shares of common stock and the combined voting power of the then outstanding voting securities entitled to vote generally in the election of directors, as the case may be, of the entity resulting from or surviving such Reorganization, Sale or Acquisition (including, without limitation, an entity which as a result of such transaction owns the Company or all or substantially all of the Company's assets or stock either directly or through one or more subsidiary entities, the "Surviving Entity") in substantially the same proportions as their ownership, immediately prior to such Reorganization, Sale or Acquisition, of the outstanding Company Common Stock and the outstanding Company Voting Securities, as the case may be, and (B) no person (other than (x) the Company or any subsidiary of the Company, (y) the Surviving Entity or its ultimate parent entity, or (z) any employee benefit plan (or related trust) sponsored or maintained by any of the foregoing) is the beneficial owner, directly or indirectly, of 35% or more of the total common stock or 35% or more of the total voting power of the outstanding voting securities eligible to elect directors of the Surviving Entity, and (C) at least a majority of the members of the board of directors of the Surviving Entity were Incumbent Directors at the time of the Board's approval of the execution of the initial agreement providing for such Reorganization, Sale or Acquisition (any Reorganization, Sale or Acquisition which satisfies all of the criteria specified in (A), (B) and (C) above shall be deemed to be a "Non-Qualifying Transaction"); or
(d) approval by the members or stockholders of the Company, as the case may be, of a complete liquidation or dissolution of the Company.
7. Termination of Employment.
(a) Death or Retirement. Executive's employment shall terminate automatically upon Executive's death or Retirement during the Employment Period. For purposes of this Agreement, "Retirement" shall mean normal retirement as defined in the Company's then-current retirement plan, or if there is no such retirement plan, "Retirement" shall mean voluntary termination after age 65 with at least ten years of service.
(b) Disability. If the Company determines in good faith that the Disability (as defined below) of Executive has occurred during the Employment Period, it may give to Executive written notice of its intention to terminate Executive's employment. In such event, Executive's employment with the Company shall terminate effective on the 30th day after receipt of such written notice by Executive (the "Disability Effective Date"), provided that, within the 30 days after such receipt, Executive shall not have returned to full-time performance of Executive's duties. For purposes of this Agreement, "Disability" shall have the same meaning as provided in the long-term disability plan or policy maintained by the Company and covering Executive. If no such long-term disability plan or policy is maintained, "Disability" shall mean the inability of Executive, as determined by the Board, to perform the essential functions of his regular duties and responsibilities, with or without reasonable accommodation, due to a medically determinable
physical or mental illness which has lasted (or can reasonably be expected to last) for a period of six consecutive months.
(c) Termination by the Company. The Company may terminate Executive's employment during the Employment Period with or without Cause. For purposes of this Agreement, "Cause" shall mean:
(i) the continued failure of Executive to perform substantially Executive's duties with the Company (other than any such failure resulting from incapacity due to physical or mental illness, or following Executive's delivery of notice of termination for Good Reason, and specifically excluding any failure by Executive, after reasonable efforts, to meet performance expectations), after a written demand for substantial performance is delivered to Executive by the Board which specifically identifies the manner in which the Board believes that Executive has not substantially performed Executive's duties, or
(ii) the engaging by Executive in illegal conduct or gross misconduct which is injurious to the Company, or
(iii) the conviction of Executive, or a plea of guilty or nolo contendere by Executive, to a felony or other crime involving moral turpitude.
(d) Termination by Executive. Executive's employment may be terminated by Executive for Good Reason or no reason. For purposes of this Agreement, unless written consent of Executive is obtained, "Good Reason" shall mean:
(i) the assignment to Executive of duties inconsistent in material respect with Executive's position (including status, offices, titles and reporting requirements), authority, duties or responsibilities as in effect on the Effective Date, or a material diminution in such position, authority, duties or responsibilities, excluding for this purpose an isolated, insubstantial and inadvertent action not taken in bad faith and which is remedied by the Company promptly after receipt of notice thereof given by Executive;
(ii) a reduction by the Company in Executive's Base Salary or Target Bonus as in effect on the Effective Date or, with respect to Executive's Base Salary, as the same may be increased from time to time;
(iii) any failure by the Company to comply with and satisfy 16(c) of this Agreement; or
(v) the material breach by the Company of any other provision of this Agreement.
Any claim of "Good Reason" under this Agreement shall be communicated by Executive to the Company in writing, which writing shall specifically identify the factual details concerning the event(s) giving rise to Executive's claim of Good Reason under this Section 7(d). The Company shall have an opportunity to cure any claimed event of Good Reason within 30 days of such notice from Executive.
(e) Notice of Termination. Any termination by the Company for Cause, or by Executive for Good Reason, shall be communicated by Notice of Termination to the other party hereto given in accordance with Section 17(f) of this Agreement. For purposes of this
Agreement, a "Notice of Termination" means a written notice which (i) indicates the specific termination provision in this Agreement relied upon, (ii) to the extent applicable, sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of Executive's employment under the provision so indicated, and (iii) specifies the termination date. The failure by Executive or the Company to set forth in the Notice of Termination any fact or circumstance which contributes to a showing of Good Reason or Cause shall not waive any right of Executive or the Company, respectively, hereunder or preclude Executive or the Company, respectively, from asserting such fact or circumstance in enforcing Executive's or the Company's rights hereunder.
(f) Date of Termination. "Date of Termination" means (i) if Executive's employment is terminated by the Company for Cause, or by Executive for Good Reason, the date of receipt of the Notice of Termination or a date within 30 days after receipt of the Notice of Termination, as specified in such notice, (ii) if Executive's employment is terminated by the Company other than for Cause or Disability, the Date of Termination shall be the date of receipt of the Notice of Termination or a date within 90 days after receipt of the Notice of Termination, as specified in such notice, (iii) if Executive's employment is terminated by reason of death or Disability, the Date of Termination shall be the date of death of Executive or the Disability Effective Date, as the case may be, and (iv) if Executive's employment is terminated by Executive without Good Reason, the Date of Termination shall be 60 days following the Company's receipt of the Notice of Termination, unless the Company specifies an earlier Date of Termination.
8. Obligations of the Company upon Termination.
(a) Termination by Executive for Good Reason; Termination by the Company Other Than for Cause or Disability. If, during the Employment Period, the Company shall terminate Executive's employment other than for Cause or Disability, or Executive shall terminate employment for Good Reason within a period of 90 days after the occurrence of the event giving rise to Good Reason, then and, with respect to the payments and benefits described in clauses (i)(B) and (ii) below, only if Executive executes a Release in substantially the form of Exhibit A hereto (the "Release"):
(i) the Company shall provide to Executive in a single lump sum cash payment within 30 days after the Date of Termination, or if later, within five days after the Release becomes effective and nonrevocable, the aggregate of the following amounts:
A. the sum of the following amounts, to the extent not previously paid to Executive (the "Accrued Obligations"): (1) Executive's Base Salary through the Date of Termination, (2) a pro-rata bonus for the year in which the Date of Termination occurs, computed as the product of (x) Executive's Target Bonus for such year and (y) a fraction, the numerator of which is the number of days in the current fiscal year through the Date of Termination, and the denominator of which is 365, (3) any accrued pay in lieu of unused vacation (in accordance with the Company's vacation policy), and (4) unless Executive has a later payout date that is required in connection with the terms of a deferral plan or agreement, any vested compensation previously deferred by Executive (together with any amount equivalent to accrued interest or earnings thereon); and
B. a severance payment as determined pursuant to clause (x) or (y) below, as applicable:
(x) if the Date of Termination occurs before, or more than two years after, the occurrence of a Change of Control, the severance payment shall be the product of 24 (the "Regular Severance Factor") times one twelfth of the sum of (1) Executive's Base Salary in effect as of the Date of Termination (ignoring any decrease in Executive's Base Salary unless consented to by Executive), and (2) the greater of the average of the annual bonuses earned by Executive for the two fiscal years in which annual bonuses were paid immediately preceding the year in which the Date of Termination occurs, or Executive's Target Bonus for the year in which the Date of Termination occurs; or
(y) if the Date of Termination occurs within two years after the occurrence of a Change of Control, the severance payment shall be the product of 30 (the "Change of Control Severance Factor") times one twelfth of the sum of (1) Executive's Base Salary in effect as of the Date of Termination, and (2) the greater of the average of the annual bonuses earned by Executive for the two fiscal years in which annual bonuses were paid immediately preceding the year in which the Date of Termination occurs, or Executive's Target Bonus for the year in which the Date of Termination occurs; and
(ii) the Company shall continue to provide, for a number of months equal to the Regular Severance Factor or the Change of Control Severance Factor (determined in Section 8(a)(i)(B)(x) or (y) above, as applicable) after Executive's Date of Termination (the "Welfare Benefits Continuation Period"), or such longer period as may be provided by the terms of the appropriate plan, program, practice or policy, any group health benefits to which Executive and/or Executive's eligible dependents would otherwise be entitled to continue under COBRA, or benefits substantially equivalent to those group health benefits which would have been provided to them in accordance with the Welfare Plans described in Section 5(c) of this Agreement if Executive's employment had not been terminated, provided, however, that if Executive becomes employed with another employer (including self-employment) and receives group health benefits under another employer provided plan, the Company's obligation to provide group health benefits described herein shall cease, except as otherwise provided by law and provided, further, that the Welfare Benefits Continuation Period shall run concurrently with any period for which Executive is eligible to elect health coverage under COBRA; and
(iii) all grants of stock options and other equity awards granted by the Company and held by Executive as of the Date of Termination will become immediately vested and exercisable as of the Date of Termination and, to the extent necessary, this Agreement is hereby deemed an amendment of any such outstanding stock option or other equity award; and
(iv) to the extent not theretofore paid or provided, the Company shall timely pay or provide to Executive any other amounts or benefits required to be paid or provided or which Executive is eligible to receive under any plan, program, policy or practice of the Company to the extent provided to Peer Executives prior to the Date of Termination (such other amounts and benefits shall be hereinafter referred to as the "Other Benefits").
If Executive's employment is terminated by the Company without Cause prior to the occurrence of a Change in Control and if it can reasonably be shown that Executive's termination (i) was at the direction or request of a third party that had taken steps reasonably calculated to effect a Change in Control after such termination, or (ii) otherwise occurred in anticipation of a Change in Control, and in either case a Change in Control as defined hereunder does, in fact,
occur, then Executive shall have the rights described in this Section 8(a) as if the Change in Control had occurred on the date immediately preceding the Date of Termination.
Executive acknowledges and agrees that the receipt of severance benefits provided in this Section 8(a) constitutes consideration for the restrictions on the conduct of Executive contained in Section 14 of this Agreement.
(b) Death, Disability or Retirement. If Executive's employment is terminated by reason of his death, Disability or Retirement during the Employment Period, this Agreement shall terminate without further obligations to Executive or his estate, beneficiaries or legal representatives, other than for payment of Accrued Obligations and the timely payment or provision of Other Benefits. Accrued Obligations shall be paid to Executive or his estate, beneficiary or legal representative, as applicable, in a lump sum in cash within 30 days of the Date of Termination. With respect to the provision of Other Benefits, the term Other Benefits as used in this Section 8(b) shall include, without limitation, and Executive or his estate, beneficiaries or legal representatives, as applicable, shall be entitled to receive, benefits under such plans, programs, practices and policies relating to death, disability or retirement benefits, if any, as are applicable to Executive or his family on the Date of Termination.
(c) Cause or Voluntary Termination without Good Reason. If Executive's employment shall be terminated for Cause during the Employment Period, or if Executive voluntarily terminates employment during the Employment Period without Good Reason, this Agreement shall terminate without further obligations to Executive, other than for payment of Accrued Obligations (excluding the pro-rata bonus described in clause 2 of Section 8(a)(i)(A)) and the timely payment or provision of Other Benefits.
(d) Expiration of Employment Period. If Executive's employment shall be terminated due to the normal expiration of the Employment Period, this Agreement shall terminate without further obligations to Executive, other than for payment of Accrued Obligations and the timely payment or provision of Other Benefits.
(e) Resignations. Termination of Executive's employment for any reason whatsoever shall constitute Executive's resignation from the Board of Directors of the Company and resignation as an officer of the Company, its subsidiaries and affiliates.
9. Non-exclusivity of Rights. Nothing in this Agreement shall prevent or limit Executive's continuing or future participation in any employee benefit plan, program, policy or practice provided by the Company and for which Executive may qualify, except as specifically provided herein. Amounts which are vested benefits or which Executive is otherwise entitled to receive under any employee benefit plan, policy, practice or program of the Company, its subsidiaries or any of its affiliated companies at or subsequent to the Date of Termination shall be payable in accordance with such plan, policy, practice or program except as explicitly modified by this Agreement.
10. Full Settlement; No Obligation to Mitigate. The Company's obligation to make the payments provided for in this Agreement and otherwise to perform its obligations hereunder shall not be affected by any set-off, counterclaim, recoupment, defense or other claim, right or action which the Company may have against Executive or others. In no event shall Executive be obligated to seek other employment or take any other action by way of mitigation of the amounts payable to Executive under any of the provisions of this Agreement and, except as explicitly
provided herein, such amounts shall not be reduced whether or not Executive obtains other employment.
11. Certain Additional Payments by the Company.
(a) Anything in this Agreement to the contrary
notwithstanding and except as set forth below, in the event it shall be
determined that any payment or distribution by the Company to or for the benefit
of Executive (whether paid or payable or distributed or distributable pursuant
to the terms of this Agreement or otherwise, but determined without regard to
any additional payments required under this Section 11) (a "Payment") would be
subject to the excise tax imposed by Section 4999 of the Internal Revenue Code
of 1986, as amended (the "Code") or any interest or penalties are incurred by
Executive with respect to such excise tax (such excise tax, together with any
such interest and penalties, are hereinafter collectively referred to as the
"Excise Tax"), then Executive shall be entitled to receive an additional payment
(a "Gross-Up Payment") in an amount such that after payment by Executive of all
taxes (including any interest or penalties imposed with respect to such taxes),
including, without limitation, any income taxes (and any interest and penalties
imposed with respect thereto) and Excise Tax imposed upon the Gross-Up Payment,
Executive retains an amount of the Gross-Up Payment equal to the Excise Tax
imposed upon the Payments. Notwithstanding the foregoing provisions of this
Section 1l(a), if it shall be determined that Executive is entitled to a
Gross-Up Payment, but that Executive, after taking into account the Payments and
the Gross-Up Payment, would not receive a net after-tax benefit of at least
$50,000 (taking into account both income taxes and any Excise Tax) as compared
to the net after-tax proceeds to Executive resulting from an elimination of the
Gross-Up Payment and a reduction of the Payments, in the aggregate, to an amount
(the "Reduced Amount") such that the receipt of Payments would not give rise to
any Excise Tax, then no Gross-Up Payment shall be made to Executive and the
Payments, in the aggregate, shall be reduced to the Reduced Amount. Executive
may select the Payments to be limited or reduced.
(b) Subject to the provisions of Section 1l(c), all
determinations required to be made under this Section 11, including whether and
when a Gross-Up Payment is required and the amount of such Gross-Up Payment and
the assumptions to be used in arriving at such determination, shall be made by a
certified public accounting firm selected by Executive (other than the Company's
regular accounting firm) and reasonably acceptable to the Company (the
"Accounting Firm") which shall provide detailed supporting calculations both to
the Company and Executive within 15 business days of the receipt of notice from
Executive that there has been a Payment, or such earlier time as is reasonably
requested by the Company. All fees and expenses of the Accounting Firm shall be
borne solely by the Company. Any Gross-Up Payment, as determined pursuant to
this Section 11, shall be paid by the Company to Executive within five days of
the receipt of the Accounting Firm's determination. Any determination by the
Accounting Firm shall be binding upon the Company and Executive. As a result of
the uncertainty in the application of Section 4999 of the Code at the time of
the initial determination by the Accounting Firm hereunder, it is possible that
Gross-Up Payments which will not have been made by the Company should have been
made ("Underpayment"), consistent with the calculations required to be made
hereunder. In the event that the Company exhausts its remedies pursuant to
Section 1l(c) and Executive thereafter is required to make a payment of any
Excise Tax, the Accounting Firm shall determine the amount of the Underpayment
that has occurred and any such Underpayment shall be promptly paid by the
Company to or for the benefit of Executive.
(c) Executive shall notify the Company in writing of any claim by the Internal Revenue Service that, if successful, would require the payment by the Company of a Gross-Up
Payment (or an additional Gross-Up Payment). Such notification shall be given as soon as practicable but no later than ten business days after Executive is informed in writing of such claim and shall apprise the Company of the nature of such claim and the date on which such claim is requested to be paid. Executive shall not pay such claim prior to the expiration of the 30-day period following the date on which he gives such notice to the Company (or such shorter period ending on the date that any payment of taxes with respect to such claim is due). If the Company notifies Executive in writing prior to the expiration of such period that it desires to contest such claim, Executive shall:
(i) give the Company any information reasonably requested by the Company relating to such claim,
(ii) take such action in connection with contesting such claim as the Company shall reasonably request in writing from time to time, including, without limitation, accepting legal representation with respect to such claim by an attorney reasonably selected by the Company,
(iii) cooperate with the Company in good faith in order effectively to contest such claim, and
(iv) permit the Company to participate in any proceedings relating to such claim;
provided, however, that the Company shall bear and pay directly all costs and expenses (including additional interest and penalties) incurred in connection with such contest and shall indemnify and hold Executive harmless, on an after-tax basis, for any Excise Tax or income tax (including interest and penalties with respect thereto) imposed as a result of such representation and payment of costs and expenses. Without limitation of the foregoing provisions of this Section ll(c), the Company shall control all proceedings taken in connection with such contest (to the extent applicable to the Excise Tax and the Gross-Up Payment) and, at its sole option, may pursue or forgo any and all administrative appeals, proceedings, hearings and conferences with the taxing authority in respect of such claim and may, at its sole option, either direct Executive to pay the tax claimed and sue for a refund or contest the claim in any permissible manner, and Executive agrees to prosecute such contest to a determination before any administrative tribunal, in a court of initial jurisdiction and in one or more appellate courts, as the Company shall determine; provided, however, that if the Company directs Executive to pay such claim and sue for a refund, the Company shall advance the amount of such payment to Executive, on an interest-free basis and shall indemnify and hold Executive harmless, on an after-tax basis, from any Excise Tax or income tax (including interest or penalties with respect thereto) imposed with respect to such advance or with respect to any imputed income with respect to such advance; and further provided that any extension of the statute of limitations relating to payment of taxes for the taxable year of Executive with respect to which such contested amount is claimed to be due is limited solely to such contested amount. Furthermore, the Company's control of the contest shall be limited to issues with respect to which a Gross-Up Payment would be payable hereunder and Executive shall be entitled to settle or contest, as the case may be, any other issue raised by the Internal Revenue Service or any other taxing authority.
(d) If, after the receipt by Executive of an amount advanced by the Company pursuant to Section 11(c), Executive becomes entitled to receive any refund with respect to such claim, Executive shall (subject to the Company's complying with the requirements of Section 11(c)) promptly pay to the Company the amount of such refund (together with any interest paid or
credited thereon after taxes applicable thereto). If, after the receipt by Executive of an amount advanced by the Company pursuant to Section 11(c), a determination is made that Executive shall not be entitled to any refiind with respect to such claim and the Company does not notify Executive in writing of its intent to contest such denial of refund prior to the expiration of 30 days after such determination, then such advance shall be forgiven and shall not be required to be repaid and the amount of such advance shall offset, to the extent thereof, the amount of Gross-Up Payment required to be paid.
12. Costs of Enforcement. In any action taken in good faith relating to the enforcement of this Agreement or any provision herein, Executive shall be entitled to reimbursement for any and all costs and expenses incurred by him in enforcing or establishing his rights thereunder, including, without limitation, reasonable attorneys' fees, whether suit be brought or not, and whether or not incurred in arbitration, trial, bankruptcy or appellate proceedings, but only if and to the extent Executive is successful in asserting such rights. Executive shall also be entitled to be paid all reasonable legal fees and expenses, if any, incurred in connection with any tax audit or proceeding to the extent attributable to the application of Section 4999 of the Internal Revenue Code to any payment or benefit hereunder.
13. Representations and Warranties. Executive hereby represents and warrants to the Company that Executive is not a party to, or otherwise subject to, any covenant not to compete with any person or entity, and Executive's execution of this Agreement and performance of his obligations hereunder will not violate the terms or conditions of any contract or obligation, written or oral, between Executive and any other person or entity.
14. Restrictions on Conduct of Executive.
(a) General. Executive and the Company understand and agree that the purpose of the provisions of this Section 14 is to protect legitimate business interests of the Company, as more fully described below, and is not intended to impair or infringe upon Executive's right to work, earn a living, or acquire and possess property from the fruits of his labor. Executive hereby acknowledges that Executive has received good and valuable consideration for the post-employment restrictions set forth in this Section 14 in the form of the compensation and benefits provided for herein. Executive hereby further acknowledges that the post-employment restrictions set forth in this Section 14 are reasonable and that they do not, and will not, unduly impair his ability to earn a living after the termination of this Agreement.
In addition, the parties acknowledge: (A) that Executive's services under this Agreement require unique expertise and talent in the provision of Competitive Services and that Executive will have substantial contacts with customers, suppliers, advertisers and vendors of the Company; (B) that pursuant to this Agreement, Executive will be placed in a position of trust and responsibility and he will have access to a substantial amount of Confidential Information and Trade Secrets and that the Company is placing him in such position and giving him access to such information in reliance upon his agreement not to solicit customers during the Restricted Period; (C) that due to Executive's unique experience and talent, the loss of Executive's services to the Company under this Agreement cannot reasonably or adequately be compensated solely by damages in an action at law; (D) that Executive is capable of competing with the Company; and (E) that Executive is capable of obtaining gainful, lucrative and desirable employment that does not violate the restrictions contained in this Agreement.
Therefore, Executive shall be subject to the restrictions set forth in this Section 14.
(b) Definitions. The following capitalized terms used in this Section 14 shall have the meanings assigned to them below, which definitions shall apply to both the singular and the plural forms of such terms:
"Competitive Services" means the business of providing post-acute healthcare services, including home-based services through home nursing agencies and hospices and facility-based services through long-term acute care hospitals and outpatient rehabilitation clinics.
"Confidential Information" means all information regarding the Company, its activities, business or clients that is the subject of reasonable efforts by the Company to maintain its confidentiality and that is not generally disclosed by practice or authority to persons not employed by the Company, but that does not rise to the level of a Trade Secret. "Confidential Information" shall include, but is not limited to, financial plans and data concerning the Company; management planning information; business plans; operational methods; market studies; marketing plans or strategies; product development techniques or plans; customer lists; customer files, data and financial information, details of customer contracts; current and anticipated customer requirements; identifying and other information pertaining to business referral sources; past, current and planned research and development; business acquisition plans; and new personnel acquisition plans. "Confidential Information" shall not include information that has become generally available to the public by the act of one who has the right to disclose such information without violating any right or privilege of the Company. This definition shall not limit any definition of "confidential information" or any equivalent term under state or federal law.
"Determination Date" means the date of termination of Executive's employment with the Company for any reason whatsoever or any earlier date (during the Employment Period) of an alleged breach of the Restrictive Covenants by Executive.
"Person" means any individual or any corporation, partnership, joint venture, limited liability company, association or other entity or enterprise.
"Principal or Representative" means a principal, owner, partner, stockholder, joint venturer, investor, member, trustee, director, officer, manager, employee, agent, representative or consultant.
"Protected Customers" means any Person to whom the Company has sold its products or services or solicited to sell its products or services, other than through general advertising targeted at consumers, during the 12 months prior to the Determination Date.
"Protected Employees" means employees of the Company who were employed by the Company or its affiliates at any time within six months prior to the Determination Date, other than those who were discharged by the Company or such affiliated employer without cause.
"Restricted Period" means the Employment Period plus 24 months (or the Employment Period plus 6 months if Executive's termination occurs within two years after the occurrence of a Change in Control); provided, however, that the Restricted Period shall end with respect to the covenants in clauses (ii) and (iii) of Section 14(c) on the 60th day after the Date of Termination in the event the Company breaches its obligation, if any, to make any payment required under Section 8(a)(i).
"Restricted Territory" means the geographical territory described on Exhibit B hereto.
"Restrictive Covenants" means the restrictive covenants contained in Section 14(c) hereof.
"Third Party Information" means confidential or proprietary information subject to a duty on the Company's and its affiliates' part to maintain the confidentiality of such information and to use it only for certain limited purposes.
"Trade Secret" means all information, without regard to form, including, but not limited to, technical or nontechnical data, a formula, a pattern, a compilation, a program, a device, a method, a technique, a drawing, a process, financial data, financial plans, product plans, distribution lists or a list of actual or potential customers, advertisers or suppliers which is not commonly known by or available to the public and which information: (A) derives economic value, actual or potential, from not being generally known to, and not being readily ascertainable by proper means by, other persons who can obtain economic value from its disclosure or use; and (B) is the subject of efforts that are reasonable under the circumstances to maintain its secrecy. Without limiting the foregoing, Trade Secret means any item of confidential information that constitutes a "trade secret(s)" under the common law or statutory law of the State of Delaware.
"Work Product" means all inventions, innovations, improvements, developments, methods, processes, programs, designs, analyses, drawings, reports, and all similar or related information (whether or not patentable) that relate to the Company's or its affiliates' actual or anticipated business, research and development, or existing or future products or services and that are conceived, developed, contributed to, made, or reduced to practice by Executive (either solely or jointly with others) while employed by the Company or its affiliates.
(c) Restrictive Covenants.
(i) Restriction on Disclosure and Use of Confidential Information and Trade Secrets. Executive understands and agrees that the Confidential Information and Trade Secrets constitute valuable assets of the Company and its affiliated entities, and may not be converted to Executive's own use. Accordingly, Executive hereby agrees that Executive shall not, directly or indirectly, at any time during the Restricted Period reveal, divulge, or disclose to any Person not expressly authorized by the Company any Confidential Information, and Executive shall not, directly or indirectly, at any time during the Restricted Period use or make use of any Confidential Information in connection with any business activity other than that of the Company. Throughout the term of this Agreement and at all times after the date that this Agreement terminates for any reason, Executive shall not directly or indirectly transmit or disclose any Trade Secret of the Company to any Person, and shall not make use of any such Trade Secret, directly or indirectly, for himself or for others, without the prior written consent of the Company. The parties acknowledge and agree that this Agreement is not intended to, and does not, alter either the Company's rights or Executive's obligations under any state or federal statutory or common law regarding trade secrets and unfair trade practices.
Anything herein to the contrary notwithstanding, Executive shall not be restricted from disclosing or using Confidential Information or any Trade Secret that is required to be disclosed by law, court order or other legal process; provided, however, that in the event disclosure is required by law, Executive shall provide the Company with prompt notice of such
requirement so that the Company may seek an appropriate protective order prior to any such required disclosure by Executive.
Executive acknowledges that any and all Confidential Information is the exclusive property of the Company and agrees to deliver to the Company on the Date of Termination, or at any other time the Company may request in writing, any and all Confidential Information which he may then possess or have under his control in whatever form same may exist, including, but not by way of limitation, hard copy files, soft copy files, computer disks, and all copies thereof.
(ii) Nonsolicitation of Protected Employees. Executive understands and agrees that the relationship between the Company and each of its Protected Employees constitutes a valuable asset of the Company and may not be converted to Executive's own use. Accordingly, Executive hereby agrees that during the Restricted Period, Executive shall not directly or indirectly on Executive's own behalf or as a Principal or Representative of any Person or otherwise solicit or induce any Protected Employee to terminate his employment relationship with the Company or to enter into employment with any other Person.
(iii) Restriction on Relationships with Protected Customers. Executive understands and agrees that the relationship between the Company and each of its Protected Customers constitutes a valuable asset of the Company and may not be converted to Executive's own use. Accordingly, Executive hereby agrees that, during the Restricted Period and in the Restricted Territory, Executive shall not, without the prior written consent of the Company, directly or indirectly, on Executive's own behalf or as a Principal or Representative of any Person, solicit, divert, take away or attempt to solicit, divert or take away a Protected Customer for the purpose of providing or selling Competitive Services; provided, however, that the prohibition of this covenant shall apply only to Protected Customers with whom Executive had Material Contact on the Company's behalf during the 12 months immediately preceding the Date of Termination; and, provided further, that the prohibition of this covenant shall not apply to the conduct of general advertising activities. For purposes of this Agreement, Executive had "Material Contact" with a Protected Customer if (a) he had business dealings with the Protected Customer on the Company's behalf; (b) he was responsible for supervising or coordinating the dealings between the Company and the Protected Customer; or (c) he obtained Trade Secrets or Confidential Information about the customer as a result of his association with the Company.
(iv) Ownership of Work Product. Executive acknowledges that the Work Product belongs to the Company or its affiliates and Executive hereby assigns, and agrees to assign, all of the Work Product to the Company or its affiliates. Any copyrightable work prepared in whole or in part by Executive in the course of his work for any of the foregoing entities shall be deemed a "work made for hire" under the copyright laws, and the Company or such affiliate shall own all rights therein. To the extent that any such copyrightable work is not a "work made for hire," Executive hereby assigns and agrees to assign to the Company or such affiliate all right, title, and interest, including without limitation, copyright in and to such copyrightable work. Executive shall promptly disclose such Work Product and copyrightable work to the Board and perform all actions reasonably requested by the Board (whether during or after the Employment Period) to establish and confirm the Company's or such affiliate's ownership (including, without limitation, assignments, consents, powers of attorney, and other instruments).
(v) Third Party Information. Executive understands that the Company and its affiliates will receive Third Party Information. During the Employment Period and thereafter,
and without in any way limiting the provisions of Section 14(c)(i) above, Executive will hold Third Party Information in the strictest confidence and will not disclose to anyone (other than personnel of the Company or its affiliates who need to know such information in connection with their work for the Company or its affiliates) or use, except in connection with his work for the Company or its affiliates, Third Party Information unless expressly authorized by a member of the Board (other than Executive) in writing.
(vi) Use of Information of Prior Employers. During the Employment Period, Executive will not improperly use or disclose any confidential information or trade secrets, if any, of any former employers or any other person to whom Executive has an obligation of confidentiality, and will not bring onto the premises of the Company or any of its affiliates any unpublished documents or any property belonging to any former employer or any other person to whom Executive has an obligation of confidentiality unless consented to by in writing the former employer or person. Executive will use in the performance of his duties only information which is (i) generally known and used by persons with training and experience comparable to Executive's and which is (x) common knowledge in the industry or (y) is otherwise legally in the public domain, (ii) is otherwise provided or developed by the Company or its affiliates or (iii) in the case of materials, property or information belonging to any former employer or other person to whom Executive has an obligation of confidentiality, approved for such use in writing by such former employer or person.
(d) Enforcement of Restrictive Covenants.
(i) Rights and Remedies Upon Breach. In the event Executive breaches, or threatens to commit a breach of, any of the provisions of the Restrictive Covenants, the Company shall have the right and remedy to enjoin, preliminarily and permanently, Executive from violating or threatening to violate the Restrictive Covenants and to have the Restrictive Covenants specifically enforced by any court or tribunal of competent jurisdiction, it being agreed that any breach or threatened breach of the Restrictive Covenants would cause irreparable injury to the Company and that money damages would not provide an adequate remedy to the Company. Such right and remedy shall be independent of any others and severally enforceable, and shall be in addition to, and not in lieu of, any other rights and remedies available to the Company at law or in equity.
(ii) Severabilitv of Covenants. Executive acknowledges and agrees that the Restrictive Covenants are reasonable and valid in time and scope and in all other respects. The covenants set forth in this Agreement shall be considered and construed as separate and independent covenants. Should any part or provision of any covenant be held invalid, void or unenforceable, such invalidity, voidness or unenforceability shall not render invalid, void or unenforceable any other part or provision of this Agreement. If any portion of the foregoing provisions is found to be invalid or unenforceable because its duration, the territory, the definition of activities or the definition of information covered is considered to be invalid or unreasonable in scope, the invalid or unreasonable term shall be redefined, or a new enforceable term provided, such that the intent of the Company and Executive in agreeing to the provisions of this Agreement will not be impaired and the provision in question shall be enforceable to the fullest extent of the applicable laws.
(iii) Reformation. The parties hereunder agree that it is their intention that the Restrictive Covenants be enforced in accordance with their terms to the maximum extent possible under applicable law. The parties further agree that, in the event any tribunal of competent jurisdiction shall find that any provision hereof is not enforceable in accordance with
its terms, the tribunal shall reform the Restrictive Covenants such that they shall be enforceable to the maximum extent permissible at law.
15. Arbitration. Any claim or dispute arising under or relating to this Agreement or the breach, termination, or validity of any term of this Agreement, including, but not by way of limitation, the legality and enforceability of the Restrictive Covenants, shall be subject to arbitration, and prior to commencing any court action, the parties agree that they shall arbitrate all controversies; provided, however, that nothing in this Section 15 shall prohibit the Company from exercising its right under Section 14(d)(i) to pursue injunctive remedies with respect to a breach or threatened breach of the Restrictive Covenants. The arbitration shall be conducted in Lafayette, Louisiana, in accordance with the Employment Dispute Rules of the American Arbitration Association and the Federal Arbitration Act, 9 U.S.C. Section 1, et. seq. The arbitrators) shall be authorized to award both liquidated and actual damages, in addition to injunctive relief, but no punitive damages. The arbitrators) may also award attorney's fees and costs, without regard to any restriction on the amount of such award under Delaware or other applicable law. Such an award shall be binding and conclusive upon the parties hereto, subject to 9 U.S.C. Section 10. Each party shall have the right to have the award made the judgment of a court of competent jurisdiction.
16. Assignment and Successors.
(a) This Agreement is personal to Executive and without the prior written consent of the Company shall not be assignable by Executive otherwise than by will or the laws of descent and distribution. This Agreement shall inure to the benefit of and be enforceable by Executive's legal representatives.
(b) This Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns.
(c) The Company will require any Surviving Entity resulting from a Reorganization, Sale or Acquisition (if other than the Company) to assume expressly and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no Reorganization, Sale or Acquisition had taken place. As used in this Agreement, "Company" shall mean the Company as hereinbefore defined and any successor to its business and/or assets as aforesaid which assumes and agrees to perform this Agreement by operation of law, or otherwise.
17. Miscellaneous.
(a) Waiver. Failure of either party to insist, in one or more instances, on performance by the other in strict accordance with the terms and conditions of this Agreement shall not be deemed a waiver or relinquishment of any right granted in this Agreement or of the future performance of any such term or condition or of any other term or condition of this Agreement, unless such waiver is contained in a writing signed by the party making the waiver.
(b) Severabilitv. If any provision or covenant, or any part thereof, of this Agreement should be held by any tribunal of competent jurisdiction to be invalid, illegal or unenforceable, either in whole or in part, such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of the remaining provisions or covenants, or any part thereof, of this Agreement, all of which shall remain in full force and effect.
(c) Other Agents. Nothing in this Agreement is to be interpreted as limiting the Company from employing other personnel on such terms and conditions as may be satisfactory to it, except that this Section 17(c) shall not override the provision of Section 7(d)(i).
(d) Entire Agreement. Except as provided herein, this Agreement contains the entire agreement between the Company and Executive with respect to the subject matter hereof and, from and after the Effective Date, this Agreement shall supersede any other agreement between the parties with respect to the subject matter hereof, including without limitation, the Prior Agreement.
(e) Governing Law. Except to the extent preempted by federal law, and without regard to conflict of laws principles, the laws of the State of Delaware shall govern this Agreement in all respects, whether as to its validity, construction, capacity, performance or otherwise.
(f) Notices. All notices, requests, demands and other communications required or permitted hereunder shall be in writing and shall be deemed to have been duly given if delivered or three days after mailing if mailed, first class, certified mail, postage prepaid:
To the Company: LHC Group, Inc. Suite A 420 W. Pinhook Road Lafayette, LA 70503 Attention: General Counsel To Executive: Keith G. Myers |
Any party may change the address to which notices, requests, demands and other communications shall be delivered or mailed by giving notice thereof to the other party in the same manner provided herein.
(g) Amendments and Modifications. This Agreement may be amended or modified only by a writing signed by both parties hereto, which makes specific reference to this Agreement.
(h) Construction. Each party and his or its counsel have reviewed this Agreement and have been provided the opportunity to revise this Agreement and accordingly, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this Agreement. Instead, the language of all parts of this Agreement shall be construed as a whole, and according to its fair meaning, and not strictly for or against either party.
(i) Withholding. The Company or its subsidiaries, if applicable, shall be entitled to deduct or withhold from any amounts owing from the Company or any such affiliate to Executive any federal, state, local or foreign withholding taxes, excise taxes, or employment taxes ("Taxes") imposed with respect to Executive's compensation or other payments from the Company or any of its affiliates. In the event the Company or its affiliates do not make such deductions or withholdings, Executive shall indemnify the Company and its affiliates for any amounts paid with respect to any such Taxes.
IN WITNESS WHEREOF, the parties hereto have duly executed and delivered this Employment Agreement as of the date first above written.
18
LHC GROUP, INC.
EXECUTIVE:
/s/ Keith G. Myers -------------------------- Keith G. Myers |
EXHIBIT A
Form of Release
THIS RELEASE ("Release") is granted effective as of the______day of ________, 20__ , by_______("Executive") in favor of LHC Group, Inc. (the "Company"). This is the Release referred to that certain Employment Agreement effective as of ________, 200_ by and between the Company and Executive (the "Employment Agreement"), with respect to which this Release is an integral part.
FOR AND IN CONSIDERATION of the payments and benefits provided by
Section 8 of the Employment Agreement and the Company's other promises and
covenants as recited in the Employment Agreement, the receipt and sufficiency of
which are hereby acknowledged, Executive, for himself, his successors and
assigns, now and forever hereby releases and discharges the Company and all its
past and present officers, directors, stockholders, employees, agents, parent
corporations, predecessors, subsidiaries, affiliates, estates, successors,
assigns, benefit plans, consultants, administrators, and attorneys (hereinafter
collectively referred to as "Releasees") from any and all claims, charges,
actions, causes of action, sums of money due, suits, debts, covenants,
contracts, agreements, promises, demands or liabilities (hereinafter
collectively referred to as "Claims") whatsoever, in law or in equity, whether
known or unknown, which Executive ever had or now has from the beginning of time
up to the date this Release ("Release") is executed, including, but not limited
to, claims under the Age Discrimination in Employment Act, as amended by the
Older Workers Benefit Protection Act, Title VII of the Civil Rights Act of 1964
(and all of its amendments), the Americans with Disabilities Act, as amended, or
any other federal or state statutes, all tort claims, all claims for wrongful
employment termination or breach of contract, and any other claims which
Executive has, had, or may have against the Releasees on account of or arising
out of Executive's employment with or termination from the Company; provided,
however, that nothing contained in this Release shall in any way diminish or
impair (i) any rights of Executive to the benefits conferred or referenced in
the Employment Agreement or Executive's Retention Bonus Agreement with the
Company, (ii) any rights to indemnification that may exist from time to time
under the Company's bylaws, certificate of incorporation, Delaware law or
otherwise, or (iii) Executive's ability to raise an affirmative defense in
connection with any lawsuit or other legal claim or charge instituted or
asserted by the Company against Executive.
Without limiting the generality of the foregoing, Executive hereby acknowledges and covenants that in consideration for the sums being paid to him he has knowingly waived any right or opportunity to assert any claim that is in any way connected with any employment relationship or the termination of any employment relationship which existed between the Company and Executive. Executive further understands and agrees that he has knowingly relinquished, waived and forever released any and all remedies arising out of the aforesaid employment relationship or the termination thereof, including, without limitation, claims for backpay, front pay, liquidated damages, compensatory damages, general damages, special damages, punitive damages, exemplary damages, costs, expenses and attorneys' fees.
Executive specifically acknowledges and agrees that he has knowingly and voluntarily released the Company and all other Releasees from any and all claims arising under the Age Discrimination in Employment Act ("ADEA"), 29 U.S.C. Section 621, et seq., which Executive ever had or now has from the beginning of time up to the date this Release is executed, including but not limited to those claims which are in any way connected with any employment relationship or
the termination of any employment relationship which existed between the Company and Executive. Executive further acknowledges and agrees that he has been advised to consult with an attorney prior to executing this Release and that he has been given twenty-one (21) days to consider this Release prior to its execution. Executive also understands that he may revoke this Release at any time within seven (7) days following its execution. Executive understands, however, that this Release shall not become effective and that none of the consideration described above shall be paid to him until the expiration of the seven-day revocation period.
Executive agrees never to seek reemployment or future employment with the Company or any of the other Releasees.
Executive acknowledges that the terms of this Release must be kept confidential. Accordingly, Executive agrees not to disclose or publish to any person or entity, except as required by law or as necessary to prepare tax returns, the terms and conditions or sums being paid in connection with this Release.
It is understood and agreed by Executive that the payment made to him is not to be construed as an admission of any liability whatsoever on the part of the Company or any of the other Releasees, by whom liability is expressly denied.
This Release is executed by Executive voluntarily and is not based upon any representations or statements of any kind made by the Company or any of the other Releasees as to the merits, legal liabilities or value of his claims. Executive further acknowledges that he has had a full and reasonable opportunity to consider this Release and that he has not been pressured or in any way coerced into executing this Release.
Executive acknowledges and agrees that this Release may not be revoked at any time after the expiration of the seven-day revocation period and that he will not institute any suit, action, or proceeding, whether at law or equity, challenging the enforceability of this Release. Executive further acknowledges and agrees that, with the exception of an action to challenge his waiver of claims under the ADEA, he shall not ever attempt to challenge the terms of this Release, attempt to obtain an order declaring this Release to be null and void, or institute litigation against the Company or any other Releasee based upon a claim which is covered by the terms of the release contained herein, without first repaying all monies paid to him under Section 8 of the Employment Agreement. Furthermore, with the exception of an action to challenge his waiver of claims under the ADEA, if Executive does not prevail in an action to challenge this Release, to obtain an order declaring this Release to be null and void, or in any action against the Company or any other Releasee based upon a claim which is covered by the release set forth herein, Executive shall pay to the Company and/or the appropriate Releasee all their costs and attorneys' fees incurred in their defense of Executive's action.
This Release and the rights and obligations of the parties hereto shall be governed and construed in accordance with the laws of the State of Georgia. If any provision hereof is unenforceable or is held to be unenforceable, such provision shall be fully severable, and this document and its terms shall be construed and enforced as if such unenforceable provision had never comprised a part hereof, the remaining provisions hereof shall remain in full force and effect, and the court construing the provisions shall add as a part hereof a provision as similar in terms and effect to such unenforceable provision as may be enforceable, in lieu of the unenforceable provision.
This document contains all terms of the Release and supersedes and invalidates any previous agreements or contracts. No representations, inducements, promises or agreements, oral or otherwise, which are not embodied herein shall be of any force or effect.
IN WITNESS WHEREOF, the undersigned acknowledges that he has read these three pages and he sets his hand and seal this________day of ____________, 20__.
Sworn to and subscribed
before me this _____ day of
_____________, 20__.
My Commission Expires:
EXHIBIT B
Restricted Territory
EXHIBIT 10.7
EMPLOYMENT AGREEMENT
BETWEEN
R. BARR BROWN
AND
LHC GROUP, INC.
EMPLOYMENT AGREEMENT
1. Effective Date.............................................................1 2. Employment and Directorship................................................1 3. Employment Period..........................................................1 4. Extent of Service..........................................................1 5. Compensation and Benefits..................................................2 (a) Base Salary.....................................................2 (b) Incentive, Savings and Retirement Plans.........................2 (c) Welfare Benefit Plans...........................................2 (d) Expenses........................................................2 (e) Fringe Benefits.................................................3 (f) Vacation........................................................3 (g) Office and Support Staff........................................3 6. Change of Control..........................................................3 7. Termination of Employment..................................................4 (a) Death or Retirement.............................................4 (b) Disability......................................................4 (c) Termination by the Company......................................5 (d) Termination by Executive........................................5 (e) Notice of Termination...........................................5 (f) Date of Termination.............................................6 8. Obligations of the Company upon Termination................................6 (a) Termination by Executive for Good Reason; Termination by the Company Other Than for Cause or Disability...................................................6 (b) Death, Disability or Retirement.................................8 (c) Cause or Voluntary Termination without Good Reason..........................................................8 (d) Expiration of Employment Period.................................8 (e) Resignations....................................................8 9. Non-exclusivity of Rights.................................................8 10. Full Settlement; No Obligation to Mitigate................................8 11. Certain Additional Payments by the Company................................9 |
12. Costs of Enforcement.....................................................11 13. Representations and Warranties...........................................11 14. Restrictions on Conduct of Executive.....................................11 (a) General..........................................................11 (b) Definitions......................................................11 (c) Restrictive Covenants............................................13 (d) Enforcement of Restrictive Covenants.............................15 15. Arbitration..............................................................16 16. Assignment and Successors................................................16 17. Miscellaneous............................................................16 |
EMPLOYMENT AGREEMENT
THIS EMPLOYMENT AGREEMENT (this "Agreement") is made and entered into this ________ day of January, 2005 by and between LHC Group, Inc., a Delaware corporation (the "Company"), and R. Barr Brown ("Executive"), to be effective as of the Effective Date, as defined in Section 1.
BACKGROUND
Executive currently serves as Senior Vice President and Chief Financial Officer of the Company. The Company desires to continue to engage Executive in such capacity from and after the Effective Date, in accordance with the terms of this Agreement. Executive is willing to serve as such in accordance with the terms and conditions of this Agreement.
NOW, THEREFORE, in consideration of the foregoing and of the mutual covenants and agreements set forth herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:
1. Effective Date. The effective date of this Agreement (the "Effective Date") shall be the effective date of a registration statement on Form S-l for the initial public offering of the common stock of the Company.
2. Employment. Executive is hereby employed on the Effective Date as Senior Vice President and Chief Financial Officer of the Company. In his capacity as Senior Vice President and Chief Financial Officer of the Company, Executive shall have the duties, responsibilities and authority commensurate with such position as shall be assigned to him by the Chief Executive Officer and/or the Board of Directors of the Company. In his capacity as Senior Vice President and Chief Financial Officer of the Company, Executive will report directly to the Chief Executive Officer of the Company.
3. Employment Period. Unless earlier terminated herein in accordance with Section 7 hereof, Executive's employment shall be for a three year term, beginning on the Effective Date and ending on the third anniversary of the Effective Date (the "Employment Period"). Beginning on the third anniversary of the Effective Date and on each subsequent anniversary of the Effective Date, the Employment Period shall, without further action by Executive or the Company, be extended by an additional one-year period; provided, however, that either the Company or the Executive may, by notice to the other given at least sixty (60) days prior to the scheduled expiration of the Employment Period, cause the Employment Period to cease to extend automatically. Upon such notice, the Employment Period shall terminate upon the expiration of the then-current term, including any prior extensions.
4. Extent of Service. During the Employment Period, and excluding any periods of vacation, holiday, sick leave and Company-approved leave of absence to which Executive is entitled in accordance with Company policies, Executive agrees to devote substantially all of his business time, attention, skill and efforts exclusively to the faithful performance of his duties hereunder. It shall not be a violation of this Agreement for Executive to (i) devote reasonable time to charitable or community activities, (ii) serve on corporate, civic, educational or charitable boards or committees, subject to the Company's standards of business conduct or other code of ethics, (iii) deliver lectures or fulfill speaking engagements from time to time on an infrequent basis, and/or (iv) manage personal business interests and investments, subject to the Company's standards of business conduct or other code of ethics, and so long as such activities do not
interfere in a material manner or on a routine basis with the performance of Executive's responsibilities under this Agreement.
5. Compensation and Benefits.
(a) Base Salary. During the Employment Period, the Company will pay to Executive base salary at the rate of U.S. $250,000 per year ("Base Salary"), less normal withholdings, payable in approximately equal bi-weekly or other installments as are or become customary under the Company's payroll practices for its employees from time to time. The compensation committee of the Board of Directors of the Company (or the full Board, if there is no compensation committee) shall review Executive's Base Salary annually and may increase (but not decrease) Executive's Base Salary from year to year. Such adjusted salary then shall become Executive's Base Salary for purposes of this Agreement. The annual review of Executive's salary by the Board will consider, among other things, Executive's own performance, and the Company's performance.
(b) Incentive, Savings and Retirement Plans. During the Employment Period, Executive shall be entitled to participate in all incentive, savings and retirement plans, practices, policies and programs available to senior executive officers of the Company ("Peer Executives"), and on the same basis as such Peer Executives. Without limiting the foregoing, the following shall apply:
(i) during the Employment Period, Executive will be entitled to participate in the Company's executive bonus plan, pursuant to which he will have an opportunity to receive an annual cash bonus based upon the achievement of performance goals established from year to year by the compensation committee of the Board of Directors of the Company (such bonus earned at the stated "goal" level of achievement being referred to herein as the "Target Bonus"); and
(ii) during the Employment Period, Executive will be eligible for grants, under the Company's long-term incentive plan or plans, of stock options and/or restricted stock awards (or such other stock-based awards as the Company makes to Peer Executives), having terms and determined in the same manner as awards to other Peer Executives, unless the Executive consents to a different type of award or different terms of such award than are applicable to other Peer Executives. Nothing herein requires the Board of Directors to make grants of options or other awards in any year.
(c) Welfare Benefit Plans. During the Employment Period, Executive and Executive's eligible dependents shall be eligible for participation in, and shall receive all benefits under, the welfare benefit plans, practices, policies and programs provided by the Company (including, without limitation, medical, prescription drug, dental, disability, employee life, dependent life, accidental death and travel accident insurance plans and programs) ("Welfare Plans") to the extent available to other Peer Executives.
(d) Expenses. During the Employment Period, Executive shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by Executive in the course of performing his duties and responsibilities under this Agreement, in accordance with the policies, practices and procedures of the Company to the extent available to other Peer Executives with respect to travel, entertainment and other business expenses.
(e) Fringe Benefits. During the Employment Period, Executive shall be entitled to fringe benefits in accordance with the plans, practices, programs and policies of the Company available to other Peer Executives.
(f) Vacation. During the Employment Period, Executive will be entitled to such paid vacation time as may be provided from time to time under any plans, practices, programs and policies of the Company available to other Peer Executives.
(g) Office and Support Staff. During the Employment Period, Executive will be entitled to office, furnishings and equipment of similar type and quality made available to other Peer Executives. During the Employment Period, Executive will be entitled to secretarial and other assistance reasonably necessary for the performance of his duties and responsibilities.
6. Change of Control. For the purposes of this Agreement, a "Change of Control" shall mean the occurrence of any of the following events:
(a) individuals who, on the Effective Date, constitute the Board of Directors of the Company (the "Incumbent Directors") cease for any reason to constitute at least a majority of such Board, provided that any person becoming a director after the Effective Date and whose election or nomination for election was approved by a vote of at least a majority of the Incumbent Directors then on the Board shall be an Incumbent Director; provided, however, that no individual initially elected or nominated as a director of the Company as a result of an actual or threatened election contest with respect to the election or removal of directors ("Election Contest") or other actual or threatened solicitation of proxies or consents by or on behalf of any "person" (such term for purposes of this Section 6 being as defined in Section 3(a)(9) of the Securities Exchange Act of 1934 (the "Exchange Act") and as used in Section 13(d)(3) and 14(d)(2) of the Exchange Act) other than the Board ("Proxy Contest"), including by reason of any agreement intended to avoid or settle any Election Contest or Proxy Contest, shall be deemed an Incumbent Director; or
(b) any person is or becomes a "beneficial owner" (as defined in
Rule 13d-3 under the Exchange Act), directly or indirectly, of
either (i) 35% or more of the then-outstanding shares of common
stock of the Company ("Company Common Stock") or (ii) securities of
the Company representing 35% or more of the combined voting power of
the Company's then outstanding securities eligible to vote for the
election of directors (the "Company Voting Securities"); provided,
however, that for purposes of this paragraph (b), the following
acquisitions of Company Common Stock or Company Voting Securities
shall not constitute a Change of Control: (A) an acquisition
directly from the Company, (B) an acquisition by the Company or a
subsidiary of the Company, (C) an acquisition by any employee
benefit plan (or related trust) sponsored or maintained by the
Company or any subsidiary of the Company, or (D) an acquisition
pursuant to a Non-Qualifying Transaction (as defined in paragraph
(c) below); or
(c) the consummation of a recapitalization, reorganization, merger, consolidation, statutory share exchange or similar form of transaction involving the Company or a subsidiary of the Company (a "Reorganization"), or the sale or other disposition of all or substantially all of the Company's assets (a "Sale") or the acquisition of assets or stock of another entity (an "Acquisition"), unless immediately following such Reorganization, Sale or Acquisition: (A) all or substantially all of the individuals
and entities who were the beneficial owners, respectively, of the
outstanding Company Common Stock and outstanding Company Voting
Securities immediately prior to such Reorganization, Sale or
Acquisition beneficially own, directly or indirectly, more than 50%
of, respectively, the then outstanding shares of common stock and
the combined voting power of the then outstanding voting securities
entitled to vote generally in the election of directors, as the case
may be, of the entity resulting from or surviving such
Reorganization, Sale or Acquisition (including, without limitation,
an entity which as a result of such transaction owns the Company or
all or substantially all of the Company's assets or stock either
directly or through one or more subsidiary entities, the "Surviving
Entity") in substantially the same proportions as their ownership,
immediately prior to such Reorganization, Sale or Acquisition, of
the outstanding Company Common Stock and the outstanding Company
Voting Securities, as the case may be, and (B) no person (other than
(x) the Company or any subsidiary of the Company, (y) the Surviving
Entity or its ultimate parent entity, or (z) any employee benefit
plan (or related trust) sponsored or maintained by any of the
foregoing) is the beneficial owner, directly or indirectly, of 35%
or more of the total common stock or 35% or more of the total voting
power of the outstanding voting securities eligible to elect
directors of the Surviving Entity, and (C) at least a majority of
the members of the board of directors of the Surviving Entity were
Incumbent Directors at the time of the Board's approval of the
execution of the initial agreement providing for such
Reorganization, Sale or Acquisition (any Reorganization, Sale or
Acquisition which satisfies all of the criteria specified in (A),
(B) and (C) above shall be deemed to be a "Non-Qualifying
Transaction"); or
(d) approval by the members or stockholders of the Company, as the case may be, of a complete liquidation or dissolution of the Company.
7. Termination of Employment.
(a) Death or Retirement. Executive's employment shall terminate automatically upon Executive's death or Retirement during the Employment Period. For purposes of this Agreement, "Retirement" shall mean normal retirement as defined in the Company's then-current retirement plan, or if there is no such retirement plan, "Retirement" shall mean voluntary termination after age 65 with at least ten years of service.
(b) Disability. If the Company determines in good faith that the Disability (as defined below) of Executive has occurred during the Employment Period, it may give to Executive written notice of its intention to terminate Executive's employment. In such event, Executive's employment with the Company shall terminate effective on the 30th day after receipt of such written notice by Executive (the "Disability Effective Date"), provided that, within the 30 days after such receipt, Executive shall not have returned to full-time performance of Executive's duties. For purposes of this Agreement, "Disability" shall have the same meaning as provided in the long-term disability plan or policy maintained by the Company and covering Executive. If no such long-term disability plan or policy is maintained, "Disability" shall mean the inability of Executive, as determined by the Board, to perform the essential functions of his regular duties and responsibilities, with or without reasonable accommodation, due to a medically determinable physical or mental illness which has lasted (or can reasonably be expected to last) for a period of six consecutive months.
(c) Termination by the Company. The Company may terminate Executive's employment during the Employment Period with or without Cause. For purposes of this Agreement, "Cause" shall mean:
(i) the continued failure of Executive to perform substantially Executive's duties with the Company (other than any such failure resulting from incapacity due to physical or mental illness, or following Executive's delivery of notice of termination for Good Reason, and specifically excluding any failure by Executive, after reasonable efforts, to meet performance expectations), after a written demand for substantial performance is delivered to Executive by the Board which specifically identifies the manner in which the Board believes that Executive has not substantially performed Executive's duties, or
(ii) the engaging by Executive in illegal conduct or gross misconduct which is injurious to the Company, or
(iii) the conviction of Executive, or a plea of guilty or nolo contendere by Executive, to a felony or other crime involving moral turpitude.
(d) Termination by Executive. Executive's employment may be terminated by Executive for Good Reason or no reason. For purposes of this Agreement, unless written consent of Executive is obtained, "Good Reason" shall mean:
(i) the assignment to Executive of duties inconsistent in material respect with Executive's position (including status, offices, titles and reporting requirements), authority, duties or responsibilities as in effect on the Effective Date, or a material diminution in such position, authority, duties or responsibilities, excluding for this purpose an isolated, insubstantial and inadvertent action not taken in bad faith and which is remedied by the Company promptly after receipt of notice thereof given by Executive;
(ii) a reduction by the Company in Executive's Base Salary or Target Bonus as in effect on the Effective Date or, with respect to Executive's Base Salary, as the same may be increased from time to time;
(iii) any failure by the Company to comply with and satisfy 16(c) of this Agreement; or
(v) the material breach by the Company of any other provision of this Agreement.
Any claim of "Good Reason" under this Agreement shall be communicated by Executive to the Company in writing, which writing shall specifically identify the factual details concerning the event(s) giving rise to Executive's claim of Good Reason under this Section 7(d). The Company shall have an opportunity to cure any claimed event of Good Reason within 30 days of such notice from Executive.
(e) Notice of Termination. Any termination by the Company for Cause, or by Executive for Good Reason, shall be communicated by Notice of Termination to the other party hereto given in accordance with Section 17(f) of this Agreement. For purposes of this Agreement, a "Notice of Termination" means a written notice which (i) indicates the specific termination provision in this Agreement relied upon, (ii) to the extent applicable, sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of
Executive's employment under the provision so indicated, and (iii) specifies the termination date. The failure by Executive or the Company to set forth in the Notice of Termination any fact or circumstance which contributes to a showing of Good Reason or Cause shall not waive any right of Executive or the Company, respectively, hereunder or preclude Executive or the Company, respectively, from asserting such fact or circumstance in enforcing Executive's or the Company's rights hereunder.
(f) Date of Termination. "Date of Termination" means (i) if Executive's employment is terminated by the Company for Cause, or by Executive for Good Reason, the date of receipt of the Notice of Termination or a date within 30 days after receipt of the Notice of Termination, as specified in such notice, (ii) if Executive's employment is terminated by the Company other than for Cause or Disability, the Date of Termination shall be the date of receipt of the Notice of Termination or a date within 90 days after receipt of the Notice of Termination, as specified in such notice, (iii) if Executive's employment is terminated by reason of death or Disability, the Date of Termination shall be the date of death of Executive or the Disability Effective Date, as the case may be, and (iv) if Executive's employment is terminated by Executive without Good Reason, the Date of Termination shall be 60 days following the Company's receipt of the Notice of Termination, unless the Company specifies an earlier Date of Termination.
8. Obligations of the Company upon Termination.
(a) Termination by Executive for Good Reason; Termination by the Company Other Than for Cause or Disability. If, during the Employment Period, the Company shall terminate Executive's employment other than for Cause or Disability, or Executive shall terminate employment for Good Reason within a period of 90 days after the occurrence of the event giving rise to Good Reason, then and, with respect to the payments and benefits described in clauses (i)(B) and (ii) below, only if Executive executes a Release in substantially the form of Exhibit A hereto (the "Release"):
(i) the Company shall provide to Executive in a single lump sum cash payment within 30 days after the Date of Termination, or if later, within five days after the Release becomes effective and nonrevocable, the aggregate of the following amounts:
A. the sum of the following amounts, to the extent not previously paid to Executive (the "Accrued Obligations"): (1) Executive's Base Salary through the Date of Termination, (2) a pro-rata bonus for the year in which the Date of Termination occurs, computed as the product of (x) Executive's Target Bonus for such year and (y) a fraction, the numerator of which is the number of days in the current fiscal year through the Date of Termination, and the denominator of which is 365, (3) any accrued pay in lieu of unused vacation (in accordance with the Company's vacation policy), and (4) unless Executive has a later payout date that is required in connection with the terms of a deferral plan or agreement, any vested compensation previously deferred by Executive (together with any amount equivalent to accrued interest or earnings thereon); and
B. a severance payment as determined pursuant to clause (x) or (y) below, as applicable:
(x) if the Date of Termination occurs before, or more than two years after, the occurrence of a Change of Control, the severance payment shall be the product of 24 (the "Regular Severance Factor") times one twelfth of the sum of
(1) Executive's Base Salary in effect as of the Date of Termination (ignoring any decrease in Executive's Base Salary unless consented to by Executive), and (2) the greater of the average of the annual bonuses earned by Executive for the two fiscal years in which annual bonuses were paid immediately preceding the year in which the Date of Termination occurs, or Executive's Target Bonus for the year in which the Date of Termination occurs; or
(y) if the Date of Termination occurs within two years after the occurrence of a Change of Control, the severance payment shall be the product of 30 (the "Change of Control Severance Factor") times one twelfth of the sum of (1) Executive's Base Salary in effect as of the Date of Termination, and (2) the greater of the average of the annual bonuses earned by Executive for the two fiscal years in which annual bonuses were paid immediately preceding the year in which the Date of Termination occurs, or Executive's Target Bonus for the year in which the Date of Termination occurs; and
(ii) the Company shall continue to provide, for a number of months equal to the Regular Severance Factor or the Change of Control Severance Factor (determined in Section 8(a)(i)(B)(x) or (y) above, as applicable) after Executive's Date of Termination (the "Welfare Benefits Continuation Period"), or such longer period as may be provided by the terms of the appropriate plan, program, practice or policy, any group health benefits to which Executive and/or Executive's eligible dependents would otherwise be entitled to continue under COBRA, or benefits substantially equivalent to those group health benefits which would have been provided to them in accordance with the Welfare Plans described in Section 5(c) of this Agreement if Executive's employment had not been terminated, provided, however, that if Executive becomes employed with another employer (including self-employment) and receives group health benefits under another employer provided plan, the Company's obligation to provide group health benefits described herein shall cease, except as otherwise provided by law and provided, further, that the Welfare Benefits Continuation Period shall run concurrently with any period for which Executive is eligible to elect health coverage under COBRA; and
(iii) all grants of stock options and other equity awards granted by the Company and held by Executive as of the Date of Termination will become immediately vested and exercisable as of the Date of Termination and, to the extent necessary, this Agreement is hereby deemed an amendment of any such outstanding stock option or other equity award; and
(iv) to the extent not theretofore paid or provided, the Company shall timely pay or provide to Executive any other amounts or benefits required to be paid or provided or which Executive is eligible to receive under any plan, program, policy or practice of the Company to the extent provided to Peer Executives prior to the Date of Termination (such other amounts and benefits shall be hereinafter referred to as the "Other Benefits").
If Executive's employment is terminated by the Company without Cause
prior to the occurrence of a Change in Control and if it can reasonably be
shown that Executive's termination (i) was at the direction or request of a
third party that had taken steps reasonably calculated to effect a Change in
Control after such termination, or (ii) otherwise occurred in anticipation of a
Change in Control, and in either case a Change in Control as defined hereunder
does, in fact, occur, then Executive shall have the rights described in this
Section 8(a) as if the Change in Control had occurred on the date immediately
preceding the Date of Termination.
Executive acknowledges and agrees that the receipt of severance benefits provided in this Section 8(a) constitutes consideration for the restrictions on the conduct of Executive contained in Section 14 of this Agreement.
(b) Death, Disability or Retirement. If Executive's employment is terminated by reason of his death, Disability or Retirement during the Employment Period, this Agreement shall terminate without further obligations to Executive or his estate, beneficiaries or legal representatives, other than for payment of Accrued Obligations and the timely payment or provision of Other Benefits. Accrued Obligations shall be paid to Executive or his estate, beneficiary or legal representative, as applicable, in a lump sum in cash within 30 days of the Date of Termination. With respect to the provision of Other Benefits, the term Other Benefits as used in this Section 8(b) shall include, without limitation, and Executive or his estate, beneficiaries or legal representatives, as applicable, shall be entitled to receive, benefits under such plans, programs, practices and policies relating to death, disability or retirement benefits, if any, as are applicable to Executive or his family on the Date of Termination.
(c) Cause or Voluntary Termination without Good Reason. If Executive's employment shall be terminated for Cause during the Employment Period, or if Executive voluntarily terminates employment during the Employment Period without Good Reason, this Agreement shall terminate without further obligations to Executive, other than for payment of Accrued Obligations (excluding the pro-rata bonus described in clause 2 of Section 8(a)(i)(A)) and the timely payment or provision of Other Benefits.
(d) Expiration of Employment Period. If Executive's employment shall be terminated due to the normal expiration of the Employment Period, this Agreement shall terminate without further obligations to Executive, other than for payment of Accrued Obligations and the timely payment or provision of Other Benefits.
(e) Resignations. Termination of Executive's employment for any reason whatsoever shall constitute Executive's resignation from the Board of Directors of the Company and resignation as an officer of the Company, its subsidiaries and affiliates.
9. Non-exclusivity of Rights. Nothing in this Agreement shall prevent or limit Executive's continuing or future participation in any employee benefit plan, program, policy or practice provided by the Company and for which Executive may qualify, except as specifically provided herein. Amounts which are vested benefits or which Executive is otherwise entitled to receive under any employee benefit plan, policy, practice or program of the Company, its subsidiaries or any of its affiliated companies at or subsequent to the Date of Termination shall be payable in accordance with such plan, policy, practice or program except as explicitly modified by this Agreement.
10. Full Settlement; No Obligation to Mitigate. The Company's obligation to make the payments provided for in this Agreement and otherwise to perform its obligations hereunder shall not be affected by any set-off, counterclaim, recoupment, defense or other claim, right or action which the Company may have against Executive or others. In no event shall Executive be obligated to seek other employment or take any other action by way of mitigation of the amounts payable to Executive under any of the provisions of this Agreement and, except as explicitly provided herein, such amounts shall not be reduced whether or not Executive obtains other employment.
11. Certain Additional Payments by the Company.
(a) Anything in this Agreement to the contrary notwithstanding and
except as set forth below, in the event it shall be determined that any payment
or distribution by the Company to or for the benefit of Executive (whether paid
or payable or distributed or distributable pursuant to the terms of this
Agreement or otherwise, but determined without regard to any additional
payments required under this Section 11) (a "Payment") would be subject to the
excise tax imposed by Section 4999 of the Internal Revenue Code of 1986, as
amended (the "Code") or any interest or penalties are incurred by Executive
with respect to such excise tax (such excise tax, together with any such
interest and penalties, are hereinafter collectively referred to as the "Excise
Tax"), then Executive shall be entitled to receive an additional payment (a
"Gross-Up Payment") in an amount such that after payment by Executive of all
taxes (including any interest or penalties imposed with respect to such taxes),
including, without limitation, any income taxes (and any interest and penalties
imposed with respect thereto) and Excise Tax imposed upon the Gross-Up Payment,
Executive retains an amount of the Gross-Up Payment equal to the Excise Tax
imposed upon the Payments. Notwithstanding the foregoing provisions of this
Section 11(a), if it shall be determined that Executive is entitled to a
Gross-Up Payment, but that Executive, after taking into account the Payments
and the Gross-Up Payment, would not receive a net after-tax benefit of at least
$50,000 (taking into account both income taxes and any Excise Tax) as compared
to the net after-tax proceeds to Executive resulting from an elimination of the
Gross-Up Payment and a reduction of the Payments, in the aggregate, to an
amount (the "Reduced Amount") such that the receipt of Payments would not give
rise to any Excise Tax, then no Gross-Up Payment shall be made to Executive and
the Payments, in the aggregate, shall be reduced to the Reduced Amount.
Executive may select the Payments to be limited or reduced.
(b) Subject to the provisions of Section 11(c), all determinations required to be made under this Section 11, including whether and when a Gross-Up Payment is required and the amount of such Gross-Up Payment and the assumptions to be used in arriving at such determination, shall be made by a certified public accounting firm selected by Executive (other than the Company's regular accounting firm) and reasonably acceptable to the Company (the "Accounting Firm") which shall provide detailed supporting calculations both to the Company and Executive within 15 business days of the receipt of notice from Executive that there has been a Payment, or such earlier time as is reasonably requested by the Company. All fees and expenses of the Accounting Firm shall be borne solely by the Company. Any Gross-Up Payment, as determined pursuant to this Section 11, shall be paid by the Company to Executive within five days of the receipt of the Accounting Firm's determination. Any determination by the Accounting Firm shall be binding upon the Company and Executive. As a result of the uncertainty in the application of Section 4999 of the Code at the time of the initial determination by the Accounting Firm hereunder, it is possible that Gross-Up Payments which will not have been made by the Company should have been made ("Underpayment"), consistent with the calculations required to be made hereunder. In the event that the Company exhausts its remedies pursuant to Section ll(c) and Executive thereafter is required to make a payment of any Excise Tax, the Accounting Firm shall determine the amount of the Underpayment that has occurred and any such Underpayment shall be promptly paid by the Company to or for the benefit of Executive.
(c) Executive shall notify the Company in writing of any claim by the Internal Revenue Service that, if successful, would require the payment by the Company of a Gross-Up Payment (or an additional Gross-Up Payment). Such notification shall be given as soon as practicable but no later than ten business days after Executive is informed in writing of such claim and shall apprise the Company of the nature of such claim and the date on which such
claim is requested to be paid. Executive shall not pay such claim prior to the expiration of the 30-day period following the date on which he gives such notice to the Company (or such shorter period ending on the date that any payment of taxes with respect to such claim is due). If the Company notifies Executive in writing prior to the expiration of such period that it desires to contest such claim, Executive shall:
(i) give the Company any information reasonably requested by the Company relating to such claim,
(ii) take such action in connection with contesting such claim as the Company shall reasonably request in writing from time to time, including, without limitation, accepting legal representation with respect to such claim by an attorney reasonably selected by the Company,
(iii) cooperate with the Company in good faith in order effectively to contest such claim, and
(iv) permit the Company to participate in any proceedings relating to such claim;
provided, however, that the Company shall bear and pay directly all costs and expenses (including additional interest and penalties) incurred in connection with such contest and shall indemnify and hold Executive harmless, on an after-tax basis, for any Excise Tax or income tax (including interest and penalties with respect thereto) imposed as a result of such representation and payment of costs and expenses. Without limitation of the foregoing provisions of this Section 11(c), the Company shall control all proceedings taken in connection with such contest (to the extent applicable to the Excise Tax and the Gross-Up Payment) and, at its sole option, may pursue or forgo any and all administrative appeals, proceedings, hearings and conferences with the taxing authority in respect of such claim and may, at its sole option, either direct Executive to pay the tax claimed and sue for a refund or contest the claim in any permissible manner, and Executive agrees to prosecute such contest to a determination before any administrative tribunal, in a court of initial jurisdiction and in one or more appellate courts, as the Company shall determine; provided, however, that if the Company directs Executive to pay such claim and sue for a refund, the Company shall advance the amount of such payment to Executive, on an interest-free basis and shall indemnify and hold Executive harmless, on an after-tax basis, from any Excise Tax or income tax (including interest or penalties with respect thereto) imposed with respect to such advance or with respect to any imputed income with respect to such advance; and further provided that any extension of the statute of limitations relating to payment of taxes for the taxable year of Executive with respect to which such contested amount is claimed to be due is limited solely to such contested amount. Furthermore, the Company's control of the contest shall be limited to issues with respect to which a Gross-Up Payment would be payable hereunder and Executive shall be entitled to settle or contest, as the case may be, any other issue raised by the Internal Revenue Service or any other taxing authority.
(d) If, after the receipt by Executive of an amount advanced by the Company pursuant to Section ll(c), Executive becomes entitled to receive any refund with respect to such claim, Executive shall (subject to the Company's complying with the requirements of Section 11(c)) promptly pay to the Company the amount of such refund (together with any interest paid or credited thereon after taxes applicable thereto). If, after the receipt by Executive of an amount advanced by the Company pursuant to Section 11(c), a determination is made that Executive shall not be entitled to any refund with respect to such claim and the Company does not notify
Executive in writing of its intent to contest such denial of refund prior to the expiration of 30 days after such determination, then such advance shall be forgiven and shall not be required to be repaid and the amount of such advance shall offset, to the extent thereof, the amount of Gross-Up Payment required to be paid.
12. Costs of Enforcement. In any action taken in good faith relating to the enforcement of this Agreement or any provision herein, Executive shall be entitled to reimbursement for any and all costs and expenses incurred by him in enforcing or establishing his rights thereunder, including, without limitation, reasonable attorneys' fees, whether suit be brought or not, and whether or not incurred in arbitration, trial, bankruptcy or appellate proceedings, but only if and to the extent Executive is successful in asserting such rights. Executive shall also be entitled to be paid all reasonable legal fees and expenses, if any, incurred in connection with any tax audit or proceeding to the extent attributable to the application of Section 4999 of the Internal Revenue Code to any payment or benefit hereunder.
13. Representations and Warranties. Executive hereby represents and warrants to the Company that Executive is not a party to, or otherwise subject to, any covenant not to compete with any person or entity, and Executive's execution of this Agreement and performance of his obligations hereunder will not violate the terms or conditions of any contract or obligation, written or oral, between Executive and any other person or entity.
14. Restrictions on Conduct of Executive.
(a) General. Executive and the Company understand and agree that the purpose of the provisions of this Section 14 is to protect legitimate business interests of the Company, as more fully described below, and is not intended to impair or infringe upon Executive's right to work, earn a living, or acquire and possess property from the fruits of his labor. Executive hereby acknowledges that Executive has received good and valuable consideration for the post-employment restrictions set forth in this Section 14 in the form of the compensation and benefits provided for herein. Executive hereby further acknowledges that the post-employment restrictions set forth in this Section 14 are reasonable and that they do not, and will not, unduly impair his ability to earn a living after the termination of this Agreement.
In addition, the parties acknowledge: (A) that Executive's services under this Agreement require unique expertise and talent in the provision of Competitive Services and that Executive will have substantial contacts with customers, suppliers, advertisers and vendors of the Company; (B) that pursuant to this Agreement, Executive will be placed in a position of trust and responsibility and he will have access to a substantial amount of Confidential Information and Trade Secrets and that the Company is placing him in such position and giving him access to such information in reliance upon his agreement not to solicit customers during the Restricted Period; (C) that due to Executive's unique experience and talent, the loss of Executive's services to the Company under this Agreement cannot reasonably or adequately be compensated solely by damages in an action at law; (D) that Executive is capable of competing with the Company; and (E) that Executive is capable of obtaining gainful, lucrative and desirable employment that does not violate the restrictions contained in this Agreement.
Therefore, Executive shall be subject to the restrictions set forth in this Section 14.
(b) Definitions. The following capitalized terms used in this
Section 14 shall have the meanings assigned to them below, which definitions
shall apply to both the singular and the plural forms of such terms:
"Competitive Services" means the business of providing post-acute healthcare services, including home-based services through home nursing agencies and hospices and facility-based services through long-term acute care hospitals and outpatient rehabilitation clinics.
"Confidential Information" means all information regarding the Company, its activities, business or clients that is the subject of reasonable efforts by the Company to maintain its confidentiality and that is not generally disclosed by practice or authority to persons not employed by the Company, but that does not rise to the level of a Trade Secret. "Confidential Information" shall include, but is not limited to, financial plans and data concerning the Company; management planning information; business plans; operational methods; market studies; marketing plans or strategies; product development techniques or plans; customer lists; customer files, data and financial information, details of customer contracts; current and anticipated customer requirements; identifying and other information pertaining to business referral sources; past, current and planned research and development; business acquisition plans; and new personnel acquisition plans. "Confidential Information" shall not include information that has become generally available to the public by the act of one who has the right to disclose such information without violating any right or privilege of the Company. This definition shall not limit any definition of "confidential information" or any equivalent term under state or federal law.
"Determination Date" means the date of termination of Executive's employment with the Company for any reason whatsoever or any earlier date (during the Employment Period) of an alleged breach of the Restrictive Covenants by Executive.
"Person " means any individual or any corporation, partnership, joint venture, limited liability company, association or other entity or enterprise.
"Principal or Representative" means a principal, owner, partner, stockholder, joint venturer, investor, member, trustee, director, officer, manager, employee, agent, representative or consultant.
"Protected Customers" means any Person to whom the Company has sold its products or services or solicited to sell its products or services, other than through general advertising targeted at consumers, during the 12 months prior to the Determination Date.
"Protected Employees" means employees of the Company who were employed by the Company or its affiliates at any time within six months prior to the Determination Date, other than those who were discharged by the Company or such affiliated employer without cause.
"Restricted Period" means the Employment Period plus 24 months (or the Employment Period plus 6 months if Executive's termination occurs within two years after the occurrence of a Change in Control); provided, however, that the Restricted Period shall end with respect to the covenants in clauses (ii) and (iii) of Section 14(c) on the 60th day after the Date of Termination in the event the Company breaches its obligation, if any, to make any payment required under Section 8(a)(i).
"Restricted Territory" means the geographical territory described on Exhibit B hereto.
"Restrictive Covenants" means the restrictive covenants contained in Section 14(c) hereof.
"Third Party Information" means confidential or proprietary information subject to a duty on the Company's and its affiliates' part to maintain the confidentiality of such information and to use it only for certain limited purposes.
"Trade Secret" means all information, without regard to form, including, but not limited to, technical or nontechnical data, a formula, a pattern, a compilation, a program, a device, a method, a technique, a drawing, a process, financial data, financial plans, product plans, distribution lists or a list of actual or potential customers, advertisers or suppliers which is not commonly known by or available to the public and which information: (A) derives economic value, actual or potential, from not being generally known to, and not being readily ascertainable by proper means by, other persons who can obtain economic value from its disclosure or use; and (B) is the subject of efforts that are reasonable under the circumstances to maintain its secrecy. Without limiting the foregoing, Trade Secret means any item of confidential information that constitutes a "trade secret(s)" under the common law or statutory law of the State of Delaware.
"Work Product" means all inventions, innovations, improvements, developments, methods, processes, programs, designs, analyses, drawings, reports, and all similar or related information (whether or not patentable) that relate to the Company's or its affiliates' actual or anticipated business, research and development, or existing or future products or services and that are conceived, developed, contributed to, made, or reduced to practice by Executive (either solely or jointly with others) while employed by the Company or its affiliates.
(c) Restrictive Covenants.
(i) Restriction on Disclosure and Use of Confidential Information and Trade Secrets. Executive understands and agrees that the Confidential Information and Trade Secrets constitute valuable assets of the Company and its affiliated entities, and may not be converted to Executive's own use. Accordingly, Executive hereby agrees that Executive shall not, directly or indirectly, at any time during the Restricted Period reveal, divulge, or disclose to any Person not expressly authorized by the Company any Confidential Information, and Executive shall not, directly or indirectly, at any time during the Restricted Period use or make use of any Confidential Information in connection with any business activity other than that of the Company. Throughout the term of this Agreement and at all times after the date that this Agreement terminates for any reason, Executive shall not directly or indirectly transmit or disclose any Trade Secret of the Company to any Person, and shall not make use of any such Trade Secret, directly or indirectly, for himself or for others, without the prior written consent of the Company. The parties acknowledge and agree that this Agreement is not intended to, and does not, alter either the Company's rights or Executive's obligations under any state or federal statutory or common law regarding trade secrets and unfair trade practices.
Anything herein to the contrary notwithstanding, Executive shall not be restricted from disclosing or using Confidential Information or any Trade Secret that is required to be disclosed by law, court order or other legal process; provided, however, that in the event disclosure is required by law, Executive shall provide the Company with prompt notice of such requirement so that the Company may seek an appropriate protective order prior to any such required disclosure by Executive.
Executive acknowledges that any and all Confidential Information is the exclusive property of the Company and agrees to deliver to the Company on the Date of Termination, or at any other time the Company may request in writing, any and all Confidential Information which he may then possess or have under his control in whatever form same may exist, including, but not by way of limitation, hard copy files, soft copy files, computer disks, and all copies thereof.
(ii) Nonsolicitation of Protected Employees. Executive understands and agrees that the relationship between the Company and each of its Protected Employees constitutes a valuable asset of the Company and may not be converted to Executive's own use. Accordingly, Executive hereby agrees that during the Restricted Period, Executive shall not directly or indirectly on Executive's own behalf or as a Principal or Representative of any Person or otherwise solicit or induce any Protected Employee to terminate his employment relationship with the Company or to enter into employment with any other Person.
(iii) Restriction on Relationships with Protected Customers.
Executive understands and agrees that the relationship between the Company and
each of its Protected Customers constitutes a valuable asset of the Company and
may not be converted to Executive's own use. Accordingly, Executive hereby
agrees that, during the Restricted Period and in the Restricted Territory,
Executive shall not, without the prior written consent of the Company, directly
or indirectly, on Executive's own behalf or as a Principal or Representative of
any Person, solicit, divert, take away or attempt to solicit, divert or take
away a Protected Customer for the purpose of providing or selling Competitive
Services; provided, however, that the prohibition of this covenant shall apply
only to Protected Customers with whom Executive had Material Contact on the
Company's behalf during the 12 months immediately preceding the Date of
Termination; and, provided further, that the prohibition of this covenant shall
not apply to the conduct of general advertising activities. For purposes of
this Agreement, Executive had "Material Contact" with a Protected Customer if
(a) he had business dealings with the Protected Customer on the Company's
behalf; (b) he was responsible for supervising or coordinating the dealings
between the Company and the Protected Customer; or (c) he obtained Trade
Secrets or Confidential Information about the customer as a result of his
association with the Company.
(iv) Ownership of Work Product. Executive acknowledges that the Work Product belongs to the Company or its affiliates and Executive hereby assigns, and agrees to assign, all of the Work Product to the Company or its affiliates. Any copyrightable work prepared in whole or in part by Executive in the course of his work for any of the foregoing entities shall be deemed a "work made for hire" under the copyright laws, and the Company or such affiliate shall own all rights therein. To the extent that any such copyrightable work is not a "work made for hire," Executive hereby assigns and agrees to assign to the Company or such affiliate all right, title, and interest, including without limitation, copyright in and to such copyrightable work. Executive shall promptly disclose such Work Product and copyrightable work to the Board and perform all actions reasonably requested by the Board (whether during or after the Employment Period) to establish and confirm the Company's or such affiliate's ownership (including, without limitation, assignments, consents, powers of attorney, and other instruments).
(v) Third Party Information. Executive understands that the Company and its affiliates will receive Third Party Information. During the Employment Period and thereafter, and without in any way limiting the provisions of Section 14(c)(i) above, Executive will hold Third Party Information in the strictest confidence and will not disclose to anyone (other than personnel of the Company or its affiliates who need to know such information in connection with
their work for the Company or its affiliates) or use, except in connection with his work for the Company or its affiliates, Third Party Information unless expressly authorized by a member of the Board (other than Executive) in writing.
(vi) Use of Information of Prior Employers. During the Employment Period, Executive will not improperly use or disclose any confidential information or trade secrets, if any, of any former employers or any other person to whom Executive has an obligation of confidentiality, and will not bring onto the premises of the Company or any of its affiliates any unpublished documents or any property belonging to any former employer or any other person to whom Executive has an obligation of confidentiality unless consented to by in writing the former employer or person. Executive will use in the performance of his duties only information which is (i) generally known and used by persons with training and experience comparable to Executive's and which is (x) common knowledge in the industry or (y) is otherwise legally in the public domain, (ii) is otherwise provided or developed by the Company or its affiliates or (iii) in the case of materials, property or information belonging to any former employer or other person to whom Executive has an obligation of confidentiality, approved for such use in writing by such former employer or person.
(d) Enforcement of Restrictive Covenants.
(i) Rights and Remedies Upon Breach. In the event Executive breaches, or threatens to commit a breach of, any of the provisions of the Restrictive Covenants, the Company shall have the right and remedy to enjoin, preliminarily and permanently, Executive from violating or threatening to violate the Restrictive Covenants and to have the Restrictive Covenants specifically enforced by any court or tribunal of competent jurisdiction, it being agreed that any breach or threatened breach of the Restrictive Covenants would cause irreparable injury to the Company and that money damages would not provide an adequate remedy to the Company. Such right and remedy shall be independent of any others and severally enforceable, and shall be in addition to, and not in lieu of, any other rights and remedies available to the Company at law or in equity.
(ii) Severability of Covenants. Executive acknowledges and agrees that the Restrictive Covenants are reasonable and valid in time and scope and in all other respects. The covenants set forth in this Agreement shall be considered and construed as separate and independent covenants. Should any part or provision of any covenant be held invalid, void or unenforceable, such invalidity, voidness or unenforceability shall not render invalid, void or unenforceable any other part or provision of this Agreement. If any portion of the foregoing provisions is found to be invalid or unenforceable because its duration, the territory, the definition of activities or the definition of information covered is considered to be invalid or unreasonable in scope, the invalid or unreasonable term shall be redefined, or a new enforceable term provided, such that the intent of the Company and Executive in agreeing to the provisions of this Agreement will not be impaired and the provision in question shall be enforceable to the fullest extent of the applicable laws.
(iii) Reformation. The parties hereunder agree that it is their intention that the Restrictive Covenants be enforced in accordance with their terms to the maximum extent possible under applicable law. The parties further agree that, in the event any tribunal of competent jurisdiction shall find that any provision hereof is not enforceable in accordance with its terms, the tribunal shall reform the Restrictive Covenants such that they shall be enforceable to the maximum extent permissible at law.
15. Arbitration. Any claim or dispute arising under or relating to this Agreement or the breach, termination, or validity of any term of this Agreement, including, but not by way of limitation, the legality and enforceability of the Restrictive Covenants, shall be subject to arbitration, and prior to commencing any court action, the parties agree that they shall arbitrate all controversies; provided, however, that nothing in this Section 15 shall prohibit the Company from exercising its right under Section 14(d)(i) to pursue injunctive remedies with respect to a breach or threatened breach of the Restrictive Covenants. The arbitration shall be conducted in Lafayette, Louisiana, in accordance with the Employment Dispute Rules of the American Arbitration Association and the Federal Arbitration Act, 9 U.S.C. Section 1, et. seq. The arbitrator(s) shall be authorized to award both liquidated and actual damages, in addition to injunctive relief, but no punitive damages. The arbitrator(s) may also award attorney's fees and costs, without regard to any restriction on the amount of such award under Delaware or other applicable law. Such an award shall be binding and conclusive upon the parties hereto, subject to 9 U.S.C. Section 10. Each party shall have the right to have the award made the judgment of a court of competent jurisdiction.
16. Assignment and Successors.
(a) This Agreement is personal to Executive and without the prior written consent of the Company shall not be assignable by Executive otherwise than by will or the laws of descent and distribution. This Agreement shall inure to the benefit of and be enforceable by Executive's legal representatives.
(b) This Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns.
(c) The Company will require any Surviving Entity resulting from a Reorganization, Sale or Acquisition (if other than the Company) to assume expressly and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no Reorganization, Sale or Acquisition had taken place. As used in this Agreement, "Company" shall mean the Company as hereinbefore defined and any successor to its business and/or assets as aforesaid which assumes and agrees to perform this Agreement by operation of law, or otherwise.
17. Miscellaneous.
(a) Waiver. Failure of either party to insist, in one or more instances, on performance by the other in strict accordance with the terms and conditions of this Agreement shall not be deemed a waiver or relinquishment of any right granted in this Agreement or of the future performance of any such term or condition or of any other term or condition of this Agreement, unless such waiver is contained in a writing signed by the party making the waiver.
(b) Severability. If any provision or covenant, or any part thereof, of this Agreement should be held by any tribunal of competent jurisdiction to be invalid, illegal or unenforceable, either in whole or in part, such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of the remaining provisions or covenants, or any part thereof, of this Agreement, all of which shall remain in full force and effect.
(c) Other Agents. Nothing in this Agreement is to be interpreted as limiting the Company from employing other personnel on such terms and conditions as may be satisfactory to it, except that this Section 17(c) shall not override the provision of Section 7(d)(i).
(d) Entire Agreement. Except as provided herein, this Agreement contains the entire agreement between the Company and Executive with respect to the subject matter hereof and, from and after the Effective Date, this Agreement shall supersede any other agreement between the parties with respect to the subject matter hereof, including without limitation, the Prior Agreement.
(e) Governing Law. Except to the extent preempted by federal law, and without regard to conflict of laws principles, the laws of the State of Delaware shall govern this Agreement in all respects, whether as to its validity, construction, capacity, performance or otherwise.
(f) Notices. All notices, requests, demands and other communications required or permitted hereunder shall be in writing and shall be deemed to have been duly given if delivered or three days after mailing if mailed, first class, certified mail, postage prepaid:
To the Company: LHC Group, Inc. Suite A 420 W. Pinhook Road Lafayette, LA 70503 Attention: General Counsel To Executive: R. Barr Brown |
Any party may change the address to which notices, requests, demands and other communications shall be delivered or mailed by giving notice thereof to the other party in the same manner provided herein.
(g) Amendments and Modifications. This Agreement may be amended or modified only by a writing signed by both parties hereto, which makes specific reference to this Agreement.
(h) Construction. Each party and his or its counsel have reviewed this Agreement and have been provided the opportunity to revise this Agreement and accordingly, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this Agreement. Instead, the language of all parts of this Agreement shall be construed as a whole, and according to its fair meaning, and not strictly for or against either party.
(i) Withholding. The Company or its subsidiaries, if applicable, shall be entitled to deduct or withhold from any amounts owing from the Company or any such affiliate to Executive any federal, state, local or foreign withholding taxes, excise taxes, or employment taxes ("Taxes") imposed with respect to Executive's compensation or other payments from the Company or any of its affiliates. In the event the Company or its affiliates do not make such deductions or withholdings, Executive shall indemnify the Company and its affiliates for any amounts paid with respect to any such Taxes.
IN WITNESS WHEREOF, the parties hereto have duly executed and delivered this Employment Agreement as of the date first above written.
LHC GROUP, INC.
EXECUTIVE:
/s/ R. Barr Brown ---------------------------- R. Barr Brown |
EXHIBIT A
Form of Release
THIS RELEASE ("Release") is granted effective as of the_________________________________________day of_______________________, 20_, by__________________("Executive") in favor of LHC Group, Inc. (the "Company"). This is the Release referred to that certain Employment Agreement effective as of_________________________________________________, 200_ by and between the Company and Executive (the "Employment Agreement"), with respect to which this Release is an integral part.
FOR AND IN CONSIDERATION of the payments and benefits provided by
Section 8 of the Employment Agreement and the Company's other promises and
covenants as recited in the Employment Agreement, the receipt and sufficiency
of which are hereby acknowledged, Executive, for himself, his successors and
assigns, now and forever hereby releases and discharges the Company and all its
past and present officers, directors, stockholders, employees, agents, parent
corporations, predecessors, subsidiaries, affiliates, estates, successors,
assigns, benefit plans, consultants, administrators, and attorneys (hereinafter
collectively referred to as "Releasees") from any and all claims, charges,
actions, causes of action, sums of money due, suits, debts, covenants,
contracts, agreements, promises, demands or liabilities (hereinafter
collectively referred to as "Claims") whatsoever, in law or in equity, whether
known or unknown, which Executive ever had or now has from the beginning of
time up to the date this Release ("Release") is executed, including, but not
limited to, claims under the Age Discrimination in Employment Act, as amended
by the Older Workers Benefit Protection Act, Title VII of the Civil Rights Act
of 1964 (and all of its amendments), the Americans with Disabilities Act, as
amended, or any other federal or state statutes, all tort claims, all claims
for wrongful employment termination or breach of contract, and any other claims
which Executive has, had, or may have against the Releasees on account of or
arising out of Executive's employment with or termination from the Company;
provided, however, that nothing contained in this Release shall in any way
diminish or impair (i) any rights of Executive to the benefits conferred or
referenced in the Employment Agreement or Executive's Retention Bonus Agreement
with the Company, (ii) any rights to indemnification that may exist from time
to time under the Company's bylaws, certificate of incorporation, Delaware law
or otherwise, or (iii) Executive's ability to raise an affirmative defense in
connection with any lawsuit or other legal claim or charge instituted or
asserted by the Company against Executive.
Without limiting the generality of the foregoing, Executive hereby acknowledges and covenants that in consideration for the sums being paid to him he has knowingly waived any right or opportunity to assert any claim that is in any way connected with any employment relationship or the termination of any employment relationship which existed between the Company and Executive. Executive further understands and agrees that he has knowingly relinquished, waived and forever released any and all remedies arising out of the aforesaid employment relationship or the termination thereof, including, without limitation, claims for backpay, front pay, liquidated damages, compensatory damages, general damages, special damages, punitive damages, exemplary damages, costs, expenses and attorneys' fees.
Executive specifically acknowledges and agrees that he has knowingly and voluntarily released the Company and all other Releasees from any and all claims arising under the Age Discrimination in Employment Act ("ADEA"), 29 U.S.C. Section 621, et seq., which Executive ever had or now has from the beginning of time up to the date this Release is executed, including but not limited to those claims which are in any way connected with any employment relationship or
the termination of any employment relationship which existed between the Company and Executive. Executive further acknowledges and agrees that he has been advised to consult with an attorney prior to executing this Release and that he has been given twenty-one (21) days to consider this Release prior to its execution. Executive also understands that he may revoke this Release at any time within seven (7) days following its execution. Executive understands, however, that this Release shall not become effective and that none of the consideration described above shall be paid to him until the expiration of the seven-day revocation period.
Executive agrees never to seek reemployment or future employment with the Company or any of the other Releasees.
Executive acknowledges that the terms of this Release must be kept confidential. Accordingly, Executive agrees not to disclose or publish to any person or entity, except as required by law or as necessary to prepare tax returns, the terms and conditions or sums being paid in connection with this Release.
It is understood and agreed by Executive that the payment made to him is not to be construed as an admission of any liability whatsoever on the part of the Company or any of the other Releasees, by whom liability is expressly denied.
This Release is executed by Executive voluntarily and is not based upon any representations or statements of any kind made by the Company or any of the other Releasees as to the merits, legal liabilities or value of his claims. Executive further acknowledges that he has had a full and reasonable opportunity to consider this Release and that he has not been pressured or in any way coerced into executing this Release.
Executive acknowledges and agrees that this Release may not be revoked at any time after the expiration of the seven-day revocation period and that he will not institute any suit, action, or proceeding, whether at law or equity, challenging the enforceability of this Release. Executive further acknowledges and agrees that, with the exception of an action to challenge his waiver of claims under the ADEA, he shall not ever attempt to challenge the terms of this Release, attempt to obtain an order declaring this Release to be null and void, or institute litigation against the Company or any other Releasee based upon a claim which is covered by the terms of the release contained herein, without first repaying all monies paid to him under Section 8 of the Employment Agreement. Furthermore, with the exception of an action to challenge his waiver of claims under the ADEA, if Executive does not prevail in an action to challenge this Release, to obtain an order declaring this Release to be null and void, or in any action against the Company or any other Releasee based upon a claim which is covered by the release set forth herein, Executive shall pay to the Company and/or the appropriate Releasee all their costs and attorneys' fees incurred in their defense of Executive's action.
This Release and the rights and obligations of the parties hereto shall be governed and construed in accordance with the laws of the State of Georgia. If any provision hereof is unenforceable or is held to be unenforceable, such provision shall be fully severable, and this document and its terms shall be construed and enforced as if such unenforceable provision had never comprised a part hereof, the remaining provisions hereof shall remain in full force and effect, and the court construing the provisions shall add as a part hereof a provision as similar in terms and effect to such unenforceable provision as may be enforceable, in lieu of the unenforceable provision.
This document contains all terms of the Release and supersedes and invalidates any previous agreements or contracts. No representations, inducements, promises or agreements, oral or otherwise, which are not embodied herein shall be of any force or effect.
IN WITNESS WHEREOF, the undersigned acknowledges that he has read these three pages and he sets his hand and seal this__________________________day of___________________________, 20_______.
Sworn to and subscribed
before me this_________________day of
___________________________, 20_______.
Notary Public
My Commission Expires:
EXHIBIT B
Restricted Territory
EXHIBIT 10.8
EMPLOYMENT AGREEMENT
BETWEEN JOHN L. INDEST
AND LHC GROUP, INC.
EMPLOYMENT AGREEMENT
1. Effective Date.............................................................1 2. Employment and Directorship................................................1 3. Employment Period..........................................................1 4. Extent of Service..........................................................1 5. Compensation and Benefits..................................................2 (a) Base Salary...................................................2 (b) Incentive, Savings and Retirement Plans.......................2 (c) Welfare Benefit Plans.........................................2 (d) Expenses......................................................2 (e) Fringe Benefits...............................................3 (f) Vacation......................................................3 (g) Office and Support Staff......................................3 6. Change of Control..........................................................3 7. Termination of Employment..................................................4 (a) Death or Retirement...........................................4 (b) Disability....................................................4 (c) Termination by the Company....................................5 (d) Termination by Executive......................................5 (e) Notice of Termination.........................................5 (f) Date of Termination...........................................6 8. Obligations of the Company upon Termination................................6 (a) Termination by Executive for Good Reason; Termination by the Company Other Than for Cause or Disability.................................................6 (b) Death, Disability or Retirement...............................8 (c) Cause or Voluntary Termination without Good Reason........................................................8 (d) Expiration of Employment Period...............................8 (e) Resignations..................................................8 9. Non-exclusivity of Rights..................................................8 10. Full Settlement; No Obligation to Mitigate.................................8 11. Certain Additional Payments by the Company.................................9 |
12. Costs of Enforcement......................................................11 13. Representations and Warranties............................................11 14. Restrictions on Conduct of Executive......................................11 (a) General......................................................11 (b) Definitions..................................................11 (c) Restrictive Covenants........................................13 (d) Enforcement of Restrictive Covenants.........................15 15. Arbitration...............................................................16 16. Assignment and Successors.................................................16 17. Miscellaneous.............................................................16 |
EMPLOYMENT AGREEMENT
THIS EMPLOYMENT AGREEMENT (this "Agreement") is made and entered into this ____ day of January, 2005 by and between LHC Group, Inc., a Delaware corporation (the "Company"), and John L. Indest ("Executive"), to be effective as of the Effective Date, as defined in Section 1.
BACKGROUND
Executive currently serves as Senior Vice President and Chief Operating Officer of Home-Based Services of the Company. The Company desires to continue to engage Executive in such capacity from and after the Effective Date, in accordance with the terms of this Agreement. Executive is willing to serve as such in accordance with the terms and conditions of this Agreement.
NOW, THEREFORE, in consideration of the foregoing and of the mutual covenants and agreements set forth herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:
1. Effective Date. The effective date of this Agreement (the "Effective Date") shall be the effective date of a registration statement on Form S-l for the initial public offering of the common stock of the Company.
2. Employment. Executive is hereby employed on the Effective Date as Senior Vice President and Chief Operating Officer of Home-Based Services of the Company. In his capacity as Senior Vice President and Chief Operating Officer of Home-Based Services of the Company, Executive shall have the duties, responsibilities and authority commensurate with such position as shall be assigned to him by the Chief Executive Officer and/or the Board of Directors of the Company. In his capacity as Senior Vice President and Chief Operating Officer of Home-Based Services of the Company, Executive will report directly to the Chief Executive Officer of the Company.
3. Employment Period. Unless earlier terminated herein in accordance with
Section 7 hereof, Executive's employment shall be for a three year term,
beginning on the Effective Date and ending on the third anniversary of the
Effective Date (the "Employment Period"). Beginning on the third anniversary of
the Effective Date and on each subsequent anniversary of the Effective Date, the
Employment Period shall, without further action by Executive or the Company, be
extended by an additional one-year period; provided, however, that either the
Company or the Executive may, by notice to the other given at least sixty (60)
days prior to the scheduled expiration of the Employment Period, cause the
Employment Period to cease to extend automatically. Upon such notice, the
Employment Period shall terminate upon the expiration of the then-current term,
including any prior extensions.
4. Extent of Service. During the Employment Period, and excluding any periods of vacation, holiday, sick leave and Company-approved leave of absence to which Executive is entitled in accordance with Company policies, Executive agrees to devote substantially all of his business time, attention, skill and efforts exclusively to the faithful performance of his duties hereunder. It shall not be a violation of this Agreement for Executive to (i) devote reasonable time to charitable or community activities, (ii) serve on corporate, civic, educational or charitable boards or committees, subject to the Company's standards of business conduct or other code of ethics, (iii) deliver lectures or fulfill speaking engagements from time to time on an infrequent
basis, and/or (iv) manage personal business interests and investments, subject to the Company's standards of business conduct or other code of ethics, and so long as such activities do not interfere in a material manner or on a routine basis with the performance of Executive's responsibilities under this Agreement.
5. Compensation and Benefits.
(a) Base Salary. During the Employment Period, the Company will pay to Executive base salary at the rate of U.S. $250,000 per year ("Base Salary"), less normal withholdings, payable in approximately equal bi-weekly or other installments as are or become customary under the Company's payroll practices for its employees from time to time. The compensation committee of the Board of Directors of the Company (or the full Board, if there is no compensation committee) shall review Executive's Base Salary annually and may increase (but not decrease) Executive's Base Salary from year to year. Such adjusted salary then shall become Executive's Base Salary for purposes of this Agreement. The annual review of Executive's salary by the Board will consider, among other things, Executive's own performance, and the Company's performance.
(b) Incentive. Savings and Retirement Plans. During the Employment Period, Executive shall be entitled to participate in all incentive, savings and retirement plans, practices, policies and programs available to senior executive officers of the Company ("Peer Executives"), and on the same basis as such Peer Executives. Without limiting the foregoing, the following shall apply:
(i) during the Employment Period, Executive will be entitled to participate in the Company's executive bonus plan, pursuant to which he will have an opportunity to receive an annual cash bonus based upon the achievement of performance goals established from year to year by the compensation committee of the Board of Directors of the Company (such bonus earned at the stated "goal" level of achievement being referred to herein as the "Target Bonus"); and
(ii) during the Employment Period, Executive will be eligible for grants, under the Company's long-term incentive plan or plans, of stock options and/or restricted stock awards (or such other stock-based awards as the Company makes to Peer Executives), having terms and determined in the same manner as awards to other Peer Executives, unless the Executive consents to a different type of award or different terms of such award than are applicable to other Peer Executives. Nothing herein requires the Board of Directors to make grants of options or other awards in any year.
(c) Welfare Benefit Plans. During the Employment Period, Executive and Executive's eligible dependents shall be eligible for participation in, and shall receive all benefits under, the welfare benefit plans, practices, policies and programs provided by the Company (including, without limitation, medical, prescription drug, dental, disability, employee life, dependent life, accidental death and travel accident insurance plans and programs) ("Welfare Plans") to the extent available to other Peer Executives.
(d) Expenses. During the Employment Period, Executive shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by Executive in the course of performing his duties and responsibilities under this Agreement, in accordance with the policies, practices and procedures of the Company to the extent available to other Peer Executives with respect to travel, entertainment and other business expenses.
(e) Fringe Benefits. During the Employment Period, Executive shall be entitled to fringe benefits in accordance with the plans, practices, programs and policies of the Company available to other Peer Executives.
(f) Vacation. During the Employment Period, Executive will be entitled to such paid vacation time as may be provided from time to time under any plans, practices, programs and policies of the Company available to other Peer Executives.
(g) Office and Support Staff. During the Employment Period, Executive will be entitled to office, furnishings and equipment of similar type and quality made available to other Peer Executives. During the Employment Period, Executive will be entitled to secretarial and other assistance reasonably necessary for the performance of his duties and responsibilities.
6. Change of Control. For the purposes of this Agreement, a "Change of Control" shall mean the occurrence of any of the following events:
(a) individuals who, on the Effective Date, constitute the Board of
Directors of the Company (the "Incumbent Directors") cease for any
reason to constitute at least a majority of such Board, provided that
any person becoming a director after the Effective Date and whose
election or nomination for election was approved by a vote of at least
a majority of the Incumbent Directors then on the Board shall be an
Incumbent Director; provided, however, that no individual initially
elected or nominated as a director of the Company as a result of an
actual or threatened election contest with respect to the election or
removal of directors ("Election Contest") or other actual or
threatened solicitation of proxies or consents by or on behalf of any
"person" (such term for purposes of this Section 6 being as defined in
Section 3(a)(9) of the Securities Exchange Act of 1934 (the "Exchange
Act") and as used in Section 13(d)(3) and 14(d)(2) of the Exchange
Act) other than the Board ("Proxy Contest"), including by reason of
any agreement intended to avoid or settle any Election Contest or
Proxy Contest, shall be deemed an Incumbent Director; or
(b) any person is or becomes a "beneficial owner" (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of either (i) 35% or more of the then-outstanding shares of common stock of the Company ("Company Common Stock") or (ii) securities of the Company representing 35% or more of the combined voting power of the Company's then outstanding securities eligible to vote for the election of directors (the "Company Voting Securities"); provided, however, that for purposes of this paragraph (b), the following acquisitions of Company Common Stock or Company Voting Securities shall not constitute a Change of Control: (A) an acquisition directly from the Company, (B) an acquisition by the Company or a subsidiary of the Company, (C) an acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any subsidiary of the Company, or (D) an acquisition pursuant to a Non-Qualifying Transaction (as defined in paragraph (c) below); or
(c) the consummation of a recapitalization, reorganization, merger,
consolidation, statutory share exchange or similar form of transaction
involving the Company or a subsidiary of the Company (a
"Reorganization"), or the sale or other disposition of all or
substantially all of the Company's assets (a "Sale") or the
acquisition of assets or stock of another entity (an "Acquisition"),
unless immediately following such Reorganization, Sale or Acquisition:
(A) all or substantially all of the individuals
and entities who were the beneficial owners, respectively, of the outstanding Company Common Stock and outstanding Company Voting Securities immediately prior to such Reorganization, Sale or Acquisition beneficially own, directly or indirectly, more than 50% of, respectively, the then outstanding shares of common stock and the combined voting power of the then outstanding voting securities entitled to vote generally in the election of directors, as the case may be, of the entity resulting from or surviving such Reorganization, Sale or Acquisition (including, without limitation, an entity which as a result of such transaction owns the Company or all or substantially all of the Company's assets or stock either directly or through one or more subsidiary entities, the "Surviving Entity") in substantially the same proportions as their ownership, immediately prior to such Reorganization, Sale or Acquisition, of the outstanding Company Common Stock and the outstanding Company Voting Securities, as the case may be, and (B) no person (other than (x) the Company or any subsidiary of the Company, (y) the Surviving Entity or its ultimate parent entity, or (z) any employee benefit plan (or related trust) sponsored or maintained by any of the foregoing) is the beneficial owner, directly or indirectly, of 35% or more of the total common stock or 35% or more of the total voting power of the outstanding voting securities eligible to elect directors of the Surviving Entity, and (C) at least a majority of the members of the board of directors of the Surviving Entity were Incumbent Directors at the time of the Board's approval of the execution of the initial agreement providing for such Reorganization, Sale or Acquisition (any Reorganization, Sale or Acquisition which satisfies all of the criteria specified in (A), (B) and (C) above shall be deemed to be a "Non-Qualifying Transaction"); or
(d) approval by the members or stockholders of the Company, as the case may be, of a complete liquidation or dissolution of the Company.
7. Termination of Employment.
(a) Death or Retirement. Executive's employment shall terminate automatically upon Executive's death or Retirement during the Employment Period. For purposes of this Agreement, "Retirement" shall mean normal retirement as defined in the Company's then-current retirement plan, or if there is no such retirement plan, "Retirement" shall mean voluntary termination after age 65 with at least ten years of service.
(b) Disability. If the Company determines in good faith that the Disability (as defined below) of Executive has occurred during the Employment Period, it may give to Executive written notice of its intention to terminate Executive's employment. In such event, Executive's employment with the Company shall terminate effective on the 30th day after receipt of such written notice by Executive (the "Disability Effective Date"), provided that, within the 30 days after such receipt, Executive shall not have returned to full-time performance of Executive's duties. For purposes of this Agreement, "Disability" shall have the same meaning as provided in the long-term disability plan or policy maintained by the Company and covering Executive. If no such long-term disability plan or policy is maintained, "Disability" shall mean the inability of Executive, as determined by the Board, to perform the essential functions of his regular duties and responsibilities, with or without reasonable accommodation, due to a medically determinable physical or mental illness which has lasted (or can reasonably be expected to last) for a period of six consecutive months.
(c) Termination by the Company. The Company may terminate Executive's employment during the Employment Period with or without Cause. For purposes of this Agreement, "Cause" shall mean:
(i) the continued failure of Executive to perform substantially Executive's duties with the Company (other than any such failure resulting from incapacity due to physical or mental illness, or following Executive's delivery of notice of termination for Good Reason, and specifically excluding any failure by Executive, after reasonable efforts, to meet performance expectations), after a written demand for substantial performance is delivered to Executive by the Board which specifically identifies the manner in which the Board believes that Executive has not substantially performed Executive's duties, or
(ii) the engaging by Executive in illegal conduct or gross misconduct which is injurious to the Company, or
(iii) the conviction of Executive, or a plea of guilty or nolo contendere by Executive, to a felony or other crime involving moral turpitude.
(d) Termination by Executive. Executive's employment may be terminated by Executive for Good Reason or no reason. For purposes of this Agreement, unless written consent of Executive is obtained, "Good Reason" shall mean:
(i) the assignment to Executive of duties inconsistent in material respect with Executive's position (including status, offices, titles and reporting requirements), authority, duties or responsibilities as in effect on the Effective Date, or a material diminution in such position, authority, duties or responsibilities, excluding for this purpose an isolated, insubstantial and inadvertent action not taken in bad faith and which is remedied by the Company promptly after receipt of notice thereof given by Executive;
(ii) a reduction by the Company in Executive's Base Salary or Target Bonus as in effect on the Effective Date or, with respect to Executive's Base Salary, as the same may be increased from time to time;
(iii) any failure by the Company to comply with and satisfy 16(c) of this Agreement; or
(v) the material breach by the Company of any other provision of this Agreement.
Any claim of "Good Reason" under this Agreement shall be communicated by Executive to the Company in writing, which writing shall specifically identify the factual details concerning the event(s) giving rise to Executive's claim of Good Reason under this Section 7(d). The Company shall have an opportunity to cure any claimed event of Good Reason within 30 days of such notice from Executive.
(e) Notice of Termination. Any termination by the Company for Cause, or by Executive for Good Reason, shall be communicated by Notice of Termination to the other party hereto given in accordance with Section 17(f) of this Agreement. For purposes of this Agreement, a "Notice of Termination" means a written notice which (i) indicates the specific termination provision in this Agreement relied upon, (ii) to the extent applicable, sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of
Executive's employment under the provision so indicated, and (iii) specifies the termination date. The failure by Executive or the Company to set forth in the Notice of Termination any fact or circumstance which contributes to a showing of Good Reason or Cause shall not waive any right of Executive or the Company, respectively, hereunder or preclude Executive or the Company, respectively, from asserting such fact or circumstance in enforcing Executive's or the Company's rights hereunder.
(f) Date of Termination. "Date of Termination" means (i) if Executive's
employment is terminated by the Company for Cause, or by Executive for Good
Reason, the date of receipt of the Notice of Termination or a date within 30
days after receipt of the Notice of Termination, as specified in such notice,
(ii) if Executive's employment is terminated by the Company other than for Cause
or Disability, the Date of Termination shall be the date of receipt of the
Notice of Termination or a date within 90 days after receipt of the Notice of
Termination, as specified in such notice, (iii) if Executive's employment is
terminated by reason of death or Disability, the Date of Termination shall be
the date of death of Executive or the Disability Effective Date, as the case may
be, and (iv) if Executive's employment is terminated by Executive without Good
Reason, the Date of Termination shall be 60 days following the Company's receipt
of the Notice of Termination, unless the Company specifies an earlier Date of
Termination.
8. Obligations of the Company upon Termination.
(a) Termination by Executive for Good Reason: Termination by the Company Other Than for Cause or Disability. If, during the Employment Period, the Company shall terminate Executive's employment other than for Cause or Disability, or Executive shall terminate employment for Good Reason within a period of 90 days after the occurrence of the event giving rise to Good Reason, then and, with respect to the payments and benefits described in clauses (i)(B) and (ii) below, only if Executive executes a Release in substantially the form of Exhibit A hereto (the "Release"):
(i) the Company shall provide to Executive in a single lump sum cash payment within 30 days after the Date of Termination, or if later, within five days after the Release becomes effective and nonrevocable, the aggregate of the following amounts:
A. the sum of the following amounts, to the extent not
previously paid to Executive (the "Accrued Obligations"): (1) Executive's
Base Salary through the Date of Termination, (2) a pro-rata bonus for the
year in which the Date of Termination occurs, computed as the product of
(x) Executive's Target Bonus for such year and (y) a fraction, the
numerator of which is the number of days in the current fiscal year through
the Date of Termination, and the denominator of which is 365, (3) any
accrued pay in lieu of unused vacation (in accordance with the Company's
vacation policy), and (4) unless Executive has a later payout date that is
required in connection with the terms of a deferral plan or agreement, any
vested compensation previously deferred by Executive (together with any
amount equivalent to accrued interest or earnings thereon); and
B. a severance payment as determined pursuant to clause
(x) or (y) below, as applicable:
(x) if the Date of Termination occurs before, or more than two years after, the occurrence of a Change of Control, the severance payment shall be the product of 24 (the "Regular Severance Factor") times one twelfth of the sum of
(1) Executive's Base Salary in effect as of the Date of Termination (ignoring any decrease in Executive's Base Salary unless consented to by Executive), and (2) the greater of the average of the annual bonuses earned by Executive for the two fiscal years in which annual bonuses were paid immediately preceding the year in which the Date of Termination occurs, or Executive's Target Bonus for the year in which the Date of Termination occurs; or
(y) if the Date of Termination occurs within two years after the occurrence of a Change of Control, the severance payment shall be the product of 30 (the "Change of Control Severance Factor") times one twelfth of the sum of (1) Executive's Base Salary in effect as of the Date of Termination, and (2) the greater of the average of the annual bonuses earned by Executive for the two fiscal years in which annual bonuses were paid immediately preceding the year in which the Date of Termination occurs, or Executive's Target Bonus for the year in which the Date of Termination occurs; and
(ii) the Company shall continue to provide, for a number of months equal to the Regular Severance Factor or the Change of Control Severance Factor (determined in Section 8(a)(i)(B)(x) or (y) above, as applicable) after Executive's Date of Termination (the "Welfare Benefits Continuation Period"), or such longer period as may be provided by the terms of the appropriate plan, program, practice or policy, any group health benefits to which Executive and/or Executive's eligible dependents would otherwise be entitled to continue under COBRA, or benefits substantially equivalent to those group health benefits which would have been provided to them in accordance with the Welfare Plans described in Section 5(c) of this Agreement if Executive's employment had not been terminated, provided, however, that if Executive becomes employed with another employer (including self-employment) and receives group health benefits under another employer provided plan, the Company's obligation to provide group health benefits described herein shall cease, except as otherwise provided by law and provided, further, that the Welfare Benefits Continuation Period shall run concurrently with any period for which Executive is eligible to elect health coverage under COBRA; and
(iii) all grants of stock options and other equity awards granted by the Company and held by Executive as of the Date of Termination will become immediately vested and exercisable as of the Date of Termination and, to the extent necessary, this Agreement is hereby deemed an amendment of any such outstanding stock option or other equity award; and
(iv) to the extent not theretofore paid or provided, the Company shall timely pay or provide to Executive any other amounts or benefits required to be paid or provided or which Executive is eligible to receive under any plan, program, policy or practice of the Company to the extent provided to Peer Executives prior to the Date of Termination (such other amounts and benefits shall be hereinafter referred to as the "Other Benefits").
If Executive's employment is terminated by the Company without Cause prior to the occurrence of a Change in Control and if it can reasonably be shown that Executive's termination (i) was at the direction or request of a third party that had taken steps reasonably calculated to effect a Change in Control after such termination, or (ii) otherwise occurred in anticipation of a Change in Control, and in either case a Change in Control as defined hereunder does, in fact, occur, then Executive shall have the rights described in this Section 8(a) as if the Change in Control had occurred on the date immediately preceding the Date of Termination.
Executive acknowledges and agrees that the receipt of severance benefits provided in this Section 8(a) constitutes consideration for the restrictions on the conduct of Executive contained in Section 14 of this Agreement.
(b) Death. Disability or Retirement. If Executive's employment is terminated by reason of his death, Disability or Retirement during the Employment Period, this Agreement shall terminate without further obligations to Executive or his estate, beneficiaries or legal representatives, other than for payment of Accrued Obligations and the timely payment or provision of Other Benefits. Accrued Obligations shall be paid to Executive or his estate, beneficiary or legal representative, as applicable, in a lump sum in cash within 30 days of the Date of Termination. With respect to the provision of Other Benefits, the term Other Benefits as used in this Section 8(b) shall include, without limitation, and Executive or his estate, beneficiaries or legal representatives, as applicable, shall be entitled to receive, benefits under such plans, programs, practices and policies relating to death, disability or retirement benefits, if any, as are applicable to Executive or his family on the Date of Termination.
(c) Cause or Voluntary Termination without Good Reason. If Executive's employment shall be terminated for Cause during the Employment Period, or if Executive voluntarily terminates employment during the Employment Period without Good Reason, this Agreement shall terminate without further obligations to Executive, other than for payment of Accrued Obligations (excluding the pro-rata bonus described in clause 2 of Section 8(a)(i)(A)) and the timely payment or provision of Other Benefits.
(d) Expiration of Employment Period. If Executive's employment shall be terminated due to the normal expiration of the Employment Period, this Agreement shall terminate without further obligations to Executive, other than for payment of Accrued Obligations and the timely payment or provision of Other Benefits.
(e) Resignations. Termination of Executive's employment for any reason whatsoever shall constitute Executive's resignation from the Board of Directors of the Company and resignation as an officer of the Company, its subsidiaries and affiliates.
9. Non-exclusivity of Rights. Nothing in this Agreement shall prevent or limit Executive's continuing or future participation in any employee benefit plan, program, policy or practice provided by the Company and for which Executive may qualify, except as specifically provided herein. Amounts which are vested benefits or which Executive is otherwise entitled to receive under any employee benefit plan, policy, practice or program of the Company, its subsidiaries or any of its affiliated companies at or subsequent to the Date of Termination shall be payable in accordance with such plan, policy, practice or program except as explicitly modified by this Agreement.
10. Full Settlement: No Obligation to Mitigate. The Company's obligation to make the payments provided for in this Agreement and otherwise to perform its obligations hereunder shall not be affected by any set-off, counterclaim, recoupment, defense or other claim, right or action which the Company may have against Executive or others. In no event shall Executive be obligated to seek other employment or take any other action by way of mitigation of the amounts payable to Executive under any of the provisions of this Agreement and, except as explicitly provided herein, such amounts shall not be reduced whether or not Executive obtains other employment.
11. Certain Additional Payments by the Company.
(a) Anything in this Agreement to the contrary notwithstanding and except as set forth below, in the event it shall be determined that any payment or distribution by the Company to or for the benefit of Executive (whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, but determined without regard to any additional payments required under this Section 11) (a "Payment") would be subject to the excise tax imposed by Section 4999 of the Internal Revenue Code of 1986, as amended (the "Code") or any interest or penalties are incurred by Executive with respect to such excise tax (such excise tax, together with any such interest and penalties, are hereinafter collectively referred to as the "Excise Tax"), then Executive shall be entitled to receive an additional payment (a "Gross-Up Payment") in an amount such that after payment by Executive of all taxes (including any interest or penalties imposed with respect to such taxes), including, without limitation, any income taxes (and any interest and penalties imposed with respect thereto) and Excise Tax imposed upon the Gross-Up Payment, Executive retains an amount of the Gross-Up Payment equal to the Excise Tax imposed upon the Payments. Notwithstanding the foregoing provisions of this Section 11(a), if it shall be determined that Executive is entitled to a Gross-Up Payment, but that Executive, after taking into account the Payments and the Gross-Up Payment, would not receive a net after tax benefit of at least $50,000 (taking into account both income taxes and any Excise Tax) as compared to the net after-tax proceeds to Executive resulting from an elimination of the Gross-Up Payment and a reduction of the Payments, in the aggregate, to an amount (the "Reduced Amount") such that the receipt of Payments would not give rise to any Excise Tax, then no Gross-Up Payment shall be made to Executive and the Payments, in the aggregate, shall be reduced to the Reduced Amount. Executive may select the Payments to be limited or reduced.
(b) Subject to the provisions of Section ll(c), all determinations
required to be made under this Section 11, including whether and when a Gross-Up
Payment is required and the amount of such Gross-Up Payment and the assumptions
to be used in arriving at such determination, shall be made by a certified
public accounting firm selected by Executive (other than the Company's regular
accounting firm) and reasonably acceptable to the Company (the "Accounting
Firm") which shall provide detailed supporting calculations both to the Company
and Executive within 15 business days of the receipt of notice from Executive
that there has been a Payment, or such earlier time as is reasonably requested
by the Company. All fees and expenses of the Accounting Firm shall be borne
solely by the Company. Any Gross-Up Payment, as determined pursuant to this
Section 11, shall be paid by the Company to Executive within five days of the
receipt of the Accounting Firm's determination. Any determination by the
Accounting Firm shall be binding upon the Company and Executive. As a result of
the uncertainty in the application of Section 4999 of the Code at the time of
the initial determination by the Accounting Firm hereunder, it is possible that
Gross-Up Payments which will not have been made by the Company should have been
made ("Underpayment"), consistent with the calculations required to be made
hereunder. In the event that the Company exhausts its remedies pursuant to
Section 11(c) and Executive thereafter is required to make a payment of any
Excise Tax, the Accounting Firm shall determine the amount of the Underpayment
that has occurred and any such Underpayment shall be promptly paid by the
Company to or for the benefit of Executive.
(c) Executive shall notify the Company in writing of any claim by the Internal Revenue Service that, if successful, would require the payment by the Company of a Gross-Up Payment (or an additional Gross-Up Payment). Such notification shall be given as soon as practicable but no later than ten business days after Executive is informed in writing of such claim and shall apprise the Company of the nature of such claim and the date on which such
claim is requested to be paid. Executive shall not pay such claim prior to the expiration of the 30-day period following the date on which he gives such notice to the Company (or such shorter period ending on the date that any payment of taxes with respect to such claim is due). If the Company notifies Executive in writing prior to the expiration of such period that it desires to contest such claim, Executive shall:
(i) give the Company any information reasonably requested by the Company relating to such claim,
(ii) take such action in connection with contesting such claim as the Company shall reasonably request in writing from time to time, including, without limitation, accepting legal representation with respect to such claim by an attorney reasonably selected by the Company,
(iii) cooperate with the Company in good faith in order effectively to contest such claim, and
(iv) permit the Company to participate in any proceedings relating to such claim;
provided, however, that the Company shall bear and pay directly all costs and expenses (including additional interest and penalties) incurred in connection with such contest and shall indemnify and hold Executive harmless, on an after-tax basis, for any Excise Tax or income tax (including interest and penalties with respect thereto) imposed as a result of such representation and payment of costs and expenses. Without limitation of the foregoing provisions of this Section 11(c), the Company shall control all proceedings taken in connection with such contest (to the extent applicable to the Excise Tax and the Gross-Up Payment) and, at its sole option, may pursue or forgo any and all administrative appeals, proceedings, hearings and conferences with the taxing authority in respect of such claim and may, at its sole option, either direct Executive to pay the tax claimed and sue for a refund or contest the claim in any permissible manner, and Executive agrees to prosecute such contest to a determination before any administrative tribunal, in a court of initial jurisdiction and in one or more appellate courts, as the Company shall determine; provided, however, that if the Company directs Executive to pay such claim and sue for a refund, the Company shall advance the amount of such payment to Executive, on an interest-free basis and shall indemnify and hold Executive harmless, on an after-tax basis, from any Excise Tax or income tax (including interest or penalties with respect thereto) imposed with respect to such advance or with respect to any imputed income with respect to such advance; and further provided that any extension of the statute of limitations relating to payment of taxes for the taxable year of Executive with respect to which such contested amount is claimed to be due is limited solely to such contested amount. Furthermore, the Company's control of the contest shall be limited to issues with respect to which a Gross-Up Payment would be payable hereunder and Executive shall be entitled to settle or contest, as the case may be, any other issue raised by the Internal Revenue Service or any other taxing authority.
(d) If, after the receipt by Executive of an amount advanced by the Company pursuant to Section 11 (c), Executive becomes entitled to receive any refund with respect to such claim, Executive shall (subject to the Company's complying with the requirements of Section 11(c)) promptly pay to the Company the amount of such refund (together with any interest paid or credited thereon after taxes applicable thereto). If, after the receipt by Executive of an amount advanced by the Company pursuant to Section 11(c), a determination is made that Executive shall not be entitled to any refund with respect to such claim and the Company does not notify
Executive in writing of its intent to contest such denial of refund prior to the expiration of 30 days after such determination, then such advance shall be forgiven and shall not be required to be repaid and the amount of such advance shall offset, to the extent thereof, the amount of Gross-Up Payment required to be paid.
12. Costs of Enforcement. In any action taken in good faith relating to the enforcement of this Agreement or any provision herein, Executive shall be entitled to reimbursement for any and all costs and expenses incurred by him in enforcing or establishing his rights thereunder, including, without limitation, reasonable attorneys' fees, whether suit be brought or not, and whether or not incurred in arbitration, trial, bankruptcy or appellate proceedings, but only if and to the extent Executive is successful in asserting such rights. Executive shall also be entitled to be paid all reasonable legal fees and expenses, if any, incurred in connection with any tax audit or proceeding to the extent attributable to the application of Section 4999 of the Internal Revenue Code to any payment or benefit hereunder.
13. Representations and Warranties. Executive hereby represents and warrants to the Company that Executive is not a party to, or otherwise subject to, any covenant not to compete with any person or entity, and Executive's execution of this Agreement and performance of his obligations hereunder will not violate the terms or conditions of any contract or obligation, written or oral, between Executive and any other person or entity.
14. Restrictions on Conduct of Executive.
(a) General. Executive and the Company understand and agree that the purpose of the provisions of this Section 14 is to protect legitimate business interests of the Company, as more fully described below, and is not intended to impair or infringe upon Executive's right to work, earn a living, or acquire and possess property from the fruits of his labor. Executive hereby acknowledges that Executive has received good and valuable consideration for the post- employment restrictions set forth in this Section 14 in the form of the compensation and benefits provided for herein. Executive hereby further acknowledges that the post-employment restrictions set forth in this Section 14 are reasonable and that they do not, and will not, unduly impair his ability to earn a living after the termination of this Agreement.
In addition, the parties acknowledge: (A) that Executive's services under this Agreement require unique expertise and talent in the provision of Competitive Services and that Executive will have substantial contacts with customers, suppliers, advertisers and vendors of the Company; (B) that pursuant to this Agreement, Executive will be placed in a position of trust and responsibility and he will have access to a substantial amount of Confidential Information and Trade Secrets and that the Company is placing him in such position and giving him access to such information in reliance upon his agreement not to solicit customers during the Restricted Period; (C) that due to Executive's unique experience and talent, the loss of Executive's services to the Company under this Agreement cannot reasonably or adequately be compensated solely by damages in an action at law; (D) that Executive is capable of competing with the Company; and (E) that Executive is capable of obtaining gainful, lucrative and desirable employment that does not violate the restrictions contained in this Agreement.
Therefore, Executive shall be subject to the restrictions set forth in this Section 14.
(b) Definitions. The following capitalized terms used in this Section 14 shall have the meanings assigned to them below, which definitions shall apply to both the singular and the plural forms of such terms:
"Competitive Services" means the business of providing post-acute healthcare services, including home-based services through home nursing agencies and hospices and facility-based services through long-term acute care hospitals and outpatient rehabilitation clinics.
"Confidential Information" means all information regarding the Company, its activities, business or clients that is the subject of reasonable efforts by the Company to maintain its confidentiality and that is not generally disclosed by practice or authority to persons not employed by the Company, but that does not rise to the level of a Trade Secret. "Confidential Information" shall include, but is not limited to, financial plans and data concerning the Company; management planning information; business plans; operational methods; market studies; marketing plans or strategies; product development techniques or plans; customer lists; customer files, data and financial information, details of customer contracts; current and anticipated customer requirements; identifying and other information pertaining to business referral sources; past, current and planned research and development; business acquisition plans; and new personnel acquisition plans. "Confidential Information" shall not include information that has become generally available to the public by the act of one who has the right to disclose such information without violating any right or privilege of the Company. This definition shall not limit any definition of "confidential information" or any equivalent term under state or federal law.
"Determination Date" means the date of termination of Executive's employment with the Company for any reason whatsoever or any earlier date (during the Employment Period) of an alleged breach of the Restrictive Covenants by Executive.
"Person" means any individual or any corporation, partnership, joint venture, limited liability company, association or other entity or enterprise.
"Principal or Representative" means a principal, owner, partner, stockholder, joint venturer, investor, member, trustee, director, officer, manager, employee, agent, representative or consultant.
"Protected Customers" means any Person to whom the Company has sold its products or services or solicited to sell its products or services, other than through general advertising targeted at consumers, during the 12 months prior to the Determination Date.
"Protected Employees" means employees of the Company who were employed by the Company or its affiliates at any time within six months prior to the Determination Date, other than those who were discharged by the Company or such affiliated employer without cause.
"Restricted Period" means the Employment Period plus 24 months (or the Employment Period plus 6 months if Executive's termination occurs within two years after the occurrence of a Change in Control); provided, however, that the Restricted Period shall end with respect to the covenants in clauses (ii) and (iii) of Section 14(c) on the 60th day after the Date of Termination in the event the Company breaches its obligation, if any, to make any payment required under Section 8(a)(i).
"Restricted Territory" means the geographical territory described on Exhibit B hereto.
"Restrictive Covenants" means the restrictive covenants contained in Section 14(c) hereof.
"Third Party Information" means confidential or proprietary information subject to a duty on the Company's and its affiliates' part to maintain the confidentiality of such information and to use it only for certain limited purposes.
"Trade Secret" means all information, without regard to form, including, but not limited to, technical or nontechnical data, a formula, a pattern, a compilation, a program, a device, a method, a technique, a drawing, a process, financial data, financial plans, product plans, distribution lists or a list of actual or potential customers, advertisers or suppliers which is not commonly known by or available to the public and which information: (A) derives economic value, actual or potential, from not being generally known to, and not being readily ascertainable by proper means by, other persons who can obtain economic value from its disclosure or use; and (B) is the subject of efforts that are reasonable under the circumstances to maintain its secrecy. Without limiting the foregoing, Trade Secret means any item of confidential information that constitutes a "trade secret(s)" under the common law or statutory law of the State of Delaware.
"Work Product" means all inventions, innovations, improvements, developments, methods, processes, programs, designs, analyses, drawings, reports, and all similar or related information (whether or not patentable) that relate to the Company's or its affiliates' actual or anticipated business, research and development, or existing or future products or services and that are conceived, developed, contributed to, made, or reduced to practice by Executive (either solely or jointly with others) while employed by the Company or its affiliates.
(c) Restrictive Covenants.
(i) Restriction on Disclosure and Use of Confidential Information and Trade Secrets. Executive understands and agrees that the Confidential Information and Trade Secrets constitute valuable assets of the Company and its affiliated entities, and may not be converted to Executive's own use. Accordingly, Executive hereby agrees that Executive shall not, directly or indirectly, at any time during the Restricted Period reveal, divulge, or disclose to any Person not expressly authorized by the Company any Confidential Information, and Executive shall not, directly or indirectly, at any time during the Restricted Period use or make use of any Confidential Information in connection with any business activity other than that of the Company. Throughout the term of this Agreement and at all times after the date that this Agreement terminates for any reason, Executive shall not directly or indirectly transmit or disclose any Trade Secret of the Company to any Person, and shall not make use of any such Trade Secret, directly or indirectly, for himself or for others, without the prior written consent of the Company. The parties acknowledge and agree that this Agreement is not intended to, and does not, alter either the Company's rights or Executive's obligations under any state or federal statutory or common law regarding trade secrets and unfair trade practices.
Anything herein to the contrary notwithstanding, Executive shall not be restricted from disclosing or using Confidential Information or any Trade Secret that is required to be disclosed by law, court order or other legal process; provided, however, that in the event disclosure is required by law, Executive shall provide the Company with prompt notice of such requirement so that the Company may seek an appropriate protective order prior to any such required disclosure by Executive.
Executive acknowledges that any and all Confidential Information is the exclusive property of the Company and agrees to deliver to the Company on the Date of Termination, or at any other time the Company may request in writing, any and all Confidential Information which he may then possess or have under his control in whatever form same may exist, including, but not by way of limitation, hard copy files, soft copy files, computer disks, and all copies thereof.
(ii) Nonsolicitation of Protected Employees. Executive understands and agrees that the relationship between the Company and each of its Protected Employees constitutes a valuable asset of the Company and may not be converted to Executive's own use. Accordingly, Executive hereby agrees that during the Restricted Period, Executive shall not directly or indirectly on Executive's own behalf or as a Principal or Representative of any Person or otherwise solicit or induce any Protected Employee to terminate his employment relationship with the Company or to enter into employment with any other Person.
(iii) Restriction on Relationships with Protected Customers. Executive understands and agrees that the relationship between the Company and each of its Protected Customers constitutes a valuable asset of the Company and may not be converted to Executive's own use. Accordingly, Executive hereby agrees that, during the Restricted Period and in the Restricted Territory, Executive shall not, without the prior written consent of the Company, directly or indirectly, on Executive's own behalf or as a Principal or Representative of any Person, solicit, divert, take away or attempt to solicit, divert or take away a Protected Customer for the purpose of providing or selling Competitive Services; provided, however, that the prohibition of this covenant shall apply only to Protected Customers with whom Executive had Material Contact on the Company's behalf during the 12 months immediately preceding the Date of Termination; and, provided further, that the prohibition of this covenant shall not apply to the conduct of general advertising activities. For purposes of this Agreement, Executive had "Material Contact" with a Protected Customer if (a) he had business dealings with the Protected Customer on the Company's behalf; (b) he was responsible for supervising or coordinating the dealings between the Company and the Protected Customer; or (c) he obtained Trade Secrets or Confidential Information about the customer as a result of his association with the Company.
(iv) Ownership of Work Product. Executive acknowledges that the Work Product belongs to the Company or its affiliates and Executive hereby assigns, and agrees to assign, all of the Work Product to the Company or its affiliates. Any copyrightable work prepared in whole or in part by Executive in the course of his work for any of the foregoing entities shall be deemed a "work made for hire" under the copyright laws, and the Company or such affiliate shall own all rights therein. To the extent that any such copyrightable work is not a "work made for hire," Executive hereby assigns and agrees to assign to the Company or such affiliate all right, title, and interest, including without limitation, copyright in and to such copyrightable work. Executive shall promptly disclose such Work Product and copyrightable work to the Board and perform all actions reasonably requested by the Board (whether during or after the Employment Period) to establish and confirm the Company's or such affiliate's ownership (including, without limitation, assignments, consents, powers of attorney, and other instruments).
(v) Third Party Information. Executive understands that the Company and its affiliates will receive Third Party Information. During the Employment Period and thereafter, and without in any way limiting the provisions of Section 14(c)(i) above, Executive will hold Third Party Information in the strictest confidence and will not disclose to anyone (other than personnel of the Company or its affiliates who need to know such information in connection with
their work for the Company or its affiliates) or use, except in connection with his work for the Company or its affiliates, Third Party Information unless expressly authorized by a member of the Board (other than Executive) in writing.
(vi) Use of Information of Prior Employers. During the Employment Period, Executive will not improperly use or disclose any confidential information or trade secrets, if any, of any former employers or any other person to whom Executive has an obligation of confidentiality, and will not bring onto the premises of the Company or any of its affiliates any unpublished documents or any property belonging to any former employer or any other person to whom Executive has an obligation of confidentiality unless consented to by in writing the former employer or person. Executive will use in the performance of his duties only information which is (i) generally known and used by persons with training and experience comparable to Executive's and which is (x) common knowledge in the industry or (y) is otherwise legally in the public domain, (ii) is otherwise provided or developed by the Company or its affiliates or (iii) in the case of materials, property or information belonging to any former employer or other person to whom Executive has an obligation of confidentiality, approved for such use in writing by such former employer or person.
(d) Enforcement of Restrictive Covenants.
(i) Rights and Remedies Upon Breach. In the event Executive breaches, or threatens to commit a breach of, any of the provisions of the Restrictive Covenants, the Company shall have the right and remedy to enjoin, preliminarily and permanently, Executive from violating or threatening to violate the Restrictive Covenants and to have the Restrictive Covenants specifically enforced by any court or tribunal of competent jurisdiction, it being agreed that any breach or threatened breach of the Restrictive Covenants would cause irreparable injury to the Company and that money damages would not provide an adequate remedy to the Company. Such right and remedy shall be independent of any others and severally enforceable, and shall be in addition to, and not in lieu of, any other rights and remedies available to the Company at law or in equity.
(ii) Severability of Covenants. Executive acknowledges and agrees that the Restrictive Covenants are reasonable and valid in time and scope and in all other respects. The covenants set forth in this Agreement shall be considered and construed as separate and independent covenants. Should any part or provision of any covenant be held invalid, void or unenforceable, such invalidity, voidness or unenforceability shall not render invalid, void or unenforceable any other part or provision of this Agreement. If any portion of the foregoing provisions is found to be invalid or unenforceable because its duration, the territory, the definition of activities or the definition of information covered is considered to be invalid or unreasonable in scope, the invalid or unreasonable term shall be redefined, or a new enforceable term provided, such that the intent of the Company and Executive in agreeing to the provisions of this Agreement will not be impaired and the provision in question shall be enforceable to the fullest extent of the applicable laws.
(iii) Reformation. The parties hereunder agree that it is their intention that the Restrictive Covenants be enforced in accordance with their terms to the maximum extent possible under applicable law. The parties further agree that, in the event any tribunal of competent jurisdiction shall find that any provision hereof is not enforceable in accordance with its terms, the tribunal shall reform the Restrictive Covenants such that they shall be enforceable to the maximum extent permissible at law.
15. Arbitration. Any claim or dispute arising under or relating to this Agreement or the breach, termination, or validity of any term of this Agreement, including, but not by way of limitation, the legality and enforceability of the Restrictive Covenants, shall be subject to arbitration, and prior to commencing any court action, the parties agree that they shall arbitrate all controversies; provided, however, that nothing in this Section 15 shall prohibit the Company from exercising its right under Section 14(d)(i) to pursue injunctive remedies with respect to a breach or threatened breach of the Restrictive Covenants. The arbitration shall be conducted in Lafayette, Louisiana, in accordance with the Employment Dispute Rules of the American Arbitration Association and the Federal Arbitration Act, 9 U.S.C. Section 1, et. seq. The arbitrators) shall be authorized to award both liquidated and actual damages, in addition to injunctive relief, but no punitive damages. The arbitrators) may also award attorney's fees and costs, without regard to any restriction on the amount of such award under Delaware or other applicable law. Such an award shall be binding and conclusive upon the parties hereto, subject to 9 U.S.C. Section 10. Each party shall have the right to have the award made the judgment of a court of competent jurisdiction.
16. Assignment and Successors.
(a) This Agreement is personal to Executive and without the prior written consent of the Company shall not be assignable by Executive otherwise than by will or the laws of descent and distribution. This Agreement shall inure to the benefit of and be enforceable by Executive's legal representatives.
(b) This Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns.
(c) The Company will require any Surviving Entity resulting from a Reorganization, Sale or Acquisition (if other than the Company) to assume expressly and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no Reorganization, Sale or Acquisition had taken place. As used in this Agreement, "Company" shall mean the Company as hereinbefore defined and any successor to its business and/or assets as aforesaid which assumes and agrees to perform this Agreement by operation of law, or otherwise.
17. Miscellaneous.
(a) Waiver. Failure of either party to insist, in one or more instances, on performance by the other in strict accordance with the terms and conditions of this Agreement shall not be deemed a waiver or relinquishment of any right granted in this Agreement or of the future performance of any such term or condition or of any other term or condition of this Agreement, unless such waiver is contained in a writing signed by the party making the waiver.
(b) Severability. If any provision or covenant, or any part thereof, of this Agreement should be held by any tribunal of competent jurisdiction to be invalid, illegal or unenforceable, either in whole or in part, such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of the remaining provisions or covenants, or any part thereof, of this Agreement, all of which shall remain in full force and effect.
(c) Other Agents. Nothing in this Agreement is to be interpreted as limiting the Company from employing other personnel on such terms and conditions as may be satisfactory to it, except that this Section 17(c) shall not override the provision of Section 7(d)(i).
(d) Entire Agreement. Except as provided herein, this Agreement contains the entire agreement between the Company and Executive with respect to the subject matter hereof and, from and after the Effective Date, this Agreement shall supersede any other agreement between the parties with respect to the subject matter hereof, including without limitation, the Prior Agreement.
(e) Governing Law. Except to the extent preempted by federal law, and without regard to conflict of laws principles, the laws of the State of Delaware shall govern this Agreement in all respects, whether as to its validity, construction, capacity, performance or otherwise.
(f) Notices. All notices, requests, demands and other communications required or permitted hereunder shall be in writing and shall be deemed to have been duly given if delivered or three days after mailing if mailed, first class, certified mail, postage prepaid:
To the Company: LHC Group, Inc. Suite A 420 W. Pinhook Road Lafayette, LA 70503 Attention: General Counsel To Executive: John L. Indest ----------------- ----------------- |
Any party may change the address to which notices, requests, demands and other communications shall be delivered or mailed by giving notice thereof to the other party in the same manner provided herein.
(g) Amendments and Modifications. This Agreement may be amended or modified only by a writing signed by both parties hereto, which makes specific reference to this Agreement.
(h) Construction. Each party and his or its counsel have reviewed this Agreement and have been provided the opportunity to revise this Agreement and accordingly, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this Agreement. Instead, the language of all parts of this Agreement shall be construed as a whole, and according to its fair meaning, and not strictly for or against either party.
(i) Withholding. The Company or its subsidiaries, if applicable, shall be entitled to deduct or withhold from any amounts owing from the Company or any such affiliate to Executive any federal, state, local or foreign withholding taxes, excise taxes, or employment taxes ("Taxes") imposed with respect to Executive's compensation or other payments from the Company or any of its affiliates. In the event the Company or its affiliates do not make such deductions or withholdings, Executive shall indemnify the Company and its affiliates for any amounts paid with respect to any such Taxes.
IN WITNESS WHEREOF, the parties hereto have duly executed and delivered this Employment Agreement as of the date first above written.
LHC GROUP, INC.
By: /s/ [ILLEGIBLE] ------------------------------------------- Title: President/ CEO ---------------------------------------- |
EXECUTIVE:
/s/ JOHN L. INDEST ------------------------------------------------ John L. Indest |
EXHIBIT A
Form of Release
THIS RELEASE ("Release") is granted effective as of the______day of, 20_______ , by_______("Executive") in favor of LHC Group, Inc. (the "Company"). This is the Release referred to that certain Employment Agreement effective as of, 200______ by and between the Company and Executive (the "Employment Agreement"), with respect to which this Release is an integral part.
FOR AND IN CONSIDERATION of the payments and benefits provided by Section 8
of the Employment Agreement and the Company's other promises and covenants as
recited in the Employment Agreement, the receipt and sufficiency of which are
hereby acknowledged, Executive, for himself, his successors and assigns, now and
forever hereby releases and discharges the Company and all its past and present
officers, directors, stockholders, employees, agents, parent corporations,
predecessors, subsidiaries, affiliates, estates, successors, assigns, benefit
plans, consultants, administrators, and attorneys (hereinafter collectively
referred to as "Releasees") from any and all claims, charges, actions, causes of
action, sums of money due, suits, debts, covenants, contracts, agreements,
promises, demands or liabilities (hereinafter collectively referred to as
"Claims") whatsoever, in law or in equity, whether known or unknown, which
Executive ever had or now has from the beginning of time up to the date this
Release ("Release") is executed, including, but not limited to, claims under the
Age Discrimination in Employment Act, as amended by the Older Workers Benefit
Protection Act, Title VII of the Civil Rights Act of 1964 (and all of its
amendments), the Americans with Disabilities Act, as amended, or any other
federal or state statutes, all tort claims, all claims for wrongful employment
termination or breach of contract, and any other claims which Executive has,
had, or may have against the Releasees on account of or arising out of
Executive's employment with or termination from the Company; provided, however,
that nothing contained in this Release shall in any way diminish or impair (i)
any rights of Executive to the benefits conferred or referenced in the
Employment Agreement or Executive's Retention Bonus Agreement with the Company,
(ii) any rights to indemnification that may exist from time to time under the
Company's bylaws, certificate of incorporation, Delaware law or otherwise, or
(iii) Executive's ability to raise an affirmative defense in connection with any
lawsuit or other legal claim or charge instituted or asserted by the Company
against Executive.
Without limiting the generality of the foregoing, Executive hereby acknowledges and covenants that in consideration for the sums being paid to him he has knowingly waived any right or opportunity to assert any claim that is in any way connected with any employment relationship or the termination of any employment relationship which existed between the Company and Executive. Executive further understands and agrees that he has knowingly relinquished, waived and forever released any and all remedies arising out of the aforesaid employment relationship or the termination thereof, including, without limitation, claims for backpay, front pay, liquidated damages, compensatory damages, general damages, special damages, punitive damages, exemplary damages, costs, expenses and attorneys' fees.
Executive specifically acknowledges and agrees that he has knowingly and
voluntarily released the Company and all other Releasees from any and all claims
arising under the Age Discrimination in Employment Act ("ADEA"), 29U.S.C.
Section 621, et seq., which Executive ever had or now has from the beginning of
time up to the date this Release is executed, including but not limited to those
claims which are in any way connected with any employment relationship or
the termination of any employment relationship which existed between the Company and Executive. Executive further acknowledges and agrees that he has been advised to consult with an attorney prior to executing this Release and that he has been given twenty-one (21) days to consider this Release prior to its execution. Executive also understands that he may revoke this Release at any time within seven (7) days following its execution. Executive understands, however, that this Release shall not become effective and that none of the consideration described above shall be paid to him until the expiration of the seven-day revocation period.
Executive agrees never to seek reemployment or future employment with the Company or any of the other Releasees.
Executive acknowledges that the terms of this Release must be kept confidential. Accordingly, Executive agrees not to disclose or publish to any person or entity, except as required by law or as necessary to prepare tax returns, the terms and conditions or sums being paid in connection with this Release.
It is understood and agreed by Executive that the payment made to him is not to be construed as an admission of any liability whatsoever on the part of the Company or any of the other Releasees, by whom liability is expressly denied.
This Release is executed by Executive voluntarily and is not based upon any representations or statements of any kind made by the Company or any of the other Releasees as to the merits, legal liabilities or value of his claims. Executive further acknowledges that he has had a full and reasonable opportunity to consider this Release and that he has not been pressured or in any way coerced into executing this Release.
Executive acknowledges and agrees that this Release may not be revoked at any time after the expiration of the seven-day revocation period and that he will not institute any suit, action, or proceeding, whether at law or equity, challenging the enforceability of this Release. Executive further acknowledges and agrees that, with the exception of an action to challenge his waiver of claims under the ADEA, he shall not ever attempt to challenge the terms of this Release, attempt to obtain an order declaring this Release to be null and void, or institute litigation against the Company or any other Releasee based upon a claim which is covered by the terms of the release contained herein, without first repaying all monies paid to him under Section 8 of the Employment Agreement. Furthermore, with the exception of an action to challenge his waiver of claims under the ADEA, if Executive does not prevail in an action to challenge this Release, to obtain an order declaring this Release to be null and void, or in any action against the Company or any other Releasee based upon a claim which is covered by the release set forth herein, Executive shall pay to the Company and/or the appropriate Releasee all their costs and attorneys' fees incurred in their defense of Executive's action.
This Release and the rights and obligations of the parties hereto shall be governed and construed in accordance with the laws of the State of Georgia. If any provision hereof is unenforceable or is held to be unenforceable, such provision shall be fully severable, and this document and its terms shall be construed and enforced as if such unenforceable provision had never comprised a part hereof, the remaining provisions hereof shall remain in full force and effect, and the court construing the provisions shall add as a part hereof a provision as similar in terms and effect to such unenforceable provision as may be enforceable, in lieu of the unenforceable provision.
This document contains all terms of the Release and supersedes and invalidates any previous agreements or contracts. No representations, inducements, promises or agreements, oral or otherwise, which are not embodied herein shall be of any force or effect.
IN WITNESS WHEREOF, the undersigned acknowledges that he has read these
three pages and he sets his hand and seal this________day of ___________,
20 _____ .
Sworn to and subscribed
before me this ______________day of
_____________, 20__.
My Commission Expires:
EXHIBIT B
Restricted Territory
EXHIBIT 10.9
EMPLOYMENT AGREEMENT
BETWEEN
DARYL J. DOISE
AND
LHC GROUP, INC.
EMPLOYMENT AGREEMENT
1. Effective Date.............................................................1 2. Employment.................................................................1 3. Employment Period..........................................................1 4. Extent of Service..........................................................1 5. Compensation and Benefits..................................................2 (a) Base Salary....................................................2 (b) Incentive, Savings and Retirement Plans........................2 (c) Welfare Benefit Plans..........................................2 (d) Expenses.......................................................2 (e) Fringe Benefits................................................3 (f) Vacation.......................................................3 (g) Office and Support Staff.......................................3 6. Change of Control..........................................................3 7. Termination of Employment..................................................4 (a) Death or Retirement............................................4 (b) Disability.....................................................4 (c) Termination by the Company.....................................5 (d) Termination by Executive.......................................5 (e) Notice of Termination..........................................5 (f) Date of Termination............................................6 8. Obligations of the Company upon Termination................................6 (a) Termination by Executive for Good Reason; Termination by the Company Other Than for Cause or Disability..................................................6 (b) Death, Disability or Retirement................................8 (c) Cause or Voluntary Termination without Good Reason.........................................................8 (d) Expiration of Employment Period................................8 (e) Resignations...................................................8 9. Non-exclusivity of Rights..................................................8 10. Full Settlement; No Obligation to Mitigate.................................8 11. Certain Additional Payments by the Company.................................9 |
12. Costs of Enforcement......................................................11 13. Representations and Warranties............................................11 14. Restrictions on Conduct of Executive......................................11 (a) General.......................................................11 (b) Definitions...................................................11 (c) Restrictive Covenants.........................................13 (d) Enforcement of Restrictive Covenants..........................15 15. Arbitration...............................................................16 16. Assignment and Successors.................................................16 17. Miscellaneous.............................................................16 |
EMPLOYMENT AGREEMENT
THIS EMPLOYMENT AGREEMENT (this "Agreement") is made and entered into this ____ day of January, 2005 by and between LHC Group, Inc., a Delaware corporation (the "Company"), and Daryl J. Doise ("Executive"), to be effective as of the Effective Date, as defined in Section 1.
BACKGROUND
Executive currently serves as Senior Vice President and Chief Operating Officer of Facility-Based Services of the Company. The Company desires to continue to engage Executive in such capacity from and after the Effective Date, in accordance with the terms of this Agreement. Executive is willing to serve as such in accordance with the terms and conditions of this Agreement.
NOW, THEREFORE, in consideration of the foregoing and of the mutual covenants and agreements set forth herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:
1. Effective Date. The effective date of this Agreement (the "Effective Date") shall be the effective date of a registration statement on Form S-l for the initial public offering of the common stock of the Company.
2. Employment. Executive is hereby employed on the Effective Date as Senior Vice President and Chief Operating Officer of Facility-Based Services of the Company. In his capacity as Senior Vice President and Chief Operating Officer of Facility-Based Services of the Company, Executive shall have the duties, responsibilities and authority commensurate with such position as shall be assigned to him by the Chief Executive Officer and/or the Board of Directors of the Company. In his capacity as Senior Vice President and Chief Operating Officer of Facility-Based Services of the Company, Executive will report directly to the Chief Executive Officer of the Company.
3. Employment Period. Unless earlier terminated herein in accordance with
Section 7 hereof, Executive's employment shall be for a three year term,
beginning on the Effective Date and ending on the third anniversary of the
Effective Date (the "Employment Period"). Beginning on the third anniversary of
the Effective Date and on each subsequent anniversary of the Effective Date, the
Employment Period shall, without further action by Executive or the Company, be
extended by an additional one-year period; provided, however, that either the
Company or the Executive may, by notice to the other given at least sixty (60)
days prior to the scheduled expiration of the Employment Period, cause the
Employment Period to cease to extend automatically. Upon such notice, the
Employment Period shall terminate upon the expiration of the then-current term,
including any prior extensions.
4. Extent of Service. During the Employment Period, and excluding any periods of vacation, holiday, sick leave and Company-approved leave of absence to which Executive is entitled in accordance with Company policies, Executive agrees to devote substantially all of his business time, attention, skill and efforts exclusively to the faithful performance of his duties hereunder. It shall not be a violation of this Agreement for Executive to (i) devote reasonable time to charitable or community activities, (ii) serve on corporate, civic, educational or charitable boards or committees, subject to the Company's standards of business conduct or other code of ethics, (iii) deliver lectures or fulfill speaking engagements from time to time on an infrequent
basis, and/or (iv) manage personal business interests and investments, subject to the Company's standards of business conduct or other code of ethics, and so long as such activities do not interfere in a material manner or on a routine basis with the performance of Executive's responsibilities under this Agreement.
5. Compensation and Benefits.
(a) Base Salary. During the Employment Period, the Company will pay to Executive base salary at the rate of U.S. $200,000 per year ("Base Salary"), less normal withholdings, payable in approximately equal bi-weekly or other installments as are or become customary under the Company's payroll practices for its employees from time to time. The compensation committee of the Board of Directors of the Company (or the full Board, if there is no compensation committee) shall review Executive's Base Salary annually and may increase (but not decrease) Executive's Base Salary from year to year. Such adjusted salary then shall become Executive's Base Salary for purposes of this Agreement. The annual review of Executive's salary by the Board will consider, among other things, Executive's own performance, and the Company's performance.
(b) Incentive, Savings and Retirement Plans. During the Employment Period, Executive shall be entitled to participate in all incentive, savings and retirement plans, practices, policies and programs available to senior executive officers of the Company ("Peer Executives"), and on the same basis as such Peer Executives. Without limiting the foregoing, the following shall apply:
(i) during the Employment Period, Executive will be entitled to participate in the Company's executive bonus plan, pursuant to which he will have an opportunity to receive an annual cash bonus based upon the achievement of performance goals established from year to year by the compensation committee of the Board of Directors of the Company (such bonus earned at the stated "goal" level of achievement being referred to herein as the "Target Bonus"); and
(ii) during the Employment Period, Executive will be eligible for grants, under the Company's long-term incentive plan or plans, of stock options and/or restricted stock awards (or such other stock-based awards as the Company makes to Peer Executives), having terms and determined in the same manner as awards to other Peer Executives, unless the Executive consents to a different type of award or different terms of such award than are applicable to other Peer Executives. Nothing herein requires the Board of Directors to make grants of options or other awards in any year.
(c) Welfare Benefit Plans. During the Employment Period, Executive and Executive's eligible dependents shall be eligible for participation in, and shall receive all benefits under, the welfare benefit plans, practices, policies and programs provided by the Company (including, without limitation, medical, prescription drug, dental, disability, employee life, dependent life, accidental death and travel accident insurance plans and programs) ("Welfare Plans") to the extent available to other Peer Executives.
(d) Expenses. During the Employment Period, Executive shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by Executive in the course of performing his duties and responsibilities under this Agreement, in accordance with the policies, practices and procedures of the Company to the extent available to other Peer Executives with respect to travel, entertainment and other business expenses.
(e) Fringe Benefits. During the Employment Period, Executive shall be entitled to fringe benefits in accordance with the plans, practices, programs and policies of the Company available to other Peer Executives.
(f) Vacation. During the Employment Period, Executive will be entitled to such paid vacation time as may be provided from time to time under any plans, practices, programs and policies of the Company available to other Peer Executives.
(g) Office and Support Staff. During the Employment Period, Executive will be entitled to office, furnishings and equipment of similar type and quality made available to other Peer Executives. During the Employment Period, Executive will be entitled to secretarial and other assistance reasonably necessary for the performance of his duties and responsibilities.
6. Change of Control. For the purposes of this Agreement, a "Change of Control" shall mean the occurrence of any of the following events:
(a) individuals who, on the Effective Date, constitute the Board of
Directors of the Company (the "Incumbent Directors") cease for any
reason to constitute at least a majority of such Board, provided that
any person becoming a director after the Effective Date and whose
election or nomination for election was approved by a vote of at least
a majority of the Incumbent Directors then on the Board shall be an
Incumbent Director; provided, however, that no individual initially
elected or nominated as a director of the Company as a result of an
actual or threatened election contest with respect to the election or
removal of directors ("Election Contest") or other actual or
threatened solicitation of proxies or consents by or on behalf of any
"person" (such term for purposes of this Section 6 being as defined in
Section 3(a)(9) of the Securities Exchange Act of 1934 (the "Exchange
Act") and as used in Section 13(d)(3) and 14(d)(2) of the Exchange
Act) other than the Board ("Proxy Contest"), including by reason of
any agreement intended to avoid or settle any Election Contest or
Proxy Contest, shall be deemed an Incumbent Director; or
(b) any person is or becomes a "beneficial owner" (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of either (i) 35% or more of the then-outstanding shares of common stock of the Company ("Company Common Stock") or (ii) securities of the Company representing 35% or more of the combined voting power of the Company's then outstanding securities eligible to vote for the election of directors (the "Company Voting Securities"); provided, however, that for purposes of this paragraph (b), the following acquisitions of Company Common Stock or Company Voting Securities shall not constitute a Change of Control: (A) an acquisition directly from the Company, (B) an acquisition by the Company or a subsidiary of the Company, (C) an acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any subsidiary of the Company, or (D) an acquisition pursuant to a Non-Qualifying Transaction (as defined in paragraph (c) below); or
(c) the consummation of a recapitalization, reorganization, merger,
consolidation, statutory share exchange or similar form of transaction
involving the Company or a subsidiary of the Company (a
"Reorganization"), or the sale or other disposition of all or
substantially all of the Company's assets (a "Sale") or the
acquisition of assets or stock of another entity (an "Acquisition"),
unless immediately following such Reorganization, Sale or Acquisition:
(A) all or substantially all of the individuals
and entities who were the beneficial owners, respectively, of the outstanding Company Common Stock and outstanding Company Voting Securities immediately prior to such Reorganization, Sale or Acquisition beneficially own, directly or indirectly, more than 50% of, respectively, the then outstanding shares of common stock and the combined voting power of the then outstanding voting securities entitled to vote generally in the election of directors, as the case may be, of the entity resulting from or surviving such Reorganization, Sale or Acquisition (including, without limitation, an entity which as a result of such transaction owns the Company or all or substantially all of the Company's assets or stock either directly or through one or more subsidiary entities, the "Surviving Entity") in substantially the same proportions as their ownership, immediately prior to such Reorganization, Sale or Acquisition, of the outstanding Company Common Stock and the outstanding Company Voting Securities, as the case may be, and (B) no person (other than (x) the Company or any subsidiary of the Company, (y) the Surviving Entity or its ultimate parent entity, or (z) any employee benefit plan (or related trust) sponsored or maintained by any of the foregoing) is the beneficial owner, directly or indirectly, of 35% or more of the total common stock or 35% or more of the total voting power of the outstanding voting securities eligible to elect directors of the Surviving Entity, and (C) at least a majority of the members of the board of directors of the Surviving Entity were Incumbent Directors at the time of the Board's approval of the execution of the initial agreement providing for such Reorganization, Sale or Acquisition (any Reorganization, Sale or Acquisition which satisfies all of the criteria specified in (A), (B) and (C) above shall be deemed to be a "Non-Qualifying Transaction"); or
(d) approval by the members or stockholders of the Company, as the case may be, of a complete liquidation or dissolution of the Company.
7. Termination of Employment.
(a) Death or Retirement. Executive's employment shall terminate automatically upon Executive's death or Retirement during the Employment Period. For purposes of this Agreement, "Retirement" shall mean normal retirement as defined in the Company's then-current retirement plan, or if there is no such retirement plan, "Retirement" shall mean voluntary termination after age 65 with at least ten years of service.
(b) Disability. If the Company determines in good faith that the Disability (as defined below) of Executive has occurred during the Employment Period, it may give to Executive written notice of its intention to terminate Executive's employment. In such event, Executive's employment with the Company shall terminate effective on the 30th day after receipt of such written notice by Executive (the "Disability Effective Date"), provided that, within the 30 days after such receipt, Executive shall not have returned to full-time performance of Executive's duties. For purposes of this Agreement, "Disability" shall have the same meaning as provided in the long-term disability plan or policy maintained by the Company and covering Executive. If no such long-term disability plan or policy is maintained, "Disability" shall mean the inability of Executive, as determined by the Board, to perform the essential functions of his regular duties and responsibilities, with or without reasonable accommodation, due to a medically determinable physical or mental illness which has lasted (or can reasonably be expected to last) for a period of six consecutive months.
(c) Termination by the Company. The Company may terminate Executive's employment during the Employment Period with or without Cause. For purposes of this Agreement, "Cause" shall mean:
(i) the continued failure of Executive to perform substantially Executive's duties with the Company (other than any such failure resulting from incapacity due to physical or mental illness, or following Executive's delivery of notice of termination for Good Reason, and specifically excluding any failure by Executive, after reasonable efforts, to meet performance expectations), after a written demand for substantial performance is delivered to Executive by the Board which specifically identifies the manner in which the Board believes that Executive has not substantially performed Executive's duties, or
(ii) the engaging by Executive in illegal conduct or gross misconduct which is injurious to the Company, or
(iii) the conviction of Executive, or a plea of guilty or nolo contendere by Executive, to a felony or other crime involving moral turpitude.
(d) Termination by Executive. Executive's employment may be terminated by Executive for Good Reason or no reason. For purposes of this Agreement, unless written consent of Executive is obtained, "Good Reason" shall mean:
(i) the assignment to Executive of duties inconsistent in material respect with Executive's position (including status, offices, titles and reporting requirements), authority, duties or responsibilities as in effect on the Effective Date, or a material diminution in such position, authority, duties or responsibilities, excluding for this purpose an isolated, insubstantial and inadvertent action not taken in bad faith and which is remedied by the Company promptly after receipt of notice thereof given by Executive;
(ii) a reduction by the Company in Executive's Base Salary or Target Bonus as in effect on the Effective Date or, with respect to Executive's Base Salary, as the same may be increased from time to time;
(iii) any failure by the Company to comply with and satisfy 16(c) of this Agreement; or
(v) the material breach by the Company of any other provision of this Agreement.
Any claim of "Good Reason" under this Agreement shall be communicated by Executive to the Company in writing, which writing shall specifically identify the factual details concerning the event(s) giving rise to Executive's claim of Good Reason under this Section 7(d). The Company shall have an opportunity to cure any claimed event of Good Reason within 30 days of such notice from Executive.
(e) Notice of Termination. Any termination by the Company for Cause, or by Executive for Good Reason, shall be communicated by Notice of Termination to the other party hereto given in accordance with Section 17(f) of this Agreement. For purposes of this Agreement, a "Notice of Termination" means a written notice which (i) indicates the specific termination provision in this Agreement relied upon, (ii) to the extent applicable, sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of
Executive's employment under the provision so indicated, and (iii) specifies the termination date. The failure by Executive or the Company to set forth in the Notice of Termination any fact or circumstance which contributes to a showing of Good Reason or Cause shall not waive any right of Executive or the Company, respectively, hereunder or preclude Executive or the Company, respectively, from asserting such fact or circumstance in enforcing Executive's or the Company's rights hereunder.
(f) Date of Termination. "Date of Termination" means (i) if Executive's employment is terminated by the Company for Cause, or by Executive for Good Reason, the date of receipt of the Notice of Termination or a date within 30 days after receipt of the Notice of Termination, as specified in such notice, (ii) if Executive's employment is terminated by the Company other than for Cause or Disability, the Date of Termination shall be the date of receipt of the Notice of Termination or a date within 90 days after receipt of the Notice of Termination, as specified in such notice, (iii) if Executive's employment is terminated by reason of death or Disability, the Date of Termination shall be the date of death of Executive or the Disability Effective Date, as the case may be, and (iv) if Executive's employment is terminated by Executive without Good Reason, the Date of Termination shall be 60 days following the Company's receipt of the Notice of Termination, unless the Company specifies an earlier Date of Termination.
8. Obligations of the Company upon Termination.
(a) Termination by Executive for Good Reason: Termination by the Company Other Than for Cause or Disability. If, during the Employment Period, the Company shall terminate Executive's employment other than for Cause or Disability, or Executive shall terminate employment for Good Reason within a period of 90 days after the occurrence of the event giving rise to Good Reason, then and, with respect to the payments and benefits described in clauses (i)(B) and (ii) below, only if Executive executes a Release in substantially the form of Exhibit A hereto (the "Release"):
(i) the Company shall provide to Executive in a single lump sum cash payment within 30 days after the Date of Termination, or if later, within five days after the Release becomes effective and nonrevocable, the aggregate of the following amounts:
A. the sum of the following amounts, to the extent not
previously paid to Executive (the "Accrued Obligations"): (1) Executive's
Base Salary through the Date of Termination, (2) a pro-rata bonus for the
year in which the Date of Termination occurs, computed as the product of
(x) Executive's Target Bonus for such year and (y) a fraction, the
numerator of which is the number of days in the current fiscal year
through the Date of Termination, and the denominator of which is 365, (3)
any accrued pay in lieu of unused vacation (in accordance with the
Company's vacation policy), and (4) unless Executive has a later payout
date that is required in connection with the terms of a deferral plan or
agreement, any vested compensation previously deferred by Executive
(together with any amount equivalent to accrued interest or earnings
thereon); and
B. a severance payment as determined pursuant to clause
(x) or (y) below, as applicable:
(x) if the Date of Termination occurs before, or more than two years after, the occurrence of a Change of Control, the severance payment shall be the product of 24 (the "Regular Severance Factor") times one twelfth of the sum of
(1) Executive's Base Salary in effect as of the Date of Termination (ignoring any decrease in Executive's Base Salary unless consented to by Executive), and (2) the greater of the average of the annual bonuses earned by Executive for the two fiscal years in which annual bonuses were paid immediately preceding the year in which the Date of Termination occurs, or Executive's Target Bonus for the year in which the Date of Termination occurs; or
(y) if the Date of Termination occurs within two years after the occurrence of a Change of Control, the severance payment shall be the product of 30 (the "Change of Control Severance Factor") times one twelfth of the sum of (1) Executive's Base Salary in effect as of the Date of Termination, and (2) the greater of the average of the annual bonuses earned by Executive for the two fiscal years in which annual bonuses were paid immediately preceding the year in which the Date of Termination occurs, or Executive's Target Bonus for the year in which the Date of Termination occurs; and
(ii) the Company shall continue to provide, for a number of months equal to the Regular Severance Factor or the Change of Control Severance Factor (determined in Section 8(a)(i)(B)(x) or (y) above, as applicable) after Executive's Date of Termination (the "Welfare Benefits Continuation Period"), or such longer period as may be provided by the terms of the appropriate plan, program, practice or policy, any group health benefits to which Executive and/or Executive's eligible dependents would otherwise be entitled to continue under COBRA, or benefits substantially equivalent to those group health benefits which would have been provided to them in accordance with the Welfare Plans described in Section 5(c) of this Agreement if Executive's employment had not been terminated, provided, however, that if Executive becomes employed with another employer (including self-employment) and receives group health benefits under another employer provided plan, the Company's obligation to provide group health benefits described herein shall cease, except as otherwise provided by law and provided, further, that the Welfare Benefits Continuation Period shall run concurrently with any period for which Executive is eligible to elect health coverage under COBRA; and
(iii) all grants of stock options and other equity awards granted by the Company and held by Executive as of the Date of Termination will become immediately vested and exercisable as of the Date of Termination and, to the extent necessary, this Agreement is hereby deemed an amendment of any such outstanding stock option or other equity award; and
(iv) to the extent not theretofore paid or provided, the Company shall timely pay or provide to Executive any other amounts or benefits required to be paid or provided or which Executive is eligible to receive under any plan, program, policy or practice of the Company to the extent provided to Peer Executives prior to the Date of Termination (such other amounts and benefits shall be hereinafter referred to as the "Other Benefits").
If Executive's employment is terminated by the Company without Cause prior to the occurrence of a Change in Control and if it can reasonably be shown that Executive's termination (i) was at the direction or request of a third party that had taken steps reasonably calculated to effect a Change in Control after such termination, or (ii) otherwise occurred in anticipation of a Change in Control, and in either case a Change in Control as defined hereunder does, in fact, occur, then Executive shall have the rights described in this Section 8(a) as if the Change in Control had occurred on the date immediately preceding the Date of Termination.
Executive acknowledges and agrees that the receipt of severance benefits provided in this Section 8(a) constitutes consideration for the restrictions on the conduct of Executive contained in Section 14 of this Agreement.
(b) Death, Disability or Retirement. If Executive's employment is terminated by reason of his death, Disability or Retirement during the Employment Period, this Agreement shall terminate without further obligations to Executive or his estate, beneficiaries or legal representatives, other than for payment of Accrued Obligations and the timely payment or provision of Other Benefits. Accrued Obligations shall be paid to Executive or his estate, beneficiary or legal representative, as applicable, in a lump sum in cash within 30 days of the Date of Termination. With respect to the provision of Other Benefits, the term Other Benefits as used in this Section 8(b) shall include, without limitation, and Executive or his estate, beneficiaries or legal representatives, as applicable, shall be entitled to receive, benefits under such plans, programs, practices and policies relating to death, disability or retirement benefits, if any, as are applicable to Executive or his family on the Date of Termination.
(c) Cause or Voluntary Termination without Good Reason. If Executive's employment shall be terminated for Cause during the Employment Period, or if Executive voluntarily terminates employment during the Employment Period without Good Reason, this Agreement shall terminate without further obligations to Executive, other than for payment of Accrued Obligations (excluding the pro-rata bonus described in clause 2 of Section 8(a)(i)(A)) and the timely payment or provision of Other Benefits.
(d) Expiration of Employment Period. If Executive's employment shall be terminated due to the normal expiration of the Employment Period, this Agreement shall terminate without further obligations to Executive, other than for payment of Accrued Obligations and the timely payment or provision of Other Benefits.
(e) Resignations. Termination of Executive's employment for any reason whatsoever shall constitute Executive's resignation as an officer of the Company, its subsidiaries and affiliates.
9. Non-exclusivity of Rights. Nothing in this Agreement shall prevent or limit Executive's continuing or future participation in any employee benefit plan, program, policy or practice provided by the Company and for which Executive may qualify, except as specifically provided herein. Amounts which are vested benefits or which Executive is otherwise entitled to receive under any employee benefit plan, policy, practice or program of the Company, its subsidiaries or any of its affiliated companies at or subsequent to the Date of Termination shall be payable in accordance with such plan, policy, practice or program except as explicitly modified by this Agreement.
10. Full Settlement: No Obligation to Mitigate. The Company's obligation to make the payments provided for in this Agreement and otherwise to perform its obligations hereunder shall not be affected by any set-off, counterclaim, recoupment, defense or other claim, right or action which the Company may have against Executive or others. In no event shall Executive be obligated to seek other employment or take any other action by way of mitigation of the amounts payable to Executive under any of the provisions of this Agreement and, except as explicitly provided herein, such amounts shall not be reduced whether or not Executive obtains other employment.
11. Certain Additional Payments by the Company.
(a) Anything in this Agreement to the contrary notwithstanding and except as set forth below, in the event it shall be determined that any payment or distribution by the Company to or for the benefit of Executive (whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, but determined without regard to any additional payments required under this Section 11) (a "Payment") would be subject to the excise tax imposed by Section 4999 of the Internal Revenue Code of 1986, as amended (the "Code") or any interest or penalties are incurred by Executive with respect to such excise tax (such excise tax, together with any such interest and penalties, are hereinafter collectively referred to as the "Excise Tax"), then Executive shall be entitled to receive an additional payment (a "Gross-Up Payment") in an amount such that after payment by Executive of all taxes (including any interest or penalties imposed with respect to such taxes), including, without limitation, any income taxes (and any interest and penalties imposed with respect thereto) and Excise Tax imposed upon the Gross-Up Payment, Executive retains an amount of the Gross-Up Payment equal to the Excise Tax imposed upon the Payments. Notwithstanding the foregoing provisions of this Section 1l(a), if it shall be determined that Executive is entitled to a Gross-Up Payment, but that Executive, after taking into account the Payments and the Gross-Up Payment, would not receive a net after-tax benefit of at least $50,000 (taking into account both income taxes and any Excise Tax) as compared to the net after-tax proceeds to Executive resulting from an elimination of the Gross-Up Payment and a reduction of the Payments, in the aggregate, to an amount (the "Reduced Amount") such that the receipt of Payments would not give rise to any Excise Tax, then no Gross-Up Payment shall be made to Executive and the Payments, in the aggregate, shall be reduced to the Reduced Amount. Executive may select the Payments to be limited or reduced.
(b) Subject to the provisions of Section 1l(c), all determinations
required to be made under this Section 11, including whether and when a Gross-Up
Payment is required and the amount of such Gross-Up Payment and the assumptions
to be used in arriving at such determination, shall be made by a certified
public accounting firm selected by Executive (other than the Company's regular
accounting firm) and reasonably acceptable to the Company (the "Accounting
Firm") which shall provide detailed supporting calculations both to the Company
and Executive within 15 business days of the receipt of notice from Executive
that there has been a Payment, or such earlier time as is reasonably requested
by the Company. All fees and expenses of the Accounting Firm shall be borne
solely by the Company. Any Gross-Up Payment, as determined pursuant to this
Section 11, shall be paid by the Company to Executive within five days of the
receipt of the Accounting Firm's determination. Any determination by the
Accounting Firm shall be binding upon the Company and Executive. As a result of
the uncertainty in the application of Section 4999 of the Code at the time of
the initial determination by the Accounting Firm hereunder, it is possible that
Gross-Up Payments which will not have been made by the Company should have been
made ("Underpayment"), consistent with the calculations required to be made
hereunder. In the event that the Company exhausts its remedies pursuant to
Section 1l(c) and Executive thereafter is required to make a payment of any
Excise Tax, the Accounting Firm shall determine the amount of the Underpayment
that has occurred and any such Underpayment shall be promptly paid by the
Company to or for the benefit of Executive.
(c) Executive shall notify the Company in writing of any claim by the Internal Revenue Service that, if successful, would require the payment by the Company of a Gross-Up Payment (or an additional Gross-Up Payment). Such notification shall be given as soon as practicable but no later than ten business days after Executive is informed in writing of such claim and shall apprise the Company of the nature of such claim and the date on which such
claim is requested to be paid. Executive shall not pay such claim prior to the expiration of the 30-day period following the date on which he gives such notice to the Company (or such shorter period ending on the date that any payment of taxes with respect to such claim is due). If the Company notifies Executive in writing prior to the expiration of such period that it desires to contest such claim, Executive shall:
(i) give the Company any information reasonably requested by the Company relating to such claim,
(ii) take such action in connection with contesting such claim as the Company shall reasonably request in writing from time to time, including, without limitation, accepting legal representation with respect to such claim by an attorney reasonably selected by the Company,
(iii) cooperate with the Company in good faith in order effectively to contest such claim, and
(iv) permit the Company to participate in any proceedings relating to such claim;
provided, however, that the Company shall bear and pay directly all costs and expenses (including additional interest and penalties) incurred in connection with such contest and shall indemnify and hold Executive harmless, on an after-tax basis, for any Excise Tax or income tax (including interest and penalties with respect thereto) imposed as a result of such representation and payment of costs and expenses. Without limitation of the foregoing provisions of this Section 11(c), the Company shall control all proceedings taken in connection with such contest (to the extent applicable to the Excise Tax and the Gross-Up Payment) and, at its sole option, may pursue or forgo any and all administrative appeals, proceedings, hearings and conferences with the taxing authority in respect of such claim and may, at its sole option, either direct Executive to pay the tax claimed and sue for a refund or contest the claim in any permissible manner, and Executive agrees to prosecute such contest to a determination before any administrative tribunal, in a court of initial jurisdiction and in one or more appellate courts, as the Company shall determine; provided, however, that if the Company directs Executive to pay such claim and sue for a refund, the Company shall advance the amount of such payment to Executive, on an interest-free basis and shall indemnify and hold Executive harmless, on an after-tax basis, from any Excise Tax or income tax (including interest or penalties with respect thereto) imposed with respect to such advance or with respect to any imputed income with respect to such advance; and further provided that any extension of the statute of limitations relating to payment of taxes for the taxable year of Executive with respect to which such contested amount is claimed to be due is limited solely to such contested amount. Furthermore, the Company's control of the contest shall be limited to issues with respect to which a Gross-Up Payment would be payable hereunder and Executive shall be entitled to settle or contest, as the case may be, any other issue raised by the Internal Revenue Service or any other taxing authority.
(d) If, after the receipt by Executive of an amount advanced by the Company pursuant to Section 11(c), Executive becomes entitled to receive any refund with respect to such claim, Executive shall (subject to the Company's complying with the requirements of Section 11(c)) promptly pay to the Company the amount of such refund (together with any interest paid or credited thereon after taxes applicable thereto). If, after the receipt by Executive of an amount advanced by the Company pursuant to Section 11(c), a determination is made that Executive shall not be entitled to any refund with respect to such claim and the Company does not notify
Executive in writing of its intent to contest such denial of refund prior to the expiration of 30 days after such determination, then such advance shall be forgiven and shall not be required to be repaid and the amount of such advance shall offset, to the extent thereof, the amount of Gross-Up Payment required to be paid.
12. Costs of Enforcement. In any action taken in good faith relating to the enforcement of this Agreement or any provision herein, Executive shall be entitled to reimbursement for any and all costs and expenses incurred by him in enforcing or establishing his rights thereunder, including, without limitation, reasonable attorneys' fees, whether suit be brought or not, and whether or not incurred in arbitration, trial, bankruptcy or appellate proceedings, but only if and to the extent Executive is successful in asserting such rights. Executive shall also be entitled to be paid all reasonable legal fees and expenses, if any, incurred in connection with any tax audit or proceeding to the extent attributable to the application of Section 4999 of the Internal Revenue Code to any payment or benefit hereunder.
13. Representations and Warranties. Executive hereby represents and warrants to the Company that Executive is not a party to, or otherwise subject to, any covenant not to compete with any person or entity, and Executive's execution of this Agreement and performance of his obligations hereunder will not violate the terms or conditions of any contract or obligation, written or oral, between Executive and any other person or entity.
14. Restrictions on Conduct of Executive.
(a) General. Executive and the Company understand and agree that the purpose of the provisions of this Section 14 is to protect legitimate business interests of the Company, as more fully described below, and is not intended to impair or infringe upon Executive's right to work, earn a living, or acquire and possess property from the fruits of his labor. Executive hereby acknowledges that Executive has received good and valuable consideration for the post- employment restrictions set forth in this Section 14 in the form of the compensation and benefits provided for herein. Executive hereby further acknowledges that the post-employment restrictions set forth in this Section 14 are reasonable and that they do not, and will not, unduly impair his ability to earn a living after the termination of this Agreement.
In addition, the parties acknowledge: (A) that Executive's services under this Agreement require unique expertise and talent in the provision of Competitive Services and that Executive will have substantial contacts with customers, suppliers, advertisers and vendors of the Company; (B) that pursuant to this Agreement, Executive will be placed in a position of trust and responsibility and he will have access to a substantial amount of Confidential Information and Trade Secrets and that the Company is placing him in such position and giving him access to such information in reliance upon his agreement not to solicit customers during the Restricted Period; (C) that due to Executive's unique experience and talent, the loss of Executive's services to the Company under this Agreement cannot reasonably or adequately be compensated solely by damages in an action at law; (D) that Executive is capable of competing with the Company; and (E) that Executive is capable of obtaining gainful, lucrative and desirable employment that does not violate the restrictions contained in this Agreement.
Therefore, Executive shall be subject to the restrictions set forth in this Section 14.
(b) Definitions. The following capitalized terms used in this Section 14 shall have the meanings assigned to them below, which definitions shall apply to both the singular and the plural forms of such terms:
"Competitive Services" means the business of providing post-acute healthcare services, including home-based services through home nursing agencies and hospices and facility-based services through long-term acute care hospitals and outpatient rehabilitation clinics.
"Confidential Information " means all information regarding the Company, its activities, business or clients that is the subject of reasonable efforts by the Company to maintain its confidentiality and that is not generally disclosed by practice or authority to persons not employed by the Company, but that does not rise to the level of a Trade Secret. "Confidential Information" shall include, but is not limited to, financial plans and data concerning the Company; management planning information; business plans; operational methods; market studies; marketing plans or strategies; product development techniques or plans; customer lists; customer files, data and financial information, details of customer contracts; current and anticipated customer requirements; identifying and other information pertaining to business referral sources; past, current and planned research and development; business acquisition plans; and new personnel acquisition plans. "Confidential Information" shall not include information that has become generally available to the public by the act of one who has the right to disclose such information without violating any right or privilege of the Company. This definition shall not limit any definition of "confidential information" or any equivalent term under state or federal law.
"Determination Date" means the date of termination of Executive's employment with the Company for any reason whatsoever or any earlier date (during the Employment Period) of an alleged breach of the Restrictive Covenants by Executive.
"Person " means any individual or any corporation, partnership, joint venture, limited liability company, association or other entity or enterprise.
"Principal or Representative" means a principal, owner, partner, stockholder, joint venturer, investor, member, trustee, director, officer, manager, employee, agent, representative or consultant.
"Protected Customers" means any Person to whom the Company has sold its products or services or solicited to sell its products or services, other than through general advertising targeted at consumers, during the 12 months prior to the Determination Date.
"Protected Employees" means employees of the Company who were employed by the Company or its affiliates at any time within six months prior to the Determination Date, other than those who were discharged by the Company or such affiliated employer without cause.
"Restricted Period" means the Employment Period plus 24 months (or the Employment Period plus 6 months if Executive's termination occurs within two years after the occurrence of a Change in Control); provided, however, that the Restricted Period shall end with respect to the covenants in clauses (ii) and (iii) of Section 14(c) on the 60th day after the Date of Termination in the event the Company breaches its obligation, if any, to make any payment required under Section 8(a)(i).
"Restricted Territory" means the geographical territory described on Exhibit B hereto.
"Restrictive Covenants" means the restrictive covenants contained in Section 14(c) hereof.
"Third Party Information" means confidential or proprietary information subject to a duty on the Company's and its affiliates' part to maintain the confidentiality of such information and to use it only for certain limited purposes.
"Trade Secret" means all information, without regard to form, including, but not limited to, technical or nontechnical data, a formula, a pattern, a compilation, a program, a device, a method, a technique, a drawing, a process, financial data, financial plans, product plans, distribution lists or a list of actual or potential customers, advertisers or suppliers which is not commonly known by or available to the public and which information: (A) derives economic value, actual or potential, from not being generally known to, and not being readily ascertainable by proper means by, other persons who can obtain economic value from its disclosure or use; and (B) is the subject of efforts that are reasonable under the circumstances to maintain its secrecy. Without limiting the foregoing, Trade Secret means any item of confidential information that constitutes a "trade secret(s)" under the common law or statutory law of the State of Delaware.
"Work Product" means all inventions, innovations, improvements, developments, methods, processes, programs, designs, analyses, drawings, reports, and all similar or related information (whether or not patentable) that relate to the Company's or its affiliates' actual or anticipated business, research and development, or existing or future products or services and that are conceived, developed, contributed to, made, or reduced to practice by Executive (either solely or jointly with others) while employed by the Company or its affiliates.
(c) Restrictive Covenants.
(i) Restriction on Disclosure and Use of Confidential Information and Trade Secrets. Executive understands and agrees that the Confidential Information and Trade Secrets constitute valuable assets of the Company and its affiliated entities, and may not be converted to Executive's own use. Accordingly, Executive hereby agrees that Executive shall not, directly or indirectly, at any time during the Restricted Period reveal, divulge, or disclose to any Person not expressly authorized by the Company any Confidential Information, and Executive shall not, directly or indirectly, at any time during the Restricted Period use or make use of any Confidential Information in connection with any business activity other than that of the Company. Throughout the term of this Agreement and at all times after the date that this Agreement terminates for any reason, Executive shall not directly or indirectly transmit or disclose any Trade Secret of the Company to any Person, and shall not make use of any such Trade Secret, directly or indirectly, for himself or for others, without the prior written consent of the Company. The parties acknowledge and agree that this Agreement is not intended to, and does not, alter either the Company's rights or Executive's obligations under any state or federal statutory or common law regarding trade secrets and unfair trade practices.
Anything herein to the contrary notwithstanding, Executive shall not be restricted from disclosing or using Confidential Information or any Trade Secret that is required to be disclosed by law, court order or other legal process; provided, however, that in the event disclosure is required by law, Executive shall provide the Company with prompt notice of such requirement so that the Company may seek an appropriate protective order prior to any such required disclosure by Executive.
Executive acknowledges that any and all Confidential Information is the exclusive property of the Company and agrees to deliver to the Company on the Date of Termination, or at any other time the Company may request in writing, any and all Confidential Information which he may then possess or have under his control in whatever form same may exist, including, but not by way of limitation, hard copy files, soft copy files, computer disks, and all copies thereof.
(ii) Nonsolicitation of Protected Employees. Executive understands and agrees that the relationship between the Company and each of its Protected Employees constitutes a valuable asset of the Company and may not be converted to Executive's own use. Accordingly, Executive hereby agrees that during the Restricted Period, Executive shall not directly or indirectly on Executive's own behalf or as a Principal or Representative of any Person or otherwise solicit or induce any Protected Employee to terminate his employment relationship with the Company or to enter into employment with any other Person.
(iii) Restriction on Relationships with Protected Customers. Executive understands and agrees that the relationship between the Company and each of its Protected Customers constitutes a valuable asset of the Company and may not be converted to Executive's own use. Accordingly, Executive hereby agrees that, during the Restricted Period and in the Restricted Territory, Executive shall not, without the prior written consent of the Company, directly or indirectly, on Executive's own behalf or as a Principal or Representative of any Person, solicit, divert, take away or attempt to solicit, divert or take away a Protected Customer for the purpose of providing or selling Competitive Services; provided, however, that the prohibition of this covenant shall apply only to Protected Customers with whom Executive had Material Contact on the Company's behalf during the 12 months immediately preceding the Date of Termination; and, provided further, that the prohibition of this covenant shall not apply to the conduct of general advertising activities. For purposes of this Agreement, Executive had "Material Contact" with a Protected Customer if (a) he had business dealings with the Protected Customer on the Company's behalf; (b) he was responsible for supervising or coordinating the dealings between the Company and the Protected Customer; or (c) he obtained Trade Secrets or Confidential Information about the customer as a result of his association with the Company.
(iv) Ownership of Work Product. Executive acknowledges that the Work Product belongs to the Company or its affiliates and Executive hereby assigns, and agrees to assign, all of the Work Product to the Company or its affiliates. Any copyrightable work prepared in whole or in part by Executive in the course of his work for any of the foregoing entities shall be deemed a "work made for hire" under the copyright laws, and the Company or such affiliate shall own all rights therein. To the extent that any such copyrightable work is not a "work made for hire," Executive hereby assigns and agrees to assign to the Company or such affiliate all right, title, and interest, including without limitation, copyright in and to such copyrightable work. Executive shall promptly disclose such Work Product and copyrightable work to the Board and perform all actions reasonably requested by the Board (whether during or after the Employment Period) to establish and confirm the Company's or such affiliate's ownership (including, without limitation, assignments, consents, powers of attorney, and other instruments).
(v) Third Party Information. Executive understands that the Company and its affiliates will receive Third Party Information. During the Employment Period and thereafter, and without in any way limiting the provisions of Section 14(c)(i) above, Executive will hold Third Party Information in the strictest confidence and will not disclose to anyone (other than personnel of the Company or its affiliates who need to know such information in connection with
their work for the Company or its affiliates) or use, except in connection with his work for the Company or its affiliates, Third Party Information unless expressly authorized by a member of the Board (other than Executive) in writing.
(vi) Use of Information of Prior Employers. During the Employment Period, Executive will not improperly use or disclose any confidential information or trade secrets, if any, of any former employers or any other person to whom Executive has an obligation of confidentiality, and will not bring onto the premises of the Company or any of its affiliates any unpublished documents or any property belonging to any former employer or any other person to whom Executive has an obligation of confidentiality unless consented to by in writing the former employer or person. Executive will use in the performance of his duties only information which is (i) generally known and used by persons with training and experience comparable to Executive's and which is (x) common knowledge in the industry or (y) is otherwise legally in the public domain, (ii) is otherwise provided or developed by the Company or its affiliates or (iii) in the case of materials, property or information belonging to any former employer or other person to whom Executive has an obligation of confidentiality, approved for such use in writing by such former employer or person.
(d) Enforcement of Restrictive Covenants.
(i) Rights and Remedies Upon Breach. In the event Executive breaches, or threatens to commit a breach of, any of the provisions of the Restrictive Covenants, the Company shall have the right and remedy to enjoin, preliminarily and permanently, Executive from violating or threatening to violate the Restrictive Covenants and to have the Restrictive Covenants specifically enforced by any court or tribunal of competent jurisdiction, it being agreed that any breach or threatened breach of the Restrictive Covenants would cause irreparable injury to the Company and that money damages would not provide an adequate remedy to the Company. Such right and remedy shall be independent of any others and severally enforceable, and shall be in addition to, and not in lieu of, any other rights and remedies available to the Company at law or in equity.
(ii) Severability of Covenants. Executive acknowledges and agrees that the Restrictive Covenants are reasonable and valid in time and scope and in all other respects. The covenants set forth in this Agreement shall be considered and construed as separate and independent covenants. Should any part or provision of any covenant be held invalid, void or unenforceable, such invalidity, voidness or unenforceability shall not render invalid, void or unenforceable any other part or provision of this Agreement. If any portion of the foregoing provisions is found to be invalid or unenforceable because its duration, the territory, the definition of activities or the definition of information covered is considered to be invalid or unreasonable in scope, the invalid or unreasonable term shall be redefined, or a new enforceable term provided, such that the intent of the Company and Executive in agreeing to the provisions of this Agreement will not be impaired and the provision in question shall be enforceable to the fullest extent of the applicable laws.
(iii) Reformation. The parties hereunder agree that it is their intention that the Restrictive Covenants be enforced in accordance with their terms to the maximum extent possible under applicable law. The parties further agree that, in the event any tribunal of competent jurisdiction shall find that any provision hereof is not enforceable in accordance with its terms, the tribunal shall reform the Restrictive Covenants such that they shall be enforceable to the maximum extent permissible at law.
15. Arbitration. Any claim or dispute arising under or relating to this Agreement or the breach, termination, or validity of any term of this Agreement, including, but not by way of limitation, the legality and enforceability of the Restrictive Covenants, shall be subject to arbitration, and prior to commencing any court action, the parties agree that they shall arbitrate all controversies; provided, however, that nothing in this Section 15 shall prohibit the Company from exercising its right under Section 14(d)(i) to pursue injunctive remedies with respect to a breach or threatened breach of the Restrictive Covenants. The arbitration shall be conducted in Lafayette, Louisiana, in accordance with the Employment Dispute Rules of the American Arbitration Association and the Federal Arbitration Act, 9 U.S.C. Section 1, et. seq. The arbitrator(s) shall be authorized to award both liquidated and actual damages, in addition to injunctive relief, but no punitive damages. The arbitrator(s) may also award attorney's fees and costs, without regard to any restriction on the amount of such award under Delaware or other applicable law. Such an award shall be binding and conclusive upon the parties hereto, subject to 9 U.S.C. Section 10. Each party shall have the right to have the award made the judgment of a court of competent jurisdiction.
16. Assignment and Successors.
(a) This Agreement is personal to Executive and without the prior written consent of the Company shall not be assignable by Executive otherwise than by will or the laws of descent and distribution. This Agreement shall inure to the benefit of and be enforceable by Executive's legal representatives.
(b) This Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns.
(c) The Company will require any Surviving Entity resulting from a Reorganization, Sale or Acquisition (if other than the Company) to assume expressly and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no Reorganization, Sale or Acquisition had taken place. As used in this Agreement, "Company" shall mean the Company as hereinbefore defined and any successor to its business and/or assets as aforesaid which assumes and agrees to perform this Agreement by operation of law, or otherwise.
17. Miscellaneous.
(a) Waiver. Failure of either party to insist, in one or more instances, on performance by the other in strict accordance with the terms and conditions of this Agreement shall not be deemed a waiver or relinquishment of any right granted in this Agreement or of the future performance of any such term or condition or of any other term or condition of this Agreement, unless such waiver is contained in a writing signed by the party making the waiver.
(b) Severability. If any provision or covenant, or any part thereof, of this Agreement should be held by any tribunal of competent jurisdiction to be invalid, illegal or unenforceable, either in whole or in part, such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of the remaining provisions or covenants, or any part thereof, of this Agreement, all of which shall remain in full force and effect.
(c) Other Agents. Nothing in this Agreement is to be interpreted as limiting the Company from employing other personnel on such terms and conditions as may be satisfactory to it, except that this Section 17(c) shall not override the provision of Section 7(d)(i).
(d) Entire Agreement. Except as provided herein, this Agreement contains the entire agreement between the Company and Executive with respect to the subject matter hereof and, from and after the Effective Date, this Agreement shall supersede any other agreement between the parties with respect to the subject matter hereof, including without limitation, the Prior Agreement.
(e) Governing Law. Except to the extent preempted by federal law, and without regard to conflict of laws principles, the laws of the State of Delaware shall govern this Agreement in all respects, whether as to its validity, construction, capacity, performance or otherwise.
(f) Notices. All notices, requests, demands and other communications required or permitted hereunder shall be in writing and shall be deemed to have been duly given if delivered or three days after mailing if mailed, first class, certified mail, postage prepaid:
To the Company: LHC Group, Inc. Suite A 420 W. Pinhook Road Lafayette, LA 70503 Attention: General Counsel To Executive: Daryl J. Doise ------------------------ ------------------------ |
Any party may change the address to which notices, requests, demands and other communications shall be delivered or mailed by giving notice thereof to the other party in the same manner provided herein.
(g) Amendments and Modifications. This Agreement may be amended or modified only by a writing signed by both parties hereto, which makes specific reference to this Agreement.
(h) Construction. Each party and his or its counsel have reviewed this Agreement and have been provided the opportunity to revise this Agreement and accordingly, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this Agreement. Instead, the language of all parts of this Agreement shall be construed as a whole, and according to its fair meaning, and not strictly for or against either party.
(i) Withholding. The Company or its subsidiaries, if applicable, shall be entitled to deduct or withhold from any amounts owing from the Company or any such affiliate to Executive any federal, state, local or foreign withholding taxes, excise taxes, or employment taxes ("Taxes") imposed with respect to Executive's compensation or other payments from the Company or any of its affiliates. In the event the Company or its affiliates do not make such deductions or withholdings, Executive shall indemnify the Company and its affiliates for any amounts paid with respect to any such Taxes.
IN WITNESS WHEREOF, the parties hereto have duly executed and delivered this Employment Agreement as of the date first above written.
LHC GROUP, INC.
By: /s/ ------------------------------------------- Title: President/CEO ---------------------------------------- |
EXECUTIVE:
/s/ DARYL J. DOISE ---------------------------------------------- Daryl J. Doise |
EXHIBIT A
Form of Release
THIS RELEASE ("Release") is granted effective as of the______day of ______, 20__, by_______("Executive") in favor of LHC Group, Inc. (the "Company"). This is the Release referred to that certain Employment Agreement effective as of _______, 200_ by and between the Company and Executive (the "Employment Agreement"), with respect to which this Release is an integral part.
FOR AND IN CONSIDERATION of the payments and benefits provided by Section 8
of the Employment Agreement and the Company's other promises and covenants as
recited in the Employment Agreement, the receipt and sufficiency of which are
hereby acknowledged, Executive, for himself, his successors and assigns, now and
forever hereby releases and discharges the Company and all its past and present
officers, directors, stockholders, employees, agents, parent corporations,
predecessors, subsidiaries, affiliates, estates, successors, assigns, benefit
plans, consultants, administrators, and attorneys (hereinafter collectively
referred to as "Releasees") from any and all claims, charges, actions, causes of
action, sums of money due, suits, debts, covenants, contracts, agreements,
promises, demands or liabilities (hereinafter collectively referred to as
"Claims") whatsoever, in law or in equity, whether known or unknown, which
Executive ever had or now has from the beginning of time up to the date this
Release ("Release") is executed, including, but not limited to, claims under the
Age Discrimination in Employment Act, as amended by the Older Workers Benefit
Protection Act, Title VII of the Civil Rights Act of 1964 (and all of its
amendments), the Americans with Disabilities Act, as amended, or any other
federal or state statutes, all tort claims, all claims for wrongful employment
termination or breach of contract, and any other claims which Executive has,
had, or may have against the Releasees on account of or arising out of
Executive's employment with or termination from the Company; provided, however,
that nothing contained in this Release shall in any way diminish or impair (i)
any rights of Executive to the benefits conferred or referenced in the
Employment Agreement or Executive's Retention Bonus Agreement with the Company,
(ii) any rights to indemnification that may exist from time to time under the
Company's bylaws, certificate of incorporation, Delaware law or otherwise, or
(iii) Executive's ability to raise an affirmative defense in connection with any
lawsuit or other legal claim or charge instituted or asserted by the Company
against Executive.
Without limiting the generality of the foregoing, Executive hereby acknowledges and covenants that in consideration for the sums being paid to him he has knowingly waived any right or opportunity to assert any claim that is in any way connected with any employment relationship or the termination of any employment relationship which existed between the Company and Executive. Executive further understands and agrees that he has knowingly relinquished, waived and forever released any and all remedies arising out of the aforesaid employment relationship or the termination thereof, including, without limitation, claims for backpay, front pay, liquidated damages, compensatory damages, general damages, special damages, punitive damages, exemplary damages, costs, expenses and attorneys' fees.
Executive specifically acknowledges and agrees that he has knowingly and
voluntarily released the Company and all other Releasees from any and all claims
arising under the Age Discrimination in Employment Act ("ADEA"), 29 U.S.C.
Section 621, et seq., which Executive ever had or now has from the beginning of
time up to the date this Release is executed, including but not limited to those
claims which are in any way connected with any employment relationship or
the termination of any employment relationship which existed between the Company and Executive. Executive further acknowledges and agrees that he has been advised to consult with an attorney prior to executing this Release and that he has been given twenty-one (21) days to consider this Release prior to its execution. Executive also understands that he may revoke this Release at any time within seven (7) days following its execution. Executive understands, however, that this Release shall not become effective and that none of the consideration described above shall be paid to him until the expiration of the seven-day revocation period.
Executive agrees never to seek reemployment or future employment with the Company or any of the other Releasees.
Executive acknowledges that the terms of this Release must be kept confidential. Accordingly, Executive agrees not to disclose or publish to any person or entity, except as required by law or as necessary to prepare tax returns, the terms and conditions or sums being paid in connection with this Release.
It is understood and agreed by Executive that the payment made to him is not to be construed as an admission of any liability whatsoever on the part of the Company or any of the other Releasees, by whom liability is expressly denied.
This Release is executed by Executive voluntarily and is not based upon any representations or statements of any kind made by the Company or any of the other Releasees as to the merits, legal liabilities or value of his claims. Executive further acknowledges that he has had a full and reasonable opportunity to consider this Release and that he has not been pressured or in any way coerced into executing this Release.
Executive acknowledges and agrees that this Release may not be revoked at any time after the expiration of the seven-day revocation period and that he will not institute any suit, action, or proceeding, whether at law or equity, challenging the enforceability of this Release. Executive further acknowledges and agrees that, with the exception of an action to challenge his waiver of claims under the ADEA, he shall not ever attempt to challenge the terms of this Release, attempt to obtain an order declaring this Release to be null and void, or institute litigation against the Company or any other Releasee based upon a claim which is covered by the terms of the release contained herein, without first repaying all monies paid to him under Section 8 of the Employment Agreement. Furthermore, with the exception of an action to challenge his waiver of claims under the ADEA, if Executive does not prevail in an action to challenge this Release, to obtain an order declaring this Release to be null and void, or in any action against the Company or any other Releasee based upon a claim which is covered by the release set forth herein, Executive shall pay to the Company and/or the appropriate Releasee all their costs and attorneys' fees incurred in their defense of Executive's action.
This Release and the rights and obligations of the parties hereto shall be governed and construed in accordance with the laws of the State of Georgia. If any provision hereof is unenforceable or is held to be unenforceable, such provision shall be fully severable, and this document and its terms shall be construed and enforced as if such unenforceable provision had never comprised a part hereof, the remaining provisions hereof shall remain in full force and effect, and the court construing the provisions shall add as a part hereof a provision as similar in terms and effect to such unenforceable provision as may be enforceable, in lieu of the unenforceable provision.
This document contains all terms of the Release and supersedes and invalidates any previous agreements or contracts. No representations, inducements, promises or agreements, oral or otherwise, which are not embodied herein shall be of any force or effect.
IN WITNESS WHEREOF, the undersigned acknowledges that he has read these three pages and he sets his hand and seal this________day of ________, 20 __ .
Sworn to and subscribed
before me this__day of
_____________,20 ____ .
Notary Public
My Commission Expires:
EXHIBIT B
Restricted Territory
EXHIBIT 10.10
DIRECTOR INDEMNIFICATION AGREEMENT
This Director Indemnification Agreement, dated as of ___________ ___, 2005 (this "AGREEMENT"), is made by and between LHC Group, Inc., a Delaware corporation (the "COMPANY"), and _____________________ ("INDEMNITEE").
RECITALS:
A. Section 141 of the Delaware General Corporation Law provides that the business and affairs of a corporation shall be managed by or under the direction of its board of directors.
B. By virtue of the managerial prerogatives vested in the directors of a Delaware corporation, directors act as fiduciaries of the corporation and its stockholders.
C. Thus, it is critically important to the Company and its stockholders that the Company be able to attract and retain the most capable persons reasonably available to serve as directors of the Company.
D. In recognition of the need for corporations to be able to induce capable and responsible persons to accept positions in corporate management, Delaware law authorizes (and in some instances requires) corporations to indemnify their directors and officers, and further authorizes corporations to purchase and maintain insurance for the benefit of their directors and officers.
E. The Delaware courts have recognized that indemnification by a corporation serves the dual policies of (1) allowing corporate officials to resist unjustified lawsuits, secure in the knowledge that, if vindicated, the corporation will bear the expense of litigation, and (2) encouraging capable women and men to serve as corporate directors and officers, secure in the knowledge that the corporation will absorb the costs of defending their honesty and integrity.
F. The number of lawsuits challenging the judgment and actions of directors of Delaware corporations, the costs of defending those lawsuits and the threat to directors' personal assets have all materially increased over the past several years, chilling the willingness of capable women and men to undertake the responsibilities imposed on corporate directors.
G. Recent federal legislation and rules adopted by the Securities and Exchange Commission and the national securities exchanges have exposed such directors to new and substantially broadened civil liabilities.
H. Under Delaware law, a director's right to be reimbursed for the costs of defense of criminal actions, whether such claims are asserted under state or federal law, does not depend upon the merits of the claims asserted against the director and is separate and distinct from any right to indemnification the director may be able to establish.
I. Indemnitee is, or will be, a director of the Company and his willingness to serve in such capacity is predicated, in substantial part, upon the Company's willingness to indemnify him in accordance with the principles reflected above, to the fullest extent permitted by the laws of the State of Delaware, and upon the other undertakings set forth in this Agreement.
J. Therefore, in recognition of the need to provide Indemnitee with substantial protection against personal liability, in order to procure Indemnitee's continued service as a director of the Company and to enhance Indemnitee's ability to serve the Company in an effective manner, and in order to provide such protection pursuant to express contract rights (intended to be enforceable irrespective of, among other things, any amendment to the Company's certificate of incorporation or bylaws (collectively, the "CONSTITUENT DOCUMENTS"), any change in the composition of the Company's Board of Directors (the "BOARD") or any change-in-control or business combination transaction relating to the Company), the Company wishes to provide in this Agreement for the indemnification of and the advancement of Expenses to Indemnitee as set forth in this Agreement and for the continued coverage of Indemnitee under the Company's directors' and officers' liability insurance policies.
K. In light of the considerations referred to in the preceding recitals, it is the Company's intention and desire that the provisions of this Agreement be construed liberally, subject to their express terms, to maximize the protections to be provided to Indemnitee hereunder.
AGREEMENT:
NOW, THEREFORE, the parties hereby agree as follows:
1. CERTAIN DEFINITIONS. In addition to terms defined elsewhere herein, the following terms have the following meanings when used in this Agreement with initial capital letters:
(a) "CHANGE IN CONTROL" shall have occurred at such time, if any, as Incumbent Directors cease for any reason to constitute a majority of Directors. For purpose of this Section 1(a), "INCUMBENT DIRECTORS" means the individuals who, as of the date hereof, are Directors of the Company and any individual becoming a Director subsequent to the date hereof whose election, nomination for election by the Company's stockholders, or appointment, was approved by a vote of at least two-thirds of the then Incumbent Directors (either by a specific vote or by approval of the proxy statement of the Company in which such person is named as a nominee for director, without objection to such nomination); provided, however, that an individual shall not be an Incumbent Director if such individual's election or appointment to the Board occurs as a result of an actual or threatened election contest (as described in Rule 14a-12(c) of the Securities Exchange Act of 1934, as amended) with respect to the election or removal of Directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board.
(b) "CLAIM" means (i) any threatened, asserted, pending or completed claim, demand, action, suit or proceeding, whether civil, criminal, administrative, arbitrative, investigative or other, and whether made pursuant to federal, state or other law; and (ii) any inquiry or investigation, whether made, instituted or conducted, by the Company or any other Person, including without limitation any federal, state or other governmental entity, that Indemnitee determines might lead to the institution of any such claim, demand, action, suit or proceeding. For the avoidance of doubt, the Company intends indemnity to be provided hereunder in respect of acts or failure to act prior to, on or after the date hereof.
(c) "CONTROLLED AFFILIATE" means any corporation, limited liability company, partnership, joint venture, trust or other entity or enterprise, whether or not for profit, that is
directly or indirectly controlled by the Company. For purposes of this definition, "control" means the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of an entity or enterprise, whether through the ownership of voting securities, through other voting rights, by contract or otherwise; provided that direct or indirect Beneficial Ownership of capital stock or other interests in an entity or enterprise entitling the holder to cast 15% or more of the total number of votes generally entitled to be cast in the election of directors (or persons performing comparable functions) of such entity or enterprise shall be deemed to constitute control for purposes of this definition.
(d) "DISINTERESTED DIRECTOR" means a director of the Company who is not and was not a party to the Claim in respect of which indemnification is sought by Indemnitee.
(e) "EXPENSES" means attorneys' and experts' fees and expenses and all other costs and expenses paid or payable in connection with investigating, defending, being a witness in or participating in (including on appeal), or preparing to investigate, defend, be a witness in or participate in (including on appeal), any Claim.
(f) "INDEMNIFIABLE CLAIM" means any Claim based upon, arising out of or resulting from (i) any actual, alleged or suspected act or failure to act by Indemnitee in his or her capacity as a director, officer, employee or agent of the Company or as a director, officer, employee, member, manager, trustee or agent of any other corporation, limited liability company, partnership, joint venture, trust or other entity or enterprise, whether or not for profit, as to which Indemnitee is or was serving at the request of the Company, (ii) any actual, alleged or suspected act or failure to act by Indemnitee in respect of any business, transaction, communication, filing, disclosure or other activity of the Company or any other entity or enterprise referred to in clause (i) of this sentence, or (iii) Indemnitee's status as a current or former director, officer, employee or agent of the Company or as a current or former director, officer, employee, member, manager, trustee or agent of the Company or any other entity or enterprise referred to in clause (i) of this sentence or any actual, alleged or suspected act or failure to act by Indemnitee in connection with any obligation or restriction imposed upon Indemnitee by reason of such status. In addition to any service at the actual request of the Company, for purposes of this Agreement, Indemnitee shall be deemed to be serving or to have served at the request of the Company as a director, officer, employee, member, manager, agent, trustee or other fiduciary of another entity or enterprise if Indemnitee is or was serving as a director, officer, employee, member, manager, agent, trustee or other fiduciary of such entity or enterprise and (A) such entity or enterprise is or at the time of such service was a Controlled Affiliate, (B) such entity or enterprise is or at the time of such service was an employee benefit plan (or related trust) sponsored or maintained by the Company or a Controlled Affiliate, or (C) the Company or a Controlled Affiliate (by action of the Board, any committee thereof or the Company's Chief Executive Officer ("CEO") (other than as the CEO him or herself)) caused or authorized Indemnitee to be nominated, elected, appointed, designated, employed, engaged or selected to serve in such capacity.
(g) "INDEMNIFIABLE LOSSES" means any and all Losses relating to, arising out of or resulting from any Indemnifiable Claim; provided, however, that Indemnifiable Losses shall not include Losses incurred by Indemnitee in respect of any Indemnifiable Claim (or any matter or issue therein) as to which Indemnitee shall have been adjudged liable to the Company, unless and only to the extent that the Delaware Court of Chancery or the court in which such
Indemnifiable Claim was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnification for such Expenses as the court shall deem proper.
(h) "INDEPENDENT COUNSEL" means a law firm, or a member of a law firm, that is experienced in matters of corporation law and neither presently is, nor in the past five years has been, retained to represent: (i) the Company (or any Subsidiary) or Indemnitee in any matter material to either such party (other than with respect to matters concerning the Indemnitee under this Agreement, or of other indemnitees under similar indemnification agreements) or (ii) any other named (or, as to a threatened matter, reasonably likely to be named) party to the Indemnifiable Claim giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term "Independent Counsel" shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee's rights under this Agreement.
(i) "LOSSES" means any and all Expenses, damages, losses, liabilities, judgments, fines, penalties (whether civil, criminal or other) and amounts paid or payable in settlement, including without limitation all interest, assessments and other charges paid or payable in connection with or in respect of any of the foregoing.
(j) "PERSON" means any individual, entity, or group, within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended.
(k) "STANDARD OF CONDUCT" means the standard for conduct by Indemnitee that is a condition precedent to indemnification of Indemnitee hereunder against Indemnifiable Losses relating to, arising out of or resulting from an Indemnifiable Claim. The Standard of Conduct is (i) good faith and reasonable belief by Indemnitee that his action was in or not opposed to the best interests of the Company and, with respect to any criminal action or proceeding, that Indemnitee had no reasonable cause to believe that his conduct was unlawful, or (ii) any other applicable standard of conduct that may hereafter be substituted under Section 145(a) or (b) of the Delaware General Corporation Law or any successor to such provision(s).
2. INDEMNIFICATION OBLIGATION. Subject only to Section 7 and to the proviso in this Section, the Company shall indemnify, defend and hold harmless Indemnitee, to the fullest extent permitted or required by the laws of the State of Delaware in effect on the date hereof or as such laws may from time to time hereafter be amended to increase the scope of such permitted indemnification, against any and all Indemnifiable Claims and Indemnifiable Losses; provided, however, that, except as provided in Sections 4 and 20, Indemnitee shall not be entitled to indemnification pursuant to this Agreement in connection with any Claim initiated by Indemnitee against the Company or any director or officer of the Company unless the Company has joined in or consented to the initiation of such Claim. The Company acknowledges that the foregoing obligation is substantially broader than that now provided by applicable law and the Company's Constituent Documents and intends that it be interpreted consistently with this Section and the recitals to this Agreement.
3. ADVANCEMENT OF EXPENSES. Indemnitee shall have the right to advancement by the Company prior to the final disposition of any Indemnifiable Claim of any and all Expenses relating to, arising out of or resulting from any Indemnifiable Claim paid or incurred by
Indemnitee or which Indemnitee determines in good faith are reasonably likely to
be paid or incurred by Indemnitee and as to which Indemnitee's counsel provides
supporting documentation. Without limiting the generality or effect of any other
provision hereof, Indemnitee's right to such advancement is not subject to the
satisfaction of any Standard of Conduct. Without limiting the generality or
effect of the foregoing, within five business days after any request by
Indemnitee that is accompanied by supporting documentation for specific Expenses
to be reimbursed or advanced, the Company shall, in accordance with such request
(but without duplication), (a) pay such Expenses on behalf of Indemnitee, (b)
advance to Indemnitee funds in an amount sufficient to pay such Expenses, or (c)
reimburse Indemnitee for such Expenses; provided that Indemnitee shall repay,
without interest any amounts actually advanced to Indemnitee that, at the final
disposition of the Indemnifiable Claim to which the advance related, were in
excess of amounts paid or payable by Indemnitee in respect of Expenses relating
to, arising out of or resulting from such Indemnifiable Claim. In connection
with any such payment, advancement or reimbursement, at the request of the
Company, Indemnitee shall execute and deliver to the Company an undertaking,
which need not be secured and shall be accepted without reference to
Indemnitee's ability to repay the Expenses, by or on behalf of the Indemnitee,
to repay any amounts paid, advanced or reimbursed by the Company in respect of
Expenses relating to, arising out of or resulting from any Indemnifiable Claim
in respect of which it shall have been determined, following the final
disposition of such Indemnifiable Claim and in accordance with Section 7, that
Indemnitee is not entitled to indemnification hereunder.
4. INDEMNIFICATION FOR ADDITIONAL EXPENSES. Without limiting the generality or effect of the foregoing, the Company shall indemnify and hold harmless Indemnitee against and, if requested by Indemnitee, shall reimburse Indemnitee for, or advance to Indemnitee, within five business days of such request accompanied by supporting documentation for specific Expenses to be reimbursed or advanced, any and all Expenses paid or incurred by Indemnitee or which Indemnitee determines in good faith are reasonably likely to be paid or incurred by Indemnitee in connection with any Claim made, instituted or conducted by Indemnitee for (a) indemnification or reimbursement or advance payment of Expenses by the Company under any provision of this Agreement, or under any other agreement or provision of the Constituent Documents now or hereafter in effect relating to Indemnifiable Claims, and/or (b) recovery under any directors' and officers' liability insurance policies maintained by the Company, regardless in each case of whether Indemnitee ultimately is determined to be entitled to such indemnification, reimbursement, advance or insurance recovery, as the case may be; provided, however, that Indemnitee shall return, without interest, any such advance of Expenses (or portion thereof) which remains unspent at the final disposition of the Claim to which the advance related.
5. PARTIAL INDEMNITY. If Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for some or a portion of any Indemnifiable Loss but not for all of the total amount thereof, the Company shall nevertheless indemnify Indemnitee for the portion thereof to which Indemnitee is entitled.
6. PROCEDURE FOR NOTIFICATION. To obtain indemnification under this Agreement in respect of an Indemnifiable Claim or Indemnifiable Loss, Indemnitee shall submit to the Company a written request therefor, including a brief description (based upon information then available to Indemnitee) of such Indemnifiable Claim or Indemnifiable Loss. If, at the time of the receipt of such request, the Company has directors' and officers' liability insurance in effect under which coverage for such Indemnifiable Claim or Indemnifiable Loss is potentially
available, the Company shall give prompt written notice of such Indemnifiable Claim or Indemnifiable Loss to the applicable insurers in accordance with the procedures set forth in the applicable policies. The Company shall provide to Indemnitee a copy of such notice delivered to the applicable insurers and, upon Indemnitee's request, copies of all subsequent correspondence between the Company and such insurers regarding the Indemnifiable Claim or Indemnifiable Loss, in each case substantially concurrently with the delivery thereof by the Company. The failure by Indemnitee to timely notify the Company of any Indemnifiable Claim or Indemnifiable Loss shall not relieve the Company from any liability hereunder unless, and only to the extent that, the Company did not otherwise learn of such Indemnifiable Claim or Indemnifiable Loss and such failure results in forfeiture by the Company of substantial defenses, rights or insurance coverage.
7. DETERMINATION OF RIGHT TO INDEMNIFICATION.
(a) To the extent that Indemnitee shall have been successful on the merits or otherwise in defense of any Indemnifiable Claim or any portion thereof or in defense of any issue or matter therein, including without limitation dismissal without prejudice, Indemnitee shall be indemnified against all Indemnifiable Losses relating to, arising out of or resulting from such Indemnifiable Claim in accordance with Section 2 and no Standard of Conduct Determination (as defined in Section 7(b)) shall be required.
(b) To the extent that the provisions of Section 7(a) are inapplicable to an Indemnifiable Claim that shall have been finally disposed of, any determination of whether Indemnitee has satisfied the applicable Standard of Conduct (a "STANDARD OF CONDUCT DETERMINATION") shall be made as follows: (i) if a Change in Control shall not have occurred, or if a Change in Control shall have occurred but Indemnitee shall have requested that the Standard of Conduct Determination be made pursuant to this clause (i), (A) by a majority vote of the Disinterested Directors, even if less than a quorum of the Board, (B) if such Disinterested Directors so direct, by a majority vote of a committee of Disinterested Directors designated by a majority vote of all Disinterested Directors, or (C) if there are no such Disinterested Directors, or if a majority of the Disinterested Directors so direct, by Independent Counsel in a written opinion addressed to the Board, a copy of which shall be delivered to Indemnitee; and (ii) if a Change in Control shall have occurred and Indemnitee shall not have requested that the Standard of Conduct Determination be made pursuant to clause (i), by Independent Counsel in a written opinion addressed to the Board, a copy of which shall be delivered to Indemnitee. Indemnitee shall cooperate with reasonable requests of the individual or firm making such Standard of Conduct Determination, including providing to such Person documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination without incurring any unreimbursed cost in connection therewith. The Company shall indemnify and hold harmless Indemnitee against and, if requested by Indemnitee, shall reimburse Indemnitee for, or advance to Indemnitee, within five business days of such request accompanied by supporting documentation for specific costs and expenses to be reimbursed or advanced, any and all costs and expenses (including attorneys' and experts' fees and expenses) incurred by Indemnitee in so cooperating with the Person making such Standard of Conduct Determination.
(c) The Company shall use its reasonable efforts to cause any Standard of Conduct Determination required under Section 7(b) to be made as promptly as practicable. If
(i) the Person empowered or selected under Section 7 to make the Standard of Conduct Determination shall not have made a determination within 30 calendar days after the later of (A) receipt by the Company of written notice from Indemnitee advising the Company of the final disposition of the applicable Indemnifiable Claim (the date of such receipt being the "NOTIFICATION DATE") and (B) the selection of an Independent Counsel, if such determination is to be made by Independent Counsel, that is permitted under the provisions of Section 7(e) to make such determination, and (ii) Indemnitee shall have fulfilled his/her obligations set forth in the second sentence of Section 7(b), then Indemnitee shall be deemed to have satisfied the applicable Standard of Conduct; provided that such 30-day period may be extended for a reasonable time, not to exceed an additional 30 calendar days, if the Person making such determination in good faith requires such additional time for the obtaining or evaluation or documentation and/or information relating thereto.
(d) If (i) Indemnitee shall be entitled to indemnification
hereunder against any Indemnifiable Losses pursuant to Section 7(a), (ii) no
determination of whether Indemnitee has satisfied any applicable standard of
conduct under Delaware law is a legally required condition precedent to
indemnification of Indemnitee hereunder against any Indemnifiable Losses, or
(iii) Indemnitee has been determined or deemed pursuant to Section 7(b) or (c)
to have satisfied the applicable Standard of Conduct, then the Company shall pay
to Indemnitee, within five business days after the later of (x) the Notification
Date in respect of the Indemnifiable Claim or portion thereof to which such
Indemnifiable Losses are related, out of which such Indemnifiable Losses arose
or from which such Indemnifiable Losses resulted and (y) the earliest date on
which the applicable criterion specified in clause (i), (ii) or (iii) above
shall have been satisfied, an amount equal to the amount of such Indemnifiable
Losses. Nothing herein is intended to mean or imply that the Company is
intending to use Section 145(f) of the Delaware General Corporation Law to
dispense with a requirement that Indemnitee meet the applicable Standard of
Conduct where it is otherwise required by such statute.
(e) If a Standard of Conduct Determination is required to be,
but has not been, made by Independent Counsel pursuant to Section 7(b)(i), the
Independent Counsel shall be selected by the Board or a Board Committee, and the
Company shall give written notice to Indemnitee advising him or her of the
identity of the Independent Counsel so selected. If a Standard of Conduct
Determination is required to be, or to have been, made by Independent Counsel
pursuant to Section 7(b)(ii), the Independent Counsel shall be selected by
Indemnitee, and Indemnitee shall give written notice to the Company advising it
of the identity of the Independent Counsel so selected. In either case,
Indemnitee or the Company, as applicable, may, within five business days after
receiving written notice of selection from the other, deliver to the other a
written objection to such selection; provided, however, that such objection may
be asserted only on the ground that the Independent Counsel so selected does not
satisfy the criteria set forth in the definition of "Independent Counsel" in
Section 1(h), and the objection shall set forth with particularity the factual
basis of such assertion. Absent a proper and timely objection, the Person so
selected shall act as Independent Counsel. If such written objection is properly
and timely made and substantiated, (i) the Independent Counsel so selected may
not serve as Independent Counsel unless and until such objection is withdrawn or
a court has determined that such objection is without merit and (ii) the
non-objecting party may, at its option, select an alternative Independent
Counsel and give written notice to the other party advising such other party of
the identity of the alternative Independent Counsel so selected, in which case
the provisions of the two immediately preceding sentences and clause (i) of this
sentence shall apply
to such subsequent selection and notice. If applicable, the provisions of clause
(ii) of the immediately preceding sentence shall apply to successive alternative
selections. If no Independent Counsel that is permitted under the foregoing
provisions of this Section 7(e) to make the Standard of Conduct Determination
shall have been selected within 30 calendar days after the Company gives its
initial notice pursuant to the first sentence of this Section 7(e) or Indemnitee
gives its initial notice pursuant to the second sentence of this Section 7(e),
as the case may be, either the Company or Indemnitee may petition the Court of
Chancery of the State of Delaware for resolution of any objection which shall
have been made by the Company or Indemnitee to the other's selection of
Independent Counsel and/or for the appointment as Independent Counsel of a
person or firm selected by the Court or by such other person as the Court shall
designate, and the person or firm with respect to whom all objections are so
resolved or the person or firm so appointed will act as Independent Counsel. In
all events, the Company shall pay all of the actual and reasonable fees and
expenses of the Independent Counsel incurred in connection with the Independent
Counsel's determination pursuant to Section 7(b).
8. PRESUMPTION OF ENTITLEMENT. Notwithstanding any other provision hereof, in making any Standard of Conduct Determination, the Person making such determination shall presume that Indemnitee has satisfied the applicable Standard of Conduct, and the Company may overcome such presumption only by its adducing clear and convincing evidence to the contrary. Any Standard of Conduct Determination that is adverse to Indemnitee may be challenged by the Indemnitee in the Court of Chancery of the State of Delaware. No determination by the Company (including by its directors or any Independent Counsel) that Indemnitee has not satisfied any applicable Standard of Conduct shall be a defense to any Claim by Indemnitee for indemnification or reimbursement or advance payment of Expenses by the Company hereunder or create a presumption that Indemnitee has not met any applicable Standard of Conduct.
9. NO OTHER PRESUMPTION. For purposes of this Agreement, the termination of any Claim by judgment, order, settlement (whether with or without court approval) or conviction, or upon a plea of nolo contendere or its equivalent, will not create a presumption that Indemnitee did not meet any applicable Standard of Conduct or that indemnification hereunder is otherwise not permitted.
10. NON-EXCLUSIVITY. The rights of Indemnitee hereunder will be in addition to any other rights Indemnitee may have under the Constituent Documents, or the substantive laws of the Company's jurisdiction of incorporation, any other contract or otherwise (collectively, "OTHER INDEMNITY PROVISIONS"); provided, however, that (a) to the extent that Indemnitee otherwise would have any greater right to indemnification under any Other Indemnity Provision, Indemnitee will without further action be deemed to have such greater right hereunder, and (b) to the extent that any change is made to any Other Indemnity Provision which permits any greater right to indemnification than that provided under this Agreement as of the date hereof, Indemnitee will be deemed to have such greater right hereunder. The Company may not, without the consent of Indemnitee, adopt any amendment to any of the Constituent Documents the effect of which would be to deny, diminish or encumber Indemnitee's right to indemnification under this Agreement or any Other Indemnity Provision.
11. LIABILITY INSURANCE AND FUNDING. For the duration of Indemnitee's service as a director and/or officer of the Company and for not less than five years thereafter, the Company shall use commercially reasonable efforts (taking into account the scope and amount of coverage
available relative to the cost thereof) to cause to be maintained in effect policies of directors' and officers' liability insurance providing coverage for Indemnitee that is at least as favorable in scope and amount to that provided by the Company's current policies of directors' and officers' liability insurance. Upon request, the Company shall provide Indemnitee or his or her counsel with a copy of all directors' and officers' liability insurance applications, binders, policies, declarations, endorsements and other related materials. In all policies of directors' and officers' liability insurance obtained by the Company, Indemnitee shall be named as an insured in such a manner as to provide Indemnitee the same rights and benefits, subject to the same limitations, as are accorded to the Company's directors and officers most favorably insured by such policy. Notwithstanding the foregoing, (i) the Company may, but shall not be required to, create a trust fund, grant a security interest or use other means, including without limitation a letter of credit, to ensure the payment of such amounts as may be necessary to satisfy its obligations to indemnify and advance expenses pursuant to this Agreement and (ii) in renewing or seeking to renew any insurance hereunder, the Company will not be required to expend more than 3.0 times the premium amount of the immediately preceding policy period (equitably adjusted if necessary to reflect differences in policy periods).
12. SUBROGATION. In the event of payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the related rights of recovery of Indemnitee against other Persons (other than Indemnitee's successors), including any entity or enterprise referred to in clause (i) of the definition of "Indemnifiable Claim" in Section 1(f). Indemnitee shall execute all papers reasonably required to evidence such rights (all of Indemnitee's reasonable Expenses, including attorneys' fees and charges, related thereto to be reimbursed by or, at the option of Indemnitee, advanced by the Company).
13. NO DUPLICATION OF PAYMENTS. The Company shall not be liable under this Agreement to make any payment to Indemnitee in respect of any Indemnifiable Losses to the extent Indemnitee has otherwise already actually received payment (net of Expenses incurred in connection therewith) under any insurance policy, the Constituent Documents and Other Indemnity Provisions or otherwise (including from any entity or enterprise referred to in clause (i) of the definition of "Indemnifiable Claim" in Section 1(f)) in respect of such Indemnifiable Losses otherwise indemnifiable hereunder.
14. DEFENSE OF CLAIMS. Subject to the provisions of applicable policies of directors' and officers' liability insurance, the Company shall be entitled to participate in the defense of any Indemnifiable Claim or to assume or lead the defense thereof with counsel reasonably satisfactory to the Indemnitee; provided that if Indemnitee determines, after consultation with counsel selected by Indemnitee, that (a) the use of counsel chosen by the Company to represent Indemnitee would present such counsel with an actual or potential conflict, (b) the named parties in any such Indemnifiable Claim (including any impleaded parties) include both the Company and Indemnitee and Indemnitee shall conclude that there may be one or more legal defenses available to him or her that are different from or in addition to those available to the Company, (c) any such representation by such counsel would be precluded under the applicable standards of professional conduct then prevailing, or (d) Indemnitee has interests in the claim or underlying subject matter that are different from or in addition to those of other Persons against whom the Claim has been made or might reasonably be expected to be made, then Indemnitee shall be entitled to retain separate counsel (but not more than one law firm plus, if applicable, local counsel in respect of any particular Indemnifiable Claim for all indemnitees in Indemnitee's
circumstances) at the Company's expense. The Company shall not be liable to Indemnitee under this Agreement for any amounts paid in settlement of any threatened or pending Indemnifiable Claim effected without the Company's prior written consent. The Company shall not, without the prior written consent of the Indemnitee, effect any settlement of any threatened or pending Indemnifiable Claim which the Indemnitee is or could have been a party unless such settlement solely involves the payment of money and includes a complete and unconditional release of the Indemnitee from all liability on any claims that are the subject matter of such Indemnifiable Claim. Neither the Company nor Indemnitee shall unreasonably withhold its consent to any proposed settlement; provided that Indemnitee may withhold consent to any settlement that does not provide a complete and unconditional release of Indemnitee.
15. SUCCESSORS AND BINDING AGREEMENT.
(a) The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation, reorganization or otherwise) to all or substantially all of the business or assets of the Company expressly to assume and agree to perform this Agreement in the same manner and to the same extent the Company would be required to perform if no such succession had taken place. This Agreement shall be binding upon and inure to the benefit of the Company and any successor to the Company, including without limitation any Person acquiring directly or indirectly all or substantially all of the business or assets of the Company whether by purchase, merger, consolidation, reorganization or otherwise (and such successor will thereafter be deemed the "COMPANY" for purposes of this Agreement), but shall not otherwise be assignable or delegable by the Company.
(b) This Agreement shall inure to the benefit of and be enforceable by the Indemnitee's personal or legal representatives, executors, administrators, heirs, distributees, legatees and other successors.
(c) This Agreement is personal in nature and neither of the parties hereto shall, without the consent of the other, assign or delegate this Agreement or any rights or obligations hereunder except as expressly provided in Sections 15(a) and 15(b). Without limiting the generality or effect of the foregoing, Indemnitee's right to receive payments hereunder shall not be assignable, whether by pledge, creation of a security interest or otherwise, other than by a transfer by the Indemnitee's will or by the laws of descent and distribution, and, in the event of any attempted assignment or transfer contrary to this Section 15(c), the Company shall have no liability to pay any amount so attempted to be assigned or transferred.
16. NOTICES. For all purposes of this Agreement, all communications, including without limitation notices, consents, requests or approvals, required or permitted to be given hereunder must be in writing and shall be deemed to have been duly given when hand delivered or dispatched by electronic facsimile transmission (with receipt thereof orally confirmed), or one business day after having been sent for next-day delivery by a nationally recognized overnight courier service, addressed to the Company (to the attention of the Secretary of the Company) and to Indemnitee at the applicable address shown on the signature page hereto, or to such other address as any party may have furnished to the other in writing and in accordance herewith, except that notices of changes of address will be effective only upon receipt.
17. GOVERNING LAW. The validity, interpretation, construction and performance of this Agreement shall be governed by and construed in accordance with the substantive laws of the
State of Delaware, without giving effect to the principles of conflict of laws
of such State. The Company and Indemnitee each hereby irrevocably consent to the
jurisdiction of the Chancery Court of the State of Delaware for all purposes in
connection with any action or proceeding which arises out of or relates to this
Agreement, waive all procedural objections to suit in that jurisdiction,
including without limitation objections as to venue or inconvenience, agree that
service in any such action may be made by notice given in accordance with
Section 16 and also agree that any action instituted under this Agreement shall
be brought only in the Chancery Court of the State of Delaware.
18. VALIDITY. If any provision of this Agreement or the application of any provision hereof to any Person or circumstance is held invalid, unenforceable or otherwise illegal, the remainder of this Agreement and the application of such provision to any other Person or circumstance shall not be affected, and the provision so held to be invalid, unenforceable or otherwise illegal shall be reformed to the extent, and only to the extent, necessary to make it enforceable, valid or legal. In the event that any court or other adjudicative body shall decline to reform any provision of this Agreement held to be invalid, unenforceable or otherwise illegal as contemplated by the immediately preceding sentence, the parties thereto shall take all such action as may be necessary or appropriate to replace the provision so held to be invalid, unenforceable or otherwise illegal with one or more alternative provisions that effectuate the purpose and intent of the original provisions of this Agreement as fully as possible without being invalid, unenforceable or otherwise illegal.
19. MISCELLANEOUS. No provision of this Agreement may be waived, modified or discharged unless such waiver, modification or discharge is agreed to in writing signed by Indemnitee and the Company. No waiver by either party hereto at any time of any breach by the other party hereto or compliance with any condition or provision of this Agreement to be performed by such other party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time. No agreements or representations, oral or otherwise, expressed or implied with respect to the subject matter hereof have been made by either party that are not set forth expressly in this Agreement.
20. LEGAL FEES AND EXPENSES. It is the intent of the Company that Indemnitee not be required to incur legal fees and or other Expenses associated with the interpretation, enforcement or defense of Indemnitee's rights under this Agreement by litigation or otherwise because the cost and expense thereof would substantially detract from the benefits intended to be extended to Indemnitee hereunder. Accordingly, without limiting the generality or effect of any other provision hereof, if it should reasonably appear to Indemnitee that the Company has failed to comply with any of its obligations under this Agreement or in the event that the Company or any other Person takes or threatens to take any action to declare this Agreement void or unenforceable, or institutes any litigation or other action or proceeding designed to improperly deny, or to improperly recover from, Indemnitee the benefits provided or intended to be provided to Indemnitee hereunder, the Company irrevocably authorizes the Indemnitee from time to time to retain counsel of Indemnitee's choice, at the expense of the Company as hereafter provided, to advise and represent Indemnitee in connection with any such interpretation, enforcement or defense, including without limitation the initiation or defense of any litigation or other legal action, whether by or against the Company or any director, officer, stockholder or other Person affiliated with the Company, in any jurisdiction. Without limiting the generality or effect of any other provision hereof or respect to whether Indemnitee prevails, in whole or in part, in
connection with any of the foregoing, the Company will pay and be solely financially responsible for any and all attorneys' and related fees and expenses actually and reasonably incurred by Indemnitee in connection with any of the foregoing.
21. CERTAIN INTERPRETIVE MATTERS. Unless the context of this Agreement otherwise requires, (1) "it" or "its" or words of any gender include each other gender, (2) words using the singular or plural number also include the plural or singular number, respectively, (3) the terms "hereof," "herein," "hereby" and derivative or similar words refer to this entire Agreement, (4) the terms "Article," "Section," "Annex" or "Exhibit" refer to the specified Article, Section, Annex or Exhibit of or to this Agreement, (5) the terms "include," "includes" and "including" will be deemed to be followed by the words "without limitation" (whether or not so expressed), and (6) the word "or" is disjunctive but not exclusive. Whenever this Agreement refers to a number of days, such number will refer to calendar days unless business days are specified and whenever action must be taken (including the giving of notice or the delivery of documents) under this Agreement during a certain period of time or by a particular date that ends or occurs on a non-business day, then such period or date will be extended until the immediately following business day. As used herein, "business day" means any day other than Saturday, Sunday or a United States federal holiday.
22. ENTIRE AGREEMENT. This Agreement and the Constituent Documents constitute the entire agreement, and supersede all prior agreements and understandings, both written and oral, between the parties hereto with respect to the subject matter of this Agreement. Any prior agreements or understandings between the parties hereto with respect to indemnification are hereby terminated and of no further force or effect.
23. COUNTERPARTS. This Agreement may be executed in one or more counterparts, each of which will be deemed to be an original but all of which together shall constitute one and the same agreement.
[ SIGNATURE PAGE FOLLOWS ]
IN WITNESS WHEREOF, Indemnitee has executed and the Company has caused its duly authorized representative to execute this Agreement as of the date first above written.
LHC GROUP, INC.
INDEMNITEE
EXHIBIT 10.11
LHC GROUP, INC.
2005 NON-EMPLOYEE DIRECTORS COMPENSATION PLAN
LHC GROUP, INC.
2005 NON-EMPLOYEE DIRECTORS COMPENSATION PLAN
ARTICLE 1 PURPOSE..................................................1 1.1 Purpose...................................................1 1.2 Eligibility...............................................1 ARTICLE 2 DEFINITIONS..............................................1 2.1 Definitions...............................................1 ARTICLE 3 ADMINISTRATION...........................................3 3.1 Administration............................................3 3.2 Reliance..................................................3 3.3 Indemnification...........................................3 ARTICLE 4 SHARES...................................................3 4.1 Source of Shares for the Plan.............................3 ARTICLE 5 CASH COMPENSATION........................................4 5.1 Base Annual Retainer......................................4 5.2 Supplemental Annual Retainer..............................4 5.3 Meeting Fees..............................................5 5.4 Travel Expense Reimbursement..............................5 ARTICLE 6 EQUITY COMPENSATION......................................5 6.1 Restricted Stock..........................................5 6.2 Stock Options.............................................6 ARTICLE 7 AMENDMENT, MODIFICATION AND TERMINATION..................6 7.1 Amendment, Modification and Termination...................6 ARTICLE 8 GENERAL PROVISIONS.......................................6 8.1 Adjustments...............................................6 8.2 Duration of the Plan......................................6 8.3 Expenses of the Plan......................................6 8.4 Effective Date............................................7 |
LHC GROUP, INC.
2005 NON-EMPLOYEE DIRECTORS COMPENSATION PLAN
ARTICLE 1
PURPOSE
1.1. PURPOSE. The purpose of the LHC Group, Inc. 2005 Non-Employee Directors Compensation Plan is to attract, retain and compensate highly-qualified individuals who are not employees of LHC Group, Inc. or any of its subsidiaries or affiliates for service as members of the Board by providing them with competitive compensation and an ownership interest in the Common Stock of the Company. The Company intends that the Plan will benefit the Company and its stockholders by allowing Non-Employee Directors to have a personal financial stake in the Company through an ownership interest in the Common Stock and will closely associate the interests of Non-Employee Directors with that of the Company's stockholders.
1.2. ELIGIBILITY. Non-Employee Directors of the Company who are Eligible Participants, as defined below, shall automatically be participants in the Plan.
ARTICLE 2
DEFINITIONS
2.1. DEFINITIONS. Unless the context clearly indicates otherwise, the following terms shall have the following meanings:
"Annual Retainer" means the Base Annual Retainer and the Supplemental Annual Retainers.
"Base Annual Retainer" means the annual retainer (excluding meeting
fees and expenses) payable by the Company to a Non-Employee Director pursuant to
Section 5.1 hereof for service as a director of the Company (i.e., excluding any
Supplemental Annual Retainer), as such amount may be changed from time to time.
"Board" means the Board of Directors of the Company.
"Common Stock" means the common stock, par value $0.01 per share, of the Company.
"Company" means LHC Group, Inc., a Delaware corporation.
"Disability" means any illness or other physical or mental condition of a Non-Employee Director that renders him or her incapable of performing as a director of the Company, or any medically determinable illness or other physical or mental condition resulting from a bodily injury, disease or mental disorder which, in the judgment of the Board, is permanent and continuous in nature. The Board may require such medical or
other evidence as it deems necessary to judge the nature and permanency of a Non-Employee Director's condition.
"Effective Date" has the meaning set forth in Section 9.4 of the Plan.
"Eligible Participant" means any person who is a Non-Employee Director on the Effective Date or becomes a Non-Employee Director while this Plan is in effect; except that during any period a director is prohibited from participating in the Plan by his or her employer or otherwise waives participation in the Plan, such director shall not be an Eligible Participant.
"Fair Market Value", on any date, has the meaning given such term in the Incentive Plan.
"Incentive Plan" means the LHC Group, Inc. 2005 Incentive Plan, or any subsequent equity compensation plan approved by the Company's stockholders Board and designated as the Incentive Plan for purposes of this Plan.
"Lead Director" means the Non-Employee Director who has been designated by the Board as the Lead Director for the Plan Year in question. The Board may change the designation of Lead Director from time to time.
"Non-Employee Director" means a director of the Company who is not an employee of the Company or of any of its subsidiaries or affiliates.
"Option" means a right granted to an Eligible Participant under Article 6 of the Plan to purchase Stock at a specified price during specified time periods. Options granted under the Plan are nonstatutory stock options.
"Plan" means this LHC Group, Inc. 2004 Non-Employee Directors Compensation Plan, as amended from time to time.
"Plan Year" means the approximate twelve-month period between annual meetings of the stock holders of the Company, which, for purposes of the Plan, is the period for which Annual Retainers are earned.
"Retirement" means retirement of the director in accordance with the provisions of the Company's bylaws as in effect from time to time, or the failure to be re-elected or re-nominated as a director.
"Restricted Stock" means shares of Common Stock that are subject to certain restrictions and to risk of forfeiture.
"Supplemental Annual Retainer" means the annual retainer (excluding meeting fees and expenses) payable by the Company to a Non-Employee Director pursuant to Section 5.2 hereof for service as Lead Director or as a chair or member of a committee of
the Board, as such amount may be changed from time to time.
ARTICLE 3
ADMINISTRATION
3.1. ADMINISTRATION. The Plan shall be administered by the Board. Subject to the provisions of the Plan, the Board shall be authorized to interpret the Plan, to establish, amend and rescind any rules and regulations relating to the Plan, and to make all other determinations necessary or advisable for the administration of the Plan. The Board's interpretation of the Plan, and all actions taken and determinations made by the Board pursuant to the powers vested in it hereunder, shall be conclusive and binding upon all parties concerned including the Company, its stockholders and persons granted awards under the Plan. The Board may appoint a plan administrator to carry out the ministerial functions of the Plan, but the administrator shall have no other authority or powers of the Board.
3.2. RELIANCE. In administering the Plan, the Board may rely upon any information furnished by the Company, its public accountants and other experts. No individual will have personal liability by reason of anything done or omitted to be done by the Company or the Board in connection with the Plan. This limitation of liability shall not be exclusive of any other limitation of liability to which any such person may be entitled under the Company's certificate of incorporation or otherwise.
3.3. INDEMNIFICATION. Each person who is or has been a member of the Board or who otherwise participates in the administration or operation of this Plan shall be indemnified by the Company against, and held harmless from, any loss, cost, liability or expense that may be imposed upon or incurred by him or her in connection with or resulting from any claim, action, suit or proceeding in which such person may be involved by reason of any action taken or failure to act under the Plan and shall be fully reimbursed by the Company for any and all amounts paid by such person in satisfaction of judgment against him or her in any such action, suit or proceeding, provided he or she will give the Company an opportunity, by written notice to the Board, to defend the same at the Company's own expense before he or she undertakes to defend it on his or her own behalf. This right of indemnification shall not be exclusive of any other rights of indemnification to which any such person may be entitled under the Company's certificate of incorporation, bylaws, contract or Delaware law.
ARTICLE 4
SHARES
4.1. SOURCE OF SHARES FOR THE PLAN. The shares of Common Stock that may be issued pursuant to the Plan shall be issued under the Incentive Plan, subject to all of the terms and conditions of the Incentive Plan. The terms contained in the Incentive Plan are incorporated into and made a part of this Plan with respect to Restricted Stock and Options granted pursuant hereto and any such awards shall be governed by and construed in accordance with the Incentive Plan. In the event of any
actual or alleged conflict between the provisions of the Incentive Plan and the provisions of this Plan, the provisions of the Incentive Plan shall be controlling and determinative. This Plan does not constitute a separate source of shares for the grant of the equity awards described herein.
ARTICLE 5
CASH COMPENSATION
5.1. BASE ANNUAL RETAINER. Each Eligible Participant shall be paid a Base Annual Retainer for service as a director during each Plan Year. The amount of the Base Annual Retainer shall be established from time to time by the Board. Until changed by the Board, the Base Annual Retainer shall be $24,000 for each Non-Employee Director. A pro-rata Base Annual Retainer will be paid to any Eligible Participant who joins the Board on a date other than the beginning of a Plan Year, based on the number of full months between the date such Non-Employee Director joined the Board and the following June 1. Payment of such prorated Base Annual Retainer shall begin on the later of (i) the Effective Date, or (ii) the date that the person first becomes an Eligible Participant.
5.2. SUPPLEMENTAL ANNUAL RETAINER.
(a) Supplemental Annual Retainer for Service as Lead Director. In addition to the Base Annual Retainer, the Lead Director shall be paid an additional Supplemental Annual Retainer for service as Lead Director during each Plan Year, payable at the same time as the Base Annual Retainer is paid. The amount of such Supplemental Annual Retainer shall be established from time to time by the Board. Until changed by the Board, the special additional Supplemental Annual Retainer for the Lead Director for a full Plan Year shall be $26,000. A prorata payment will be paid to any Non-Employee Director who becomes the Lead Director on a date other than the beginning of a Plan Year, based on the number of full calendar months served in such position during the Plan Year.
(b) Supplemental Annual Retainer for Committee Service. Any Non-Employee Director [(other than the Lead Director)] who serves as the chair or member of a committee of the Board shall be paid a Supplemental Annual Retainer, payable at the same time as the Base Annual Retainer is paid. The amount of the Supplemental Annual Retainer shall be established from time to time by the Board. Until changed by the Board, the Supplemental Annual Retainer for a full Plan Year shall be as follows:
COMMITTEE CHAIR NON-CHAIR MEMBER --------- ----- ---------------- Audit Committee $12,000 $6,000 Compensation Committee $12,000 $6,000 Nominating and Corporate Governance Committee $12,000 $6,000 |
A prorata Supplemental Annual Retainer will be paid to any Non-Employee Director who
becomes the chair or member of a committee of the Board on a date other than the beginning of a Plan Year, based on the number of full calendar months served in such position during the Plan Year.
5.3. MEETING FEES. Each Non-Employee Director shall be paid a $300 meeting fee for each non-regularly scheduled, specially-called meeting of the Board or committee thereof he or she attends.
5.4. TRAVEL EXPENSE REIMBURSEMENT. All Non-Employee Directors shall be reimbursed for reasonable travel expenses (including spouse's expenses to attend events to which spouses are invited) in connection with attendance at meetings of the Board and its committees, or other Company functions at which the Chief Executive Officer requests the Non-Employee Director to participate. If the travel expense is related to the reimbursement of commercial airfare, such reimbursement will not exceed full-coach rates. If the travel expense is related to reimbursement of non-commercial air travel, such reimbursement shall not exceed the rate for comparable travel by means of commercial airlines.
ARTICLE 6
EQUITY COMPENSATION
6.1. RESTRICTED STOCK.
(a) Initial Grant of Restricted Stock. Following the initial public offering of the Company's Common Stock, and effective as of a date specified by the Board, each Eligible Participant in service on that date will receive an award of Restricted Stock. The number of shares so awarded shall be 3,500 to each Eligible Participant other than the Lead Director, and shall be 7,000 to the Lead Director. Such shares of Restricted Stock shall be evidenced by a written Award Certificate, and shall be subject to such restrictions and risk of forfeiture as determined by the Board, and shall be granted under and pursuant to the terms of the Incentive Plan, subject to share availability under the Incentive Plan.
(b) Vesting of Restricted Stock. The shares of Restricted Stock Units shall vest shall vest and become non-forfeitable as to one-third of the shares on each of the first three anniversaries of the grant date or, if earlier, upon the termination of the grantee's service as a director of the Company due to his or her death, Disability or Retirement. If the grantee's service as a director of the Company (whether or not in a Non-Employee Director capacity) terminates prior to the third anniversary of the date of grant other than by reason of his or her death, Disability or Retirement, then the grantee shall forfeit all of his or her right, title and interest in and to any unvested shares of Restricted Stock as of the date of such termination from the Board and such shares Restricted Stock shall be reconveyed to the Company without further consideration or any act or action by the grantee.
6.2 STOCK OPTIONS.
(a) Annual Grant of Stock Options. On the day following the 2006 annual meeting of the Company's stockholders, and on the day following each subsequent annual meeting of the Company's stockholders, each Eligible Participant (other than the Lead Director) in service on that date will receive a fully-vested Option grant to purchase 2,000 shares of the Company's Stock, and the Lead Director will receive a fully-vested Option grant to purchase 3,500 shares of the Company's Stock. Such Options shall be evidenced by a written Award Certificate, and shall be subject to the terms and conditions described below in this Section 6.2, and shall be granted under and pursuant to the terms of the Incentive Plan, subject to share availability under the Incentive Plan.
(b) Exercise Price. The exercise price for each Option granted under the Plan shall be the Fair Market Value of the shares of Stock subject to the Option on the date of grant of the Option.
(c) Term. Each Option granted under the Plan shall, to the extent not previously exercised, terminate and expire on the date ten (10) years after the date of grant of the Option.
ARTICLE 7
AMENDMENT, MODIFICATION AND TERMINATION
7.1. AMENDMENT, MODIFICATION AND TERMINATION. The Board may terminate or suspend the Plan at any time, without stockholder approval. The Board may amend the Plan at any time and for any reason without stockholder approval; provided, however, that the Board may condition any amendment on the approval of stockholders of the Company if such approval is necessary or deemed advisable with respect to tax, securities or other applicable laws, policies or regulations. Except as provided in Section 7.1, no termination, modification or amendment of the Plan may, without the consent of a Non-Employee Director, adversely affect a Non-Employee Director's rights under an award granted prior thereto.
ARTICLE 8
GENERAL PROVISIONS
8.1. ADJUSTMENTS. The adjustment provisions of the Incentive Plan shall apply with respect to awards of Restricted Stock and Options outstanding or to be granted pursuant to this Plan.
8.2. DURATION OF THE PLAN. The Plan shall remain in effect until January 20, 2015, unless terminated earlier by the Board.
8.3. EXPENSES OF THE PLAN. The expenses of administering the Plan shall be borne by the Company.
8.4. EFFECTIVE DATE. The Plan was originally adopted by the Board on January 20, 2005, and became effective on that date (the "Effective Date").
LHC GROUP, INC.
By: /s/ R. Barr Brown ------------------------- |
EXHIBIT 23.2
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption "Experts" and to the use of our report dated October 25, 2004 (except for Note 1, as to which the date is February 10, 2005) in Amendment No. 2 to the Registration Statement (Form S-1 No. 333-120792) and related Prospectus of LHC Group, Inc. for the registration of 4,000,000 shares of its common stock.
/s/ Ernst & Young LLP New Orleans, Louisiana February 10, 2005 |